US8409856B2	NNP	O
-	:	O
Compositions	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
directed	VBN	O
to	TO	O
gemin	VB	O
genes	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
application	NN	O
under	IN	O
35	CD	O
U.S.C	NNP	O
.	.	O
§121	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/226,884	CD	O
,	,	O
filed	VBD	O
Sep.	NNP	O
13	CD	O
,	,	O
2005	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,759,479	CD	O
,	,	O
which	WDT	O
claims	VBZ	O
benefit	NN	O
of	IN	O
U.S.	NNP	O
provisional	JJ	O
application	NN	O
60/609,711	CD	O
,	,	O
filed	VBD	O
Sep.	NNP	O
13	CD	O
,	,	O
2004	CD	O
,	,	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
each	DT	O
is	VBZ	O
being	VBG	O
expressly	RB	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
SEQUENCE	NNP	O
LISTING	NNP	O
The	DT	O
present	JJ	O
application	NN	O
is	VBZ	O
being	VBG	O
filed	VBN	O
along	IN	O
with	IN	O
a	DT	O
Sequence	NNP	O
Listing	NNP	O
in	IN	O
electronic	JJ	O
format	NN	O
.	.	O
The	DT	O
Sequence	NNP	O
Listing	NNP	O
is	VBZ	O
provided	VBN	O
as	IN	O
a	DT	O
file	NN	O
entitled	VBN	O
RTS0491USC1SEQ.txt	NNP	O
,	,	O
created	VBN	O
on	IN	O
May	NNP	O
26	CD	O
,	,	O
2010	CD	O
which	WDT	O
is	VBZ	O
261	CD	O
Kb	NNP	O
in	IN	O
size	NN	O
.	.	O
The	DT	O
information	NN	O
in	IN	O
the	DT	O
electronic	JJ	O
format	NN	O
of	IN	O
the	DT	O
sequence	NN	O
listing	NN	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Disclosed	VBD	O
herein	NNS	O
are	VBP	O
compounds	NNS	O
,	,	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
gene	NN	O
in	IN	O
a	DT	O
cell	NN	O
,	,	O
tissue	NN	O
or	CC	O
animal	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Targeting	NNP	O
disease-causing	JJ	O
gene	NN	O
sequences	NNS	O
was	VBD	O
first	RB	O
suggested	VBN	O
more	JJR	O
than	IN	O
thirty	CD	O
years	NNS	O
ago	RB	O
(	(	O
Belikova	NNP	B
et	RB	I
al.	RB	I
,	,	I
Tet	NNP	I
.	.	I
Lett.	NNP	I
,	,	I
1967	CD	I
,	,	I
37	CD	I
,	,	I
3557-3562	JJ	I
)	)	O
,	,	O
and	CC	O
antisense	JJ	O
activity	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
cell	NN	O
culture	NN	O
more	JJR	O
than	IN	O
a	DT	O
decade	NN	O
later	RB	O
(	(	O
Zamecnik	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
1978	CD	I
,	,	I
75	CD	I
,	,	I
280-284	JJ	I
)	)	O
.	.	O
One	CD	O
advantage	NN	O
of	IN	O
antisense	JJ	O
technology	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
that	WDT	O
stems	VBZ	O
from	IN	O
a	DT	O
disease-causing	JJ	O
gene	NN	O
is	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
a	DT	O
direct	JJ	O
genetic	JJ	O
approach	NN	O
that	WDT	O
has	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
modulate	VB	O
(	(	O
increase	NN	O
or	CC	O
decrease	NN	O
)	)	O
the	DT	O
expression	NN	O
of	IN	O
specific	JJ	O
disease-causing	JJ	O
genes	NNS	O
.	.	O
Another	DT	O
advantage	NN	O
is	VBZ	O
that	IN	O
validation	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
target	NN	O
using	VBG	O
antisense	JJ	O
compounds	NNS	O
results	NNS	O
in	IN	O
direct	JJ	O
and	CC	O
immediate	JJ	O
discovery	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidate	NN	O
;	:	O
the	DT	O
antisense	NN	O
compound	NN	O
is	VBZ	O
the	DT	O
potential	JJ	O
therapeutic	JJ	O
agent	NN	O
.	.	O
Generally	RB	O
,	,	O
the	DT	O
principle	NN	O
behind	IN	O
antisense	JJ	O
technology	NN	O
is	VBZ	O
that	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
hybridizes	VBZ	O
to	TO	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
modulates	NNS	O
gene	NN	O
expression	NN	O
activities	NNS	O
or	CC	O
function	NN	O
,	,	O
such	JJ	O
as	IN	O
transcription	NN	O
or	CC	O
translation	NN	O
.	.	O
The	DT	O
modulation	NN	O
of	IN	O
gene	NN	O
expression	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
target	VB	O
degradation	NN	O
or	CC	O
occupancy-based	JJ	O
inhibition	NN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
modulation	NN	O
of	IN	O
RNA	NNP	O
target	NN	O
function	NN	O
by	IN	O
degradation	NN	O
is	VBZ	O
RNase	NNP	O
H-based	JJ	O
degradation	NN	O
of	IN	O
the	DT	O
target	NN	O
RNA	NNP	O
upon	IN	O
hybridization	NN	O
with	IN	O
a	DT	O
DNA-like	JJ	O
antisense	NN	O
compound	NN	O
.	.	O
Another	DT	O
example	NN	O
of	IN	O
modulation	NN	O
of	IN	O
gene	NN	O
expression	NN	O
by	IN	O
target	NN	O
degradation	NN	O
is	VBZ	O
RNA	NNP	O
interference	NN	O
(	(	O
RNAi	NNP	O
)	)	O
.	.	O
RNAi	NNP	O
generally	RB	O
refers	VBZ	O
to	TO	O
antisense-mediated	JJ	O
gene	NN	O
silencing	VBG	O
involving	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
dsRNA	NN	O
leading	VBG	O
to	TO	O
the	DT	O
sequence-specific	JJ	O
reduction	NN	O
of	IN	O
targeted	VBN	O
endogenous	JJ	O
mRNA	NN	O
levels	NNS	O
.	.	O
Regardless	RB	O
of	IN	O
the	DT	O
specific	JJ	O
mechanism	NN	O
,	,	O
this	DT	O
sequence-specificity	NN	O
makes	VBZ	O
antisense	JJ	O
compounds	NNS	O
extremely	RB	O
attractive	JJ	O
as	IN	O
tools	NNS	O
for	IN	O
target	NN	O
validation	NN	O
and	CC	O
gene	NN	O
functionalization	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
therapeutics	NNS	O
to	TO	O
selectively	RB	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
malignancies	NNS	O
and	CC	O
other	JJ	O
diseases	NNS	O
.	.	O
Antisense	NNP	O
compounds	NNS	O
have	VBP	O
been	VBN	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disease	NN	O
states	NNS	O
in	IN	O
animals	NNS	O
,	,	O
including	VBG	O
humans	NNS	O
.	.	O
Antisense	NNP	O
oligonucleotide	NN	O
drugs	NNS	O
are	VBP	O
being	VBG	O
safely	RB	O
and	CC	O
effectively	RB	O
administered	VBN	O
to	TO	O
humans	NNS	O
in	IN	O
numerous	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	O
In	IN	O
1998	CD	O
,	,	O
the	DT	O
antisense	NN	O
compound	NN	O
,	,	O
Vitravene®	NNP	O
(	(	O
fomivirsen	VBN	O
;	:	O
developed	VBN	O
by	IN	O
Isis	NNP	O
Pharmaceuticals	NNP	O
Inc.	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
was	VBD	O
the	DT	O
first	JJ	O
antisense	JJ	O
drug	NN	O
to	TO	O
achieve	VB	O
marketing	NN	O
clearance	NN	O
from	IN	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
(	(	O
FDA	NNP	O
)	)	O
,	,	O
and	CC	O
is	VBZ	O
currently	RB	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
-induced	VBD	O
retinitis	NN	O
in	IN	O
AIDS	NNP	O
patients	NNS	O
.	.	O
A	DT	O
New	NNP	O
Drug	NNP	O
Application	NNP	O
(	(	O
NDA	NNP	O
)	)	O
for	IN	O
Genasense™	NNP	O
(	(	O
oblimersen	JJ	O
sodium	NN	O
;	:	O
developed	VBN	O
by	IN	O
Genta	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Berkeley	NNP	O
Heights	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
which	WDT	O
targets	VBZ	O
the	DT	O
Bc1-2	NNP	O
mRNA	NN	O
overexpressed	VBD	O
in	IN	O
many	JJ	O
cancers	NNS	O
,	,	O
was	VBD	O
accepted	VBN	O
by	IN	O
the	DT	O
FDA	NNP	O
.	.	O
Many	JJ	O
other	JJ	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
in	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
including	VBG	O
those	DT	O
targeting	VBG	O
c-myc	JJ	O
(	(	O
NeuGene®	NNP	O
AVI-4126	NNP	O
,	,	O
AVI	NNP	O
BioPharma	NNP	O
,	,	O
Ridgefield	NNP	O
Park	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
,	,	O
TNF-alpha	NNP	O
(	(	O
ISIS	NNP	O
104838	CD	O
,	,	O
developed	VBN	O
by	IN	O
Isis	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc.	NNP	O
)	)	O
,	,	O
VLA4	NNP	O
(	(	O
ATL1102	NNP	O
,	,	O
Antisense	NNP	O
Therapeutics	NNPS	O
Ltd.	NNP	O
,	,	O
Toorak	NNP	O
,	,	O
Victoria	NNP	O
,	,	O
Australia	NNP	O
)	)	O
and	CC	O
DNA	NNP	O
methyltransferase	NN	O
(	(	O
MG98	NNP	O
,	,	O
developed	VBN	O
by	IN	O
MGI	NNP	O
Pharma	NNP	O
,	,	O
Bloomington	NNP	O
,	,	O
Minn.	NNP	O
)	)	O
,	,	O
to	TO	O
name	VB	O
a	DT	O
few	JJ	O
.	.	O
New	NNP	O
chemical	NN	O
modifications	NNS	O
have	VBP	O
improved	VBN	O
the	DT	O
potency	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
,	,	O
uncovering	VBG	O
the	DT	O
potential	NN	O
for	IN	O
oral	JJ	O
delivery	NN	O
as	RB	O
well	RB	O
as	IN	O
enhancing	VBG	O
subcutaneous	JJ	O
administration	NN	O
,	,	O
decreasing	VBG	O
potential	JJ	O
for	IN	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
leading	VBG	O
to	TO	O
improvements	NNS	O
in	IN	O
patient	JJ	O
convenience	NN	O
.	.	O
Chemical	NNP	O
modifications	NNS	O
increasing	VBG	O
potency	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
allow	JJ	O
administration	NN	O
of	IN	O
lower	JJR	O
doses	NNS	O
,	,	O
which	WDT	O
reduces	VBZ	O
the	DT	O
potential	NN	O
for	IN	O
toxicity	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
decreasing	VBG	O
overall	JJ	O
cost	NN	O
of	IN	O
therapy	NN	O
.	.	O
Modifications	NNS	O
increasing	VBG	O
the	DT	O
resistance	NN	O
to	TO	O
degradation	VB	O
result	NN	O
in	IN	O
slower	JJR	O
clearance	NN	O
from	IN	O
the	DT	O
body	NN	O
,	,	O
allowing	VBG	O
for	IN	O
less	JJR	O
frequent	JJ	O
dosing	NN	O
.	.	O
Different	NNP	O
types	NNS	O
of	IN	O
chemical	NN	O
modifications	NNS	O
can	MD	O
be	VB	O
combined	VBN	O
in	IN	O
one	CD	O
compound	NN	O
to	TO	O
further	JJ	O
optimize	VB	O
the	DT	O
compound	NN	O
's	POS	O
efficacy	NN	O
.	.	O
Much	JJ	O
of	IN	O
the	DT	O
information	NN	O
regarding	VBG	O
the	DT	O
biogenesis	NN	O
of	IN	O
the	DT	O
small	JJ	O
nuclear	JJ	O
ribonucleoproteins	NNS	O
(	(	O
snRNPs	NN	O
)	)	O
came	VBD	O
from	IN	O
studies	NNS	O
of	IN	O
spinal	JJ	O
muscular	JJ	O
atrophy	NN	O
(	(	O
SMA	NNP	O
)	)	O
.	.	O
SMA	NNP	O
,	,	O
a	DT	O
motor	NN	O
neuron	NN	O
degenerative	JJ	O
disease	NN	O
that	WDT	O
results	NNS	O
from	IN	O
deletions	NNS	O
or	CC	O
mutations	NNS	O
in	IN	O
the	DT	O
Survival	NNP	O
of	IN	O
Motor	NNP	O
Neurons	NNP	O
(	(	O
SMN	NNP	O
)	)	O
gene	NN	O
,	,	O
is	VBZ	O
an	DT	O
autosomal	JJ	O
recessive	JJ	O
disease	NN	O
that	WDT	O
is	VBZ	O
the	DT	O
leading	VBG	O
hereditary	JJ	O
cause	NN	O
of	IN	O
infant	JJ	O
mortality	NN	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
)	)	O
.	.	O
The	DT	O
SMN	NNP	O
protein	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
cytoplasm	NN	O
and	CC	O
nucleus	NN	O
,	,	O
where	WRB	O
it	PRP	O
is	VBZ	O
enriched	VBN	O
within	IN	O
discrete	JJ	O
bodies	NNS	O
called	VBN	O
Gems	NNP	O
(	(	O
for	IN	O
“	NNP	O
Gemini	NNP	O
of	IN	O
Cajal	NNP	O
bodies	NNS	O
”	NNP	O
)	)	O
which	WDT	O
are	VBP	O
related	VBN	O
to	TO	O
and	CC	O
often	RB	O
associated	VBN	O
with	IN	O
Cajal	NNP	O
bodies	NNS	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
;	:	O
Liu	NNP	B
and	CC	I
Dreyfuss	NNP	I
,	,	I
Embo	NNP	I
J.	NNP	I
,	,	I
1996	CD	I
,	,	I
15	CD	I
,	,	I
3555-3565	CD	I
;	:	O
Yong	NNP	B
et	FW	I
al.	NN	I
,	,	I
Trends	NNP	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2004	CD	I
,	,	I
14	CD	I
,	,	I
226-232	JJ	I
)	)	O
.	.	O
Cajal	NNP	O
bodies	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
contain	VB	O
high	JJ	O
levels	NNS	O
of	IN	O
factors	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
transcription	NN	O
and	CC	O
processing	NN	O
of	IN	O
many	JJ	O
types	NNS	O
of	IN	O
nuclear	JJ	O
RNAs	NNP	O
,	,	O
including	VBG	O
snRNPs	NN	O
,	,	O
nucleolar	JJ	O
ribonucleoproteins	NNS	O
(	(	O
snoRNPs	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
three	CD	O
eukaryotic	JJ	O
RNA	NNP	O
polymerases	NNS	O
,	,	O
and	CC	O
are	VBP	O
most	RBS	O
likely	JJ	O
sites	NNS	O
of	IN	O
assembly	NN	O
and	CC	O
modification	NN	O
of	IN	O
the	DT	O
nuclear	JJ	O
transcription	NN	O
and	CC	O
RNA	NNP	O
machinery	NN	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
)	)	O
.	.	O
The	DT	O
snRNP	NN	O
particles	NNS	O
are	VBP	O
components	NNS	O
of	IN	O
the	DT	O
spliceosome	NN	O
,	,	O
the	DT	O
eukaryotic	JJ	O
pre-mRNA	JJ	O
splicing	NN	O
machinery	NN	O
.	.	O
Each	DT	O
major	JJ	O
snRNP	NN	O
contains	VBZ	O
a	DT	O
small	JJ	O
nuclear	JJ	O
RNA	NNP	O
(	(	O
snRNA	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
common	JJ	O
set	NN	O
of	IN	O
Sm	NNP	O
proteins	NNS	O
and	CC	O
a	DT	O
set	NN	O
of	IN	O
proteins	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
particular	JJ	O
snRNA	NN	O
.	.	O
The	DT	O
common	JJ	O
Sm	NNP	O
proteins	NNS	O
are	VBP	O
arranged	VBN	O
into	IN	O
a	DT	O
core	NN	O
on	IN	O
a	DT	O
uridine-rich	JJ	O
sequence	NN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
after	IN	O
nuclear	JJ	O
export	NN	O
of	IN	O
the	DT	O
nacent	JJ	O
snRNAs	NN	O
.	.	O
Proper	NNP	O
assembly	NN	O
of	IN	O
the	DT	O
core	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
subsequent	JJ	O
import	NN	O
of	IN	O
the	DT	O
snRNPs	NN	O
into	IN	O
the	DT	O
nucleus	NN	O
.	.	O
As	IN	O
compared	VBN	O
to	TO	O
other	JJ	O
RNP	NNP	O
complexes	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
small	JJ	O
nucleolar	JJ	O
RNPs	NNP	O
which	WDT	O
are	VBP	O
assembled	VBN	O
in	IN	O
the	DT	O
nucleus	NN	O
where	WRB	O
they	PRP	O
function	VBP	O
,	,	O
the	DT	O
assembly	NN	O
of	IN	O
snRNPs	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
strictly	RB	O
regulated	VBN	O
and	CC	O
complex	JJ	O
(	(	O
Yong	JJ	B
et	NN	I
al.	NN	I
,	,	I
Trends	NNP	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2004	CD	I
,	,	I
14	CD	I
,	,	I
226-232	JJ	I
)	)	O
.	.	O
The	DT	O
SMN	NNP	O
protein	NN	O
oligomerizes	VBZ	O
with	IN	O
a	DT	O
group	NN	O
of	IN	O
proteins	NNS	O
named	VBN	O
the	DT	O
Gemins	NNP	O
.	.	O
The	DT	O
Gemins	NNP	O
include	VBP	O
Gemin2	NNP	O
,	,	O
Gemin3	NNP	O
,	,	O
a	DT	O
DEAD/H	NNP	O
box	NN	O
helicase	NN	O
,	,	O
Gemin4	NNP	O
,	,	O
Gemin5	NNP	O
,	,	O
Gemin6	NNP	O
,	,	O
and	CC	O
Gemin7	NNP	O
.	.	O
The	DT	O
Gemins	NNP	O
colocalize	VB	O
with	IN	O
SMN	NNP	O
in	IN	O
gems	NNS	O
and	CC	O
are	VBP	O
present	JJ	O
in	IN	O
the	DT	O
cytoplasm	NN	O
and	CC	O
nucleoplasm	NN	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
)	)	O
.	.	O
It	PRP	O
appears	VBZ	O
that	IN	O
individual	JJ	O
Gemins	NNP	O
of	IN	O
the	DT	O
SMN	NNP	O
complex	JJ	O
interact	NN	O
with	IN	O
distinct	JJ	O
sets	NNS	O
of	IN	O
Sm	NNP	O
proteins	NNS	O
indicating	VBG	O
that	IN	O
multiple	JJ	O
contacts	NNS	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
important	JJ	O
for	IN	O
the	DT	O
function	NN	O
of	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
in	IN	O
snRNP	NN	O
core	NN	O
assembly	NN	O
(	(	O
Baccon	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
31957-31962	JJ	I
)	)	O
.	.	O
The	DT	O
SMN	NNP	O
complex	NN	O
was	VBD	O
found	VBN	O
to	TO	O
function	VB	O
as	IN	O
a	DT	O
specificity	NN	O
factor	NN	O
for	IN	O
the	DT	O
assembly	NN	O
of	IN	O
spliceosomal	JJ	O
snRNP	NN	O
,	,	O
ensuring	VBG	O
that	IN	O
Sm	NNP	O
cores	NNS	O
are	VBP	O
only	RB	O
formed	VBN	O
on	IN	O
the	DT	O
correct	JJ	O
RNA	NNP	O
molecules	NNS	O
(	(	O
Pellizzoni	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
298	CD	I
,	,	I
1775-1779	JJ	I
)	)	O
.	.	O
Gemin2	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
SIP1	NNP	O
,	,	O
SMP-interacting	NNP	O
protein	NN	O
1	CD	O
,	,	O
and	CC	O
survival	NN	O
of	IN	O
motor	NN	O
neuron	NN	O
protein	NN	O
interacting	VBG	O
protein	RB	O
1	CD	O
)	)	O
was	VBD	O
isolated	VBN	O
in	IN	O
a	DT	O
yeast	JJ	O
two-hybrid	JJ	O
screen	NN	O
of	IN	O
a	DT	O
HeLa	NNP	O
cell	NN	O
library	NN	O
using	VBG	O
SMN	NNP	O
as	IN	O
bait	NN	O
.	.	O
These	DT	O
proteins	NNS	O
were	VBD	O
tightly	RB	O
associated	VBN	O
and	CC	O
colocalized	VBN	O
to	TO	O
Gems	NNP	O
,	,	O
prompting	VBG	O
a	DT	O
search	NN	O
for	IN	O
other	JJ	O
protein	JJ	O
components	NNS	O
of	IN	O
the	DT	O
complex	NN	O
.	.	O
The	DT	O
SMN/Gemin2	NNP	O
pair	NN	O
was	VBD	O
found	VBN	O
to	TO	O
interact	VB	O
directly	RB	O
with	IN	O
several	JJ	O
of	IN	O
the	DT	O
snRNP	JJ	O
Sm	NNP	O
core	NN	O
proteins	NNS	O
(	(	O
Liu	NNP	B
et	RB	I
al.	RB	I
,	,	I
Cell	NNP	I
,	,	I
1997	CD	I
,	,	I
90	CD	I
,	,	I
1013-1021	JJ	I
)	)	O
.	.	O
Further	RB	O
implicating	VBG	O
the	DT	O
pair	NN	O
in	IN	O
snRNP	JJ	O
biogenesis	NN	O
,	,	O
the	DT	O
SMN/Gemin2	NNP	O
complex	NN	O
associated	VBN	O
with	IN	O
spliceosomal	JJ	O
snRNAs	NN	O
U1	NNP	O
and	CC	O
U5	NNP	O
in	IN	O
the	DT	O
cytoplasm	NN	O
of	IN	O
Xenopus	NNP	O
oocytes	NNS	O
,	,	O
and	CC	O
antibodies	NNS	O
against	IN	O
Gemin2	NNP	O
inhibited	VBD	O
Sm	NNP	O
core	NN	O
assembly	NN	O
of	IN	O
the	DT	O
spliceosomal	JJ	O
snRNPs	NN	O
U1	NNP	O
,	,	O
U2	NNP	O
,	,	O
U4	NNP	O
,	,	O
and	CC	O
U5	NNP	O
and	CC	O
their	PRP$	O
transport	NN	O
to	TO	O
the	DT	O
nucleus	NN	O
(	(	O
Fischer	NNP	B
et	RB	I
al.	RB	I
,	,	I
Cell	NNP	I
,	,	I
1997	CD	I
,	,	I
90	CD	I
,	,	I
1023-1029	JJ	I
)	)	O
.	.	O
Together	RB	O
with	IN	O
Gemin2	NNP	O
,	,	O
Gemin3	NNP	O
and	CC	O
Gemin4	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
GIP1	NNP	O
or	CC	O
gem-associated	JJ	O
protein	NN	O
4	CD	O
)	)	O
were	VBD	O
also	RB	O
found	VBN	O
to	TO	O
complex	VB	O
with	IN	O
SMN	NNP	O
and	CC	O
snRNP	JJ	O
proteins	NNS	O
(	(	O
Charroux	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
1999	CD	I
,	,	I
147	CD	I
,	,	I
1181-1194	CD	I
;	:	O
Charroux	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2000	CD	I
,	,	I
148	CD	I
,	,	I
1177-1186	JJ	I
)	)	O
.	.	O
Gemin3	NNP	O
was	VBD	O
the	DT	O
only	JJ	O
protein	NN	O
of	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
that	WDT	O
bound	VBZ	O
specifically	RB	O
to	TO	O
GST-Gemin4	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
presence	NN	O
of	IN	O
Gemin4	NNP	O
in	IN	O
the	DT	O
complex	NN	O
is	VBZ	O
a	DT	O
result	NN	O
of	IN	O
its	PRP$	O
direct	JJ	O
interaction	NN	O
with	IN	O
Gemin3	NNP	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
SMN	NNP	O
.	.	O
The	DT	O
direct	JJ	O
and	CC	O
avid	JJ	O
interaction	NN	O
of	IN	O
Gemin4	NNP	O
with	IN	O
the	DT	O
DEAD/H	NNP	O
box-containing	JJ	O
helicase	NN	O
protein	NN	O
Gemin3	NNP	O
may	MD	O
indicate	VB	O
that	IN	O
they	PRP	O
function	VBP	O
together	RB	O
.	.	O
Gemin4	NNP	O
also	RB	O
interacts	VBZ	O
with	IN	O
several	JJ	O
of	IN	O
the	DT	O
core	NN	O
Sm	NNP	O
proteins	VBZ	O
,	,	O
and	CC	O
co-localizes	NNS	O
with	IN	O
SMN	NNP	O
to	TO	O
gems	VB	O
.	.	O
Gemin4	NNP	O
localizes	VBZ	O
to	TO	O
the	DT	O
nucleolus	NN	O
,	,	O
potentially	RB	O
indicating	VBG	O
additional	JJ	O
functions	NNS	O
in	IN	O
ribosome	JJ	O
biogenesis	NN	O
(	(	O
Charroux	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2000	CD	I
,	,	I
148	CD	I
,	,	I
1177-1186	JJ	I
)	)	O
.	.	O
Gemin4	NNP	O
proteins	NNS	O
are	VBP	O
found	VBN	O
predominantly	RB	O
in	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
,	,	O
however	RB	O
,	,	O
a	DT	O
less	RBR	O
abundant	JJ	O
Gemin3-Gemin4	NNP	O
complex	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
found	VBN	O
(	(	O
Charroux	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2000	CD	I
,	,	I
148	CD	I
,	,	I
1177-1186	CD	I
;	:	O
Mourelatos	NNP	B
et	FW	I
al.	NN	I
,	,	I
Genes	NNP	I
&	CC	I
Development	NNP	I
,	,	I
2002	CD	I
,	,	I
16	CD	I
,	,	I
720-728	JJ	I
)	)	O
.	.	O
Immunoprecipitation	NN	O
studies	NNS	O
showed	VBD	O
that	IN	O
Gemin3	NNP	O
and	CC	O
Gemin4	NNP	O
are	VBP	O
associated	VBN	O
in	IN	O
a	DT	O
complex	JJ	O
with	IN	O
eIF2c2	NN	O
,	,	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
large	JJ	O
Argonaute	NNP	O
family	NN	O
of	IN	O
proteins	NNS	O
,	,	O
members	NNS	O
of	IN	O
which	WDT	O
have	VBP	O
been	VBN	O
implicated	VBN	O
in	IN	O
RNA	NNP	O
interference	NN	O
(	(	O
RNAi	NNP	O
)	)	O
mechanisms	NN	O
and	CC	O
developmental	JJ	O
regulation	NN	O
by	IN	O
short	JJ	O
temporal	JJ	O
RNAs	NNP	O
(	(	O
stRNAs	NN	O
)	)	O
.	.	O
The	DT	O
complex	NN	O
,	,	O
a	DT	O
miRNP	NN	O
,	,	O
also	RB	O
contained	VBN	O
RNAs	NNP	O
about	IN	O
22	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
microRNAs	VB	O
(	(	O
miRNAs	NN	O
)	)	O
.	.	O
40	CD	O
miRNAs	NNS	O
were	VBD	O
captured	VBN	O
in	IN	O
these	DT	O
studies	NNS	O
(	(	O
Mourelatos	NNP	B
et	RB	I
al.	RB	I
,	,	I
Genes	NNP	I
&	CC	I
Development	NNP	I
,	,	I
2002	CD	I
,	,	I
16	CD	I
,	,	I
720-728	JJ	I
)	)	O
.	.	O
Monoclonal	JJ	O
antibodies	NNS	O
to	TO	O
either	DT	O
Gemin3	NNP	O
or	CC	O
Gemin4	NNP	O
immunoprecipitated	VBD	O
let-7-programmed	JJ	O
RNA-induced	JJ	O
silencing	NN	O
complex	NN	O
(	(	O
RISC	NNP	O
)	)	O
activity	NN	O
,	,	O
leading	VBG	O
to	TO	O
the	DT	O
notion	NN	O
that	IN	O
the	DT	O
Gemin4-containing	NNP	O
miRNP	NN	O
may	MD	O
be	VB	O
the	DT	O
human	JJ	O
RISC	NNP	O
which	WDT	O
can	MD	O
carry	VB	O
out	RP	O
both	DT	O
target	NN	O
cleavage	NN	O
in	IN	O
the	DT	O
RNAi	NNP	O
pathway	NN	O
and	CC	O
translational	JJ	O
control	NN	O
in	IN	O
the	DT	O
miRNA	NN	O
pathway	NN	O
(	(	O
Hutvagner	NNP	B
and	CC	I
Zamore	NNP	I
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
297	CD	I
,	,	I
2056-2060	JJ	I
)	)	O
.	.	O
In	IN	O
a	DT	O
yeast-two	JJ	O
hybrid	JJ	O
assay	NN	O
,	,	O
Gemin4	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
interact	VB	O
with	IN	O
galectin-1	JJ	O
and	CC	O
galectin-3	JJ	O
,	,	O
nuclear-localized	JJ	O
proteins	NNS	O
that	WDT	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
required	VBN	O
factors	NNS	O
for	IN	O
splicing	VBG	O
in	IN	O
a	DT	O
cell-free	JJ	O
assay	NN	O
.	.	O
This	DT	O
interaction	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
functionally	RB	O
relevant	JJ	O
in	IN	O
the	DT	O
splicing	NN	O
pathway	NN	O
(	(	O
Park	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res.	NNP	I
,	,	I
2001	CD	I
,	,	I
29	CD	I
,	,	I
3595-3602	JJ	I
)	)	O
.	.	O
Gemin5	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
DKFZP586M1824	NNP	O
protein	NN	O
;	:	O
gem-associated	JJ	O
protein	NN	O
5	CD	O
)	)	O
was	VBD	O
found	VBN	O
by	IN	O
coimmunoprecipitation	NN	O
of	IN	O
proteins	NNS	O
that	WDT	O
associate	VBP	O
with	IN	O
SMN	NNP	O
in	IN	O
vivo	NN	O
.	.	O
Like	IN	O
SMN	NNP	O
,	,	O
Gemin5	NNP	O
is	VBZ	O
localized	VBN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
,	,	O
nucleoplasm	NN	O
,	,	O
and	CC	O
is	VBZ	O
highly	RB	O
enriched	VBN	O
in	IN	O
the	DT	O
nuclear	JJ	O
gems	NNS	O
.	.	O
It	PRP	O
binds	VBZ	O
to	TO	O
SMN	VB	O
by	IN	O
direct	JJ	O
protein-protein	JJ	O
interaction	NN	O
in	IN	O
vitro	NN	O
and	CC	O
interacts	NNS	O
with	IN	O
several	JJ	O
of	IN	O
the	DT	O
snRNP	NN	O
core	NN	O
Sm	NNP	O
proteins	VBZ	O
.	.	O
The	DT	O
Gemin5	NNP	O
protein	NN	O
is	VBZ	O
predicted	VBN	O
to	TO	O
contain	VB	O
up	RB	O
to	TO	O
13	CD	O
WD	NNP	O
repeats	NNS	O
in	IN	O
its	PRP$	O
amino-terminal	JJ	O
half	NN	O
,	,	O
and	CC	O
a	DT	O
coiled-coil	NN	O
near	IN	O
its	PRP$	O
carboxyl	NN	O
terminus	NN	O
.	.	O
Because	IN	O
both	DT	O
WD	NNP	O
repeats	NNS	O
and	CC	O
coiled-coil	NN	O
motifs	NNS	O
are	VBP	O
protein-protein	JJ	O
interaction	NN	O
domains	NNS	O
,	,	O
Gemin5	NNP	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
structural	JJ	O
platform	NN	O
for	IN	O
protein	NN	O
assembly	NN	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
5631-5636	JJ	I
)	)	O
.	.	O
Extracts	NNS	O
from	IN	O
stable	JJ	O
cell	NN	O
lines	NNS	O
expressing	VBG	O
epitope-tagged	JJ	O
SMN	NNP	O
or	CC	O
Gemin2	NNP	O
proteins	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
immunoprecipitation	NN	O
with	IN	O
an	DT	O
antibody	NN	O
recognizing	VBG	O
the	DT	O
epitope	NN	O
.	.	O
Both	DT	O
tagged-proteins	NNS	O
were	VBD	O
isolated	VBN	O
with	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
which	WDT	O
was	VBD	O
found	VBN	O
to	TO	O
contain	VB	O
additional	JJ	O
previously	RB	O
unidentified	JJ	O
proteins	NNS	O
including	VBG	O
Gemin6	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
GEM-associated	NNP	O
protein	NN	O
6	CD	O
or	CC	O
hypothetical	JJ	O
protein	NN	O
FLJ23459	NNP	O
)	)	O
.	.	O
Database	NNP	O
searches	NNS	O
revealed	VBD	O
that	IN	O
Gemin6	NNP	O
is	VBZ	O
not	RB	O
significantly	RB	O
homologous	JJ	O
to	TO	O
other	JJ	O
proteins	NNS	O
and	CC	O
contains	VBZ	O
no	DT	O
common	JJ	O
motifs	NNS	O
which	WDT	O
may	MD	O
be	VB	O
indicative	JJ	O
of	IN	O
function	NN	O
.	.	O
Like	IN	O
the	DT	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
,	,	O
Gemin6	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
interact	VB	O
with	IN	O
several	JJ	O
Sm	NNP	O
proteins	NNS	O
(	(	O
Baccon	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
31957-31962	JJ	I
)	)	O
.	.	O
The	DT	O
Gemin6	NNP	O
localization	NN	O
is	VBZ	O
similar	JJ	O
to	TO	O
the	DT	O
other	JJ	O
components	NNS	O
of	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
,	,	O
but	CC	O
direct	JJ	O
interaction	NN	O
of	IN	O
Gemin6	NNP	O
with	IN	O
SMN	NNP	O
,	,	O
Gemin2	NNP	O
,	,	O
Gemin3	NNP	O
,	,	O
Gemin4	NNP	O
or	CC	O
Gemin5	NNP	O
was	VBD	O
not	RB	O
detectable	JJ	O
(	(	O
Pellizzoni	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
7540-7545	JJ	I
)	)	O
.	.	O
However	RB	O
,	,	O
Gemin7	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
hypothetical	JJ	O
protein	NN	O
FLJ13956	NNP	O
)	)	O
,	,	O
also	RB	O
identified	VBN	O
using	VBG	O
the	DT	O
epitope-tagged	JJ	O
system	NN	O
to	TO	O
purify	VB	O
SMN	NNP	O
complexes	NNS	O
,	,	O
was	VBD	O
shown	VBN	O
to	TO	O
bind	VB	O
directly	RB	O
to	TO	O
Gemin6	NNP	O
and	CC	O
SMN	NNP	O
in	IN	O
vitro	NN	O
,	,	O
therefore	IN	O
it	PRP	O
likely	JJ	O
mediates	VBZ	O
the	DT	O
association	NN	O
of	IN	O
Gemin6	NNP	O
with	IN	O
the	DT	O
SMN	NNP	O
complex	NN	O
.	.	O
Like	IN	O
Gemin6	NNP	O
,	,	O
Gemin7	NNP	O
does	VBZ	O
not	RB	O
contain	VB	O
any	DT	O
known	JJ	O
motifs	NNS	O
that	WDT	O
may	MD	O
suggest	VB	O
possible	JJ	O
functions	NNS	O
,	,	O
but	CC	O
it	PRP	O
does	VBZ	O
interact	VB	O
with	IN	O
a	DT	O
subset	NN	O
of	IN	O
the	DT	O
Sm	NNP	O
proteins	NNS	O
.	.	O
Like	IN	O
the	DT	O
other	JJ	O
complex	JJ	O
members	NNS	O
,	,	O
Gemin7	NNP	O
colocalizes	VBZ	O
with	IN	O
SMN	NNP	O
in	IN	O
gems	NNS	O
(	(	O
Baccon	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
31957-31962	JJ	I
)	)	O
.	.	O
Beyond	IN	O
interactions	NNS	O
with	IN	O
Sm	NNP	O
proteins	NNS	O
and	CC	O
snRNAs	NN	O
,	,	O
the	DT	O
SMN	NNP	O
complex	JJ	O
interacts	NNS	O
directly	RB	O
with	IN	O
several	JJ	O
protein	NNS	O
targets	NNS	O
that	WDT	O
are	VBP	O
components	NNS	O
of	IN	O
RNPs	NNP	O
which	WDT	O
function	NN	O
in	IN	O
various	JJ	O
aspects	NNS	O
of	IN	O
RNA	NNP	O
metabolism	NN	O
.	.	O
Among	IN	O
these	DT	O
substrates	NNS	O
are	VBP	O
the	DT	O
Sm-like	NNP	O
(	(	O
Lsm	NNP	O
)	)	O
proteins	VBZ	O
of	IN	O
the	DT	O
snRNPs	NN	O
,	,	O
also	RB	O
essential	JJ	O
components	NNS	O
of	IN	O
the	DT	O
splicing	JJ	O
machinery	NN	O
(	(	O
Friesen	NNP	B
and	CC	I
Dreyfuss	NNP	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2000	CD	I
,	,	I
275	CD	I
,	,	I
26370-26375	JJ	I
)	)	O
.	.	O
Fibrillarin	NNP	O
and	CC	O
GAR1	NNP	O
,	,	O
components	NNS	O
of	IN	O
small	JJ	O
nucleolar	JJ	O
RNPs	NNP	O
(	(	O
snoRNPs	NN	O
)	)	O
,	,	O
also	RB	O
interact	JJ	O
with	IN	O
SMN	NNP	O
.	.	O
Fibrillarin	NNP	O
is	VBZ	O
a	DT	O
marker	NN	O
for	IN	O
Box	NNP	O
C/D	NNP	O
snoRNPs	NN	O
,	,	O
the	DT	O
class	NN	O
that	WDT	O
is	VBZ	O
necessary	JJ	O
for	IN	O
cleavage	NN	O
and	CC	O
site-specific	JJ	O
methylation	NN	O
of	IN	O
rRNA	NN	O
.	.	O
Box	NNP	O
H/ACA	NNP	O
snoRNPs	NN	O
contain	NN	O
GAR1	NNP	O
and	CC	O
guide	VB	O
the	DT	O
pseudouridylation	NN	O
of	IN	O
rRNA	NN	O
(	(	O
Pellizzoni	NNP	B
et	RB	I
al.	RB	I
,	,	I
Curr	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
2001	CD	I
,	,	I
11	CD	I
,	,	I
1079-1088	JJ	I
)	)	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
SMN	NNP	O
complex	NN	O
also	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
snoRNP	JJ	O
biogenesis	NN	O
(	(	O
Jones	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38645-38651	CD	I
;	:	O
Pellizzoni	NNP	B
et	FW	I
al.	NN	I
,	,	I
Curr	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
2001	CD	I
,	,	I
11	CD	I
,	,	I
1079-1088	JJ	I
)	)	O
.	.	O
Additional	JJ	O
SMN	NNP	O
complex	NN	O
substrates	NNS	O
are	VBP	O
hnRNP	JJ	O
U	NNP	O
and	CC	O
Q	NNP	O
,	,	O
RNA	NNP	O
helicase	VBD	O
A	NNP	O
,	,	O
and	CC	O
Epstein-Barr	NNP	O
virus	NN	O
nuclear	JJ	O
antigen	NN	O
2	CD	O
(	(	O
EBNA2	NNP	O
)	)	O
,	,	O
coilin	NN	O
,	,	O
and	CC	O
nucleolin	NN	O
(	(	O
Barth	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Virol.	NNP	I
,	,	I
2003	CD	I
,	,	I
77	CD	I
,	,	I
5008-5013	JJ	I
;	:	O
Gubitz	NNP	B
et	FW	I
al.	NN	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
;	:	O
Liu	NNP	B
and	CC	I
Dreyfuss	NNP	I
,	,	I
Embo	NNP	I
J.	NNP	I
,	,	I
1996	CD	I
,	,	I
15	CD	I
,	,	I
3555-3565	CD	I
;	:	O
Mourelatos	NNP	B
et	FW	I
al.	NN	I
,	,	I
Genes	NNP	I
&	CC	I
Development	NNP	I
,	,	I
2002	CD	I
,	,	I
16	CD	I
,	,	I
720-728	CD	I
;	:	O
Yong	NNP	B
et	FW	I
al.	NN	I
,	,	I
Trends	NNP	I
Cell	NNP	I
Biol.	NNP	I
,	,	I
2004	CD	I
,	,	I
14	CD	I
,	,	I
226-232	JJ	I
)	)	O
.	.	O
Because	IN	O
most	JJS	O
SMN	NNP	O
complex	JJ	O
substrates	NNS	O
are	VBP	O
components	NNS	O
of	IN	O
various	JJ	O
RNP	NNP	O
complexes	NNS	O
involved	VBN	O
in	IN	O
RNA	NNP	O
processing	NN	O
,	,	O
the	DT	O
SMN	NNP	O
complex	NN	O
may	MD	O
take	VB	O
part	NN	O
in	IN	O
many	JJ	O
aspects	NNS	O
of	IN	O
cellular	JJ	O
RNA	NNP	O
metabolism	NN	O
(	(	O
Gubitz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2004	CD	I
,	,	I
296	CD	I
,	,	I
51-56	JJ	I
)	)	O
.	.	O
Disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,646,113	CD	O
is	VBZ	O
an	DT	O
antisense	NN	O
isolated	VBD	O
nucleic	JJ	O
acid	JJ	O
complementary	NN	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
human	JJ	O
Survival	NN	O
of	IN	O
Motor	NNP	O
Neuron-Interacting	NNP	O
Protein	NNP	O
1	CD	O
,	,	O
wherein	NN	O
said	VBD	O
nucleic	JJ	O
acid	NN	O
encodes	VBZ	O
a	DT	O
protein	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
disclosed	VBN	O
by	IN	O
a	DT	O
mutation	NN	O
that	IN	O
inhibits	VBZ	O
binding	NN	O
of	IN	O
the	DT	O
Survival	NNP	O
of	IN	O
Motor	NNP	O
Neuron	NNP	O
protein	NN	O
,	,	O
and	CC	O
further	RB	O
wherein	NN	O
said	VBD	O
mutation	NN	O
is	VBZ	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
a	DT	O
deletion	NN	O
of	IN	O
the	DT	O
carboxyl	JJ	O
terminal	JJ	O
89	CD	O
amino	JJ	O
acids	NNS	O
relative	VBP	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
disclosed	VBD	O
therein	NNS	O
and	CC	O
a	DT	O
deletion	NN	O
of	IN	O
the	DT	O
carboxyl	JJ	O
terminal	JJ	O
162	CD	O
amino	JJ	O
acids	NNS	O
relative	VBP	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
disclosed	VBD	O
therein	RB	O
.	.	O
Also	RB	O
disclosed	VBN	O
are	VBP	O
antisense	JJ	O
oligomers	NNS	O
of	IN	O
between	IN	O
about	IN	O
10	CD	O
to	TO	O
about	IN	O
30	CD	O
,	,	O
and	CC	O
more	JJR	O
preferrably	RB	O
about	IN	O
15	CD	O
nucleotides	NNS	O
(	(	O
Dreyfuss	NNP	B
et	RB	I
al.	RB	I
,	,	I
2003	CD	I
)	)	O
.	.	O
U.S.	NNP	O
pregrant	JJ	O
publication	NN	O
20030228617	CD	O
discloses	VBZ	O
a	DT	O
kit	NN	O
comprising	VBG	O
a	DT	O
plurality	NN	O
of	IN	O
oligonucleotide	JJ	O
primers	NNS	O
and	CC	O
instructions	NNS	O
for	IN	O
employing	VBG	O
the	DT	O
plurality	NN	O
of	IN	O
oligonucleotide	JJ	O
primers	NNS	O
to	TO	O
determine	VB	O
the	DT	O
expression	NN	O
level	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
genes	NNS	O
represented	VBN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
sequences	NNS	O
,	,	O
said	VBD	O
group	NN	O
including	VBG	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
partial	JJ	O
cDNA	NN	O
and	CC	O
a	DT	O
full-length	JJ	O
cDNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
human	JJ	O
survival	NN	O
of	IN	O
motor	NN	O
neuron	NN	O
protein	NN	O
interacting	VBG	O
protein	JJ	O
1	CD	O
(	(	O
SIP1	NNP	O
)	)	O
gene	NN	O
(	(	O
Aune	NNP	B
and	CC	I
Olsen	NNP	I
,	,	I
2003	CD	I
)	)	O
.	.	O
The	DT	O
role	NN	O
of	IN	O
Gemin2	NNP	O
,	,	O
Gemin4	NNP	O
,	,	O
Gemin5	NNP	O
,	,	O
Gemin6	NNP	O
,	,	O
and	CC	O
Gemin7	NNP	O
in	IN	O
RNA	NNP	O
metabolism	NN	O
makes	VBZ	O
these	DT	O
attractive	JJ	O
targets	NNS	O
for	IN	O
therapeutic	JJ	O
and	CC	O
investigative	JJ	O
strategies	NNS	O
aimed	VBN	O
at	IN	O
antisense	JJ	O
technology	NN	O
.	.	O
Consequently	RB	O
,	,	O
there	EX	O
remains	VBZ	O
a	DT	O
need	NN	O
for	IN	O
agents	NNS	O
capable	JJ	O
of	IN	O
effectively	RB	O
modulating	VBG	O
Gemin2	NNP	O
,	,	O
Gemin4	NNP	O
,	,	O
Gemin5	NNP	O
,	,	O
Gemin6	NNP	O
,	,	O
and	CC	O
Gemin7	NNP	O
function	NN	O
.	.	O
Antisense	NNP	O
technology	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
means	NNS	O
for	IN	O
reducing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
specific	JJ	O
gene	NN	O
products	NNS	O
and	CC	O
can	MD	O
therefore	VB	O
prove	VB	O
to	TO	O
be	VB	O
uniquely	RB	O
useful	JJ	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
therapeutic	JJ	O
,	,	O
diagnostic	JJ	O
,	,	O
and	CC	O
research	NN	O
applications	NNS	O
.	.	O
Consequently	RB	O
,	,	O
there	EX	O
remains	VBZ	O
a	DT	O
long-felt	JJ	O
need	NN	O
for	IN	O
agents	NNS	O
that	WDT	O
specifically	RB	O
regulate	VBP	O
gene	NN	O
expression	NN	O
via	IN	O
antisense	JJ	O
mechanisms	NNS	O
.	.	O
Disclosed	VBN	O
herein	NNS	O
are	VBP	O
antisense	JJ	O
compounds	NNS	O
useful	JJ	O
for	IN	O
modulating	VBG	O
gene	NN	O
expression	NN	O
pathways	NNS	O
,	,	O
including	VBG	O
those	DT	O
relying	VBG	O
on	IN	O
mechanisms	NNS	O
of	IN	O
action	NN	O
such	JJ	O
as	IN	O
RNaseH	NNP	O
,	,	O
RNAi	NNP	O
and	CC	O
dsRNA	JJ	O
enzymes	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
antisense	NN	O
mechanisms	NNS	O
based	VBN	O
on	IN	O
target	NN	O
degradation	NN	O
or	CC	O
target	NN	O
occupancy	NN	O
.	.	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
once	RB	O
armed	VBN	O
with	IN	O
this	DT	O
disclosure	NN	O
will	MD	O
be	VB	O
able	JJ	O
,	,	O
without	IN	O
undue	JJ	O
experimentation	NN	O
,	,	O
to	TO	O
identify	VB	O
,	,	O
prepare	VB	O
and	CC	O
exploit	VB	O
antisense	NN	O
compounds	NNS	O
for	IN	O
these	DT	O
uses	NNS	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Provided	NNP	O
herein	NN	O
are	VBP	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
especially	RB	O
antisense	JJ	O
nucleic	JJ	O
acid	NN	O
and	CC	O
nucleic	JJ	O
acid-like	JJ	O
oligomers	NNS	O
,	,	O
e.g.	NN	O
,	,	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
which	WDT	O
are	VBP	O
targeted	VBN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
and	CC	O
which	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Gemin	NNP	O
Genes	NNP	O
disclosed	VBD	O
herein	NNS	O
include	VBP	O
Gemin2	NNP	O
,	,	O
Gemin4	NNP	O
,	,	O
Gemin5	NNP	O
,	,	O
Gemin6	NNP	O
,	,	O
Gemin7	NNP	O
.	.	O
Also	RB	O
disclosed	VBN	O
are	VBP	O
pharmaceutical	JJ	O
compositions	NNS	O
including	VBG	O
said	VBD	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
said	VBD	O
oligomeric	JJ	O
compounds	NNS	O
to	TO	O
modulate	VB	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
from	IN	O
,	,	O
e.g.	NN	O
,	,	O
13	CD	O
to	TO	O
30	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
targeted	VBN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
e.g.	RB	O
,	,	O
Gemin2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
7	CD	O
)	)	O
,	,	O
wherein	NN	O
said	VBD	O
oligomeric	JJ	O
compound	NN	O
specifically	RB	O
hybridizes	VBZ	O
with	IN	O
said	VBD	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
the	DT	O
Gemin	NNP	O
Gene	NNP	O
and	CC	O
inhibits	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
is	VBZ	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
is	VBZ	O
an	DT	O
antisense	JJ	O
oligonucleotide	NN	O
.	.	O
The	DT	O
oligomeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
chimeric	JJ	O
and	CC	O
include	VBP	O
at	IN	O
least	JJS	O
one	CD	O
modified	VBN	O
internucleoside	JJ	O
linkage	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
phosphorothioate	NN	O
internucleoside	JJ	O
linkage	NN	O
;	:	O
and/or	CC	O
at	IN	O
least	JJS	O
one	CD	O
modified	VBN	O
sugar	NN	O
moiety	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
2′-O-methoxyethyl	JJ	O
sugar	NN	O
moiety	NN	O
,	,	O
and/or	NN	O
at	IN	O
least	JJS	O
one	CD	O
modified	JJ	O
nucleobase	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
5-methylcytosine	JJ	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
is	VBZ	O
an	DT	O
antisense	NN	O
,	,	O
chimeric	JJ	O
oligonucleotide	RB	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
and	CC	O
includes	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
phosphorothioate	NN	O
internucleoside	NN	O
linkage	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
2′-O-methoxyethyl	JJ	O
sugar	NN	O
moiety	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
5-methylcytosine	JJ	O
.	.	O
Pharmaceutical	NNP	O
,	,	O
therapeutic	JJ	O
and	CC	O
other	JJ	O
compositions	NNS	O
comprising	VBG	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
also	RB	O
provided	VBN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
composition	NN	O
that	WDT	O
includes	VBZ	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
,	,	O
e.g.	NN	O
,	,	O
colloidal	JJ	O
dispersion	NN	O
system	NN	O
,	,	O
or	CC	O
diluent	NN	O
.	.	O
Further	RB	O
provided	VBN	O
are	VBP	O
methods	NNS	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
e.g.	RB	O
,	,	O
Gemin2	NNP	O
,	,	O
in	IN	O
cells	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
comprising	VBG	O
contacting	NN	O
said	VBD	O
cells	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
methods	NNS	O
are	VBP	O
performed	VBN	O
in	IN	O
vitro	NN	O
.	.	O
Methods	NNS	O
of	IN	O
treating	VBG	O
an	DT	O
animal	NN	O
,	,	O
particularly	RB	O
a	DT	O
human	JJ	O
,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
or	CC	O
at	IN	O
risk	NN	O
for	IN	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
associated	VBN	O
with	IN	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
are	VBP	O
also	RB	O
set	VBN	O
forth	NN	O
herein	NN	O
.	.	O
Such	JJ	O
methods	NNS	O
include	VBP	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
or	CC	O
prophylactically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
an	DT	O
animal	NN	O
,	,	O
particularly	RB	O
a	DT	O
human	NN	O
.	.	O
Further	RB	O
provided	VBN	O
are	VBP	O
methods	NNS	O
of	IN	O
identifying	VBG	O
the	DT	O
relationship	NN	O
between	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
and	CC	O
a	DT	O
disease	NN	O
state	NN	O
,	,	O
phenotype	NN	O
,	,	O
or	CC	O
condition	NN	O
by	IN	O
detecting	VBG	O
or	CC	O
modulating	VBG	O
said	VBD	O
Gemin	NNP	O
Gene	NNP	O
comprising	VBG	O
contacting	VBG	O
a	DT	O
sample	NN	O
,	,	O
tissue	NN	O
,	,	O
cell	NN	O
,	,	O
or	CC	O
organism	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
measuring	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
protein	JJ	O
level	NN	O
of	IN	O
said	VBD	O
Gemin	NNP	O
Gene	NNP	O
and/or	VBD	O
a	DT	O
related	JJ	O
phenotypic	NN	O
or	CC	O
chemical	NN	O
endpoint	NN	O
coincident	NN	O
with	IN	O
or	CC	O
at	IN	O
some	DT	O
time	NN	O
after	IN	O
treatment	NN	O
,	,	O
and	CC	O
optionally	RB	O
comparing	VBG	O
the	DT	O
measured	VBN	O
value	NN	O
to	TO	O
a	DT	O
non-treated	JJ	O
sample	NN	O
or	CC	O
sample	NN	O
treated	VBN	O
with	IN	O
a	DT	O
further	JJ	O
compound	NN	O
.	.	O
Further	RB	O
provided	VBN	O
are	VBP	O
methods	NNS	O
of	IN	O
screening	VBG	O
for	IN	O
modulators	NNS	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
by	IN	O
contacting	VBG	O
a	DT	O
target	NN	O
segment	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
said	VBD	O
Gemin	NNP	O
Gene	NNP	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	JJ	O
modulators	NNS	O
,	,	O
and	CC	O
selecting	VBG	O
for	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	NN	O
modulators	NNS	O
which	WDT	O
decrease	VBP	O
or	CC	O
increase	VB	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
said	VBD	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Also	RB	O
provided	VBN	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
conditions	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
target	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Further	RB	O
contemplated	VBN	O
are	VBP	O
methods	NNS	O
where	WRB	O
cells	NNS	O
or	CC	O
tissues	NNS	O
are	VBP	O
contacted	VBN	O
in	IN	O
vivo	NN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
disclosed	JJ	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
.	.	O
Also	RB	O
provided	VBN	O
are	VBP	O
ex	JJ	O
vivo	JJ	O
methods	NNS	O
of	IN	O
treatment	NN	O
that	WDT	O
include	VBP	O
contacting	VBG	O
cells	NNS	O
or	CC	O
tissues	NNS	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
then	RB	O
introducing	VBG	O
said	VBD	O
cells	NNS	O
or	CC	O
tissues	NNS	O
into	IN	O
an	DT	O
animal	NN	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Overview	NNP	O
Disclosed	VBD	O
herein	NNS	O
are	VBP	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
including	VBG	O
antisense	NN	O
oligonucleotides	NNS	O
and	CC	O
other	JJ	O
antisense	NN	O
compounds	NNS	O
for	IN	O
use	NN	O
in	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
e.g.	RB	O
,	,	O
Gemin2	NNP	O
,	,	O
Gemin4	NNP	O
,	,	O
Gemin5	NNP	O
,	,	O
Gemin6	NNP	O
,	,	O
Gemin7	NNP	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
This	DT	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
providing	VBG	O
oligomeric	JJ	O
compounds	NNS	O
which	WDT	O
hybridize	VBP	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
molecules	NNS	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
”	NN	O
and	CC	O
“	NNP	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
”	NNP	O
have	VBP	O
been	VBN	O
used	VBN	O
for	IN	O
convenience	NN	O
to	TO	O
encompass	VB	O
DNA	NNP	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
RNA	NNP	O
(	(	O
including	VBG	O
pre-mRNA	NN	O
and	CC	O
mRNA	NN	O
or	CC	O
portions	NNS	O
thereof	VBP	O
)	)	O
transcribed	VBN	O
from	IN	O
such	JJ	O
DNA	NNP	O
,	,	O
and	CC	O
also	RB	O
cDNA	VBP	O
derived	VBN	O
from	IN	O
such	JJ	O
RNA	NNP	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
antisense	JJ	O
compounds	NNS	O
,	,	O
e.g.	NN	O
,	,	O
antisense	JJ	O
oligonucleotides	NNS	O
.	.	O
The	DT	O
principle	NN	O
behind	IN	O
antisense	JJ	O
technology	NN	O
is	VBZ	O
that	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
,	,	O
which	WDT	O
hybridizes	VBZ	O
to	TO	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
,	,	O
interferes	VBZ	O
with	IN	O
gene	NN	O
expression	NN	O
activities	NNS	O
such	JJ	O
as	IN	O
transcription	NN	O
or	CC	O
translation	NN	O
.	.	O
This	DT	O
sequence	NN	O
specificity	NN	O
makes	VBZ	O
antisense	JJ	O
compounds	NNS	O
extremely	RB	O
attractive	JJ	O
as	IN	O
tools	NNS	O
for	IN	O
target	NN	O
validation	NN	O
and	CC	O
gene	NN	O
functionalization	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
therapeutics	NNS	O
to	TO	O
selectively	RB	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
disease	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
oligomeric	JJ	O
compound	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polymeric	JJ	O
structure	NN	O
capable	JJ	O
of	IN	O
hybridizing	VBG	O
to	TO	O
a	DT	O
region	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
.	.	O
This	DT	O
term	NN	O
includes	VBZ	O
oligonucleotides	NNS	O
,	,	O
oligonucleosides	NNS	O
,	,	O
oligonucleotide	JJ	O
analogs	NNS	O
,	,	O
oligonucleotide	IN	O
mimetics	NNS	O
and	CC	O
chimeric	JJ	O
combinations	NNS	O
of	IN	O
these	DT	O
.	.	O
Oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
routinely	RB	O
prepared	JJ	O
linearly	RB	O
but	CC	O
can	MD	O
be	VB	O
joined	VBN	O
or	CC	O
otherwise	RB	O
prepared	JJ	O
to	TO	O
be	VB	O
circular	JJ	O
.	.	O
Moreover	RB	O
,	,	O
branched	VBD	O
structures	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
An	DT	O
“	JJ	O
antisense	NN	O
compound	NN	O
”	NN	O
or	CC	O
“	JJ	O
antisense	NN	O
oligomeric	JJ	O
compound	NN	O
”	NN	O
or	CC	O
“	JJ	O
antisense	JJ	O
oligonucleotide	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
that	WDT	O
is	VBZ	O
at	IN	O
least	JJS	O
partially	RB	O
complementary	JJ	O
to	TO	O
the	DT	O
region	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
to	TO	O
which	WDT	O
it	PRP	O
hybridizes	VBZ	O
and	CC	O
modulates	NNS	O
(	(	O
increases	NNS	O
or	CC	O
decreases	NNS	O
)	)	O
its	PRP$	O
expression	NN	O
.	.	O
Consequently	RB	O
,	,	O
while	IN	O
all	DT	O
antisense	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
said	VBD	O
to	TO	O
be	VB	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
not	RB	O
all	DT	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
antisense	JJ	O
compounds	NNS	O
.	.	O
Antisense	NNP	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
chemically	RB	O
modified	VBN	O
or	CC	O
unmodified	VBN	O
.	.	O
Nonlimiting	VBG	O
examples	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
include	VBP	O
primers	NNS	O
,	,	O
probes	NNS	O
,	,	O
antisense	JJ	O
compounds	NNS	O
,	,	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
external	JJ	O
guide	NN	O
sequence	NN	O
(	(	O
EGS	NNP	O
)	)	O
oligonucleotides	VBZ	O
,	,	O
alternate	JJ	O
splicers	NNS	O
,	,	O
and	CC	O
siRNAs	NN	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
these	DT	O
compounds	NNS	O
can	MD	O
be	VB	O
introduced	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
single-stranded	JJ	O
,	,	O
double-stranded	JJ	O
,	,	O
circular	JJ	O
,	,	O
branched	VBD	O
or	CC	O
hairpins	NNS	O
and	CC	O
can	MD	O
contain	VB	O
structural	JJ	O
elements	NNS	O
such	JJ	O
as	IN	O
internal	JJ	O
or	CC	O
terminal	JJ	O
bulges	NNS	O
,	,	O
loops	NNS	O
or	CC	O
mismatches	NNS	O
.	.	O
Oligomeric	JJ	O
double-stranded	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
two	CD	O
strands	NNS	O
hybridized	VBN	O
to	TO	O
form	VB	O
double-stranded	JJ	O
compounds	NNS	O
or	CC	O
a	DT	O
single	JJ	O
strand	NN	O
with	IN	O
sufficient	JJ	O
self	NN	O
complementarity	NN	O
to	TO	O
allow	VB	O
for	IN	O
hybridization	NN	O
and	CC	O
formation	NN	O
of	IN	O
a	DT	O
fully	RB	O
or	CC	O
partially	RB	O
double-stranded	JJ	O
compound	NN	O
.	.	O
Antisense	NNP	O
Mechanisms	NNP	O
Oligomeric	NNP	O
compounds	VBZ	O
that	IN	O
modulate	NN	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
via	IN	O
antisense	NN	O
mechanisms	NNS	O
are	VBP	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
theory	NN	O
,	,	O
antisense	JJ	O
mechanisms	FW	O
fall	NN	O
into	IN	O
two	CD	O
general	JJ	O
non-exclusive	JJ	O
categories	NNS	O
.	.	O
These	DT	O
categories	NNS	O
are	VBP	O
antisense	JJ	O
mechanisms	NNS	O
that	WDT	O
(	(	O
1	CD	O
)	)	O
involve	VBP	O
target	NN	O
degradation	NN	O
and	CC	O
(	(	O
2	CD	O
)	)	O
involve	VB	O
an	DT	O
occupancy-based	JJ	O
mechanism	NN	O
wherein	IN	O
the	DT	O
cellular	JJ	O
machinery	NN	O
is	VBZ	O
stalled	VBN	O
and	CC	O
may	MD	O
or	CC	O
may	MD	O
not	RB	O
involve	VB	O
target	NN	O
degradation	NN	O
component	NN	O
.	.	O
A	DT	O
target	NN	O
degradation	NN	O
mechanism	NN	O
can	MD	O
include	VB	O
an	DT	O
RNase	NNP	O
H	NNP	O
mechanism	NN	O
.	.	O
RNAse	NNP	O
H	NNP	O
is	VBZ	O
a	DT	O
cellular	JJ	O
endonuclease	NN	O
which	WDT	O
cleaves	VBZ	O
the	DT	O
RNA	NNP	O
strand	NN	O
of	IN	O
an	DT	O
RNA	NN	O
:	:	O
DNA	NN	O
duplex	NN	O
.	.	O
It	PRP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
single-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
which	WDT	O
are	VBP	O
“	JJ	O
DNA-like	NNP	O
”	NNP	O
elicit	JJ	O
RNAse	NNP	O
H.	NNP	O
Activation	NNP	O
of	IN	O
RNase	NNP	O
H	NNP	O
,	,	O
therefore	RB	O
,	,	O
results	NNS	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
,	,	O
thereby	RB	O
greatly	RB	O
enhancing	VBG	O
the	DT	O
efficiency	NN	O
of	IN	O
oligonucleotide-mediated	JJ	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
A	DT	O
target	NN	O
degradation	NN	O
mechanism	NN	O
can	MD	O
include	VB	O
RNA	NNP	O
interference	NN	O
(	(	O
RNAi	NNP	O
)	)	O
.	.	O
RNAi	NNP	O
is	VBZ	O
a	DT	O
form	NN	O
of	IN	O
posttranscriptional	JJ	O
gene	NN	O
silencing	VBG	O
that	WDT	O
was	VBD	O
initially	RB	O
defined	VBN	O
in	IN	O
the	DT	O
nematode	NN	O
,	,	O
Caenorhabditis	NNP	O
elegans	VBZ	O
,	,	O
resulting	VBG	O
from	IN	O
exposure	NN	O
to	TO	O
double-stranded	JJ	O
RNA	NNP	O
(	(	O
dsRNA	NN	O
)	)	O
.	.	O
In	IN	O
many	JJ	O
species	NNS	O
the	DT	O
introduction	NN	O
of	IN	O
double-stranded	JJ	O
structures	NNS	O
,	,	O
such	JJ	O
as	IN	O
double-stranded	JJ	O
RNA	NNP	O
(	(	O
dsRNA	NN	O
)	)	O
molecules	NNS	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
induce	VB	O
potent	NN	O
and	CC	O
specific	JJ	O
antisense-mediated	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
a	DT	O
gene	NN	O
or	CC	O
its	PRP$	O
associated	VBN	O
gene	NN	O
products	NNS	O
.	.	O
This	DT	O
phenomenon	NN	O
occurs	VBZ	O
in	IN	O
both	DT	O
plants	NNS	O
and	CC	O
animals	NNS	O
and	CC	O
is	VBZ	O
believed	VBN	O
to	TO	O
have	VB	O
an	DT	O
evolutionary	JJ	O
connection	NN	O
to	TO	O
viral	JJ	O
defense	NN	O
and	CC	O
transposon	NN	O
silencing	NN	O
(	(	O
Guo	NNP	B
and	CC	I
Kempheus	NNP	I
,	,	I
Cell	NNP	I
,	,	I
1995	CD	I
,	,	I
81	CD	I
,	,	I
611-620	JJ	I
;	:	O
Montgomery	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1998	CD	I
,	,	I
95	CD	I
,	,	I
15502-15507	JJ	I
)	)	O
.	.	O
The	DT	O
RNAi	NNP	O
compounds	NNS	O
are	VBP	O
often	RB	O
referred	VBN	O
to	TO	O
as	IN	O
short	JJ	O
interfering	VBG	O
RNAs	NNP	O
or	CC	O
siRNAs	NN	O
.	.	O
Recently	RB	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
it	PRP	O
is	VBZ	O
,	,	O
in	IN	O
fact	NN	O
,	,	O
the	DT	O
single-stranded	JJ	O
RNA	NNP	O
oligomers	NNS	O
of	IN	O
antisense	JJ	O
polarity	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
which	WDT	O
are	VBP	O
the	DT	O
potent	JJ	O
inducers	NNS	O
of	IN	O
RNAi	NNP	O
(	(	O
Tijsterman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
295	CD	I
,	,	I
694-697	JJ	I
)	)	O
.	.	O
Both	DT	O
RNAi	NNP	O
compounds	NNS	O
(	(	O
i.e.	JJ	O
,	,	O
single-	JJ	O
or	CC	O
double-stranded	JJ	O
RNA	NNP	O
or	CC	O
RNA-like	NNP	O
compounds	NNS	O
)	)	O
and	CC	O
single-stranded	JJ	O
RNase	NNP	O
H-dependent	NNP	O
antisense	NN	O
compounds	VBZ	O
bind	IN	O
to	TO	O
their	PRP$	O
RNA	NNP	O
target	NN	O
by	IN	O
base	NN	O
pairing	NN	O
(	(	O
i.e.	FW	O
,	,	O
hybridization	NN	O
)	)	O
and	CC	O
induce	VB	O
site-specific	JJ	O
cleavage	NN	O
of	IN	O
the	DT	O
target	NN	O
RNA	NNP	O
by	IN	O
specific	JJ	O
RNAses	NNP	O
;	:	O
i.e.	NN	O
,	,	O
both	DT	O
work	NN	O
via	IN	O
an	DT	O
antisense	NN	O
mechanism	NN	O
(	(	O
Vickers	NNP	B
et	VBP	I
al.	NN	I
,	,	I
2003	CD	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
278	CD	I
,	,	I
7108-7118	JJ	I
)	)	O
.	.	O
Double-stranded	JJ	O
ribonucleases	NNS	O
(	(	O
dsRNases	NNS	O
)	)	O
such	JJ	O
as	IN	O
those	DT	O
in	IN	O
the	DT	O
RNase	NNP	O
III	NNP	O
and	CC	O
ribonuclease	VB	O
L	NNP	O
family	NN	O
of	IN	O
enzymes	NNS	O
have	VBP	O
been	VBN	O
postulated	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
RNA	NNP	O
target	NN	O
degradation	NN	O
.	.	O
Double-stranded	JJ	O
ribonucleases	NNS	O
and	CC	O
oligomeric	JJ	O
compounds	NNS	O
that	WDT	O
trigger	VBP	O
them	PRP	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,898,031	CD	O
and	CC	O
6,107,094	CD	O
.	.	O
Nonlimiting	VBG	O
examples	NNS	O
of	IN	O
an	DT	O
occupancy	NN	O
based	VBN	O
mechanism	NN	O
include	VBP	O
inhibition	NN	O
of	IN	O
translation	NN	O
,	,	O
modulation	NN	O
of	IN	O
splicing	NN	O
,	,	O
modulation	NN	O
of	IN	O
poly	NN	O
(	(	O
A	NNP	O
)	)	O
site	NN	O
selection	NN	O
and	CC	O
disruption	NN	O
of	IN	O
regulatory	JJ	O
RNA	NNP	O
structure	NN	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
controlling	VBG	O
the	DT	O
behavior	NN	O
of	IN	O
a	DT	O
cell	NN	O
through	IN	O
modulation	NN	O
of	IN	O
the	DT	O
processing	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
target	NN	O
by	IN	O
contacting	VBG	O
the	DT	O
cell	NN	O
with	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
acting	VBG	O
via	IN	O
such	PDT	O
a	DT	O
mechanism	NN	O
is	VBZ	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,210,892	CD	O
and	CC	O
U.S.	NNP	O
Pre-Grant	NNP	O
Publication	NNP	O
20020049173	CD	O
.	.	O
Certain	NNP	O
types	NNS	O
of	IN	O
antisense	NN	O
compounds	NNS	O
which	WDT	O
specifically	RB	O
hybridize	VBP	O
to	TO	O
the	DT	O
5′	CD	O
cap	NN	O
region	NN	O
of	IN	O
their	PRP$	O
target	NN	O
mRNA	NN	O
interfere	RB	O
with	IN	O
translation	NN	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
into	IN	O
protein	NN	O
.	.	O
Such	JJ	O
oligomers	NNS	O
include	VBP	O
peptide-nucleic	JJ	O
acid	NN	O
(	(	O
PNA	NNP	O
)	)	O
oligomers	NNS	O
,	,	O
morpholino	NN	O
oligomers	NNS	O
snf	VBP	O
oligonucleosides	NNS	O
(	(	O
such	JJ	O
as	IN	O
those	DT	O
having	VBG	O
an	DT	O
MMI	NNP	O
or	CC	O
amide	VB	O
internucleoside	JJ	O
linkage	NN	O
)	)	O
and	CC	O
oligonucleotides	VBZ	O
having	VBG	O
modifications	NNS	O
at	IN	O
the	DT	O
2′	CD	O
position	NN	O
of	IN	O
the	DT	O
sugar	NN	O
.	.	O
This	DT	O
is	VBZ	O
believed	VBN	O
to	TO	O
occur	VB	O
via	IN	O
interference	NN	O
with	IN	O
ribosome	NN	O
assembly	NN	O
on	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
.	.	O
Methods	NNS	O
for	IN	O
inhibiting	VBG	O
the	DT	O
translation	NN	O
of	IN	O
a	DT	O
selected	VBN	O
capped	NN	O
target	NN	O
mRNA	VBN	O
by	IN	O
contacting	VBG	O
target	NN	O
mRNA	NN	O
with	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,789,573	CD	O
.	.	O
Antisense	NNP	O
compounds	VBZ	O
targeted	VBN	O
to	TO	O
specific	JJ	O
splice	JJ	O
variants	NNS	O
of	IN	O
an	DT	O
RNA	NNP	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
modulate	VB	O
the	DT	O
populations	NNS	O
of	IN	O
alternatively	RB	O
spliced	VBN	O
RNA	NNP	O
products	NNS	O
(	(	O
see	VB	O
U.S.	NNP	O
Patent	NNP	O
Application	NNP	O
entitled	VBD	O
“	JJ	O
Isoform-Specific	JJ	O
Targeting	NNP	O
of	IN	O
Splice	NNP	O
Variants	NNP	O
”	NNP	O
filed	VBN	O
Aug.	NNP	O
29	CD	O
,	,	O
2003	CD	O
,	,	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/651,772	CD	O
)	)	O
.	.	O
Antisense	NNP	O
compounds	VBZ	O
targeted	VBN	O
to	TO	O
a	DT	O
specific	JJ	O
poly	NN	O
(	(	O
A	NNP	O
)	)	O
site	NN	O
of	IN	O
mRNA	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
modulate	VB	O
the	DT	O
populations	NNS	O
of	IN	O
alternatively	RB	O
polyadenylated	VBN	O
transcripts	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
antisense	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
disrupt	VB	O
RNA	NNP	O
regulatory	JJ	O
structure	NN	O
thereby	NN	O
affecting	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
targeted	JJ	O
RNA	NNP	O
and	CC	O
its	PRP$	O
subsequent	JJ	O
expression	NN	O
.	.	O
Methods	NNS	O
directed	VBN	O
to	TO	O
such	JJ	O
modulation	NN	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,210,892	CD	O
and	CC	O
Pre-Grant	JJ	O
Publication	NNP	O
20020049173.	CD	O
siRNAs	NN	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
double-stranded	JJ	O
antisense	NN	O
compounds	VBZ	O
encompassing	VBG	O
short	JJ	O
interfering	VBG	O
RNAs	NNP	O
(	(	O
siRNAs	NN	O
)	)	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
siRNA	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
double-stranded	JJ	O
compound	NN	O
having	VBG	O
a	DT	O
first	JJ	O
and	CC	O
second	JJ	O
strand	NN	O
and	CC	O
comprises	VBZ	O
a	DT	O
central	JJ	O
complementary	JJ	O
portion	NN	O
between	IN	O
said	VBD	O
first	JJ	O
and	CC	O
second	JJ	O
strands	NNS	O
and	CC	O
terminal	JJ	O
portions	NNS	O
that	WDT	O
are	VBP	O
optionally	RB	O
complementary	JJ	O
between	IN	O
said	VBD	O
first	JJ	O
and	CC	O
second	JJ	O
strands	NNS	O
or	CC	O
with	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
.	.	O
The	DT	O
ends	NNS	O
of	IN	O
the	DT	O
strands	NNS	O
may	MD	O
be	VB	O
modified	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
natural	JJ	O
or	CC	O
modified	JJ	O
nucleobases	NNS	O
to	TO	O
form	VB	O
an	DT	O
overhang	NN	O
.	.	O
In	IN	O
one	CD	O
nonlimiting	NN	O
example	NN	O
,	,	O
the	DT	O
first	JJ	O
strand	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
is	VBZ	O
antisense	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
,	,	O
while	IN	O
the	DT	O
second	JJ	O
strand	NN	O
is	VBZ	O
complementary	JJ	O
to	TO	O
the	DT	O
first	JJ	O
strand	NN	O
.	.	O
Once	RB	O
the	DT	O
antisense	NN	O
strand	NN	O
is	VBZ	O
designed	VBN	O
to	TO	O
target	VB	O
a	DT	O
particular	JJ	O
nucleic	NN	O
acid	NN	O
target	NN	O
,	,	O
the	DT	O
sense	NN	O
strand	NN	O
of	IN	O
the	DT	O
dsRNA	NN	O
is	VBZ	O
then	RB	O
designed	VBN	O
and	CC	O
synthesized	VBN	O
as	IN	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
antisense	NN	O
strand	NN	O
and	CC	O
either	DT	O
strand	NN	O
may	MD	O
contain	VB	O
modifications	NNS	O
or	CC	O
additions	NNS	O
to	TO	O
either	DT	O
terminus	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
both	DT	O
strands	NNS	O
of	IN	O
the	DT	O
siRNA	NN	O
duplex	NN	O
would	MD	O
be	VB	O
complementary	JJ	O
over	IN	O
the	DT	O
central	JJ	O
nucleobases	NNS	O
,	,	O
each	DT	O
having	VBG	O
overhangs	NNS	O
at	IN	O
one	CD	O
or	CC	O
both	DT	O
termini	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
possible	JJ	O
for	IN	O
one	CD	O
end	NN	O
of	IN	O
a	DT	O
duplex	NN	O
to	TO	O
be	VB	O
blunt	NN	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
have	VB	O
overhanging	VBG	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
overhanging	VBG	O
nucleobases	NNS	O
is	VBZ	O
from	IN	O
1	CD	O
to	TO	O
6	CD	O
on	IN	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
each	DT	O
strand	NN	O
of	IN	O
the	DT	O
duplex	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
overhanging	VBG	O
nucleobases	NNS	O
is	VBZ	O
from	IN	O
1	CD	O
to	TO	O
6	CD	O
on	IN	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
only	RB	O
one	CD	O
strand	NN	O
of	IN	O
the	DT	O
duplex	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
overhanging	VBG	O
nucleobases	NNS	O
is	VBZ	O
from	IN	O
1	CD	O
to	TO	O
6	CD	O
on	IN	O
one	CD	O
or	CC	O
both	DT	O
5′	CD	O
ends	NNS	O
of	IN	O
the	DT	O
duplexed	JJ	O
strands	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
overhanging	VBG	O
nucleobases	NNS	O
is	VBZ	O
zero	CD	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
double-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
canonical	JJ	O
siRNAs	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
canonical	JJ	O
siRNA	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
double-stranded	JJ	O
oligomeric	NN	O
compound	NN	O
having	VBG	O
a	DT	O
first	JJ	O
strand	NN	O
and	CC	O
a	DT	O
second	JJ	O
strand	NN	O
each	DT	O
strand	NN	O
being	VBG	O
21	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
with	IN	O
the	DT	O
strands	NNS	O
being	VBG	O
complementary	JJ	O
over	IN	O
19	CD	O
nucleobases	NNS	O
and	CC	O
having	VBG	O
on	IN	O
each	DT	O
3′	CD	O
termini	NN	O
of	IN	O
each	DT	O
strand	NN	O
a	DT	O
deoxy	JJ	O
thymidine	NN	O
dimer	NN	O
(	(	O
dTdT	NN	O
)	)	O
which	WDT	O
in	IN	O
the	DT	O
double-stranded	JJ	O
compound	NN	O
acts	VBZ	O
as	IN	O
a	DT	O
3′	CD	O
overhang	NN	O
.	.	O
Each	DT	O
strand	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
duplex	NN	O
may	MD	O
be	VB	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
,	,	O
10	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
80	CD	O
,	,	O
13	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
30	CD	O
,	,	O
13	CD	O
to	TO	O
24	CD	O
,	,	O
19	CD	O
to	TO	O
23	CD	O
,	,	O
20	CD	O
to	TO	O
80	CD	O
,	,	O
20	CD	O
to	TO	O
50	CD	O
,	,	O
20	CD	O
to	TO	O
30	CD	O
,	,	O
or	CC	O
20	CD	O
to	TO	O
24	CD	O
nucleobases	NNS	O
.	.	O
The	DT	O
central	JJ	O
complementary	JJ	O
portion	NN	O
may	MD	O
be	VB	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
10	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
80	CD	O
,	,	O
13	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
30	CD	O
,	,	O
13	CD	O
to	TO	O
24	CD	O
,	,	O
19	CD	O
to	TO	O
23	CD	O
,	,	O
20	CD	O
to	TO	O
80	CD	O
,	,	O
20	CD	O
to	TO	O
50	CD	O
,	,	O
20	CD	O
to	TO	O
30	CD	O
,	,	O
or	CC	O
20	CD	O
to	TO	O
24	CD	O
nucleobases	NNS	O
.	.	O
The	DT	O
terminal	JJ	O
portions	NNS	O
can	MD	O
be	VB	O
from	IN	O
1	CD	O
to	TO	O
6	CD	O
nucleobases	NNS	O
.	.	O
The	DT	O
siRNAs	NN	O
may	MD	O
also	RB	O
have	VB	O
no	DT	O
terminal	JJ	O
portions	NNS	O
.	.	O
The	DT	O
two	CD	O
strands	NNS	O
of	IN	O
an	DT	O
siRNA	NN	O
can	MD	O
be	VB	O
linked	VBN	O
internally	RB	O
leaving	VBG	O
free	JJ	O
3′	CD	O
or	CC	O
5′	CD	O
termini	NNS	O
or	CC	O
can	MD	O
be	VB	O
linked	VBN	O
to	TO	O
form	VB	O
a	DT	O
continuous	JJ	O
hairpin	NN	O
structure	NN	O
or	CC	O
loop	NN	O
.	.	O
The	DT	O
hairpin	NN	O
structure	NN	O
may	MD	O
contain	VB	O
an	DT	O
overhang	NN	O
on	IN	O
either	CC	O
the	DT	O
5′	CD	O
or	CC	O
3′	CD	O
terminus	NN	O
producing	VBG	O
an	DT	O
extension	NN	O
of	IN	O
single-stranded	JJ	O
character	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
double-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
blunt-ended	JJ	O
siRNAs	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	PDT	O
the	DT	O
term	NN	O
“	NNP	O
blunt-ended	JJ	O
siRNA	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
an	DT	O
siRNA	NN	O
having	VBG	O
no	DT	O
terminal	JJ	O
overhangs	NNS	O
.	.	O
That	DT	O
is	VBZ	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
end	NN	O
of	IN	O
the	DT	O
double-stranded	JJ	O
compound	NN	O
is	VBZ	O
blunt	JJ	O
.	.	O
siRNAs	NN	O
whether	IN	O
canonical	JJ	O
or	CC	O
blunt	NN	O
act	NN	O
to	TO	O
elicit	VB	O
dsRNAse	JJ	O
enzymes	NNS	O
and	CC	O
trigger	VB	O
the	DT	O
recruitment	NN	O
or	CC	O
activation	NN	O
of	IN	O
the	DT	O
RNAi	NNP	O
antisense	NN	O
mechanism	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
single-stranded	JJ	O
RNAi	NNP	O
(	(	O
ssRNAi	NN	O
)	)	O
compounds	VBZ	O
that	IN	O
act	NN	O
via	IN	O
the	DT	O
RNAi	NNP	O
antisense	NN	O
mechanism	NN	O
are	VBP	O
contemplated	VBN	O
.	.	O
Further	JJ	O
modifications	NNS	O
can	MD	O
be	VB	O
made	VBN	O
to	TO	O
the	DT	O
double-stranded	JJ	O
compounds	NNS	O
and	CC	O
may	MD	O
include	VB	O
conjugate	NN	O
groups	NNS	O
attached	VBD	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
termini	NN	O
,	,	O
selected	VBN	O
nucleobase	NN	O
positions	NNS	O
,	,	O
sugar	NN	O
positions	NNS	O
or	CC	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
internucleoside	NN	O
linkages	VBZ	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
two	CD	O
strands	NNS	O
can	MD	O
be	VB	O
linked	VBN	O
via	IN	O
a	DT	O
non-nucleic	JJ	O
acid	NN	O
moiety	NN	O
or	CC	O
linker	NN	O
group	NN	O
.	.	O
When	WRB	O
formed	VBN	O
from	IN	O
only	RB	O
one	CD	O
strand	NN	O
,	,	O
the	DT	O
compounds	NNS	O
can	MD	O
take	VB	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
self-complementary	JJ	O
hairpin-type	JJ	O
molecule	NN	O
that	IN	O
doubles	VBZ	O
back	RB	O
on	IN	O
itself	PRP	O
to	TO	O
form	VB	O
a	DT	O
duplex	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
compounds	NNS	O
can	MD	O
be	VB	O
fully	RB	O
or	CC	O
partially	RB	O
double-stranded	JJ	O
.	.	O
When	WRB	O
formed	VBN	O
from	IN	O
two	CD	O
strands	NNS	O
,	,	O
or	CC	O
a	DT	O
single	JJ	O
strand	NN	O
that	WDT	O
takes	VBZ	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
self-complementary	JJ	O
hairpin-type	JJ	O
molecule	NN	O
doubled	VBD	O
back	RB	O
on	IN	O
itself	PRP	O
to	TO	O
form	VB	O
a	DT	O
duplex	NN	O
,	,	O
the	DT	O
two	CD	O
strands	NNS	O
(	(	O
or	CC	O
duplex-forming	JJ	O
regions	NNS	O
of	IN	O
a	DT	O
single	JJ	O
strand	NN	O
)	)	O
are	VBP	O
complementary	JJ	O
when	WRB	O
they	PRP	O
base	VBP	O
pair	NN	O
in	IN	O
Watson-Crick	JJ	O
fashion	NN	O
.	.	O
Compounds	VBZ	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
may	MD	O
comprise	VB	O
a	DT	O
complementary	JJ	O
oligomeric	JJ	O
compound	NN	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
(	(	O
i.e	NN	O
.	.	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
linked	VBD	O
nucleosides	NNS	O
)	)	O
.	.	O
In	IN	O
other	JJ	O
words	NNS	O
,	,	O
a	DT	O
single-stranded	JJ	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
comprises	VBZ	O
from	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
,	,	O
and	CC	O
a	DT	O
double-stranded	JJ	O
antisense	NN	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
such	JJ	O
as	IN	O
a	DT	O
siRNA	NN	O
,	,	O
for	IN	O
example	NN	O
)	)	O
comprises	VBZ	O
two	CD	O
strands	NNS	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
10	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
80	CD	O
,	,	O
13	CD	O
to	TO	O
50	CD	O
,	,	O
13	CD	O
to	TO	O
30	CD	O
,	,	O
13	CD	O
to	TO	O
24	CD	O
,	,	O
19	CD	O
to	TO	O
23	CD	O
,	,	O
20	CD	O
to	TO	O
80	CD	O
,	,	O
20	CD	O
to	TO	O
50	CD	O
,	,	O
20	CD	O
to	TO	O
30	CD	O
,	,	O
or	CC	O
20	CD	O
to	TO	O
24	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
Contained	VBN	O
within	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
whether	IN	O
single	JJ	O
or	CC	O
double	JJ	O
stranded	VBN	O
and	CC	O
on	IN	O
at	IN	O
least	JJS	O
one	CD	O
strand	NN	O
)	)	O
are	VBP	O
antisense	JJ	O
portions	NNS	O
.	.	O
The	DT	O
“	NNP	O
antisense	NN	O
portion	NN	O
”	NN	O
is	VBZ	O
that	IN	O
part	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
that	WDT	O
is	VBZ	O
designed	VBN	O
to	TO	O
confer	VB	O
antisense	JJ	O
activity	NN	O
by	IN	O
one	CD	O
of	IN	O
the	DT	O
aforementioned	JJ	O
potential	JJ	O
antisense	NN	O
mechanisms	NNS	O
.	.	O
One	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
comprehends	VBZ	O
antisense	JJ	O
portions	NNS	O
of	IN	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
55	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
59	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
67	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
74	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
or	CC	O
80	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
10	CD	O
to	TO	O
50	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
or	CC	O
50	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
13	CD	O
to	TO	O
80	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
55	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
59	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
67	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
74	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
or	CC	O
80	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
13	CD	O
to	TO	O
50	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
or	CC	O
50	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
13	CD	O
to	TO	O
30	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
or	CC	O
30	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
13	CD	O
to	TO	O
24	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
or	CC	O
24	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
19	CD	O
to	TO	O
23	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
or	CC	O
23	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
20	CD	O
to	TO	O
80	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
55	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
59	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
67	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
74	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
or	CC	O
80	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
20	CD	O
to	TO	O
50	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
or	CC	O
50	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
20	CD	O
to	TO	O
30	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
or	CC	O
30	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
antisense	VBN	O
portions	NNS	O
of	IN	O
20	CD	O
to	TO	O
24	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
antisense	JJ	O
compounds	NNS	O
having	VBG	O
antisense	JJ	O
portions	NNS	O
of	IN	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
or	CC	O
24	CD	O
nucleobases	NNS	O
.	.	O
Antisense	NNP	O
compounds	VBZ	O
8-80	JJ	O
nucleobases	NNS	O
in	IN	O
length	NN	O
comprising	VBG	O
a	DT	O
stretch	NN	O
of	IN	O
at	IN	O
least	JJS	O
eight	CD	O
(	(	O
8	CD	O
)	)	O
consecutive	JJ	O
nucleobases	NNS	O
selected	VBN	O
from	IN	O
within	IN	O
the	DT	O
illustrative	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
suitable	JJ	O
antisense	JJ	O
compounds	NNS	O
as	RB	O
well	RB	O
.	.	O
Exemplary	JJ	O
compounds	NNS	O
include	VBP	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
antisense	NN	O
compounds	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
which	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
Other	JJ	O
compounds	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
antisense	NN	O
compounds	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
which	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
compounds	VBZ	O
may	MD	O
be	VB	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
illustrative	JJ	O
compound	NN	O
,	,	O
and	CC	O
may	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
about	IN	O
80	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
armed	VBN	O
with	IN	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
illustrated	JJ	O
herein	NN	O
will	MD	O
be	VB	O
able	JJ	O
,	,	O
without	IN	O
undue	JJ	O
experimentation	NN	O
,	,	O
to	TO	O
identify	VB	O
further	JJ	O
antisense	NN	O
compounds	NNS	O
.	.	O
Chemical	NNP	O
Modifications	NNP	O
As	NNP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
a	DT	O
nucleoside	NN	O
is	VBZ	O
a	DT	O
base-sugar	JJ	O
combination	NN	O
.	.	O
The	DT	O
base	JJ	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside	NN	O
is	VBZ	O
normally	RB	O
a	DT	O
heterocyclic	JJ	O
base	NN	O
(	(	O
sometimes	RB	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
“	JJ	O
nucleobase	NN	O
”	NN	O
or	CC	O
simply	RB	O
a	DT	O
“	JJ	O
base	NN	O
”	NN	O
)	)	O
.	.	O
The	DT	O
two	CD	O
most	JJS	O
common	JJ	O
classes	NNS	O
of	IN	O
such	JJ	O
heterocyclic	JJ	O
bases	NNS	O
are	VBP	O
the	DT	O
purines	NNS	O
and	CC	O
the	DT	O
pyrimidines	NNS	O
.	.	O
Nucleotides	NNS	O
are	VBP	O
nucleosides	NNS	O
that	IN	O
further	JJ	O
include	VBP	O
a	DT	O
phosphate	JJ	O
group	NN	O
covalently	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside	NN	O
.	.	O
For	IN	O
those	DT	O
nucleosides	NNS	O
that	WDT	O
include	VBP	O
a	DT	O
pentofuranosyl	NN	O
sugar	NN	O
,	,	O
the	DT	O
phosphate	NN	O
group	NN	O
can	MD	O
be	VB	O
linked	VBN	O
to	TO	O
either	CC	O
the	DT	O
2′	CD	O
,	,	O
3′	CD	O
or	CC	O
5′	CD	O
hydroxyl	JJ	O
moiety	NN	O
of	IN	O
the	DT	O
sugar	NN	O
.	.	O
In	IN	O
forming	VBG	O
oligonucleotides	NNS	O
,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
covalently	RB	O
link	VBP	O
adjacent	JJ	O
nucleosides	NNS	O
to	TO	O
one	CD	O
another	DT	O
to	TO	O
form	VB	O
a	DT	O
linear	JJ	O
polymeric	JJ	O
compound	NN	O
.	.	O
In	IN	O
turn	NN	O
,	,	O
the	DT	O
respective	JJ	O
ends	NNS	O
of	IN	O
this	DT	O
linear	JJ	O
polymeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
further	RB	O
joined	VBN	O
to	TO	O
form	VB	O
a	DT	O
circular	JJ	O
compound	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
linear	JJ	O
compounds	NNS	O
may	MD	O
have	VB	O
internal	JJ	O
nucleobase	NN	O
complementarity	NN	O
and	CC	O
may	MD	O
therefore	VB	O
fold	NN	O
in	IN	O
a	DT	O
manner	NN	O
as	IN	O
to	TO	O
produce	VB	O
a	DT	O
fully	RB	O
or	CC	O
partially	RB	O
double-stranded	JJ	O
compound	NN	O
.	.	O
Within	IN	O
oligonucleotides	NNS	O
,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
are	VBP	O
commonly	RB	O
referred	VBN	O
to	TO	O
as	IN	O
forming	VBG	O
the	DT	O
internucleoside	JJ	O
backbone	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
The	DT	O
normal	JJ	O
linkage	NN	O
or	CC	O
backbone	NN	O
of	IN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
5′	CD	O
phosphodiester	NN	O
linkage	NN	O
.	.	O
Modified	NNP	O
Internucleoside	NNP	O
Linkages	NNP	O
Specific	NNP	O
examples	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
useful	JJ	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
oligonucleotides	NNS	O
containing	VBG	O
modified	JJ	O
e.g	NN	O
.	.	O
non-naturally	RB	O
occurring	VBG	O
internucleoside	JJ	O
linkages	NNS	O
.	.	O
As	IN	O
defined	VBN	O
in	IN	O
this	DT	O
specification	NN	O
,	,	O
oligonucleotides	IN	O
having	VBG	O
modified	VBN	O
internucleoside	JJ	O
linkages	NNS	O
include	VBP	O
internucleoside	JJ	O
linkages	NNS	O
that	WDT	O
retain	VBP	O
a	DT	O
phosphorus	NN	O
atom	NN	O
and	CC	O
internucleoside	NN	O
linkages	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
.	.	O
For	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
specification	NN	O
,	,	O
and	CC	O
as	IN	O
sometimes	RB	O
referenced	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
modified	VBD	O
oligonucleotides	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
their	PRP$	O
internucleoside	JJ	O
backbone	NN	O
can	MD	O
also	RB	O
be	VB	O
considered	VBN	O
to	TO	O
be	VB	O
oligonucleosides	NNS	O
.	.	O
Oligomeric	JJ	O
compounds	NNS	O
can	MD	O
have	VB	O
one	CD	O
or	CC	O
more	JJR	O
modified	JJ	O
internucleoside	NN	O
linkages	NNS	O
.	.	O
Modified	NNP	O
oligonucleotide	MD	O
backbones	VB	O
containing	VBG	O
a	DT	O
phosphorus	NN	O
atom	NN	O
therein	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
phosphorothioates	VBZ	O
,	,	O
chiral	JJ	O
phosphorothioates	NNS	O
,	,	O
phosphorodithioates	NNS	O
,	,	O
phosphotriesters	NNS	O
,	,	O
aminoalkyl-phosphotriesters	NNS	O
,	,	O
methyl	NN	O
and	CC	O
other	JJ	O
alkyl	NN	O
phosphonates	NNS	O
including	VBG	O
3′-alkylene	JJ	O
phosphonates	NNS	O
,	,	O
5′-alkylene	JJ	O
phosphonates	NNS	O
and	CC	O
chiral	JJ	O
phosphonates	NNS	O
,	,	O
phosphinates	NNS	O
,	,	O
phosphoramidates	NNS	O
including	VBG	O
3′-amino	JJ	O
phosphoramidate	NN	O
and	CC	O
aminoalkylphosphoramidates	NNS	O
,	,	O
thionophosphoramidates	NNS	O
,	,	O
thionoalkylphosphonates	NNS	O
,	,	O
thionoalkylphosphotriesters	NNS	O
,	,	O
phosphonoacetate	NN	O
and	CC	O
thiophosphonoacetate	NN	O
(	(	O
see	VB	O
Sheehan	NNP	B
et	VB	I
al.	NN	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Research	NNP	I
,	,	I
2003	CD	I
,	,	I
31	CD	I
(	(	I
14	CD	I
)	)	I
,	,	I
4109-4118	JJ	I
and	CC	O
Dellinger	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
2003	CD	I
,	,	I
125	CD	I
,	,	I
940-950	CD	I
)	)	I
,	,	O
selenophosphates	NNS	O
and	CC	O
boranophosphates	NNS	O
having	VBG	O
normal	JJ	O
3′-5′	JJ	O
linkages	NNS	O
,	,	O
2′-5′	JJ	O
linked	VBD	O
analogs	NNS	O
of	IN	O
these	DT	O
,	,	O
and	CC	O
those	DT	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
wherein	VBP	O
one	CD	O
or	CC	O
more	JJR	O
internucleotide	JJ	O
linkages	NNS	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
3′	CD	O
,	,	O
5′	CD	O
to	TO	O
5′	CD	O
or	CC	O
2′	CD	O
to	TO	O
2′	CD	O
linkage	NN	O
.	.	O
Oligonucleotides	IN	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
comprise	NN	O
a	DT	O
single	JJ	O
3′	CD	O
to	TO	O
3′	CD	O
linkage	NN	O
at	IN	O
the	DT	O
3′-most	JJ	O
internucleotide	JJ	O
linkage	NN	O
i.e	NN	O
.	.	O
a	DT	O
single	JJ	O
inverted	JJ	O
nucleoside	NN	O
residue	NN	O
which	WDT	O
may	MD	O
be	VB	O
abasic	JJ	O
(	(	O
the	DT	O
nucleobase	NN	O
is	VBZ	O
missing	VBG	O
or	CC	O
has	VBZ	O
a	DT	O
hydroxyl	NN	O
group	NN	O
in	IN	O
place	NN	O
thereof	NN	O
)	)	O
.	.	O
Various	JJ	O
salts	NNS	O
,	,	O
mixed	JJ	O
salts	NNS	O
and	CC	O
free	JJ	O
acid	NN	O
forms	NNS	O
are	VBP	O
also	RB	O
included	VBN	O
.	.	O
N3′-P5′-phosphoramidates	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
exhibit	VB	O
both	DT	O
a	DT	O
high	JJ	O
affinity	NN	O
towards	IN	O
a	DT	O
complementary	JJ	O
RNA	NNP	O
strand	NN	O
and	CC	O
nuclease	NN	O
resistance	NN	O
(	(	O
Gryaznov	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
1994	CD	I
,	,	I
116	CD	I
,	,	I
3143-3144	JJ	I
)	)	O
.	.	O
N3′-P5′-phosphoramidates	NNS	O
have	VBP	O
been	VBN	O
studied	VBN	O
with	IN	O
some	DT	O
success	NN	O
in	IN	O
vivo	NN	O
to	TO	O
specifically	RB	O
down	RP	O
regulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
c-myc	JJ	O
gene	NN	O
(	(	O
Skorski	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1997	CD	I
,	,	I
94	CD	I
,	,	I
3966-3971	JJ	I
;	:	O
and	CC	O
Faira	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Biotechnol.	NNP	I
,	,	I
2001	CD	I
,	,	I
19	CD	I
,	,	I
40-44	JJ	I
)	)	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
phosphorus-containing	NN	O
linkages	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
3,687,808	CD	O
;	:	O
4,469,863	CD	O
;	:	O
4,476,301	CD	O
;	:	O
5,023,243	CD	O
;	:	O
5,177,196	CD	O
;	:	O
5,188,897	CD	O
;	:	O
5,264,423	CD	O
;	:	O
5,276,019	CD	O
;	:	O
5,278,302	CD	O
;	:	O
5,286,717	CD	O
;	:	O
5,321,131	CD	O
;	:	O
5,399,676	CD	O
;	:	O
5,405,939	CD	O
;	:	O
5,453,496	CD	O
;	:	O
5,455,233	CD	O
;	:	O
5,466,677	CD	O
;	:	O
5,476,925	CD	O
;	:	O
5,519,126	CD	O
;	:	O
5,536,821	CD	O
;	:	O
5,541,306	CD	O
;	:	O
5,550,111	CD	O
;	:	O
5,563,253	CD	O
;	:	O
5,571,799	CD	O
;	:	O
5,587,361	CD	O
;	:	O
5,194,599	CD	O
;	:	O
5,565,555	CD	O
;	:	O
5,527,899	CD	O
;	:	O
5,721,218	CD	O
;	:	O
5,672,697	CD	O
and	CC	O
5,625,050	CD	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
may	MD	O
have	VB	O
one	CD	O
or	CC	O
more	JJR	O
phosphorothioate	JJ	O
and/or	NN	O
heteroatom	NN	O
internucleoside	NN	O
linkages	NNS	O
,	,	O
in	IN	O
particular	JJ	O
—CH2-NH—O—CH2-	JJ	O
,	,	O
—CH2-N	JJ	O
(	(	O
CH3	NNP	O
)	)	O
-O—CH2-	NNP	O
(	(	O
known	VBN	O
as	IN	O
a	DT	O
methylene	NN	O
(	(	O
methylimino	NN	O
)	)	O
or	CC	O
MMI	NNP	O
backbone	NN	O
)	)	O
,	,	O
—CH2-O—N	JJ	O
(	(	O
CH3	NNP	O
)	)	O
-CH2-	NN	O
,	,	O
—CH2-N	JJ	O
(	(	O
CH3	NNP	O
)	)	O
-N	NN	O
(	(	O
CH3	NNP	O
)	)	O
-CH2-	NN	O
and	CC	O
—O—N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
-CH2-CH2-	NN	O
(	(	O
wherein	IN	O
the	DT	O
native	JJ	O
phosphodiester	NN	O
internucleotide	NN	O
linkage	NN	O
is	VBZ	O
represented	VBN	O
as	IN	O
—O—P	NN	O
(	(	O
═O	NN	O
)	)	O
(	(	O
OH	UH	O
)	)	O
—O—CH2-	NN	O
)	)	O
.	.	O
The	DT	O
MMI	NNP	O
type	NN	O
intemucleoside	NN	O
linkages	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
the	DT	O
above	NN	O
referenced	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,489,677	CD	O
.	.	O
Amide	NNP	O
internucleoside	NN	O
linkages	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
the	DT	O
above	NN	O
referenced	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,602,240	CD	O
.	.	O
Some	DT	O
oligonucleotide	JJ	O
backbones	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
include	VB	O
a	DT	O
phosphorus	JJ	O
atom	NN	O
therein	NNS	O
have	VBP	O
backbones	NNS	O
that	WDT	O
are	VBP	O
formed	VBN	O
by	IN	O
short	JJ	O
chain	NN	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
intemucleoside	NN	O
linkages	NNS	O
,	,	O
mixed	JJ	O
heteroatom	NN	O
and	CC	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
internucleoside	NN	O
linkages	VBZ	O
,	,	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
short	JJ	O
chain	NN	O
heteroatomic	VBD	O
or	CC	O
heterocyclic	JJ	O
internucleoside	NN	O
linkages	NNS	O
.	.	O
These	DT	O
include	VBP	O
those	DT	O
having	VBG	O
morpholino	NN	O
linkages	NNS	O
(	(	O
formed	VBN	O
in	IN	O
part	NN	O
from	IN	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
a	DT	O
nucleoside	NN	O
)	)	O
;	:	O
siloxane	JJ	O
backbones	NNS	O
;	:	O
sulfide	RB	O
,	,	O
sulfoxide	NN	O
and	CC	O
sulfone	NN	O
backbones	NNS	O
;	:	O
formacetyl	NNS	O
and	CC	O
thioformacetyl	JJ	O
backbones	NNS	O
;	:	O
methylene	CC	O
formacetyl	NN	O
and	CC	O
thioformacetyl	JJ	O
backbones	NNS	O
;	:	O
riboacetyl	VB	O
backbones	NNS	O
;	:	O
alkene	VBZ	O
containing	VBG	O
backbones	NNS	O
;	:	O
sulfamate	VB	O
backbones	NNS	O
;	:	O
methyleneimino	NN	O
and	CC	O
methylenehydrazino	NN	O
backbones	NNS	O
;	:	O
sulfonate	NN	O
and	CC	O
sulfonamide	JJ	O
backbones	NNS	O
;	:	O
amide	IN	O
backbones	NNS	O
;	:	O
and	CC	O
others	NNS	O
having	VBG	O
mixed	JJ	O
N	NNP	O
,	,	O
O	NNP	O
,	,	O
S	NNP	O
and	CC	O
CH2	NNP	O
component	NN	O
parts	NNS	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
oligonucleosides	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,034,506	CD	O
;	:	O
5,166,315	CD	O
;	:	O
5,185,444	CD	O
;	:	O
5,214,134	CD	O
;	:	O
5,216,141	CD	O
;	:	O
5,235,033	CD	O
;	:	O
5,264,562	CD	O
;	:	O
5,264,564	CD	O
;	:	O
5,405,938	CD	O
;	:	O
5,434,257	CD	O
;	:	O
5,466,677	CD	O
;	:	O
5,470,967	CD	O
;	:	O
5,489,677	CD	O
;	:	O
5,541,307	CD	O
;	:	O
5,561,225	CD	O
;	:	O
5,596,086	CD	O
;	:	O
5,602,240	CD	O
;	:	O
5,610,289	CD	O
;	:	O
5,602,240	CD	O
;	:	O
5,608,046	CD	O
;	:	O
5,610,289	CD	O
;	:	O
5,618,704	CD	O
;	:	O
5,623,070	CD	O
;	:	O
5,663,312	CD	O
;	:	O
5,633,360	CD	O
;	:	O
5,677,437	CD	O
;	:	O
5,792,608	CD	O
;	:	O
5,646,269	CD	O
and	CC	O
5,677,439	CD	O
.	.	O
Modified	NNP	O
Sugars	NNP	O
Oligomeric	NNP	O
compounds	NNS	O
may	MD	O
also	RB	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
substituted	JJ	O
sugar	NN	O
moieties	NNS	O
.	.	O
Suitable	JJ	O
compounds	NNS	O
can	MD	O
comprise	VB	O
one	CD	O
of	IN	O
the	DT	O
following	VBG	O
at	IN	O
the	DT	O
T	NNP	O
position	NN	O
:	:	O
OH	NN	O
;	:	O
F	NNP	O
;	:	O
O—	NNP	O
,	,	O
S—	NNP	O
,	,	O
or	CC	O
N-alkyl	NNP	O
;	:	O
O—	NNP	O
,	,	O
S—	NNP	O
,	,	O
or	CC	O
N-alkenyl	NNP	O
;	:	O
O—	NNP	O
,	,	O
S-	NNP	O
or	CC	O
N-alkynyl	NNP	O
;	:	O
or	CC	O
O-alkyl-O-alkyl	NNP	O
,	,	O
wherein	VBZ	O
the	DT	O
alkyl	NN	O
,	,	O
alkenyl	NN	O
and	CC	O
alkynyl	NN	O
may	MD	O
be	VB	O
substituted	VBN	O
or	CC	O
unsubstituted	VBN	O
C1	NNP	O
to	TO	O
C10	NNP	O
alkyl	NN	O
or	CC	O
C2	NNP	O
to	TO	O
C10	NNP	O
alkenyl	NN	O
and	CC	O
alkynyl	NN	O
.	.	O
Also	RB	O
suitable	JJ	O
are	VBP	O
O	NNP	O
(	(	O
(	(	O
CH2	NNP	O
)	)	O
nO	NN	O
)	)	O
mCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nOCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nNH2	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nONH2	NN	O
,	,	O
and	CC	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nON	NN	O
(	(	O
(	(	O
CH2	NNP	O
)	)	O
nCH3	NN	O
)	)	O
2	CD	O
,	,	O
where	WRB	O
n	NN	O
and	CC	O
m	NN	O
are	VBP	O
from	IN	O
1	CD	O
to	TO	O
about	IN	O
10	CD	O
.	.	O
Other	JJ	O
oligonucleotides	NNS	O
comprise	VBP	O
one	CD	O
of	IN	O
the	DT	O
following	VBG	O
at	IN	O
the	DT	O
2′	CD	O
position	NN	O
:	:	O
C1	NN	O
to	TO	O
C10	NNP	O
lower	JJR	O
alkyl	NN	O
,	,	O
substituted	VBD	O
lower	JJR	O
alkyl	NN	O
,	,	O
alkenyl	NN	O
,	,	O
alkynyl	NN	O
,	,	O
alkaryl	NN	O
,	,	O
aralkyl	NN	O
,	,	O
O-alkaryl	NNP	O
or	CC	O
O-aralkyl	NNP	O
,	,	O
SH	NNP	O
,	,	O
SCH3	NNP	O
,	,	O
OCN	NNP	O
,	,	O
Cl	NNP	O
,	,	O
Br	NNP	O
,	,	O
CN	NNP	O
,	,	O
CF3	NNP	O
,	,	O
OCF3	NNP	O
,	,	O
SOCH3	NNP	O
,	,	O
SO2CH3	NNP	O
,	,	O
ONO2	NNP	O
,	,	O
NO2	NNP	O
,	,	O
N3	NNP	O
,	,	O
NH2	NNP	O
,	,	O
heterocycloalkyl	NN	O
,	,	O
heterocycloalkaryl	NN	O
,	,	O
aminoalkylamino	NN	O
,	,	O
polyalkylamino	NN	O
,	,	O
substituted	VBD	O
silyl	NN	O
,	,	O
an	DT	O
RNA	NNP	O
cleaving	NN	O
group	NN	O
,	,	O
a	DT	O
reporter	NN	O
group	NN	O
,	,	O
an	DT	O
intercalator	NN	O
,	,	O
a	DT	O
group	NN	O
for	IN	O
improving	VBG	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
or	CC	O
a	DT	O
group	NN	O
for	IN	O
improving	VBG	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
and	CC	O
other	JJ	O
substituents	NNS	O
having	VBG	O
similar	JJ	O
properties	NNS	O
.	.	O
One	CD	O
modification	NN	O
includes	VBZ	O
2′-methoxyethoxy	JJ	O
(	(	O
2′-O—CH2CH2OCH3	JJ	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
or	CC	O
2′-MOE	JJ	O
)	)	O
(	(	O
Martin	NNP	B
et	RB	I
al.	RB	I
,	,	I
Helv	NNP	I
.	.	I
Chim	NNP	I
.	.	I
Acta	NNP	I
,	,	I
1995	CD	I
,	,	I
78	CD	I
,	,	I
486-504	JJ	I
)	)	O
i.e.	NN	O
,	,	O
an	DT	O
alkoxyalkoxy	JJ	O
group	NN	O
.	.	O
A	DT	O
further	JJ	O
modification	NN	O
includes	VBZ	O
2′-dimethylaminooxyethoxy	JJ	O
,	,	O
i.e.	FW	O
,	,	O
a	DT	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
2ON	CD	O
(	(	O
CH3	NNP	O
)	)	O
2	CD	O
group	NN	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-DMAOE	JJ	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
examples	NNS	O
hereinbelow	VBP	O
,	,	O
and	CC	O
2′-dimethylamino-ethoxyethoxy	JJ	O
(	(	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
2′-O-dimethyl-amino-ethoxy-ethyl	JJ	O
or	CC	O
2′-DMAEOE	JJ	O
)	)	O
,	,	O
i.e.	FW	O
,	,	O
2′-O—CH2—O—CH2—N	JJ	O
(	(	O
CH3	NNP	O
)	)	O
2	CD	O
,	,	O
also	RB	O
described	VBN	O
in	IN	O
examples	NNS	O
hereinbelow	VBP	O
.	.	O
Other	JJ	O
modifications	NNS	O
include	VBP	O
2′-methoxy	JJ	O
(	(	O
2′-O—CH3	JJ	O
)	)	O
,	,	O
2′-aminopropoxy	JJ	O
(	(	O
2′-OCH2CH2CH2NH2	JJ	O
)	)	O
,	,	O
2′-allyl	JJ	O
(	(	O
2′-CH2—CH═CH2	JJ	O
)	)	O
,	,	O
2′-O-allyl	JJ	O
(	(	O
2′-O—CH2—CH═CH2	JJ	O
)	)	O
and	CC	O
2′-fluoro	JJ	O
(	(	O
2′-F	JJ	O
)	)	O
.	.	O
The	DT	O
2′-modification	NN	O
may	MD	O
be	VB	O
in	IN	O
the	DT	O
arabino	NN	O
(	(	O
up	RP	O
)	)	O
position	NN	O
or	CC	O
ribo	NN	O
(	(	O
down	RP	O
)	)	O
position	NN	O
.	.	O
One	CD	O
2′-arabino	JJ	O
modification	NN	O
is	VBZ	O
2′-F	JJ	O
.	.	O
Similar	JJ	O
modifications	NNS	O
may	MD	O
also	RB	O
be	VB	O
made	VBN	O
at	IN	O
other	JJ	O
positions	NNS	O
on	IN	O
the	DT	O
oligonucleotide	NN	O
,	,	O
particularly	RB	O
the	DT	O
3′	CD	O
position	NN	O
of	IN	O
the	DT	O
sugar	NN	O
on	IN	O
the	DT	O
3′	CD	O
terminal	JJ	O
nucleotide	NN	O
or	CC	O
in	IN	O
2′-5′	JJ	O
linked	VBN	O
oligonucleotides	NNS	O
and	CC	O
the	DT	O
5′	CD	O
position	NN	O
of	IN	O
5′	CD	O
terminal	JJ	O
nucleotide	NN	O
.	.	O
Antisense	NNP	O
compounds	NNS	O
may	MD	O
also	RB	O
have	VB	O
sugar	NN	O
mimetics	NNS	O
such	JJ	O
as	IN	O
cyclobutyl	NN	O
moieties	NNS	O
in	IN	O
place	NN	O
of	IN	O
the	DT	O
pentofuranosyl	NN	O
sugar	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
modified	VBN	O
sugar	NN	O
structures	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,981,957	CD	O
;	:	O
5,118,800	CD	O
;	:	O
5,319,080	CD	O
;	:	O
5,359,044	CD	O
;	:	O
5,393,878	CD	O
;	:	O
5,446,137	CD	O
;	:	O
5,466,786	CD	O
;	:	O
5,514,785	CD	O
;	:	O
5,519,134	CD	O
;	:	O
5,567,811	CD	O
;	:	O
5,576,427	CD	O
;	:	O
5,591,722	CD	O
;	:	O
5,597,909	CD	O
;	:	O
5,610,300	CD	O
;	:	O
5,627,053	CD	O
;	:	O
5,639,873	CD	O
;	:	O
5,646,265	CD	O
;	:	O
5,658,873	CD	O
;	:	O
5,670,633	CD	O
;	:	O
5,792,747	CD	O
;	:	O
5,700,920	CD	O
;	:	O
and	CC	O
,	,	O
6,147,200	CD	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
oligomeric	JJ	O
compounds	NNS	O
include	VBP	O
nucleosides	NNS	O
synthetically	RB	O
modified	VBD	O
to	TO	O
induce	VB	O
a	DT	O
3′-endo	JJ	O
sugar	NN	O
conformation	NN	O
.	.	O
A	DT	O
nucleoside	NN	O
can	MD	O
incorporate	VB	O
synthetic	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
heterocyclic	JJ	O
base	NN	O
,	,	O
the	DT	O
sugar	NN	O
moiety	NN	O
or	CC	O
both	DT	O
to	TO	O
induce	VB	O
a	DT	O
desired	JJ	O
3′-endo	JJ	O
sugar	NN	O
conformation	NN	O
.	.	O
These	DT	O
modified	VBN	O
nucleosides	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
mimic	VB	O
RNA	NNP	O
like	IN	O
nucleosides	NNS	O
so	IN	O
that	DT	O
particular	JJ	O
properties	NNS	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
enhanced	VBN	O
while	IN	O
maintaining	VBG	O
the	DT	O
desirable	JJ	O
3′-endo	JJ	O
conformational	JJ	O
geometry	NN	O
.	.	O
There	EX	O
is	VBZ	O
an	DT	O
apparent	JJ	O
preference	NN	O
for	IN	O
an	DT	O
RNA	NNP	O
type	NN	O
duplex	NN	O
(	(	O
A	DT	O
form	NN	O
helix	NN	O
,	,	O
predominantly	RB	O
3′-endo	JJ	O
)	)	O
as	IN	O
a	DT	O
requirement	NN	O
(	(	O
e.g	NN	O
.	.	O
trigger	NN	O
)	)	O
of	IN	O
RNA	NNP	O
interference	NN	O
which	WDT	O
is	VBZ	O
supported	VBN	O
in	IN	O
part	NN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
duplexes	NNS	O
composed	VBN	O
of	IN	O
2′-deoxy-2′-F-nucleosides	JJ	O
appears	VBZ	O
efficient	JJ	O
in	IN	O
triggering	VBG	O
RNAi	NNP	O
response	NN	O
in	IN	O
the	DT	O
C.	NNP	O
elegans	VBZ	O
system	NN	O
.	.	O
Properties	NNS	O
that	WDT	O
are	VBP	O
enhanced	VBN	O
by	IN	O
using	VBG	O
more	RBR	O
stable	JJ	O
3′-endo	JJ	O
nucleosides	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
modulation	NN	O
of	IN	O
pharmacokinetic	JJ	O
properties	NNS	O
through	IN	O
modification	NN	O
of	IN	O
protein	NN	O
binding	NN	O
,	,	O
protein	JJ	O
off-rate	JJ	O
,	,	O
absorption	NN	O
and	CC	O
clearance	NN	O
;	:	O
modulation	NN	O
of	IN	O
nuclease	JJ	O
stability	NN	O
as	RB	O
well	RB	O
as	IN	O
chemical	JJ	O
stability	NN	O
;	:	O
modulation	NN	O
of	IN	O
the	DT	O
binding	NN	O
affinity	NN	O
and	CC	O
specificity	NN	O
of	IN	O
the	DT	O
oligomer	NN	O
(	(	O
affinity	NN	O
and	CC	O
specificity	NN	O
for	IN	O
enzymes	NNS	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
complementary	JJ	O
sequences	NNS	O
)	)	O
;	:	O
and	CC	O
increasing	VBG	O
efficacy	NN	O
of	IN	O
RNA	NNP	O
cleavage	NN	O
.	.	O
Also	RB	O
provided	VBN	O
herein	NN	O
are	VBP	O
oligomeric	JJ	O
triggers	NNS	O
of	IN	O
RNAi	NNP	O
having	VBG	O
one	CD	O
or	CC	O
more	JJR	O
nucleosides	NNS	O
modified	VBN	O
in	IN	O
such	JJ	O
a	DT	O
way	NN	O
as	IN	O
to	TO	O
favor	VB	O
a	DT	O
C3′-endo	JJ	O
type	NN	O
conformation	NN	O
.	.	O
Nucleoside	NNP	O
conformation	NN	O
is	VBZ	O
influenced	VBN	O
by	IN	O
various	JJ	O
factors	NNS	O
including	VBG	O
substitution	NN	O
at	IN	O
the	DT	O
2′	CD	O
,	,	O
3′	CD	O
or	CC	O
4′-positions	NNS	O
of	IN	O
the	DT	O
pentofuranosyl	NN	O
sugar	NN	O
.	.	O
Electronegative	JJ	O
substituents	NNS	O
generally	RB	O
prefer	VBP	O
the	DT	O
axial	JJ	O
positions	NNS	O
,	,	O
while	IN	O
sterically	RB	O
demanding	VBG	O
substituents	NNS	O
generally	RB	O
prefer	VBP	O
the	DT	O
equatorial	JJ	O
positions	NNS	O
(	(	O
Principles	NNS	B
of	IN	I
Nucleic	NNP	I
Acid	NNP	I
Structure	NNP	I
,	,	I
Wolfgang	NNP	I
Sanger	NNP	I
,	,	I
1984	CD	I
,	,	I
Springer-Verlag	NNP	I
.	.	I
)	)	O
Modification	NN	O
of	IN	O
the	DT	O
2′	CD	O
position	NN	O
to	TO	O
favor	VB	O
the	DT	O
3′-endo	JJ	O
conformation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
while	IN	O
maintaining	VBG	O
the	DT	O
2′-OH	JJ	O
as	IN	O
a	DT	O
recognition	NN	O
element	NN	O
(	(	O
Gallo	NNP	B
et	RB	I
al.	RB	I
,	,	I
Tetrahedron	NNP	I
(	(	I
2001	CD	I
)	)	I
,	,	I
57	CD	I
,	,	I
5707-5713	JJ	I
.	.	O
Harry-O'kuru	NNP	B
et	NN	I
al.	NN	I
,	,	I
J.	NNP	I
Org	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
(	(	I
1997	CD	I
)	)	I
,	,	I
62	CD	I
(	(	I
6	CD	I
)	)	I
,	,	I
1754-1759	JJ	I
and	CC	O
Tang	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Org	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1999	CD	I
)	)	I
,	,	I
64	CD	I
,	,	I
747-754	NNP	I
.	.	O
)	)	O
Alternatively	RB	O
,	,	O
preference	NN	O
for	IN	O
the	DT	O
3′-endo	JJ	O
conformation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
deletion	NN	O
of	IN	O
the	DT	O
2′-OH	JJ	O
as	IN	O
exemplified	VBN	O
by	IN	O
2′deoxy-2′F-nucleosides	JJ	O
(	(	O
Kawasaki	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Med	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
,	,	I
36	CD	I
,	,	I
831-841	CD	I
)	)	O
,	,	O
which	WDT	O
adopts	VBZ	O
the	DT	O
3′-endo	JJ	O
conformation	NN	O
positioning	VBG	O
the	DT	O
electronegative	JJ	O
fluorine	NN	O
atom	NN	O
in	IN	O
the	DT	O
axial	JJ	O
position	NN	O
.	.	O
Other	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
ribose	JJ	O
ring	NN	O
,	,	O
for	IN	O
example	NN	O
substitution	NN	O
at	IN	O
the	DT	O
4′-position	NN	O
to	TO	O
give	VB	O
4′-F	JJ	O
modified	VBN	O
nucleosides	NNS	O
(	(	O
Guillerm	NNP	B
et	RB	I
al.	RB	I
,	,	I
Bioorganic	NNP	I
and	CC	I
Medicinal	NNP	I
Chemistry	NNP	I
Letters	NNP	I
(	(	I
1995	CD	I
)	)	I
,	,	I
5	CD	I
,	,	I
1455-1460	JJ	I
and	CC	O
Owen	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Org	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1976	CD	I
)	)	I
,	,	I
41	CD	I
,	,	I
3010-3017	JJ	I
)	)	O
,	,	O
or	CC	O
for	IN	O
example	NN	O
modification	NN	O
to	TO	O
yield	VB	O
methanocarba	JJ	O
nucleoside	JJ	O
analogs	NNS	O
(	(	O
Jacobson	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Med	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Lett	NNP	I
.	.	I
(	(	I
2000	CD	I
)	)	I
,	,	I
43	CD	I
,	,	I
2196-2203	JJ	I
and	CC	O
Lee	NNP	B
et	NNP	I
al.	NN	I
,	,	I
Bioorganic	NNP	I
and	CC	I
Medicinal	NNP	I
Chemistry	NNP	I
Letters	NNP	I
(	(	I
2001	CD	I
)	)	I
,	,	I
11	CD	I
,	,	I
1333-1337	JJ	I
)	)	O
also	RB	O
induce	VBP	O
preference	NN	O
for	IN	O
the	DT	O
3′-endo	JJ	O
conformation	NN	O
.	.	O
Along	IN	O
similar	JJ	O
lines	NNS	O
,	,	O
triggers	NNS	O
of	IN	O
RNAi	NNP	O
response	NN	O
might	MD	O
be	VB	O
composed	VBN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleosides	NNS	O
modified	VBN	O
in	IN	O
such	JJ	O
a	DT	O
way	NN	O
that	IN	O
conformation	NN	O
is	VBZ	O
locked	VBN	O
into	IN	O
a	DT	O
C3′-endo	JJ	O
type	NN	O
conformation	NN	O
,	,	O
i.e	NN	O
.	.	O
Locked	VBN	O
Nucleic	NNP	O
Acid	NNP	O
(	(	O
LNA	NNP	B
,	,	I
Singh	NNP	I
et	FW	I
al	NN	I
,	,	I
Chem	NNP	I
.	.	I
Commun	NNP	I
.	.	I
(	(	I
1998	CD	I
)	)	I
,	,	I
4	CD	I
,	,	I
455-456	JJ	I
)	)	O
,	,	O
and	CC	O
ethylene	RB	O
bridged	VBD	O
Nucleic	NNP	O
Acids	NNP	O
(	(	O
ENA™	NNP	B
,	,	I
Morita	NNP	I
et	FW	I
al	NN	I
,	,	I
Bioorganic	NNP	I
&	CC	I
Medicinal	NNP	I
Chemistry	NNP	I
Letters	NNP	I
(	(	I
2002	CD	I
)	)	I
,	,	I
12	CD	I
,	,	I
73-76	NNP	I
.	.	O
)	)	O
One	CD	O
conformation	NN	O
of	IN	O
modified	JJ	O
nucleosides	NNS	O
and	CC	O
their	PRP$	O
oligomers	NNS	O
can	MD	O
be	VB	O
estimated	VBN	O
by	IN	O
various	JJ	O
methods	NNS	O
such	JJ	O
as	IN	O
molecular	JJ	O
dynamics	NNS	O
calculations	NNS	O
,	,	O
nuclear	JJ	O
magnetic	JJ	O
resonance	NN	O
spectroscopy	NN	O
and	CC	O
CD	NN	O
measurements	NNS	O
.	.	O
Hence	NNP	O
,	,	O
modifications	NNS	O
predicted	VBD	O
to	TO	O
induce	VB	O
RNA-like	JJ	O
conformations	NNS	O
,	,	O
A-form	NNP	O
duplex	NN	O
geometry	NN	O
in	IN	O
an	DT	O
oligomeric	JJ	O
context	NN	O
,	,	O
are	VBP	O
selected	VBN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
modified	JJ	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
synthesis	NN	O
of	IN	O
numerous	JJ	O
of	IN	O
the	DT	O
modified	JJ	O
nucleosides	NNS	O
amenable	JJ	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
for	IN	O
example	NN	O
,	,	O
Chemistry	NNP	B
of	IN	I
Nucleosides	NNP	I
and	CC	I
Nucleotides	NNP	I
Vol	NNP	I
1-3	CD	I
,	,	I
ed	NN	I
.	.	I
Leroy	NNP	I
B.	NNP	I
Townsend	NNP	I
,	,	I
1988	CD	I
,	,	I
Plenum	NNP	I
press.	NN	I
,	,	O
and	CC	O
the	DT	O
examples	NNS	O
section	NN	O
below	IN	O
.	.	O
)	)	O
Oligonucleotide	IN	O
Mimetics	NNP	O
Another	DT	O
group	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
includes	VBZ	O
oligonucleotide	IN	O
mimetics	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
mimetic	JJ	O
”	NN	O
as	IN	O
it	PRP	O
is	VBZ	O
applied	VBN	O
to	TO	O
oligonucleotides	NNS	O
includes	VBZ	O
oligomeric	JJ	O
compounds	NNS	O
wherein	VBP	O
the	DT	O
furanose	JJ	O
ring	NN	O
or	CC	O
the	DT	O
furanose	JJ	O
ring	NN	O
and	CC	O
the	DT	O
internucleotide	JJ	O
linkage	NN	O
are	VBP	O
replaced	VBN	O
with	IN	O
novel	JJ	O
groups	NNS	O
,	,	O
replacement	NN	O
of	IN	O
only	RB	O
the	DT	O
furanose	JJ	O
ring	NN	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
being	VBG	O
a	DT	O
sugar	NN	O
surrogate	NN	O
.	.	O
The	DT	O
heterocyclic	JJ	O
base	NN	O
moiety	NN	O
or	CC	O
a	DT	O
modified	VBN	O
heterocyclic	JJ	O
base	NN	O
moiety	NN	O
is	VBZ	O
maintained	VBN	O
for	IN	O
hybridization	NN	O
with	IN	O
an	DT	O
appropriate	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
One	CD	O
such	JJ	O
oligomeric	JJ	O
compound	NN	O
,	,	O
an	DT	O
oligonucleotide	JJ	O
mimetic	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
excellent	JJ	O
hybridization	NN	O
properties	NNS	O
,	,	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
peptide	NN	O
nucleic	JJ	O
acid	NN	O
(	(	O
PNA	NNP	O
)	)	O
(	(	O
Nielsen	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
,	,	I
1991	CD	I
,	,	I
254	CD	I
,	,	I
1497-1500	CD	I
)	)	O
.	.	O
PNAs	NNS	O
have	VBP	O
favorable	JJ	O
hybridization	NN	O
properties	NNS	O
,	,	O
high	JJ	O
biological	JJ	O
stability	NN	O
and	CC	O
are	VBP	O
electrostatically	RB	O
neutral	JJ	O
molecules	NNS	O
.	.	O
PNA	NNP	O
compounds	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
correct	VB	O
aberrant	JJ	O
splicing	NN	O
in	IN	O
a	DT	O
transgenic	JJ	O
mouse	NN	O
model	NN	O
(	(	O
Sazani	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nat	NNP	I
.	.	I
Biotechnol.	NNP	I
,	,	I
2002	CD	I
,	,	I
20	CD	I
,	,	I
1228-1233	JJ	I
)	)	O
.	.	O
In	IN	O
PNA	NNP	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
the	DT	O
sugar-backbone	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
an	DT	O
amide	NN	O
containing	VBG	O
backbone	NN	O
,	,	O
in	IN	O
particular	JJ	O
an	DT	O
aminoethylglycine	JJ	O
backbone	NN	O
.	.	O
The	DT	O
nucleobases	NNS	O
are	VBP	O
bound	VBN	O
directly	RB	O
or	CC	O
indirectly	RB	O
(	(	O
—C	NNP	O
(	(	O
═O	NNP	O
)	)	O
—CH2—	NN	O
as	IN	O
shown	VBN	O
below	IN	O
)	)	O
to	TO	O
aza	VB	O
nitrogen	NN	O
atoms	NNS	O
of	IN	O
the	DT	O
amide	JJ	O
portion	NN	O
of	IN	O
the	DT	O
backbone	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
PNA	NNP	O
oligomeric	JJ	O
compounds	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,539,082	CD	O
;	:	O
5,714,331	CD	O
;	:	O
and	CC	O
5,719,262	CD	O
.	.	O
PNA	NNP	O
compounds	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
commercially	RB	O
from	IN	O
Applied	NNP	O
Biosystems	NNP	O
(	(	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
USA	NNP	O
)	)	O
.	.	O
Numerous	JJ	O
modifications	NNS	O
to	TO	O
the	DT	O
basic	JJ	O
PNA	NNP	O
backbone	NN	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
;	:	O
particularly	RB	O
useful	JJ	O
are	VBP	O
PNA	NNP	O
compounds	NNS	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acids	NNS	O
conjugated	VBD	O
to	TO	O
one	CD	O
or	CC	O
both	DT	O
termini	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
1-8	JJ	O
lysine	NN	O
or	CC	O
arginine	NN	O
residues	NNS	O
are	VBP	O
useful	JJ	O
when	WRB	O
conjugated	VBN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
PNA	NNP	O
molecule	NN	O
.	.	O
Another	DT	O
class	NN	O
of	IN	O
oligonucleotide	JJ	O
mimetic	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
studied	VBN	O
is	VBZ	O
based	VBN	O
on	IN	O
linked	VBN	O
morpholino	NN	O
units	NNS	O
(	(	O
morpholino	NN	O
nucleic	RB	O
acid	RB	O
)	)	O
having	VBG	O
heterocyclic	JJ	O
bases	NNS	O
attached	VBN	O
to	TO	O
the	DT	O
morpholino	NN	O
ring	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
linking	VBG	O
groups	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
that	IN	O
link	VBP	O
the	DT	O
morpholino	NN	O
monomeric	JJ	O
units	NNS	O
in	IN	O
a	DT	O
morpholino	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
One	CD	O
class	NN	O
of	IN	O
linking	VBG	O
groups	NNS	O
have	VBP	O
been	VBN	O
selected	VBN	O
to	TO	O
give	VB	O
a	DT	O
non-ionic	JJ	O
oligomeric	JJ	O
compound	NN	O
.	.	O
The	DT	O
non-ionic	JJ	O
morpholino-based	JJ	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
less	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
undesired	JJ	O
interactions	NNS	O
with	IN	O
cellular	JJ	O
proteins	NNS	O
.	.	O
Morpholino-based	JJ	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
non-ionic	JJ	O
mimetics	NNS	O
of	IN	O
oligonucleotides	NNS	O
which	WDT	O
are	VBP	O
less	RBR	O
likely	JJ	O
to	TO	O
form	VB	O
undesired	JJ	O
interactions	NNS	O
with	IN	O
cellular	JJ	O
proteins	NNS	O
(	(	O
Dwaine	NNP	B
A.	NNP	I
Braasch	NNP	I
and	CC	I
David	NNP	I
R.	NNP	I
Corey	NNP	I
,	,	I
Biochemistry	NNP	I
,	,	I
2002	CD	I
,	,	I
41	CD	I
(	(	I
14	CD	I
)	)	I
,	,	I
4503-4510	JJ	I
)	)	O
.	.	O
Morpholino-based	JJ	O
oligomeric	JJ	O
compounds	NNS	O
have	VBP	O
been	VBN	O
studied	VBN	O
in	IN	O
zebrafish	JJ	O
embryos	NN	O
(	(	O
see	VB	O
:	:	O
Genesis	NNP	B
,	,	I
volume	NN	I
30	CD	I
,	,	I
issue	NN	I
3	CD	I
,	,	I
2001	CD	I
and	CC	O
Heasman	NNP	B
,	,	I
J.	NNP	I
,	,	I
Dev	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
2002	CD	I
,	,	I
243	CD	I
,	,	I
209-214	JJ	I
)	)	O
.	.	O
Further	JJ	O
studies	NNS	O
of	IN	O
morpholino-based	JJ	O
oligomeric	JJ	O
compounds	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
reported	VBN	O
(	(	O
Nasevicius	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nat	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2000	CD	I
,	,	I
26	CD	I
,	,	I
216-220	JJ	I
;	:	O
and	CC	O
Lacerra	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
9591-9596	CD	I
)	)	O
.	.	O
Morpholino-based	JJ	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,034,506	CD	O
.	.	O
The	DT	O
morpholino	NN	O
class	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
have	VBP	O
been	VBN	O
prepared	VBN	O
having	VBG	O
a	DT	O
variety	NN	O
of	IN	O
different	JJ	O
linking	VBG	O
groups	NNS	O
joining	VBG	O
the	DT	O
monomeric	JJ	O
subunits	NNS	O
.	.	O
Linking	VBG	O
groups	NNS	O
can	MD	O
be	VB	O
varied	VBN	O
from	IN	O
chiral	JJ	O
to	TO	O
achiral	JJ	O
,	,	O
and	CC	O
from	IN	O
charged	VBN	O
to	TO	O
neutral	JJ	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,166,315	CD	O
discloses	NNS	O
linkages	VBZ	O
including	VBG	O
—O—P	NNP	O
(	(	O
═O	NNP	O
)	)	O
(	(	O
N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
2	CD	O
)	)	O
—O—	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,034,506	CD	O
discloses	NNS	O
achiral	JJ	O
intermorpholino	NN	O
linkages	NNS	O
;	:	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,185,444	CD	O
discloses	NNS	O
phosphorus	VBP	O
containing	VBG	O
chiral	JJ	O
intermorpholino	NN	O
linkages	NNS	O
.	.	O
A	DT	O
further	JJ	O
class	NN	O
of	IN	O
oligonucleotide	JJ	O
mimetic	NN	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
cyclohexene	NN	O
nucleic	JJ	O
acids	NNS	O
(	(	O
CeNA	NNP	O
)	)	O
.	.	O
The	DT	O
furanose	JJ	O
ring	NN	O
normally	RB	O
present	JJ	O
in	IN	O
a	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
molecule	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
a	DT	O
cyclohexenyl	NN	O
ring	NN	O
.	.	O
CeNA	NNP	O
DMT	NNP	O
protected	VBD	O
phosphoramidite	JJ	O
monomers	NNS	O
have	VBP	O
been	VBN	O
prepared	VBN	O
and	CC	O
used	VBN	O
for	IN	O
oligomeric	JJ	O
compound	NN	O
synthesis	NN	O
following	VBG	O
classical	JJ	O
phosphoramidite	JJ	O
chemistry	NN	O
.	.	O
Fully	RB	O
modified	VBN	O
CeNA	NNP	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
oligonucleotides	NNS	O
having	VBG	O
specific	JJ	O
positions	NNS	O
modified	VBN	O
with	IN	O
CeNA	NNP	O
have	VBP	O
been	VBN	O
prepared	VBN	O
and	CC	O
studied	VBN	O
(	(	O
Wang	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
2000	CD	I
,	,	I
122	CD	I
,	,	I
8595-8602	JJ	I
)	)	O
.	.	O
In	IN	O
general	JJ	O
the	DT	O
incorporation	NN	O
of	IN	O
CeNA	NNP	O
monomers	NNS	O
into	IN	O
a	DT	O
DNA	NN	O
chain	NN	O
increases	VBZ	O
its	PRP$	O
stability	NN	O
of	IN	O
a	DT	O
DNA/RNA	NNP	O
hybrid	NN	O
.	.	O
CeNA	NNP	O
oligoadenylates	VBZ	O
formed	VBN	O
complexes	NNS	O
with	IN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
complements	NNS	O
with	IN	O
similar	JJ	O
stability	NN	O
to	TO	O
the	DT	O
native	JJ	O
complexes	NNS	O
.	.	O
The	DT	O
study	NN	O
of	IN	O
incorporating	VBG	O
CeNA	NNP	O
structures	VBZ	O
into	IN	O
natural	JJ	O
nucleic	JJ	O
acid	NN	O
structures	NNS	O
was	VBD	O
shown	VBN	O
by	IN	O
NMR	NNP	O
and	CC	O
circular	JJ	O
dichroism	NN	O
to	TO	O
proceed	VB	O
with	IN	O
easy	JJ	O
conformational	JJ	O
adaptation	NN	O
.	.	O
Furthermore	RB	O
the	DT	O
incorporation	NN	O
of	IN	O
CeNA	NNP	O
into	IN	O
a	DT	O
sequence	NN	O
targeting	VBG	O
RNA	NNP	O
was	VBD	O
stable	JJ	O
to	TO	O
serum	VB	O
and	CC	O
able	JJ	O
to	TO	O
activate	VB	O
E.	NNP	O
coli	JJ	O
RNase	NNP	O
H	NNP	O
resulting	VBG	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
target	NN	O
RNA	NNP	O
strand	NN	O
.	.	O
A	DT	O
further	JJ	O
modification	NN	O
includes	VBZ	O
bicyclic	JJ	O
sugar	NN	O
moieties	NNS	O
such	JJ	O
as	IN	O
“	NN	O
Locked	NNP	O
Nucleic	NNP	O
Acids	NNP	O
”	NNP	O
(	(	O
LNAs	NNP	O
)	)	O
in	IN	O
which	WDT	O
the	DT	O
2′-hydroxyl	JJ	O
group	NN	O
of	IN	O
the	DT	O
ribosyl	NN	O
sugar	NN	O
ring	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
4′	CD	O
carbon	NN	O
atom	NN	O
of	IN	O
the	DT	O
sugar	NN	O
ring	VBG	O
thereby	RB	O
forming	VBG	O
a	DT	O
2′-C,4′-C-oxymethylene	JJ	O
linkage	NN	O
to	TO	O
form	VB	O
the	DT	O
bicyclic	JJ	O
sugar	NN	O
moiety	NN	O
(	(	O
reviewed	VBN	O
in	IN	O
Elayadi	NNP	B
et	CC	I
al.	NN	I
,	,	I
Curr	NNP	I
.	.	I
Opinion	NN	I
Invens	NNS	I
.	.	I
Drugs	NNS	I
,	,	I
2001	CD	I
,	,	I
2	CD	I
,	,	I
558-561	JJ	I
;	:	O
Braasch	NNP	B
et	FW	I
al.	NN	I
,	,	I
Chem	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
2001	CD	I
,	,	I
8	CD	I
1-7	JJ	I
;	:	O
and	CC	O
Orum	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Curr	NNP	I
.	.	I
Opinion	NN	I
Mol	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
2001	CD	I
,	,	I
3	CD	I
,	,	I
239-243	JJ	I
;	:	O
see	VB	O
also	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
6,268,490	CD	O
and	CC	O
6,670,461	CD	O
)	)	O
.	.	O
The	DT	O
linkage	NN	O
can	MD	O
be	VB	O
a	DT	O
methylene	NN	O
(	(	O
—CH2—	NNP	O
)	)	O
group	NN	O
bridging	VBG	O
the	DT	O
2′	CD	O
oxygen	NN	O
atom	NN	O
and	CC	O
the	DT	O
4′	CD	O
carbon	NN	O
atom	NN	O
,	,	O
for	IN	O
which	WDT	O
the	DT	O
term	NN	O
LNA	NNP	O
is	VBZ	O
used	VBN	O
for	IN	O
the	DT	O
bicyclic	JJ	O
moiety	NN	O
;	:	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
an	DT	O
ethylene	NN	O
group	NN	O
in	IN	O
this	DT	O
position	NN	O
,	,	O
the	DT	O
term	NN	O
ENA™	NNP	O
is	VBZ	O
used	VBN	O
(	(	O
Singh	NNP	B
et	RB	I
al.	RB	I
,	,	I
Chem	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
1998	CD	I
,	,	I
4	CD	I
,	,	I
455-456	JJ	I
;	:	O
ENA™	NNP	O
:	:	O
Morita	NNP	B
et	CC	I
al.	NN	I
,	,	I
Bioorganic	NNP	I
Medicinal	NNP	I
Chemistry	NNP	I
,	,	I
2003	CD	I
,	,	I
11	CD	I
,	,	I
2211-2226	JJ	I
)	)	O
.	.	O
LNA	NNP	O
and	CC	O
other	JJ	O
bicyclic	JJ	O
sugar	NN	O
analogs	NNS	O
display	VBP	O
very	RB	O
high	JJ	O
duplex	NN	O
thermal	JJ	O
stabilities	NNS	O
with	IN	O
complementary	JJ	O
DNA	NN	O
and	CC	O
RNA	NNP	O
(	(	O
Tm=+3	NNP	O
to	TO	O
+10	VB	O
C	NNP	O
)	)	O
,	,	O
stability	JJ	O
towards	IN	O
3′-exonucleolytic	JJ	O
degradation	NN	O
and	CC	O
good	JJ	O
solubility	NN	O
properties	NNS	O
.	.	O
LNA	NNP	O
's	POS	O
are	VBP	O
commercially	RB	O
available	JJ	O
from	IN	O
ProLigo	NNP	O
(	(	O
Paris	NNP	O
,	,	O
France	NNP	O
and	CC	O
Boulder	NNP	O
,	,	O
Colo.	NNP	O
,	,	O
USA	NNP	O
)	)	O
.	.	O
An	DT	O
isomer	NN	O
of	IN	O
LNA	NNP	O
that	WDT	O
has	VBZ	O
also	RB	O
been	VBN	O
studied	VBN	O
is	VBZ	O
alpha-L-LNA	JJ	O
which	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
superior	JJ	O
stability	NN	O
against	IN	O
a	DT	O
3′-exonuclease	JJ	O
(	(	O
Frieden	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Research	NNP	I
,	,	I
2003	CD	I
,	,	I
21	CD	I
,	,	I
6365-6372	JJ	I
)	)	O
.	.	O
The	DT	O
alpha-L-LNA	NN	O
's	POS	O
were	VBD	O
incorporated	VBN	O
into	IN	O
antisense	JJ	O
gapmers	NNS	O
and	CC	O
chimeras	NNS	O
that	WDT	O
showed	VBD	O
potent	JJ	O
antisense	JJ	O
activity	NN	O
.	.	O
Another	DT	O
similar	JJ	O
bicyclic	NN	O
sugar	NN	O
moiety	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
prepared	VBN	O
and	CC	O
studied	VBN	O
has	VBZ	O
the	DT	O
bridge	NN	O
going	VBG	O
from	IN	O
the	DT	O
3′-hydroxyl	JJ	O
group	NN	O
via	IN	O
a	DT	O
single	JJ	O
methylene	NN	O
group	NN	O
to	TO	O
the	DT	O
4′	CD	O
carbon	NN	O
atom	NN	O
of	IN	O
the	DT	O
sugar	NN	O
ring	VBG	O
thereby	RB	O
forming	VBG	O
a	DT	O
3′-C,4′-C-oxymethylene	JJ	O
linkage	NN	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,043,060	CD	O
)	)	O
.	.	O
The	DT	O
conformations	NNS	O
of	IN	O
LNAs	NNP	O
determined	VBN	O
by	IN	O
2D	CD	O
NMR	NNP	O
spectroscopy	NN	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
locked	JJ	O
orientation	NN	O
of	IN	O
the	DT	O
LNA	NNP	O
nucleotides	NNS	O
,	,	O
both	DT	O
in	IN	O
single-stranded	JJ	O
LNA	NNP	O
and	CC	O
in	IN	O
duplexes	NNS	O
,	,	O
constrains	VBZ	O
the	DT	O
phosphate	NN	O
backbone	NN	O
in	IN	O
such	JJ	O
a	DT	O
way	NN	O
as	IN	O
to	TO	O
introduce	VB	O
a	DT	O
higher	JJR	O
population	NN	O
of	IN	O
the	DT	O
N-type	JJ	O
conformation	NN	O
(	(	O
Petersen	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Recognit.	NNP	I
,	,	I
2000	CD	I
,	,	I
13	CD	I
,	,	I
44-53	JJ	I
)	)	O
.	.	O
These	DT	O
conformations	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
improved	JJ	O
stacking	NN	O
of	IN	O
the	DT	O
nucleobases	NNS	O
(	(	O
Wengel	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nucleosides	NNP	I
Nucleotides	NNP	I
,	,	I
1999	CD	I
,	,	I
18	CD	I
,	,	I
1365-1370	JJ	I
)	)	O
.	.	O
LNA	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
form	VB	O
exceedingly	RB	O
stable	JJ	O
LNA	NNP	O
:	:	O
LNA	NNP	O
duplexes	NNS	O
(	(	O
Koshkin	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
1998	CD	I
,	,	I
120	CD	I
,	,	I
13252-13253	JJ	I
)	)	O
.	.	O
LNA	NN	O
:	:	O
LNA	NNP	O
hybridization	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
thermally	RB	O
stable	JJ	O
nucleic	JJ	O
acid	NN	O
type	NN	O
duplex	NN	O
system	NN	O
,	,	O
and	CC	O
the	DT	O
RNA-mimicking	JJ	O
character	NN	O
of	IN	O
LNA	NNP	O
was	VBD	O
established	VBN	O
at	IN	O
the	DT	O
duplex	JJ	O
level	NN	O
.	.	O
Introduction	NN	O
of	IN	O
3	CD	O
LNA	NNP	O
monomers	NNS	O
(	(	O
T	NNP	O
or	CC	O
A	NNP	O
)	)	O
significantly	RB	O
increased	VBD	O
melting	VBG	O
points	NNS	O
(	(	O
Tm=+15/+11	NNP	O
)	)	O
toward	IN	O
DNA	NN	O
complements	NNS	O
.	.	O
The	DT	O
universality	NN	O
of	IN	O
LNA-mediated	JJ	O
hybridization	NN	O
has	VBZ	O
been	VBN	O
stressed	VBN	O
by	IN	O
the	DT	O
formation	NN	O
of	IN	O
exceedingly	RB	O
stable	JJ	O
LNA	NNP	O
:	:	O
LNA	NNP	O
duplexes	NNS	O
.	.	O
The	DT	O
RNA-mimicking	NNP	O
of	IN	O
LNA	NNP	O
was	VBD	O
reflected	VBN	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
N-type	JJ	O
conformational	JJ	O
restriction	NN	O
of	IN	O
the	DT	O
monomers	NNS	O
and	CC	O
to	TO	O
the	DT	O
secondary	JJ	O
structure	NN	O
of	IN	O
the	DT	O
LNA	NNP	O
:	:	O
RNA	NNP	O
duplex	NN	O
.	.	O
LNAs	NNP	O
also	RB	O
form	VBP	O
duplexes	NNS	O
with	IN	O
complementary	JJ	O
DNA	NNP	O
,	,	O
RNA	NNP	O
or	CC	O
LNA	NNP	O
with	IN	O
high	JJ	O
thermal	JJ	O
affinities	NNS	O
.	.	O
Circular	JJ	O
dichroism	NN	O
(	(	O
CD	NN	O
)	)	O
spectra	VBZ	O
show	VBP	O
that	IN	O
duplexes	NNS	O
involving	VBG	O
fully	RB	O
modified	VBN	O
LNA	NNP	O
(	(	O
esp	NN	O
.	.	O
LNA	NN	O
:	:	O
RNA	NNP	O
)	)	O
structurally	RB	O
resemble	VB	O
an	DT	O
A-form	JJ	O
RNA	NN	O
:	:	O
RNA	NNP	O
duplex	NN	O
.	.	O
Nuclear	NNP	O
magnetic	JJ	O
resonance	NN	O
(	(	O
NMR	NNP	O
)	)	O
examination	NN	O
of	IN	O
an	DT	O
LNA	NNP	O
:	:	O
DNA	NN	O
duplex	NN	O
confirmed	VBD	O
the	DT	O
3′-endo	JJ	O
conformation	NN	O
of	IN	O
an	DT	O
LNA	NNP	O
monomer	NN	O
.	.	O
Recognition	NN	O
of	IN	O
double-stranded	JJ	O
DNA	NNP	O
has	VBZ	O
also	RB	O
been	VBN	O
demonstrated	VBN	O
suggesting	VBG	O
strand	NN	O
invasion	NN	O
by	IN	O
LNA	NNP	O
.	.	O
Studies	NNS	O
of	IN	O
mismatched	JJ	O
sequences	NNS	O
show	VBP	O
that	IN	O
LNAs	NNP	O
obey	VBD	O
the	DT	O
Watson-Crick	JJ	O
base	NN	O
pairing	NN	O
rules	NNS	O
with	IN	O
generally	RB	O
improved	VBN	O
selectivity	NN	O
compared	VBN	O
to	TO	O
the	DT	O
corresponding	JJ	O
unmodified	JJ	O
reference	NN	O
strands	NNS	O
.	.	O
DNA	NN	O
:	:	O
LNA	NNP	O
chimeras	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
efficiently	RB	O
inhibit	VB	O
gene	NN	O
expression	NN	O
when	WRB	O
targeted	VBN	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
regions	NNS	O
(	(	O
5′-untranslated	JJ	O
region	NN	O
,	,	O
region	NN	O
of	IN	O
the	DT	O
start	NN	O
codon	NN	O
or	CC	O
coding	VBG	O
region	NN	O
)	)	O
within	IN	O
the	DT	O
luciferase	NN	O
mRNA	NN	O
(	(	O
Braasch	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Research	NNP	I
,	,	I
2002	CD	I
,	,	I
30	CD	I
,	,	I
5160-5167	JJ	I
)	)	O
.	.	O
Potent	NN	O
and	CC	O
nontoxic	JJ	O
antisense	NN	O
oligonucleotides	IN	O
containing	VBG	O
LNAs	NNP	O
have	VBP	O
been	VBN	O
described	VBN	O
(	(	O
Wahlestedt	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
5633-5638	JJ	I
)	)	O
.	.	O
The	DT	O
authors	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
LNAs	NNP	O
confer	VBP	O
several	JJ	O
desired	JJ	O
properties	NNS	O
.	.	O
LNA/DNA	JJ	O
copolymers	NNS	O
were	VBD	O
not	RB	O
degraded	VBN	O
readily	RB	O
in	IN	O
blood	NN	O
serum	NN	O
and	CC	O
cell	NN	O
extracts	NNS	O
.	.	O
LNA/DNA	NN	O
copolymers	NNS	O
exhibited	VBD	O
potent	JJ	O
antisense	JJ	O
activity	NN	O
in	IN	O
assay	JJ	O
systems	NNS	O
as	RB	O
disparate	JJ	O
as	IN	O
G-protein-coupled	JJ	O
receptor	NN	O
signaling	VBG	O
in	IN	O
living	VBG	O
rat	NN	O
brain	NN	O
and	CC	O
detection	NN	O
of	IN	O
reporter	NN	O
genes	NNS	O
in	IN	O
Escherichia	NNP	O
coli	NN	O
.	.	O
Lipofectin-mediated	JJ	O
efficient	JJ	O
delivery	NN	O
of	IN	O
LNA	NNP	O
into	IN	O
living	VBG	O
human	JJ	O
breast	NN	O
cancer	NN	O
cells	NNS	O
has	VBZ	O
also	RB	O
been	VBN	O
accomplished	VBN	O
.	.	O
Further	RB	O
successful	JJ	O
in	IN	O
vivo	JJ	O
studies	NNS	O
involving	VBG	O
LNA	NNP	O
's	POS	O
have	VBP	O
shown	VBN	O
knock-down	NN	O
of	IN	O
the	DT	O
rat	NN	O
delta	NN	O
opioid	VBP	O
receptor	NN	O
without	IN	O
toxicity	NN	O
(	(	O
Wahlestedt	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
5633-5638	JJ	I
)	)	O
and	CC	O
in	IN	O
another	DT	O
study	NN	O
showed	VBD	O
a	DT	O
blockage	NN	O
of	IN	O
the	DT	O
translation	NN	O
of	IN	O
the	DT	O
large	JJ	O
subunit	NN	O
of	IN	O
RNA	NNP	O
polymerase	NN	O
II	NNP	O
(	(	O
Fluiter	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res.	NNP	I
,	,	I
2003	CD	I
,	,	I
31	CD	I
,	,	I
953-962	CD	I
)	)	O
.	.	O
The	DT	O
synthesis	NN	O
and	CC	O
preparation	NN	O
of	IN	O
the	DT	O
LNA	NNP	O
monomers	NNS	O
adenine	VBP	O
,	,	O
cytosine	NN	O
,	,	O
guanine	NN	O
,	,	O
5-methylcytosine	JJ	O
,	,	O
thymine	JJ	O
and	CC	O
uracil	JJ	O
,	,	O
along	IN	O
with	IN	O
their	PRP$	O
oligomerization	NN	O
,	,	O
and	CC	O
nucleic	JJ	O
acid	NN	O
recognition	NN	O
properties	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
(	(	O
Koshkin	NNP	B
et	RB	I
al.	RB	I
,	,	I
Tetrahedron	NNP	I
,	,	I
1998	CD	I
,	,	I
54	CD	I
,	,	I
3607-3630	JJ	I
)	)	O
.	.	O
LNAs	NNP	O
and	CC	O
preparation	NN	O
thereof	NN	O
are	VBP	O
also	RB	O
described	VBN	O
in	IN	O
WO	NNP	O
98/39352	CD	O
and	CC	O
WO	NNP	O
99/14226	CD	O
.	.	O
Analogs	NNS	O
of	IN	O
LNA	NNP	O
,	,	O
phosphorothioate-LNA	JJ	O
and	CC	O
2′-thio-LNAs	JJ	O
,	,	O
have	VBP	O
also	RB	O
been	VBN	O
prepared	VBN	O
(	(	O
Kumar	NNP	B
et	RB	I
al.	RB	I
,	,	I
Bioorg	NNP	I
.	.	I
Med	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Lett.	NNP	I
,	,	I
1998	CD	I
,	,	I
8	CD	I
,	,	I
2219-2222	JJ	I
)	)	O
.	.	O
Preparation	NN	O
of	IN	O
locked	JJ	O
nucleoside	JJ	O
analogs	NNS	O
containing	VBG	O
oligodeoxyribonucleotide	RB	O
duplexes	RB	O
as	IN	O
substrates	NNS	O
for	IN	O
nucleic	JJ	O
acid	NN	O
polymerases	NNS	O
has	VBZ	O
also	RB	O
been	VBN	O
described	VBN	O
(	(	O
Wengel	NNP	B
et	RB	I
al.	VBZ	I
,	,	O
WO	NNP	O
99/14226	CD	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
synthesis	NN	O
of	IN	O
2′-amino-LNA	JJ	O
,	,	O
a	DT	O
novel	JJ	O
conformationally	RB	O
restricted	VBN	O
high-affinity	NN	O
oligonucleotide	NN	O
analog	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
Singh	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Org	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1998	CD	I
,	,	I
63	CD	I
,	,	I
10035-10039	JJ	I
)	)	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
2′-Amino-	JJ	O
and	CC	O
2′-methylamino-LNA	JJ	O
's	POS	O
have	VBP	O
been	VBN	O
prepared	VBN	O
and	CC	O
the	DT	O
thermal	JJ	O
stability	NN	O
of	IN	O
their	PRP$	O
duplexes	NNS	O
with	IN	O
complementary	JJ	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
strands	VBZ	O
has	VBZ	O
been	VBN	O
previously	RB	O
reported	VBN	O
.	.	O
Another	DT	O
oligonucleotide	JJ	O
mimetic	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
prepared	VBN	O
and	CC	O
studied	VBN	O
is	VBZ	O
threose	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
This	DT	O
oligonucleotide	JJ	O
mimetic	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
threose	JJ	O
nucleosides	NNS	O
instead	RB	O
of	IN	O
ribose	JJ	O
nucleosides	NNS	O
.	.	O
Initial	JJ	O
interest	NN	O
in	IN	O
(	(	O
3′,2′	CD	O
)	)	O
-alpha-L-threose	VB	O
nucleic	JJ	O
acid	NN	O
(	(	O
TNA	NNP	O
)	)	O
was	VBD	O
directed	VBN	O
to	TO	O
the	DT	O
question	NN	O
of	IN	O
whether	IN	O
a	DT	O
DNA	NNP	O
polymerase	NN	O
existed	VBD	O
that	WDT	O
would	MD	O
copy	VB	O
the	DT	O
TNA	NNP	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
certain	JJ	O
DNA	NNP	O
polymerases	NNS	O
are	VBP	O
able	JJ	O
to	TO	O
copy	VB	O
limited	JJ	O
stretches	NNS	O
of	IN	O
a	DT	O
TNA	NNP	O
template	NN	O
(	(	O
reported	VBN	O
in	IN	O
Chemical	NNP	B
and	CC	I
Engineering	NNP	I
News	NNP	I
,	,	I
2003	CD	I
,	,	I
81	CD	I
,	,	I
9	CD	I
)	)	O
.	.	O
In	IN	O
another	DT	O
study	NN	O
it	PRP	O
was	VBD	O
determined	VBN	O
that	IN	O
TNA	NNP	O
is	VBZ	O
capable	JJ	O
of	IN	O
antiparallel	JJ	O
Watson-Crick	JJ	O
base	NN	O
pairing	VBG	O
with	IN	O
complementary	JJ	O
DNA	NNP	O
,	,	O
RNA	NNP	O
and	CC	O
TNA	NNP	O
oligonucleotides	NNS	O
(	(	O
Chaput	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
2003	CD	I
,	,	I
125	CD	I
,	,	I
856-857	JJ	I
)	)	O
.	.	O
In	IN	O
one	CD	O
study	NN	O
(	(	O
3′,2′	CD	O
)	)	O
-alpha-L-threose	VB	O
nucleic	JJ	O
acid	NN	O
was	VBD	O
prepared	VBN	O
and	CC	O
compared	VBN	O
to	TO	O
the	DT	O
2′	CD	O
and	CC	O
3′	CD	O
amidate	JJ	O
analogs	NNS	O
(	(	O
Wu	NNP	B
et	RB	I
al.	RB	I
,	,	I
Organic	NNP	I
Letters	NNP	I
,	,	I
2002	CD	I
,	,	I
4	CD	I
(	(	I
8	CD	I
)	)	I
,	,	I
1279-1282	JJ	I
)	)	O
.	.	O
The	DT	O
amidate	JJ	O
analogs	NNS	O
were	VBD	O
shown	VBN	O
to	TO	O
bind	VB	O
to	TO	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
with	IN	O
comparable	JJ	O
strength	NN	O
to	TO	O
that	DT	O
of	IN	O
RNA/DNA	NNP	O
.	.	O
Further	RB	O
oligonucleotide	RB	O
mimetics	NNS	O
have	VBP	O
been	VBN	O
prepared	VBN	O
to	TO	O
include	VB	O
bicyclic	JJ	O
and	CC	O
tricyclic	JJ	O
nucleoside	JJ	O
analogs	NNS	O
(	(	O
see	VB	O
Steffens	NNP	B
et	FW	I
al.	NN	I
,	,	I
Helv	NNP	I
.	.	I
Chim	NNP	I
.	.	I
Acta	NNP	I
,	,	I
1997	CD	I
,	,	I
80	CD	I
,	,	I
2426-2439	JJ	I
;	:	O
Steffens	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
1999	CD	I
,	,	I
121	CD	I
,	,	I
3249-3255	CD	I
;	:	O
Renneberg	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
2002	CD	I
,	,	I
124	CD	I
,	,	I
5993-6002	JJ	I
;	:	O
and	CC	O
Renneberg	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Nucleic	NNP	I
acids	VBZ	I
res.	NN	I
,	,	I
2002	CD	I
,	,	I
30	CD	I
,	,	I
2751-2757	JJ	I
)	)	O
.	.	O
These	DT	O
modified	VBD	O
nucleoside	RB	O
analogs	NNS	O
have	VBP	O
been	VBN	O
oligomerized	VBN	O
using	VBG	O
the	DT	O
phosphoramidite	JJ	O
approach	NN	O
and	CC	O
the	DT	O
resulting	VBG	O
oligomeric	JJ	O
compounds	NNS	O
containing	VBG	O
tricyclic	JJ	O
nucleoside	RB	O
analogs	NNS	O
have	VBP	O
shown	VBN	O
increased	VBN	O
thermal	JJ	O
stabilities	NNS	O
(	(	O
Tm	NNP	O
's	POS	O
)	)	O
when	WRB	O
hybridized	VBN	O
to	TO	O
DNA	NNP	O
,	,	O
RNA	NNP	O
and	CC	O
itself	PRP	O
.	.	O
Oligomeric	NNP	O
compounds	VBZ	O
containing	VBG	O
bicyclic	JJ	O
nucleoside	RB	O
analogs	NNS	O
have	VBP	O
shown	VBN	O
thermal	JJ	O
stabilities	NNS	O
approaching	VBG	O
that	IN	O
of	IN	O
DNA	NNP	O
duplexes	NNS	O
.	.	O
Another	DT	O
class	NN	O
of	IN	O
oligonucleotide	JJ	O
mimetic	NN	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
phosphonomonoester	NN	O
nucleic	NN	O
acids	NNS	O
which	WDT	O
incorporate	VBP	O
a	DT	O
phosphorus	NN	O
group	NN	O
in	IN	O
the	DT	O
backbone	NN	O
.	.	O
This	DT	O
class	NN	O
of	IN	O
olignucleotide	JJ	O
mimetic	NN	O
is	VBZ	O
reported	VBN	O
to	TO	O
have	VB	O
useful	JJ	O
physical	JJ	O
and	CC	O
biological	JJ	O
and	CC	O
pharmacological	JJ	O
properties	NNS	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
inhibiting	VBG	O
gene	NN	O
expression	NN	O
(	(	O
antisense	JJ	O
oligonucleotides	NNS	O
,	,	O
sense	NN	O
oligonucleotides	NNS	O
and	CC	O
triplex-forming	JJ	O
oligonucleotides	NNS	O
)	)	O
,	,	O
as	IN	O
probes	NNS	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
and	CC	O
as	IN	O
auxiliaries	NNS	O
for	IN	O
use	NN	O
in	IN	O
molecular	JJ	O
biology	NN	O
.	.	O
Further	RB	O
oligonucleotide	IN	O
mimetics	NNS	O
amenable	JJ	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
have	VBP	O
been	VBN	O
prepared	VBN	O
wherein	IN	O
a	DT	O
cyclobutyl	NN	O
ring	NN	O
replaces	VBZ	O
the	DT	O
naturally	RB	O
occurring	VBG	O
furanosyl	JJ	O
ring	NN	O
.	.	O
Modified	NNP	O
and	CC	O
Alternate	NNP	O
Nucleobases	NNP	O
Oligomeric	NNP	O
compounds	NNS	O
may	MD	O
also	RB	O
include	VB	O
nucleobase	NN	O
(	(	O
often	RB	O
referred	VBN	O
to	TO	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
heterocyclic	JJ	O
base	NN	O
or	CC	O
simply	RB	O
as	IN	O
“	JJ	O
base	NN	O
”	NN	O
)	)	O
modifications	NNS	O
or	CC	O
substitutions	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	NNP	O
unmodified	VBD	O
”	NNP	O
or	CC	O
“	NNP	O
natural	JJ	O
”	NNP	O
nucleobases	NNS	O
include	VBP	O
the	DT	O
purine	NN	O
bases	VBZ	O
adenine	NN	O
(	(	O
A	DT	O
)	)	O
and	CC	O
guanine	NN	O
(	(	O
G	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
pyrimidine	NN	O
bases	VBZ	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
cytosine	NN	O
(	(	O
C	NNP	O
)	)	O
and	CC	O
uracil	JJ	O
(	(	O
U	NNP	O
)	)	O
.	.	O
Modified	VBN	O
nucleobases	NNS	O
include	VBP	O
other	JJ	O
synthetic	JJ	O
and	CC	O
natural	JJ	O
nucleobases	NNS	O
such	JJ	O
as	IN	O
5-methylcytosine	JJ	O
(	(	O
5-me-C	JJ	O
)	)	O
,	,	O
5-hydroxymethyl	JJ	O
cytosine	NN	O
,	,	O
xanthine	NN	O
,	,	O
hypoxanthine	NN	O
,	,	O
2-aminoadenine	JJ	O
,	,	O
6-methyl	JJ	O
and	CC	O
other	JJ	O
alkyl	JJ	O
derivatives	NNS	O
of	IN	O
adenine	NN	O
and	CC	O
guanine	NN	O
,	,	O
2-propyl	JJ	O
and	CC	O
other	JJ	O
alkyl	JJ	O
derivatives	NNS	O
of	IN	O
adenine	NN	O
and	CC	O
guanine	NN	O
,	,	O
2-thiouracil	JJ	O
,	,	O
2-thiothymine	JJ	O
and	CC	O
2-thiocytosine	JJ	O
,	,	O
5-halouracil	JJ	O
and	CC	O
cytosine	JJ	O
,	,	O
5-propynyl	JJ	O
(	(	O
—C≡C—CH3	NNP	O
)	)	O
uracil	NN	O
and	CC	O
cytosine	NN	O
and	CC	O
other	JJ	O
alkynyl	JJ	O
derivatives	NNS	O
of	IN	O
pyrimidine	NN	O
bases	NNS	O
,	,	O
6-azo	JJ	O
uracil	NN	O
,	,	O
cytosine	NN	O
and	CC	O
thymine	NN	O
,	,	O
5-uracil	JJ	O
(	(	O
pseudouracil	NN	O
)	)	O
,	,	O
4-thiouracil	JJ	O
,	,	O
8-halo	JJ	O
,	,	O
8-amino	JJ	O
,	,	O
8-thiol	JJ	O
,	,	O
8-thioalkyl	JJ	O
,	,	O
8-hydroxyl	JJ	O
and	CC	O
other	JJ	O
8-substituted	JJ	O
adenines	NNS	O
and	CC	O
guanines	NNS	O
,	,	O
5-halo	JJ	O
particularly	RB	O
5-bromo	JJ	O
,	,	O
5-trifluoromethyl	JJ	O
and	CC	O
other	JJ	O
5-substituted	JJ	O
uracils	NNS	O
and	CC	O
cyto-sines	NNS	O
,	,	O
7-methylguanine	JJ	O
and	CC	O
7-methyladenine	JJ	O
,	,	O
2-F-adenine	JJ	O
,	,	O
2-amino-adenine	JJ	O
,	,	O
8-azaguanine	JJ	O
and	CC	O
8-azaadenine	JJ	O
,	,	O
7-deazaguanine	JJ	O
and	CC	O
7-deazaadenine	JJ	O
and	CC	O
3-deazaguanine	JJ	O
and	CC	O
3-deazaadenine	JJ	O
.	.	O
Further	RB	O
modified	VBN	O
nucleobases	NNS	O
include	VBP	O
tricyclic	JJ	O
pyrimidines	NNS	O
such	JJ	O
as	IN	O
phenoxazine	JJ	O
cytidine	NN	O
(	(	O
1H-pyrimido	JJ	O
(	(	O
5,4-b	JJ	O
)	)	O
(	(	O
1,4	CD	O
)	)	O
benzoxazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
phenothiazine	JJ	O
cytidine	NN	O
(	(	O
1H-pyrimido	JJ	O
(	(	O
5,4-b	JJ	O
)	)	O
(	(	O
1,4	CD	O
)	)	O
benzothiazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
G-clamps	NNP	O
such	JJ	O
as	IN	O
a	DT	O
substituted	JJ	O
phenoxazine	NN	O
cytidine	NN	O
(	(	O
e.g	NN	O
.	.	O
9-	CD	O
(	(	O
2-aminoethoxy	JJ	O
)	)	O
-H-pyrimido	NN	O
(	(	O
5,4-b	JJ	O
)	)	O
(	(	O
1,4	CD	O
)	)	O
benzoxazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
carbazole	JJ	O
cytidine	NN	O
(	(	O
2H-pyrimido	JJ	O
(	(	O
4,5-b	JJ	O
)	)	O
indol-2-one	NN	O
)	)	O
,	,	O
pyridoindole	JJ	O
cytidine	NN	O
(	(	O
H-pyrido	NNP	O
(	(	O
3′,2′:4,5	CD	O
)	)	O
pyrrolo	NN	O
(	(	O
2,3-d	JJ	O
)	)	O
pyrimidin-2-one	NN	O
)	)	O
.	.	O
Modified	VBN	O
nucleobases	NNS	O
may	MD	O
also	RB	O
include	VB	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
purine	NN	O
or	CC	O
pyrimidine	JJ	O
base	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
other	JJ	O
heterocycles	NNS	O
,	,	O
for	IN	O
example	NN	O
7-deaza-adenine	CD	O
,	,	O
7-deazaguanosine	CD	O
,	,	O
2-aminopyridine	JJ	O
and	CC	O
2-pyridone	CD	O
.	.	O
Further	JJ	O
nucleobases	NNS	O
include	VBP	O
those	DT	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,687,808	CD	O
,	,	O
those	DT	O
disclosed	VBN	O
in	IN	O
The	DT	O
Concise	NNP	O
Encyclopedia	NNP	O
Of	IN	O
Polymer	NNP	O
Science	NNP	O
And	CC	O
Engineering	NNP	O
,	,	O
pages	VBZ	O
858-859	CD	O
,	,	O
Kroschwitz	NNP	O
,	,	O
J.	NNP	O
I.	NNP	O
,	,	O
ed	NN	O
.	.	O
John	NNP	O
Wiley	NNP	O
&	CC	O
Sons	NNP	O
,	,	O
1990	CD	O
,	,	O
those	DT	O
disclosed	VBN	O
by	IN	O
Englisch	NNP	O
et	FW	O
al.	NN	O
,	,	O
Angewandte	NNP	O
Chemie	NNP	O
,	,	O
International	NNP	O
Edition	NNP	O
,	,	O
1991	CD	O
,	,	O
30	CD	O
,	,	O
613	CD	O
,	,	O
and	CC	O
those	DT	O
disclosed	VBN	O
by	IN	O
Sanghvi	NNP	B
,	,	I
Y.	NNP	I
S.	NNP	I
,	,	I
Chapter	NNP	I
15	CD	I
,	,	I
Antisense	NNP	I
Research	NNP	I
and	CC	I
Applications	NNP	I
,	,	I
pages	VBZ	I
289-302	JJ	I
,	,	I
Crooke	NNP	I
,	,	I
S.	NNP	I
T.	NNP	I
and	CC	I
Lebleu	NNP	I
,	,	I
B.	NNP	I
,	,	I
ed.	NN	I
,	,	I
CRC	NNP	I
Press	NNP	I
,	,	I
1993	CD	I
.	.	O
Certain	NN	O
of	IN	O
these	DT	O
nucleobases	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
ther	JJ	O
art	NN	O
as	IN	O
suitable	JJ	O
for	IN	O
increasing	VBG	O
the	DT	O
binding	NN	O
affinity	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
These	DT	O
include	VBP	O
5-substituted	JJ	O
pyrimidines	NNS	O
,	,	O
6-azapyrimidines	NNS	O
and	CC	O
N-2	NNP	O
,	,	O
N-6	NNP	O
and	CC	O
O-6	NNP	O
substituted	VBD	O
purines	NNS	O
,	,	O
including	VBG	O
2-aminopropyladenine	JJ	O
,	,	O
5-propynyluracil	JJ	O
and	CC	O
5-propynylcytosine	JJ	O
.	.	O
5-methylcytosine	JJ	O
substitutions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
nucleic	JJ	O
acid	JJ	O
duplex	JJ	O
stability	NN	O
by	IN	O
0.6-1.2°	JJ	O
C.	NNP	O
and	CC	O
are	VBP	O
presently	RB	O
suitable	JJ	O
base	NN	O
substitutions	NNS	O
,	,	O
even	RB	O
more	RBR	O
particularly	RB	O
when	WRB	O
combined	VBN	O
with	IN	O
2′-O-methoxyethyl	JJ	O
sugar	NN	O
modifications	NNS	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
certain	JJ	O
of	IN	O
the	DT	O
above	NN	O
noted	VBD	O
modified	JJ	O
nucleobases	NNS	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
modified	JJ	O
nucleobases	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
the	DT	O
above	NN	O
noted	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,687,808	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,845,205	CD	O
;	:	O
5,130,302	CD	O
;	:	O
5,134,066	CD	O
;	:	O
5,175,273	CD	O
;	:	O
5,367,066	CD	O
;	:	O
5,432,272	CD	O
;	:	O
5,457,187	CD	O
;	:	O
5,459,255	CD	O
;	:	O
5,484,908	CD	O
;	:	O
5,502,177	CD	O
;	:	O
5,525,711	CD	O
;	:	O
5,552,540	CD	O
;	:	O
5,587,469	CD	O
;	:	O
5,594,121	CD	O
,	,	O
5,596,091	CD	O
;	:	O
5,614,617	CD	O
;	:	O
5,645,985	CD	O
;	:	O
5,830,653	CD	O
;	:	O
5,763,588	CD	O
;	:	O
6,005,096	CD	O
;	:	O
5,681,941	CD	O
;	:	O
and	CC	O
5,750,692	CD	O
.	.	O
Oligomeric	NNP	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
include	VB	O
polycyclic	JJ	O
heterocyclic	JJ	O
compounds	NNS	O
in	IN	O
place	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
naturally-occurring	JJ	O
heterocyclic	JJ	O
base	NN	O
moieties	NNS	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
tricyclic	JJ	O
heterocyclic	JJ	O
compounds	NNS	O
have	VBP	O
been	VBN	O
previously	RB	O
reported	VBN	O
.	.	O
These	DT	O
compounds	NNS	O
are	VBP	O
routinely	RB	O
used	VBN	O
in	IN	O
antisense	JJ	O
applications	NNS	O
to	TO	O
increase	VB	O
the	DT	O
binding	VBG	O
properties	NNS	O
of	IN	O
the	DT	O
modified	JJ	O
strand	NN	O
to	TO	O
a	DT	O
target	NN	O
strand	NN	O
.	.	O
The	DT	O
most	RBS	O
studied	JJ	O
modifications	NNS	O
are	VBP	O
targeted	VBN	O
to	TO	O
guanosines	NNS	O
hence	RB	O
they	PRP	O
have	VBP	O
been	VBN	O
termed	VBN	O
G-clamps	NNP	O
or	CC	O
cytidine	JJ	O
analogs	NNS	O
.	.	O
Representative	JJ	O
cytosine	NN	O
analogs	NNS	O
that	WDT	O
make	VBP	O
3	CD	O
hydrogen	NN	O
bonds	NNS	O
with	IN	O
a	DT	O
guanosine	NN	O
in	IN	O
a	DT	O
second	JJ	O
strand	NN	O
include	VBP	O
1,3-diazaphenoxazine-2-one	CD	O
(	(	O
R10═O	NNP	O
,	,	O
R11—R14═H	NNP	O
)	)	O
(	(	O
Kurchavov	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Nucleosides	NNP	I
and	CC	I
Nucleotides	NNP	I
,	,	I
1997	CD	I
,	,	I
16	CD	I
,	,	I
1837-1846	JJ	I
)	)	O
,	,	O
1,3-diazaphenothiazine-2-one	JJ	O
(	(	O
R10═S	NNP	O
,	,	O
R11—R14═H	NNP	O
)	)	O
,	,	O
(	(	O
Lin	NNP	B
,	,	I
K.-Y	NNP	I
.	.	I
;	:	I
Jones	NNP	I
,	,	I
R.	NNP	I
J.	NNP	I
;	:	I
Matteucci	NNP	I
,	,	I
M.	NNP	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc	NNP	I
.	.	I
1995	CD	I
,	,	I
117	CD	I
,	,	I
3873-3874	JJ	I
)	)	O
and	CC	O
6,7,8,9-tetrafluoro-1,3-diazaphenoxazine-2-one	JJ	O
(	(	O
R10═O	NNP	O
,	,	O
R11—R14═F	NNP	O
)	)	O
(	(	O
Wang	NNP	B
,	,	I
J.	NNP	I
;	:	I
Lin	NNP	I
,	,	I
K.-Y.	NNP	I
,	,	I
Matteucci	NNP	I
,	,	I
M.	NNP	I
Tetrahedron	NNP	I
Lett	NNP	I
.	.	I
1998	CD	I
,	,	I
39	CD	I
,	,	I
8385-8388	JJ	I
)	)	O
.	.	O
Incorporated	VBN	O
into	IN	O
oligonucleotides	IN	O
these	DT	O
base	JJ	O
modifications	NNS	O
were	VBD	O
shown	VBN	O
to	TO	O
hybridize	VB	O
with	IN	O
complementary	JJ	O
guanine	NN	O
and	CC	O
the	DT	O
latter	NN	O
was	VBD	O
also	RB	O
shown	VBN	O
to	TO	O
hybridize	VB	O
with	IN	O
adenine	NN	O
and	CC	O
to	TO	O
enhance	VB	O
helical	JJ	O
thermal	JJ	O
stability	NN	O
by	IN	O
extended	JJ	O
stacking	NN	O
interactions	NNS	O
(	(	O
also	RB	O
see	VBP	O
U.S.	NNP	O
Patent	NNP	O
Application	NNP	O
entitled	VBD	O
“	NNP	O
Modified	NNP	O
Peptide	NNP	O
Nucleic	NNP	O
Acids	NNP	O
”	NNP	O
filed	VBD	O
May	NNP	O
24	CD	O
,	,	O
2002	CD	O
,	,	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/155,920	CD	O
;	:	O
and	CC	O
U.S.	NNP	O
Patent	NNP	O
Application	NNP	O
entitled	VBD	O
“	JJ	O
Nuclease	NNP	O
Resistant	NNP	O
Chimeric	NNP	O
Oligonucleotides	NNP	O
”	NNP	O
filed	VBD	O
May	NNP	O
24	CD	O
,	,	O
2002	CD	O
,	,	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/013,295	CD	O
)	)	O
.	.	O
Further	RB	O
helix-stabilizing	NN	O
properties	NNS	O
have	VBP	O
been	VBN	O
observed	VBN	O
when	WRB	O
a	DT	O
cytosine	NN	O
analog/substitute	NN	O
has	VBZ	O
an	DT	O
aminoethoxy	JJ	O
moiety	NN	O
attached	VBN	O
to	TO	O
the	DT	O
rigid	JJ	O
1,3-diazaphenoxazine-2-one	JJ	O
scaffold	NN	O
(	(	O
R10═O	NNP	O
,	,	O
R11═—O—	NNP	O
(	(	O
CH2	NNP	O
)	)	O
2—NH2	CD	O
,	,	O
R12-14═H	NNP	O
)	)	O
(	(	O
Lin	NNP	B
,	,	I
K.-Y	NNP	I
.	.	I
;	:	I
Matteucci	NNP	I
,	,	I
M.	NNP	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc	NNP	I
.	.	I
1998	CD	I
,	,	I
120	CD	I
,	,	I
8531-8532	JJ	I
)	)	O
.	.	O
Binding	VBG	O
studies	NNS	O
demonstrated	VBD	O
that	IN	O
a	DT	O
single	JJ	O
incorporation	NN	O
could	MD	O
enhance	VB	O
the	DT	O
binding	NN	O
affinity	NN	O
of	IN	O
a	DT	O
model	NN	O
oligonucleotide	NN	O
to	TO	O
its	PRP$	O
complementary	JJ	O
target	NN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
with	IN	O
a	DT	O
ΔTm	NN	O
of	IN	O
up	IN	O
to	TO	O
18°	CD	O
relative	JJ	O
to	TO	O
5-methyl	JJ	O
cytosine	NN	O
(	(	O
dC5me	NN	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
high	JJ	O
affinity	NN	O
enhancement	NN	O
for	IN	O
a	DT	O
single	JJ	O
modification	NN	O
.	.	O
On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
the	DT	O
gain	NN	O
in	IN	O
helical	JJ	O
stability	NN	O
does	VBZ	O
not	RB	O
compromise	VB	O
the	DT	O
specificity	NN	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
.	.	O
Further	RB	O
tricyclic	JJ	O
heterocyclic	JJ	O
compounds	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
them	PRP	O
that	WDT	O
are	VBP	O
amenable	JJ	O
to	TO	O
use	VB	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
6,028,183	CD	O
,	,	O
and	CC	O
6,007,992	CD	O
.	.	O
The	DT	O
enhanced	JJ	O
binding	NN	O
affinity	NN	O
of	IN	O
the	DT	O
phenoxazine	NN	O
derivatives	VBZ	O
together	RB	O
with	IN	O
their	PRP$	O
uncompromised	JJ	O
sequence	NN	O
specificity	NN	O
makes	VBZ	O
them	PRP	O
valuable	JJ	O
nucleobase	JJ	O
analogs	NNS	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
more	RBR	O
potent	JJ	O
antisense-based	JJ	O
drugs	NNS	O
.	.	O
In	IN	O
fact	NN	O
,	,	O
promising	VBG	O
data	NNS	O
have	VBP	O
been	VBN	O
derived	VBN	O
from	IN	O
in	IN	O
vitro	JJ	O
experiments	NNS	O
demonstrating	VBG	O
that	IN	O
heptanucleotides	NNS	O
containing	VBG	O
phenoxazine	NN	O
substitutions	NNS	O
are	VBP	O
capable	JJ	O
to	TO	O
activate	VB	O
RNase	NNP	O
H	NNP	O
,	,	O
enhance	NN	O
cellular	JJ	O
uptake	NN	O
and	CC	O
exhibit	NN	O
an	DT	O
increased	VBN	O
antisense	NN	O
activity	NN	O
(	(	O
Lin	NNP	B
,	,	I
K-Y	NNP	I
;	:	I
Matteucci	NNP	I
,	,	I
M.	NNP	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc	NNP	I
.	.	I
1998	CD	I
,	,	I
120	CD	I
,	,	I
8531-8532	JJ	I
)	)	O
.	.	O
The	DT	O
activity	NN	O
enhancement	NN	O
was	VBD	O
even	RB	O
more	RBR	O
pronounced	JJ	O
in	IN	O
case	NN	O
of	IN	O
G-clamp	NNP	O
,	,	O
as	IN	O
a	DT	O
single	JJ	O
substitution	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
significantly	RB	O
improve	VB	O
the	DT	O
in	IN	O
vitro	JJ	O
potency	NN	O
of	IN	O
a	DT	O
20	CD	O
mer	NN	O
2′-deoxyphosphorothioate	JJ	O
oligonucleotides	NNS	O
(	(	O
Flanagan	NNP	B
,	,	I
W.	NNP	I
M.	NNP	I
;	:	I
Wolf	NNP	I
,	,	I
J.	NNP	I
J.	NNP	I
;	:	I
Olson	NNP	I
,	,	I
P.	NNP	I
;	:	I
Grant	NNP	I
,	,	I
D.	NNP	I
;	:	I
Lin	NNP	I
,	,	I
K.-Y	NNP	I
.	.	I
;	:	I
Wagner	NNP	I
,	,	I
R.	NNP	I
W.	NNP	I
;	:	I
Matteucci	NNP	I
,	,	I
M.	NNP	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1999	CD	I
,	,	I
96	CD	I
,	,	I
3513-3518	JJ	I
)	)	O
.	.	O
Further	RB	O
modified	VBN	O
polycyclic	JJ	O
heterocyclic	JJ	O
compounds	NNS	O
useful	JJ	O
as	IN	O
heterocyclic	JJ	O
bases	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
the	DT	O
above	NN	O
noted	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,687,808	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,845,205	CD	O
;	:	O
5,130,302	CD	O
;	:	O
5,134,066	CD	O
;	:	O
5,175,273	CD	O
;	:	O
5,367,066	CD	O
;	:	O
5,432,272	CD	O
;	:	O
5,434,257	CD	O
;	:	O
5,457,187	CD	O
;	:	O
5,459,255	CD	O
;	:	O
5,484,908	CD	O
;	:	O
5,502,177	CD	O
;	:	O
5,525,711	CD	O
;	:	O
5,552,540	CD	O
;	:	O
5,587,469	CD	O
;	:	O
5,594,121	CD	O
,	,	O
5,596,091	CD	O
;	:	O
5,614,617	CD	O
;	:	O
5,645,985	CD	O
;	:	O
5,646,269	CD	O
;	:	O
5,750,692	CD	O
;	:	O
5,830,653	CD	O
;	:	O
5,763,588	CD	O
;	:	O
6,005,096	CD	O
;	:	O
and	CC	O
5,681,941	CD	O
,	,	O
and	CC	O
Unites	VBZ	O
States	NNS	O
Pre-Grant	JJ	O
Publication	NNP	O
20030158403	CD	O
filed	VBD	O
Nov.	NNP	O
28	CD	O
,	,	O
2001	CD	O
.	.	O
Conjugates	VBZ	O
Another	DT	O
modification	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
involves	VBZ	O
chemically	RB	O
linking	VBG	O
to	TO	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
one	CD	O
or	CC	O
more	JJR	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
which	WDT	O
enhance	VBP	O
the	DT	O
properties	NNS	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
,	,	O
such	JJ	O
as	IN	O
to	TO	O
enhance	VB	O
the	DT	O
activity	NN	O
,	,	O
cellular	JJ	O
distribution	NN	O
or	CC	O
cellular	JJ	O
uptake	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
.	.	O
These	DT	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
can	MD	O
include	VB	O
conjugate	JJ	O
groups	NNS	O
covalently	RB	O
bound	IN	O
to	TO	O
functional	JJ	O
groups	NNS	O
such	JJ	O
as	IN	O
primary	JJ	O
or	CC	O
secondary	JJ	O
hydroxyl	NN	O
groups	NNS	O
.	.	O
Conjugate	NNP	O
groups	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
intercalators	NNS	O
,	,	O
reporter	NN	O
molecules	NNS	O
,	,	O
polyamines	NNS	O
,	,	O
polyamides	NNS	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
,	,	O
polyethers	NNS	O
,	,	O
groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
of	IN	O
oligomers	NNS	O
,	,	O
and	CC	O
groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
oligomers	NNS	O
.	.	O
Typical	JJ	O
conjugate	NN	O
groups	NNS	O
include	VBP	O
cholesterols	NNS	O
,	,	O
lipids	NNS	O
,	,	O
phospholipids	NNS	O
,	,	O
biotin	NN	O
,	,	O
phenazine	NN	O
,	,	O
folate	NN	O
,	,	O
phenanthridine	NN	O
,	,	O
anthraquinone	NN	O
,	,	O
acridine	NN	O
,	,	O
fluoresceins	NNS	O
,	,	O
rhodamines	NNS	O
,	,	O
coumarins	NNS	O
,	,	O
and	CC	O
dyes	NNS	O
.	.	O
Groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
include	VBP	O
groups	NNS	O
that	WDT	O
improve	VBP	O
uptake	NN	O
,	,	O
enhance	NN	O
resistance	NN	O
to	TO	O
degradation	NN	O
,	,	O
and/or	JJ	O
strengthen	NN	O
sequence-specific	JJ	O
hybridization	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
include	VBP	O
groups	NNS	O
that	WDT	O
improve	VBP	O
uptake	NN	O
,	,	O
distribution	NN	O
,	,	O
metabolism	NN	O
or	CC	O
excretion	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Representative	JJ	O
conjugate	NN	O
groups	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Application	NNP	O
PCT/US92/09196	NNP	O
,	,	O
filed	VBD	O
Oct.	NNP	O
23	CD	O
,	,	O
1992	CD	O
,	,	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
6,287,860	CD	O
and	CC	O
6,762,169	CD	O
.	.	O
Conjugate	NNP	O
moieties	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
lipid	VB	O
moieties	NNS	O
such	JJ	O
as	IN	O
a	DT	O
cholesterol	NN	O
moiety	NN	O
,	,	O
cholic	JJ	O
acid	NN	O
,	,	O
a	DT	O
thioether	NN	O
,	,	O
e.g.	NN	O
,	,	O
hexyl-S-tritylthiol	NN	O
,	,	O
a	DT	O
thiocholesterol	NN	O
,	,	O
an	DT	O
aliphatic	JJ	O
chain	NN	O
,	,	O
e.g.	NN	O
,	,	O
dodecandiol	NN	O
or	CC	O
undecyl	JJ	O
residues	NNS	O
,	,	O
a	DT	O
phospholipid	NN	O
,	,	O
e.g.	NN	O
,	,	O
di-hexadecyl-rac-glycerol	NN	O
or	CC	O
triethyl-ammonium	JJ	O
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate	JJ	O
,	,	O
a	DT	O
polyamine	NN	O
or	CC	O
a	DT	O
polyethylene	JJ	O
glycol	NN	O
chain	NN	O
,	,	O
or	CC	O
adamantane	RB	O
acetic	JJ	O
acid	NN	O
,	,	O
a	DT	O
palmityl	NN	O
moiety	NN	O
,	,	O
or	CC	O
an	DT	O
octadecylamine	JJ	O
or	CC	O
hexylamino-carbonyl-oxycholesterol	JJ	O
moiety	NN	O
.	.	O
Oligomeric	NNP	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
conjugated	VBN	O
to	TO	O
drug	NN	O
substances	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
aspirin	NN	O
,	,	O
warfarin	NN	O
,	,	O
phenylbutazone	NN	O
,	,	O
ibuprofen	NN	O
,	,	O
suprofen	NN	O
,	,	O
fenbufen	NN	O
,	,	O
ketoprofen	NN	O
,	,	O
(	(	O
S	NNP	O
)	)	O
-	:	O
(	(	O
+	NN	O
)	)	O
-pranoprofen	NN	O
,	,	O
carprofen	NN	O
,	,	O
dansylsarcosine	NN	O
,	,	O
2,3,5-triiodobenzoic	JJ	O
acid	NN	O
,	,	O
flufenamic	JJ	O
acid	NN	O
,	,	O
folinic	JJ	O
acid	NN	O
,	,	O
a	DT	O
benzothiadiazide	NN	O
,	,	O
chlorothiazide	NN	O
,	,	O
a	DT	O
diazepine	NN	O
,	,	O
indomethicin	NN	O
,	,	O
a	DT	O
barbiturate	NN	O
,	,	O
a	DT	O
cephalosporin	NN	O
,	,	O
a	DT	O
sulfa	JJ	O
drug	NN	O
,	,	O
an	DT	O
antidiabetic	JJ	O
,	,	O
an	DT	O
antibacterial	NN	O
or	CC	O
an	DT	O
antibiotic	JJ	O
.	.	O
Oligonucleotide-drug	JJ	O
conjugates	NNS	O
and	CC	O
their	PRP$	O
preparation	NN	O
are	VBP	O
described	VBN	O
in	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/334,130	CD	O
(	(	O
filed	VBN	O
Jun	NNP	O
.	.	O
15	CD	O
,	,	O
1999	CD	O
)	)	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
oligonucleotide	JJ	O
conjugates	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,828,979	CD	O
;	:	O
4,948,882	CD	O
;	:	O
5,218,105	CD	O
;	:	O
5,525,465	CD	O
;	:	O
5,541,313	CD	O
;	:	O
5,545,730	CD	O
;	:	O
5,552,538	CD	O
;	:	O
5,578,717	CD	O
,	,	O
5,580,731	CD	O
;	:	O
5,580,731	CD	O
;	:	O
5,591,584	CD	O
;	:	O
5,109,124	CD	O
;	:	O
5,118,802	CD	O
;	:	O
5,138,045	CD	O
;	:	O
5,414,077	CD	O
;	:	O
5,486,603	CD	O
;	:	O
5,512,439	CD	O
;	:	O
5,578,718	CD	O
;	:	O
5,608,046	CD	O
;	:	O
4,587,044	CD	O
;	:	O
4,605,735	CD	O
;	:	O
4,667,025	CD	O
;	:	O
4,762,779	CD	O
;	:	O
4,789,737	CD	O
;	:	O
4,824,941	CD	O
;	:	O
4,835,263	CD	O
;	:	O
4,876,335	CD	O
;	:	O
4,904,582	CD	O
;	:	O
4,958,013	CD	O
;	:	O
5,082,830	CD	O
;	:	O
5,112,963	CD	O
;	:	O
5,214,136	CD	O
;	:	O
5,082,830	CD	O
;	:	O
5,112,963	CD	O
;	:	O
5,214,136	CD	O
;	:	O
5,245,022	CD	O
;	:	O
5,254,469	CD	O
;	:	O
5,258,506	CD	O
;	:	O
5,262,536	CD	O
;	:	O
5,272,250	CD	O
;	:	O
5,292,873	CD	O
;	:	O
5,317,098	CD	O
;	:	O
5,371,241	CD	O
,	,	O
5,391,723	CD	O
;	:	O
5,416,203	CD	O
,	,	O
5,451,463	CD	O
;	:	O
5,510,475	CD	O
;	:	O
5,512,667	CD	O
;	:	O
5,514,785	CD	O
;	:	O
5,565,552	CD	O
;	:	O
5,567,810	CD	O
;	:	O
5,574,142	CD	O
;	:	O
5,585,481	CD	O
;	:	O
5,587,371	CD	O
;	:	O
5,595,726	CD	O
;	:	O
5,597,696	CD	O
;	:	O
5,599,923	CD	O
;	:	O
5,599,928	CD	O
and	CC	O
5,688,941	CD	O
.	.	O
Oligomeric	JJ	O
compounds	NNS	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
have	VB	O
one	CD	O
or	CC	O
more	JJR	O
stabilizing	VBG	O
groups	NNS	O
that	WDT	O
are	VBP	O
generally	RB	O
attached	VBN	O
to	TO	O
one	CD	O
or	CC	O
both	DT	O
termini	NN	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
enhance	VB	O
properties	NNS	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
nuclease	NN	O
stability	NN	O
.	.	O
Included	VBN	O
in	IN	O
stabilizing	VBG	O
groups	NNS	O
are	VBP	O
cap	JJ	O
structures	NNS	O
.	.	O
By	IN	O
“	JJ	O
cap	NN	O
structure	NN	O
or	CC	O
terminal	JJ	O
cap	NN	O
moiety	NN	O
”	NN	O
is	VBZ	O
meant	JJ	O
chemical	JJ	O
modifications	NNS	O
,	,	O
which	WDT	O
have	VBP	O
been	VBN	O
incorporated	VBN	O
at	IN	O
either	DT	O
terminus	NN	O
of	IN	O
oligonucleotides	NNS	O
(	(	O
see	VB	O
for	IN	O
example	NN	O
Wincott	NNP	O
et	CC	O
al.	NN	O
,	,	O
WO	NNP	O
97/26270	CD	O
)	)	O
.	.	O
These	DT	O
terminal	JJ	O
modifications	NNS	O
protect	VBP	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
having	VBG	O
terminal	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
from	IN	O
exonuclease	JJ	O
degradation	NN	O
,	,	O
and	CC	O
can	MD	O
improve	VB	O
delivery	NN	O
and/or	NN	O
localization	NN	O
within	IN	O
a	DT	O
cell	NN	O
.	.	O
The	DT	O
cap	NN	O
can	MD	O
be	VB	O
present	JJ	O
at	IN	O
either	CC	O
the	DT	O
5′-terminus	JJ	O
(	(	O
5′-cap	JJ	O
)	)	O
or	CC	O
at	IN	O
the	DT	O
3′-terminus	JJ	O
(	(	O
3′-cap	JJ	O
)	)	O
or	CC	O
can	MD	O
be	VB	O
present	JJ	O
on	IN	O
both	DT	O
termini	NN	O
of	IN	O
a	DT	O
single	JJ	O
strand	NN	O
,	,	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
termini	NN	O
of	IN	O
both	DT	O
strands	NNS	O
of	IN	O
a	DT	O
double-stranded	JJ	O
compound	NN	O
.	.	O
This	DT	O
cap	NN	O
structure	NN	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
confused	VBN	O
with	IN	O
the	DT	O
inverted	JJ	O
methylguanosine	NN	O
“	$	O
5′cap	CD	O
”	JJ	O
present	NN	O
at	IN	O
the	DT	O
5′	CD	O
end	NN	O
of	IN	O
native	JJ	O
mRNA	NN	O
molecules	NNS	O
.	.	O
In	IN	O
non-limiting	JJ	O
examples	NNS	O
,	,	O
the	DT	O
5′-cap	JJ	O
includes	VBZ	O
inverted	JJ	O
abasic	JJ	O
residue	NN	O
(	(	O
moiety	NN	O
)	)	O
,	,	O
4′,5′-methylene	JJ	O
nucleotide	NN	O
;	:	O
1-	JJ	O
(	(	O
beta-D-erythrofuranosyl	JJ	O
)	)	O
nucleotide	RB	O
,	,	O
4′-thio	JJ	O
nucleotide	NN	O
,	,	O
carbocyclic	JJ	O
nucleotide	RB	O
;	:	O
1,5-anhydrohexitol	JJ	O
nucleotide	NN	O
;	:	O
L-nucleotides	NNP	O
;	:	O
alpha-nucleotides	NNS	O
;	:	O
modified	VBN	O
base	NN	O
nucleotide	NN	O
;	:	O
phosphorodithioate	JJ	O
linkage	NN	O
;	:	O
threo-pentofuranosyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3′,4′-seco	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3,4-dihydroxybutyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3,5-dihydroxypentyl	JJ	O
riucleotide	NN	O
,	,	O
3′-3′-inverted	JJ	O
nucleotide	JJ	O
moiety	NN	O
;	:	O
3′-3′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
3′-2′-inverted	JJ	O
nucleotide	IN	O
moiety	NN	O
;	:	O
3′-2′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
1,4-butanediol	JJ	O
phosphate	NN	O
;	:	O
3′-phosphoramidate	JJ	O
;	:	O
hexylphosphate	NN	O
;	:	O
aminohexyl	JJ	O
phosphate	NN	O
;	:	O
3′-phosphate	JJ	O
;	:	O
3′-phosphorothioate	JJ	O
;	:	O
phosphorodithioate	NN	O
;	:	O
or	CC	O
bridging	VBG	O
or	CC	O
non-bridging	JJ	O
methylphosphonate	NN	O
moiety	NN	O
(	(	O
for	IN	O
more	JJR	O
details	NNS	O
see	VBP	O
Wincott	NNP	O
et	FW	O
al.	NN	O
,	,	O
International	NNP	O
PCT	NNP	O
publication	NN	O
No	NNP	O
.	.	O
WO	NNP	O
97/26270	CD	O
)	)	O
.	.	O
For	IN	O
siRNA	JJ	O
constructs	NNS	O
,	,	O
the	DT	O
5′	CD	O
end	NN	O
(	(	O
5′	CD	O
cap	NN	O
)	)	O
is	VBZ	O
commonly	RB	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
5′-hydroxyl	JJ	O
or	CC	O
5′-phosphate	JJ	O
.	.	O
Particularly	RB	O
suitable	JJ	O
3′-cap	JJ	O
structures	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
4′,5′-methylene	JJ	O
nucleotide	RB	O
;	:	O
1-	JJ	O
(	(	O
beta-D-erythrofuranosyl	JJ	O
)	)	O
nucleotide	RB	O
;	:	O
4′-thio	JJ	O
nucleotide	NN	O
,	,	O
carbocyclic	JJ	O
nucleotide	RB	O
;	:	O
5′-amino-alkyl	JJ	O
phosphate	NN	O
;	:	O
1,3-diamino-2-propyl	JJ	O
phosphate	NN	O
,	,	O
3-aminopropyl	JJ	O
phosphate	NN	O
;	:	O
6-aminohexyl	JJ	O
phosphate	NN	O
;	:	O
1,2-aminododecyl	JJ	O
phosphate	NN	O
;	:	O
hydroxypropyl	JJ	O
phosphate	NN	O
;	:	O
1,5-anhydrohexitol	JJ	O
nucleotide	NN	O
;	:	O
L-nucleotide	NNP	O
;	:	O
alpha-nucleotide	JJ	O
;	:	O
modified	VBN	O
base	NN	O
nucleotide	NN	O
;	:	O
phosphorodithioate	NN	O
;	:	O
threo-pentofuranosyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3′,4′-seco	JJ	O
nucleotide	NN	O
;	:	O
3,4-dihydroxybutyl	JJ	O
nucleotide	NN	O
;	:	O
3,5-dihydroxypentyl	JJ	O
nucleotide	NN	O
,	,	O
5′-5′-inverted	JJ	O
nucleotide	JJ	O
moiety	NN	O
;	:	O
5′-5′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
5′-phosphoramidate	JJ	O
;	:	O
5′-phosphorothioate	JJ	O
;	:	O
1,4-butanediol	JJ	O
phosphate	NN	O
;	:	O
5′-amino	JJ	O
;	:	O
bridging	VBG	O
and/or	IN	O
non-bridging	JJ	O
5′-phosphoramidate	JJ	O
,	,	O
phosphorothioate	JJ	O
and/or	NN	O
phosphorodithioate	NN	O
,	,	O
bridging	VBG	O
or	CC	O
non	JJ	O
bridging	NN	O
methylphosphonate	NN	O
and	CC	O
5′-mercapto	JJ	O
moieties	NNS	O
(	(	O
for	IN	O
more	JJR	O
details	NNS	O
see	VBP	O
Beaucage	NNP	B
and	CC	I
Tyer	NNP	I
,	,	I
1993	CD	I
,	,	I
Tetrahedron	NNP	I
49	CD	I
,	,	I
1925	CD	I
)	)	O
.	.	O
Further	RB	O
3′	CD	O
and	CC	O
5′-stabilizing	JJ	O
groups	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
cap	VB	O
one	CD	O
or	CC	O
both	DT	O
ends	NNS	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
impart	VB	O
nuclease	JJ	O
stability	NN	O
include	VBP	O
those	DT	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
03/004602	CD	O
published	VBN	O
on	IN	O
Jan.	NNP	O
16	CD	O
,	,	O
2003	CD	O
.	.	O
Chimeric	NNP	O
Compounds	NNP	O
It	PRP	O
is	VBZ	O
not	RB	O
necessary	JJ	O
for	IN	O
all	DT	O
positions	NNS	O
in	IN	O
a	DT	O
given	VBN	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
be	VB	O
uniformly	RB	O
modified	VBN	O
,	,	O
and	CC	O
in	IN	O
fact	NN	O
more	JJR	O
than	IN	O
one	CD	O
of	IN	O
the	DT	O
aforementioned	JJ	O
modifications	NNS	O
may	MD	O
be	VB	O
incorporated	VBN	O
in	IN	O
a	DT	O
single	JJ	O
compound	NN	O
or	CC	O
even	RB	O
within	IN	O
a	DT	O
single	JJ	O
nucleoside	NN	O
within	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
includes	VBZ	O
oligomeric	JJ	O
compounds	NNS	O
which	WDT	O
are	VBP	O
chimeric	JJ	O
compounds	NNS	O
.	.	O
“	JJ	O
Chimeric	NNP	O
”	NNP	O
oligomeric	JJ	O
compounds	NNS	O
or	CC	O
“	JJ	O
chimeras	NNS	O
,	,	O
”	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
are	VBP	O
single-	JJ	O
or	CC	O
double-stranded	JJ	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
such	JJ	O
as	IN	O
oligonucleotides	NNS	O
,	,	O
which	WDT	O
contain	VBP	O
two	CD	O
or	CC	O
more	JJR	O
chemically	RB	O
distinct	JJ	O
regions	NNS	O
,	,	O
each	DT	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
monomer	NN	O
unit	NN	O
,	,	O
i.e.	FW	O
,	,	O
a	DT	O
nucleotide	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
an	DT	O
oligonucleotide	JJ	O
compound	NN	O
.	.	O
Chimeric	NNP	O
antisense	NN	O
oligonucleotides	NNS	O
are	VBP	O
one	CD	O
form	NN	O
of	IN	O
oligomeric	JJ	O
compound	NN	O
.	.	O
These	DT	O
oligonucleotides	NNS	O
typically	RB	O
contain	VBP	O
at	IN	O
least	JJS	O
one	CD	O
region	NN	O
which	WDT	O
is	VBZ	O
modified	VBN	O
so	RB	O
as	IN	O
to	TO	O
confer	VB	O
upon	IN	O
the	DT	O
oligonucleotide	NN	O
increased	VBD	O
resistance	NN	O
to	TO	O
nuclease	VB	O
degradation	NN	O
,	,	O
increased	VBD	O
cellular	JJ	O
uptake	NN	O
,	,	O
alteration	NN	O
of	IN	O
charge	NN	O
,	,	O
increased	JJ	O
stability	NN	O
and/or	NN	O
increased	VBD	O
binding	JJ	O
affinity	NN	O
for	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
An	DT	O
additional	JJ	O
region	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
substrate	NN	O
for	IN	O
RNAses	NNP	O
or	CC	O
other	JJ	O
enzymes	NNS	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
RNAse	NNP	O
H	NNP	O
is	VBZ	O
a	DT	O
cellular	JJ	O
endonuclease	NN	O
which	WDT	O
cleaves	VBZ	O
the	DT	O
RNA	NNP	O
strand	NN	O
of	IN	O
an	DT	O
RNA	NN	O
:	:	O
DNA	NN	O
duplex	NN	O
.	.	O
Activation	NN	O
of	IN	O
RNase	NNP	O
H	NNP	O
,	,	O
therefore	RB	O
,	,	O
results	NNS	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
when	WRB	O
bound	NN	O
by	IN	O
a	DT	O
DNA-like	JJ	O
oligomeric	JJ	O
compound	NN	O
,	,	O
thereby	RB	O
greatly	RB	O
enhancing	VBG	O
the	DT	O
efficiency	NN	O
of	IN	O
oligonucleotide-mediated	JJ	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
The	DT	O
cleavage	NN	O
of	IN	O
RNA	NNP	O
:	:	O
RNA	JJ	O
hybrids	NNS	O
can	MD	O
,	,	O
in	IN	O
like	JJ	O
fashion	NN	O
,	,	O
be	VB	O
accomplished	VBN	O
through	IN	O
the	DT	O
actions	NNS	O
of	IN	O
endoribonucleases	NNS	O
,	,	O
such	JJ	O
as	IN	O
RNase	NNP	O
III	NNP	O
or	CC	O
RNAseL	NNP	O
which	WDT	O
cleaves	VBZ	O
both	DT	O
cellular	JJ	O
and	CC	O
viral	JJ	O
RNA	NNP	O
.	.	O
Cleavage	NN	O
products	NNS	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
can	MD	O
be	VB	O
routinely	RB	O
detected	VBN	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
and	CC	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
associated	VBN	O
nucleic	JJ	O
acid	JJ	O
hybridization	NN	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Chimeric	NNP	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
formed	VBN	O
as	IN	O
composite	JJ	O
structures	NNS	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
oligonucleotides	NNS	O
,	,	O
modified	VBD	O
oligonucleotides	NNS	O
,	,	O
oligonucleosides	NNS	O
,	,	O
oligonucleotide	IN	O
mimetics	NNS	O
,	,	O
or	CC	O
regions	NNS	O
or	CC	O
portions	NNS	O
thereof	VBP	O
.	.	O
Such	JJ	O
compounds	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
referred	VBN	O
to	TO	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
hybrids	NNS	O
or	CC	O
gapmers	NNS	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
hybrid	JJ	O
structures	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,013,830	CD	O
;	:	O
5,149,797	CD	O
;	:	O
5,220,007	CD	O
;	:	O
5,256,775	CD	O
;	:	O
5,366,878	CD	O
;	:	O
5,403,711	CD	O
;	:	O
5,491,133	CD	O
;	:	O
5,565,350	CD	O
;	:	O
5,623,065	CD	O
;	:	O
5,652,355	CD	O
;	:	O
5,652,356	CD	O
;	:	O
and	CC	O
5,700,922	CD	O
.	.	O
A	DT	O
“	JJ	O
gapmer	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
,	,	O
generally	RB	O
an	DT	O
oligonucleotide	NN	O
,	,	O
having	VBG	O
a	DT	O
2′-deoxyoligonucleotide	JJ	O
flanked	VBN	O
by	IN	O
non-deoxyoligonucleotides	NNS	O
.	.	O
The	DT	O
central	JJ	O
region	NN	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
“	NNP	O
gap.	NN	O
”	VBD	O
The	DT	O
flanking	NN	O
regions	NNS	O
are	VBP	O
referred	VBN	O
to	TO	O
as	IN	O
“	NNP	O
wings.	VBD	O
”	NNP	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
theory	NN	O
,	,	O
the	DT	O
gap	NN	O
of	IN	O
the	DT	O
gapmer	NN	O
presents	VBZ	O
a	DT	O
substrate	NN	O
recognizable	JJ	O
by	IN	O
RNase	NNP	O
H	NNP	O
when	WRB	O
bound	NN	O
to	TO	O
the	DT	O
RNA	NNP	O
target	NN	O
whereas	IN	O
the	DT	O
wings	NNS	O
do	VBP	O
not	RB	O
provide	VB	O
such	PDT	O
a	DT	O
substrate	NN	O
but	CC	O
can	MD	O
confer	VB	O
other	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
contributing	VBG	O
to	TO	O
duplex	VB	O
stability	NN	O
or	CC	O
advantageous	JJ	O
pharmacokinetic	JJ	O
effects	NNS	O
.	.	O
Each	DT	O
wing	NN	O
can	MD	O
be	VB	O
one	CD	O
or	CC	O
more	JJR	O
non-deoxyoligonucleotide	JJ	O
monomers	NNS	O
(	(	O
if	IN	O
one	CD	O
of	IN	O
the	DT	O
wings	NNS	O
has	VBZ	O
zero	CD	O
non-deoxyoligonucleotide	JJ	O
monomers	NNS	O
,	,	O
a	DT	O
“	JJ	O
hemimer	NN	O
”	NN	O
is	VBZ	O
described	VBN	O
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
gapmer	NN	O
is	VBZ	O
a	DT	O
ten	JJ	O
deoxynucleotide	NN	O
gap	NN	O
flanked	VBN	O
by	IN	O
five	CD	O
non-deoxynucleotide	JJ	O
wings	NNS	O
.	.	O
This	DT	O
is	VBZ	O
refered	VBN	O
to	TO	O
as	IN	O
a	DT	O
5-10-5	JJ	O
gapmer	NN	O
.	.	O
Other	JJ	O
configurations	NNS	O
are	VBP	O
readily	RB	O
recognized	VBN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
wings	NNS	O
comprise	VBP	O
2′-MOE	JJ	O
modified	JJ	O
nucleotides	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
the	DT	O
gapmer	NN	O
has	VBZ	O
a	DT	O
phosphorothioate	NN	O
backbone	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
the	DT	O
gapmer	NN	O
has	VBZ	O
2′-MOE	JJ	O
wings	NNS	O
and	CC	O
a	DT	O
phosphorothioate	NN	O
backbone	NN	O
.	.	O
Other	JJ	O
suitable	JJ	O
modifications	NNS	O
are	VBP	O
readily	RB	O
recognizable	JJ	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Oligomer	NNP	O
Synthesis	NNP	O
Oligomerization	NNP	O
of	IN	O
modified	VBN	O
and	CC	O
unmodified	JJ	O
nucleosides	NNS	O
can	MD	O
be	VB	O
routinely	RB	O
performed	VBN	O
according	VBG	O
to	TO	O
literature	NN	O
procedures	NNS	O
for	IN	O
DNA	NNP	O
(	(	O
Protocols	NNP	B
for	IN	I
Oligonucleotides	NNP	I
and	CC	I
Analogs	NNP	I
,	,	I
Ed	NNP	I
.	.	I
Agrawal	NNP	I
(	(	I
1993	CD	I
)	)	I
,	,	I
Humana	NNP	I
Press	NNP	I
)	)	O
and/or	VBP	O
RNA	NNP	O
(	(	O
Scaringe	NNP	B
,	,	I
Methods	NNP	I
(	(	I
2001	CD	I
)	)	I
,	,	I
23	CD	I
,	,	I
206-217	JJ	I
.	.	O
Gait	NNP	B
et	CC	I
al.	NN	I
,	,	I
Applications	NNP	I
of	IN	I
Chemically	NNP	I
synthesized	VBD	I
RNA	NNP	I
in	IN	I
RNA	NNP	I
:	:	I
Protein	NNP	I
Interactions	NNP	I
,	,	I
Ed	NNP	I
.	.	I
Smith	NNP	I
(	(	I
1998	CD	I
)	)	I
,	,	I
1-36	JJ	I
.	.	O
Gallo	NNP	B
et	CC	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
(	(	I
2001	CD	I
)	)	I
,	,	I
57	CD	I
,	,	I
5707-5713	JJ	I
)	)	O
.	.	O
Oligomeric	NNP	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
conveniently	RB	O
and	CC	O
routinely	RB	O
made	VBD	O
through	IN	O
the	DT	O
well-known	JJ	O
technique	NN	O
of	IN	O
solid	JJ	O
phase	NN	O
synthesis	NN	O
.	.	O
Equipment	NN	O
for	IN	O
such	JJ	O
synthesis	NN	O
is	VBZ	O
sold	VBN	O
by	IN	O
several	JJ	O
vendors	NNS	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Applied	NNP	O
Biosystems	NNP	O
(	(	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Any	DT	O
other	JJ	O
means	NNS	O
for	IN	O
such	JJ	O
synthesis	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
may	MD	O
additionally	RB	O
or	CC	O
alternatively	RB	O
be	VB	O
employed	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
well	RB	O
known	VBN	O
to	TO	O
use	VB	O
similar	JJ	O
techniques	NNS	O
to	TO	O
prepare	VB	O
oligonucleotides	NNS	O
such	JJ	O
as	IN	O
the	DT	O
phosphorothioates	NNS	O
and	CC	O
alkylated	JJ	O
derivatives	NNS	O
.	.	O
Starting	VBG	O
Materials	NNS	O
and	CC	O
Intermediates	VBZ	O
The	DT	O
following	JJ	O
precursor	NN	O
compounds	NNS	O
,	,	O
including	VBG	O
amidites	NNS	O
and	CC	O
their	PRP$	O
intermediates	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
methods	NNS	O
routine	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
;	:	O
5′-O-Dimethoxytrityl-thymidine	JJ	O
intermediate	NN	O
for	IN	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
,	,	O
5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine	JJ	O
intermediate	NN	O
for	IN	O
5-methyl-dC	JJ	O
amidite	NN	O
,	,	O
5′-O-Dimethoxytrityl-2′-deoxy-N4-benzoyl-5-methylcytidine	JJ	O
penultimate	NN	O
intermediate	NN	O
for	IN	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
,	,	O
(	(	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-deoxy-N4-benzoyl-5-methylcytidin-3′-O-yl	NN	O
)	)	O
-2-cyanoethyl-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
)	)	O
,	,	O
2′-Fluorodeoxyadenosine	JJ	O
,	,	O
2′-Fluorodeoxyguanosine	JJ	O
,	,	O
2′-Fluorouridine	JJ	O
,	,	O
2′-Fluorodeoxycytidine	JJ	O
,	,	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
modified	VBN	O
amidites	NNS	O
,	,	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
intermediate	JJ	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
penultimate	NN	O
intermediate	NN	O
,	,	O
(	(	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridin-3′-O-yl	NN	O
)	)	O
-2-cyanoethyl-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
T	NNP	O
amidite	NN	O
)	)	O
,	,	O
5′-O-Dimethoxytrityl-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methylcytidine	NN	O
intermediate	JJ	O
,	,	O
5′-O-dimethoxytrityl-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-benzoyl-5-methylcytidine	NN	O
penultimate	NN	O
intermediate	NN	O
,	,	O
(	(	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-benzoyl-5-methylcytidin-3′-O-yl	NN	O
)	)	O
-2-cyanoethyl-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
5-Me-C	NNP	O
amidite	NN	O
)	)	O
,	,	O
(	(	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N6-benzoyladenosin-3′-O-yl	NN	O
)	)	O
-2-cyanoethyl-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
A	NNP	O
amdite	NN	O
)	)	O
,	,	O
(	(	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-isobutyrylguanosin-3′-O-yl	NN	O
)	)	O
-2-cyanoethyl-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
G	NNP	O
amidite	NN	O
)	)	O
,	,	O
2′-O-	JJ	O
(	(	O
Aminooxyethyl	NNP	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
and	CC	O
2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
,	,	O
2′-	JJ	O
(	(	O
Dimethylaminooxyethoxy	NNP	O
)	)	O
nucleoside	RB	O
amidites	VBZ	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-O2-2′-anhydro-5-methyluridine	JJ	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-2′-O-	JJ	O
(	(	O
2-hydroxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
,	,	O
2′-O-	JJ	O
(	(	O
(	(	O
2-phthalimidoxy	JJ	O
)	)	O
ethyl	NN	O
)	)	O
-5′-t-butyldiphenylsilyl-5-methyluridine	NN	O
,	,	O
5′-O-tert-butyldiphenylsilyl-2′-O-	JJ	O
(	(	O
(	(	O
2-formadoximinooxy	JJ	O
)	)	O
ethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-2′-O—	JJ	O
(	(	O
N	NNP	O
,	,	O
N	NNP	O
dimethylaminooxyethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminooxyethyl	NNP	O
)	)	O
-5-methyluridine-3′-	NN	O
(	(	O
(	(	O
2-cyanoethyl	CD	O
)	)	O
-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
)	)	O
,	,	O
2′-	JJ	O
(	(	O
Aminooxyethoxy	NNP	O
)	)	O
nucleoside	RB	O
amidites	VBZ	O
,	,	O
N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-	NNP	O
(	(	O
2-ethylacetyl	JJ	O
)	)	O
-5′-O-	NN	O
(	(	O
4,4′-dimethoxytrityl	JJ	O
)	)	O
guanosine-3′-	NN	O
(	(	O
(	(	O
2-cyanoethyl	CD	O
)	)	O
-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
)	)	O
,	,	O
2′-dimethylaminoethoxyethoxy	JJ	O
(	(	O
2′-DMAEOE	JJ	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
,	,	O
2′-O-	JJ	O
(	(	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
ethyl	NN	O
)	)	O
-5-methyl	FW	O
uridine	JJ	O
,	,	O
5′-O-dimethoxytrityl-2′-O-	JJ	O
(	(	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
-ethyl	NNP	O
)	)	O
)	)	O
-5-methyl	FW	O
uridine	JJ	O
and	CC	O
5′-O-Dimethoxytrityl-2′-O-	JJ	O
(	(	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
-ethyl	NNP	O
)	)	O
)	)	O
-5-methyl	$	O
uridine-3′-O-	JJ	O
(	(	O
cyanoethyl-N	JJ	O
,	,	O
N-diisopropyl	NNP	O
)	)	O
phosphoramidite	NN	O
.	.	O
The	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
precursor	NN	O
compounds	NNS	O
for	IN	O
oligonucleotide	JJ	O
synthesis	NN	O
are	VBP	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,426,220	CD	O
and	CC	O
published	VBN	O
PCT	NNP	O
WO	NNP	O
02/36743	CD	O
.	.	O
2′-Deoxy	JJ	O
and	CC	O
2′-methoxy	JJ	O
beta-cyanoethyldiisopropyl	JJ	O
phosphoramidites	NNS	O
can	MD	O
be	VB	O
purchased	VBN	O
from	IN	O
commercial	JJ	O
sources	NNS	O
(	(	O
e.g	NN	O
.	.	O
Chemgenes	NNS	O
,	,	O
Needham	NNP	O
,	,	O
Mass	NNP	O
.	.	O
or	CC	O
Glen	NNP	O
Research	NNP	O
,	,	O
Inc.	NNP	O
Sterling	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
Other	JJ	O
2′-O-alkoxy	JJ	O
substituted	VBN	O
nucleoside	IN	O
amidites	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,506,351	CD	O
.	.	O
Oligonucleotides	IN	O
containing	VBG	O
5-methyl-2′-deoxycytidine	JJ	O
(	(	O
5-Me-C	JJ	O
)	)	O
nucleotides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
routinely	RB	O
according	VBG	O
to	TO	O
published	VBN	O
methods	NNS	O
(	(	O
Sanghvi	NNP	B
,	,	I
et	NN	I
.	.	I
al.	NN	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Research	NNP	I
,	,	I
1993	CD	I
,	,	I
21	CD	I
,	,	I
3197-3203	JJ	I
)	)	O
using	VBG	O
commercially	RB	O
available	JJ	O
phosphoramidites	NNS	O
(	(	O
Glen	NNP	O
Research	NNP	O
,	,	O
Sterling	NNP	O
Va.	NNP	O
or	CC	O
ChemGenes	NNP	O
,	,	O
Needham	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
2′-fluoro	JJ	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
routinely	RB	O
as	IN	O
described	VBN	O
(	(	O
Kawasaki	NNP	B
,	,	I
et	NN	I
.	.	I
al.	NN	I
,	,	I
J.	NNP	I
Med	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1993	CD	I
,	,	I
36	CD	I
,	,	I
831-841	JJ	I
)	)	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,670,633	CD	O
.	.	O
2′-O-Methoxyethyl-substituted	JJ	O
nucleoside	JJ	O
amidites	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
routinely	RB	O
as	IN	O
per	IN	O
the	DT	O
methods	NNS	O
of	IN	O
Martin	NNP	B
,	,	I
P.	NNP	I
,	,	I
Helvetica	NNP	I
Chimica	NNP	I
Acta	NNP	I
,	,	I
1995	CD	I
,	,	I
78	CD	I
,	,	I
486-504	JJ	I
.	.	O
Aminooxyethyl	NNP	O
and	CC	O
dimethylaminooxyethyl	VB	O
amidites	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
routinely	RB	O
as	IN	O
per	IN	O
the	DT	O
methods	NNS	O
of	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,127,533	CD	O
.	.	O
Oligonucleotide	IN	O
Synthesis	NNP	O
Phosphorothioate-containing	NNP	O
oligonucleotides	NNS	O
(	(	O
P═S	NNP	O
)	)	O
can	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
methods	NNS	O
routine	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Protocols	NNP	B
for	IN	I
Oligonucleotides	NNP	I
and	CC	I
Analogs	NNP	I
,	,	I
Ed	NNP	I
.	.	I
Agrawal	NNP	I
(	(	I
1993	CD	I
)	)	I
,	,	I
Humana	NNP	I
Press	NNP	I
)	)	O
.	.	O
Phosphinate	NNP	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,508,270	CD	O
.	.	O
Alkyl	NNP	O
phosphonate	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,469,863	CD	O
.	.	O
3′-Deoxy-3′-methylene	JJ	O
phosphonate	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,610,289	CD	O
or	CC	O
5,625,050	CD	O
.	.	O
Phosphoramidite	NNP	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,256,775	CD	O
or	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,366,878	CD	O
.	.	O
Alkylphosphonothioate	NNP	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
published	VBN	O
PCT	NNP	O
applications	NNS	O
PCT/US94/00902	NNP	O
and	CC	O
PCT/US93/06976	NNP	O
(	(	O
published	VBN	O
as	IN	O
WO	NNP	O
94/17093	CD	O
and	CC	O
WO	NNP	O
94/02499	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O
3′-Deoxy-3′-amino	JJ	O
phosphoramidate	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,476,925	CD	O
.	.	O
Phosphotriester	NNP	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,023,243	CD	O
.	.	O
Borano	NNP	O
phosphate	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,130,302	CD	O
and	CC	O
5,177,198	CD	O
.	.	O
4′-thio-containing	JJ	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,639,873	CD	O
.	.	O
Oligonucleoside	IN	O
Synthesis	NNP	O
Methylenemethylimino	NNP	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
MMI	NNP	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
methylenedimethylhydrazo	NN	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
MDH	NNP	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
and	CC	O
methylenecarbonylamino	NN	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
amide-3	JJ	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
and	CC	O
methyleneaminocarbonyl	NN	O
linked	VBN	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
amide-4	JJ	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
mixed	JJ	O
backbone	NN	O
compounds	VBZ	O
having	VBG	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
alternating	VBG	O
MMI	NNP	O
and	CC	O
P═O	NNP	O
or	CC	O
P═S	NNP	O
linkages	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,378,825	CD	O
,	,	O
5,386,023	CD	O
,	,	O
5,489,677	CD	O
,	,	O
5,602,240	CD	O
and	CC	O
5,610,289	CD	O
.	.	O
Formacetal	NNP	O
and	CC	O
thioformacetal	JJ	O
linked	VBD	O
oligonucleosides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,264,562	CD	O
and	CC	O
5,264,564	CD	O
.	.	O
Ethylene	NNP	O
oxide	NN	O
linked	VBD	O
oligonucleosides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,223,618	CD	O
.	.	O
Peptide	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Synthesis	NNP	O
Peptide	NNP	O
nucleic	JJ	O
acids	NNS	O
(	(	O
PNAs	NNP	O
)	)	O
can	MD	O
be	VB	O
prepared	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
various	JJ	O
procedures	NNS	O
referred	VBD	O
to	TO	O
in	IN	O
Peptide	NNP	B
Nucleic	NNP	I
Acids	NNP	I
(	(	I
PNA	NNP	I
)	)	I
:	:	I
Synthesis	NN	I
,	,	I
Properties	NNPS	I
and	CC	I
Potential	NNP	I
Applications	NNP	I
,	,	I
Bioorganic	NNP	I
&	CC	I
Medicinal	NNP	I
Chemistry	NNP	I
,	,	I
1996	CD	I
,	,	I
4	CD	I
,	,	I
5-23	CD	I
.	.	O
They	PRP	O
may	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,539,082	CD	O
,	,	O
5,700,922	CD	O
,	,	O
5,719,262	CD	O
,	,	O
6,559,279	CD	O
and	CC	O
6,762,281	CD	O
.	.	O
Synthesis	NN	O
of	IN	O
2′-O-Protected	JJ	O
Oligomers/RNA	NNP	O
Synthesis	NNP	O
Oligomeric	NNP	O
compounds	VBZ	O
incorporating	VBG	O
at	IN	O
least	JJS	O
one	CD	O
2′-O-protected	JJ	O
nucleoside	NN	O
by	IN	O
methods	NNS	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
After	IN	O
incorporation	NN	O
and	CC	O
appropriate	JJ	O
deprotection	NN	O
the	DT	O
2′-O-protected	JJ	O
nucleoside	NN	O
will	MD	O
be	VB	O
converted	VBN	O
to	TO	O
a	DT	O
ribonucleoside	NN	O
at	IN	O
the	DT	O
position	NN	O
of	IN	O
incorporation	NN	O
.	.	O
The	DT	O
number	NN	O
and	CC	O
position	NN	O
of	IN	O
the	DT	O
2-ribonucleoside	JJ	O
units	NNS	O
in	IN	O
the	DT	O
final	JJ	O
oligomeric	NN	O
compound	NN	O
can	MD	O
vary	VB	O
from	IN	O
one	CD	O
at	IN	O
any	DT	O
site	NN	O
or	CC	O
the	DT	O
strategy	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
prepare	VB	O
up	RP	O
to	TO	O
a	DT	O
full	JJ	O
2′-OH	JJ	O
modified	VBN	O
oligomeric	JJ	O
compound	NN	O
.	.	O
A	DT	O
large	JJ	O
number	NN	O
of	IN	O
2′-O-protecting	JJ	O
groups	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
for	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
oligoribo-nucleotides	NNS	O
and	CC	O
any	DT	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
Some	DT	O
of	IN	O
the	DT	O
protecting	VBG	O
groups	NNS	O
used	VBN	O
initially	RB	O
for	IN	O
oligoribonucleotide	JJ	O
synthesis	NN	O
included	VBD	O
tetrahydropyran-1-yl	JJ	O
and	CC	O
4-methoxytetrahydropyran-4-yl	JJ	O
.	.	O
These	DT	O
two	CD	O
groups	NNS	O
are	VBP	O
not	RB	O
compatible	JJ	O
with	IN	O
all	DT	O
5′-O-protecting	JJ	O
groups	NNS	O
so	RB	O
modified	JJ	O
versions	NNS	O
were	VBD	O
used	VBN	O
with	IN	O
5′-DMT	JJ	O
groups	NNS	O
such	JJ	O
as	IN	O
1-	JJ	O
(	(	O
2-fluorophenyl	JJ	O
)	)	O
-4-methoxypiperidin-4-yl	NN	O
(	(	O
Fpmp	NNP	O
)	)	O
.	.	O
Reese	JJ	O
et	CC	O
al	NN	O
.	.	O
have	VB	O
identified	VBN	O
a	DT	O
number	NN	O
of	IN	O
piperidine	JJ	O
derivatives	NNS	O
(	(	O
like	IN	O
Fpmp	NNP	O
)	)	O
that	WDT	O
are	VBP	O
useful	JJ	O
in	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
oligoribonucleotides	NNS	O
including	VBG	O
1-	JJ	O
[	NN	O
(	(	O
chloro-4-methyl	JJ	O
)	)	O
phenyl	NN	O
]	JJ	O
-4′-methoxypiperidin-4-yl	NNP	O
(	(	O
Reese	JJ	B
et	NN	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
Lett.	NNP	I
,	,	I
1986	CD	I
,	,	I
(	(	I
27	CD	I
)	)	I
,	,	I
2291	CD	I
)	)	O
.	.	O
Another	DT	O
approach	NN	O
is	VBZ	O
to	TO	O
replace	VB	O
the	DT	O
standard	JJ	O
5′-DMT	JJ	O
(	(	O
dimethoxytrityl	NN	O
)	)	O
group	NN	O
with	IN	O
protecting	VBG	O
groups	NNS	O
that	WDT	O
were	VBD	O
removed	VBN	O
under	IN	O
non-acidic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
levulinyl	NN	O
and	CC	O
9-fluorenylmethoxycarbonyl	CD	O
.	.	O
Such	JJ	O
groups	NNS	O
enable	VBP	O
the	DT	O
use	NN	O
of	IN	O
acid	NN	O
labile	IN	O
2′-protecting	JJ	O
groups	NNS	O
for	IN	O
oligoribonucleotide	JJ	O
synthesis	NN	O
.	.	O
Another	DT	O
more	RBR	O
widely	RB	O
used	VBN	O
protecting	VBG	O
group	NN	O
,	,	O
initially	RB	O
used	VBN	O
for	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
oligoribonucleotides	NNS	O
,	,	O
is	VBZ	O
the	DT	O
t-butyldimethylsilyl	JJ	O
group	NN	O
(	(	O
Ogilvie	NNP	B
et	RB	I
al.	RB	I
,	,	I
Tetrahedron	NNP	I
Lett.	NNP	I
,	,	I
1974	CD	I
,	,	I
2861	CD	I
;	:	O
Hakimelahi	NNP	B
et	FW	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
Lett.	NNP	I
,	,	I
1981	CD	I
,	,	I
(	(	I
22	CD	I
)	)	I
,	,	I
2543	CD	I
;	:	O
and	CC	O
Jones	NNP	B
et	NNP	I
al.	NN	I
,	,	I
J.	NNP	I
Chem	NNP	I
.	.	I
Soc	NNP	I
.	.	I
Perkin	NNP	I
I.	NN	I
,	,	I
2762	CD	I
)	)	O
.	.	O
The	DT	O
2′-O-protecting	JJ	O
groups	NNS	O
can	MD	O
require	VB	O
special	JJ	O
reagents	NNS	O
for	IN	O
their	PRP$	O
removal	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
t-butyldimethylsilyl	JJ	O
group	NN	O
is	VBZ	O
normally	RB	O
removed	VBN	O
after	IN	O
all	DT	O
other	JJ	O
cleaving/deprotecting	VBG	O
steps	NNS	O
by	IN	O
treatment	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
with	IN	O
tetrabutylammonium	JJ	O
fluoride	NN	O
(	(	O
TBAF	NNP	O
)	)	O
.	.	O
One	CD	O
group	NN	O
of	IN	O
researchers	NNS	O
examined	VBD	O
a	DT	O
number	NN	O
of	IN	O
2′-O-protecting	JJ	O
groups	NNS	O
(	(	O
Pitsch	NNP	B
,	,	I
S.	NNP	I
,	,	I
Chimia	NNP	I
,	,	I
2001	CD	I
,	,	I
(	(	I
55	CD	I
)	)	I
,	,	I
320-324	JJ	I
.	.	O
)	)	O
The	DT	O
group	NN	O
examined	VBD	O
fluoride	RB	O
labile	JJ	O
and	CC	O
photolabile	JJ	O
protecting	VBG	O
groups	NNS	O
that	WDT	O
are	VBP	O
removed	VBN	O
using	VBG	O
moderate	JJ	O
conditions	NNS	O
.	.	O
One	CD	O
photolabile	NN	O
group	NN	O
that	WDT	O
was	VBD	O
examined	VBN	O
was	VBD	O
the	DT	O
[	JJ	O
2-	JJ	O
(	(	O
nitrobenzyl	JJ	O
)	)	O
oxy	VBP	O
]	JJ	O
methyl	NN	O
(	(	O
nbm	JJ	O
)	)	O
protecting	VBG	O
group	NN	O
(	(	O
Schwartz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Bioorg	NNP	I
.	.	I
Med	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Lett.	NNP	I
,	,	I
1992	CD	I
,	,	I
(	(	I
2	CD	I
)	)	I
,	,	I
1019	CD	I
.	.	O
)	)	O
Other	JJ	O
groups	NNS	O
examined	VBD	O
included	VBD	O
a	DT	O
number	NN	O
structurally	RB	O
related	JJ	O
formaldehyde	JJ	O
acetal-derived	JJ	O
,	,	O
2′-O-protecting	JJ	O
groups	NNS	O
.	.	O
Also	RB	O
prepared	VBN	O
were	VBD	O
a	DT	O
number	NN	O
of	IN	O
related	JJ	O
protecting	VBG	O
groups	NNS	O
for	IN	O
preparing	VBG	O
2′-O-alkylated	JJ	O
nucleoside	JJ	O
phosphoramidites	NNS	O
including	VBG	O
2′-O-	JJ	O
[	NN	O
(	(	O
triisopropylsilyl	NN	O
)	)	O
oxy	NN	O
]	NN	O
methyl	NN	O
(	(	O
2′-O—CH2-O—Si	JJ	O
(	(	O
iPr	NN	O
)	)	O
3	CD	O
,	,	O
TOM	NNP	O
)	)	O
.	.	O
One	CD	O
2′-O-protecting	JJ	O
group	NN	O
that	WDT	O
was	VBD	O
prepared	VBN	O
to	TO	O
be	VB	O
used	VBN	O
orthogonally	RB	O
to	TO	O
the	DT	O
TOM	NNP	O
group	NN	O
was	VBD	O
2′-O—	JJ	O
[	NNP	O
(	(	O
R	NNP	O
)	)	O
-1-	NN	O
(	(	O
2-nitrophenyl	JJ	O
)	)	O
ethyloxy	NN	O
)	)	O
methyl	NN	O
]	NN	O
(	(	O
(	(	O
R	NNP	O
)	)	O
-mnbm	NN	O
)	)	O
.	.	O
Another	DT	O
strategy	NN	O
using	VBG	O
a	DT	O
fluoride	JJ	O
labile	JJ	O
5′-O-protecting	JJ	O
group	NN	O
(	(	O
non-acid	JJ	O
labile	NN	O
)	)	O
and	CC	O
an	DT	O
acid	JJ	O
labile	JJ	O
2′-O-protecting	JJ	O
group	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
(	(	O
Scaringe	NNP	B
,	,	I
Stephen	NNP	I
A.	NNP	I
,	,	I
Methods	NNP	I
,	,	I
2001	CD	I
,	,	I
(	(	I
23	CD	I
)	)	I
206-217	CD	I
)	)	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
possible	JJ	O
silyl	NN	O
ethers	NNS	O
were	VBD	O
examined	VBN	O
for	IN	O
5′-O-protection	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
acetals	NNS	O
and	CC	O
orthoesters	NNS	O
were	VBD	O
examined	VBN	O
for	IN	O
2′-O-protection	NN	O
.	.	O
The	DT	O
protection	NN	O
scheme	NN	O
that	WDT	O
gave	VBD	O
the	DT	O
best	JJS	O
results	NNS	O
was	VBD	O
5′-O-silyl	JJ	O
ether-2′-ACE	JJ	O
(	(	O
5′-O-bis	JJ	O
(	(	O
trimethylsiloxy	JJ	O
)	)	O
cyclododecyloxysilyl	NN	O
ether	NN	O
(	(	O
DOD	NNP	O
)	)	O
-2′-O-bis	NN	O
(	(	O
2-acetoxyethoxy	JJ	O
)	)	O
methyl	NN	O
(	(	O
ACE	NNP	O
)	)	O
.	.	O
This	DT	O
approach	NN	O
uses	VBZ	O
a	DT	O
modified	JJ	O
phosphoramidite	NN	O
synthesis	NN	O
approach	NN	O
in	IN	O
that	DT	O
some	DT	O
different	JJ	O
reagents	NNS	O
are	VBP	O
required	VBN	O
that	IN	O
are	VBP	O
not	RB	O
routinely	RB	O
used	VBN	O
for	IN	O
RNA/DNA	NNP	O
synthesis	NN	O
.	.	O
The	DT	O
main	JJ	O
RNA	NNP	O
synthesis	NN	O
strategies	NNS	O
that	WDT	O
are	VBP	O
presently	RB	O
being	VBG	O
used	VBN	O
commercially	RB	O
include	VBP	O
5′-O-DMT-2′-O-t-butyldimethylsilyl	JJ	O
(	(	O
TBDMS	NNP	O
)	)	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
[	NN	O
1	CD	O
(	(	O
2-fluorophenyl	JJ	O
)	)	O
-4-methoxypiperidin-4-yl	FW	O
]	FW	O
(	(	O
FPMP	NNP	O
)	)	O
,	,	O
2′-O-	JJ	O
[	NN	O
(	(	O
triisopropylsilyl	NN	O
)	)	O
oxy	NN	O
]	NN	O
methyl	NN	O
(	(	O
2′-O—CH2—O—Si	JJ	O
(	(	O
iPr	NN	O
)	)	O
3	CD	O
(	(	O
TOM	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
5′-O-silyl	JJ	O
ether-2′-ACE	JJ	O
(	(	O
5′-O-bis	JJ	O
(	(	O
trimethylsiloxy	JJ	O
)	)	O
cyclododecyloxysilyl	NN	O
ether	NN	O
(	(	O
DOD	NNP	O
)	)	O
-2′-O-bis	NN	O
(	(	O
2-acetoxyethoxy	JJ	O
)	)	O
methyl	NN	O
(	(	O
ACE	NNP	O
)	)	O
.	.	O
Some	DT	O
companies	NNS	O
currently	RB	O
offering	VBG	O
RNA	NNP	O
products	NNS	O
include	VBP	O
Pierce	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Technologies	NNPS	O
(	(	O
Milwaukee	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
,	,	O
Dharmacon	NNP	O
Research	NNP	O
Inc.	NNP	O
(	(	O
a	DT	O
subsidiary	NN	O
of	IN	O
Fisher	NNP	O
Scientific	NNP	O
,	,	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
,	,	O
and	CC	O
Integrated	NNP	O
DNA	NNP	O
Technologies	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Coralville	NNP	O
,	,	O
Iowa	NNP	O
)	)	O
.	.	O
One	CD	O
company	NN	O
,	,	O
Princeton	NNP	O
Separations	NNP	O
,	,	O
markets	NNS	O
an	DT	O
RNA	NNP	O
synthesis	NN	O
activator	NN	O
advertised	VBD	O
to	TO	O
reduce	VB	O
coupling	VBG	O
times	NNS	O
especially	RB	O
with	IN	O
TOM	NNP	O
and	CC	O
TBDMS	NNP	O
chemistries	NNS	O
.	.	O
Such	JJ	O
an	DT	O
activator	NN	O
would	MD	O
also	RB	O
be	VB	O
amenable	JJ	O
to	TO	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
primary	JJ	O
groups	NNS	O
being	VBG	O
used	VBN	O
for	IN	O
commercial	JJ	O
RNA	NNP	O
synthesis	NN	O
are	VBP	O
:	:	O
All	DT	O
of	IN	O
the	DT	O
aforementioned	JJ	O
RNA	NNP	O
synthesis	NN	O
strategies	NNS	O
are	VBP	O
amenable	JJ	O
to	TO	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Strategies	NNS	O
that	WDT	O
would	MD	O
be	VB	O
a	DT	O
hybrid	NN	O
of	IN	O
the	DT	O
above	JJ	O
e.g	NN	O
.	.	O
using	VBG	O
a	DT	O
5′-protecting	JJ	O
group	NN	O
from	IN	O
one	CD	O
strategy	NN	O
with	IN	O
a	DT	O
2′-O-protecting	JJ	O
from	IN	O
another	DT	O
strategy	NN	O
is	VBZ	O
also	RB	O
contemplated	VBN	O
herein	NN	O
.	.	O
Synthesis	NN	O
of	IN	O
Chimeric	NNP	O
Oligomeric	NNP	O
Compounds	NNP	O
(	(	O
2′-O-Me	JJ	O
)	)	O
-	:	O
(	(	O
2′-deoxy	JJ	O
)	)	O
-	:	O
(	(	O
2′-O-Me	JJ	O
)	)	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Chimeric	NNP	O
oligonucleotides	IN	O
having	VBG	O
2′-O-alkyl	JJ	O
phosphorothioate	NN	O
and	CC	O
2′-deoxy	JJ	O
phosphorothioate	NN	O
oligonucleotide	IN	O
segments	NNS	O
can	MD	O
be	VB	O
routinely	RB	O
synthesized	VBN	O
by	IN	O
one	CD	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
using	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
Applied	NNP	O
Biosystems	NNP	O
automated	VBD	O
DNA	NNP	O
synthesizer	NN	O
Model	NNP	O
394	CD	O
.	.	O
Oligonucleotides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
using	VBG	O
an	DT	O
automated	JJ	O
synthesizer	NN	O
and	CC	O
2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidite	JJ	O
for	IN	O
the	DT	O
DNA	NNP	O
portion	NN	O
and	CC	O
5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite	JJ	O
for	IN	O
the	DT	O
2′-O-alkyl	JJ	O
portion	NN	O
.	.	O
In	IN	O
one	CD	O
nonlimiting	NN	O
example	NN	O
,	,	O
the	DT	O
standard	JJ	O
synthesis	NN	O
cycle	NN	O
is	VBZ	O
modified	VBN	O
by	IN	O
incorporating	VBG	O
coupling	VBG	O
steps	NNS	O
with	IN	O
increased	VBN	O
reaction	NN	O
times	NNS	O
for	IN	O
the	DT	O
5′-dimethoxy-trityl-2′-O-methyl-3′-O-phosphoramidite	JJ	O
.	.	O
The	DT	O
fully	RB	O
protected	VBN	O
oligonucleotide	NN	O
is	VBZ	O
cleaved	VBN	O
from	IN	O
the	DT	O
support	NN	O
and	CC	O
deprotected	VBN	O
in	IN	O
concentrated	JJ	O
ammonia	NN	O
(	(	O
NH4OH	NNP	O
)	)	O
for	IN	O
12-16	JJ	O
hr	NN	O
at	IN	O
55°	CD	O
C.	NNP	O
The	DT	O
deprotected	JJ	O
oligonucleotide	NN	O
is	VBZ	O
then	RB	O
recovered	VBN	O
by	IN	O
an	DT	O
appropriate	JJ	O
method	NN	O
(	(	O
precipitation	NN	O
,	,	O
column	NN	O
chromatography	NN	O
,	,	O
volume	NN	O
reduced	VBN	O
in	IN	O
vacuo	NN	O
)	)	O
and	CC	O
analyzed	VBN	O
by	IN	O
methods	NNS	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
(	(	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
)	)	O
-	:	O
(	(	O
2′-deoxy	JJ	O
)	)	O
-	:	O
(	(	O
2′-O-	JJ	O
(	(	O
Methoxyethyl	NNP	O
)	)	O
)	)	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
(	(	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
)	)	O
-	:	O
(	(	O
2′-deoxy	JJ	O
)	)	O
-	:	O
(	(	O
-2′-O-	FW	O
(	(	O
methoxyethyl	NN	O
)	)	O
)	)	O
chimeric	JJ	O
phosphorothioate	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
per	IN	O
the	DT	O
procedure	NN	O
above	IN	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
chimeric	JJ	O
oligonucleotide	NN	O
,	,	O
with	IN	O
the	DT	O
substitution	NN	O
of	IN	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
amidites	VBZ	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
amidites	NNS	O
.	.	O
(	(	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
Phosphodiester	NN	O
)	)	O
-	:	O
(	(	O
2′-deoxy	JJ	O
Phosphorothioate	NNP	O
)	)	O
-	:	O
(	(	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
Phosphodiester	NNP	O
)	)	O
Chimeric	NNP	O
Oligonucleotides	NNP	O
(	(	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
phosphodiester	NN	O
)	)	O
-	:	O
(	(	O
2′-deoxy	JJ	O
phosphorothioate	NN	O
)	)	O
-	:	O
(	(	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
phosphodiester	NN	O
)	)	O
chimeric	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
per	IN	O
the	DT	O
above	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
chimeric	JJ	O
oligonucleotide	NN	O
with	IN	O
the	DT	O
substitution	NN	O
of	IN	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
amidites	VBZ	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
amidites	NNS	O
,	,	O
oxidation	NN	O
with	IN	O
iodine	NN	O
to	TO	O
generate	VB	O
the	DT	O
phosphodiester	NN	O
internucleotide	NN	O
linkages	VBZ	O
within	IN	O
the	DT	O
wing	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
chimeric	JJ	O
structures	NNS	O
and	CC	O
sulfurization	NN	O
utilizing	VBG	O
3	CD	O
,	,	O
H-1,2	NNP	O
benzodithiole-3-one	NN	O
1,1	CD	O
dioxide	NN	O
(	(	O
Beaucage	NNP	O
Reagent	NNP	O
)	)	O
to	TO	O
generate	VB	O
the	DT	O
phosphorothioate	NN	O
internucleotide	NN	O
linkages	VBZ	O
for	IN	O
the	DT	O
center	NN	O
gap	NN	O
.	.	O
Other	JJ	O
chimeric	JJ	O
oligonucleotides	NNS	O
,	,	O
chimeric	JJ	O
oligonucleosides	NNS	O
and	CC	O
mixed	JJ	O
chimeric	JJ	O
oligonucleotides/oligonucleosides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
according	VBG	O
to	TO	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,623,065	CD	O
.	.	O
Oligomer	NNP	O
Purification	NNP	O
and	CC	O
Analysis	NNP	O
Methods	NNP	O
of	IN	O
oligomeric	JJ	O
compound	NN	O
purification	NN	O
and	CC	O
analysis	NN	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Analysis	NN	O
methods	NNS	O
include	VBP	O
capillary	JJ	O
electrophoresis	NN	O
(	(	O
CE	NNP	O
)	)	O
and	CC	O
electrospray-mass	JJ	O
spectroscopy	NN	O
.	.	O
Such	JJ	O
synthesis	NN	O
and	CC	O
analysis	NN	O
methods	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
multi-well	NN	O
plates	NNS	O
.	.	O
Hybridization	NNP	O
“	NNP	O
Hybridization	NNP	O
”	NNP	O
means	VBZ	O
the	DT	O
pairing	NN	O
of	IN	O
complementary	JJ	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
While	IN	O
not	RB	O
limited	VBN	O
to	TO	O
a	DT	O
particular	JJ	O
mechanism	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
mechanism	NN	O
of	IN	O
pairing	VBG	O
involves	NNS	O
hydrogen	NN	O
bonding	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
Watson-Crick	NNP	O
,	,	O
Hoogsteen	NNP	O
or	CC	O
reversed	VBN	O
Hoogsteen	NNP	O
hydrogen	NN	O
bonding	NN	O
,	,	O
between	IN	O
complementary	JJ	O
nucleoside	NN	O
or	CC	O
nucleotide	JJ	O
bases	NNS	O
(	(	O
nucleobases	NNS	O
)	)	O
of	IN	O
the	DT	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
adenine	NN	O
and	CC	O
thymine	NN	O
are	VBP	O
complementary	JJ	O
nucleobases	NNS	O
which	WDT	O
pair	VBP	O
through	IN	O
the	DT	O
formation	NN	O
of	IN	O
hydrogen	NN	O
bonds	NNS	O
.	.	O
Hybridization	NN	O
can	MD	O
occur	VB	O
under	IN	O
varying	VBG	O
circumstances	NNS	O
.	.	O
An	DT	O
oligomeric	JJ	O
compound	NN	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
when	WRB	O
there	EX	O
is	VBZ	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
complementarity	NN	O
to	TO	O
avoid	VB	O
non-specific	JJ	O
binding	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
non-target	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
specific	JJ	O
binding	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
i.e.	FW	O
,	,	O
under	IN	O
physiological	JJ	O
conditions	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vivo	NN	O
assays	NNS	O
or	CC	O
therapeutic	JJ	O
treatment	NN	O
,	,	O
and	CC	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
assays	NNS	O
are	VBP	O
performed	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vitro	NN	O
assays	NNS	O
.	.	O
“	JJ	O
Stringent	NNP	O
hybridization	NN	O
conditions	NNS	O
”	VBP	O
or	CC	O
“	VBP	O
stringent	JJ	O
conditions	NNS	O
”	VBP	O
refers	NNS	O
to	TO	O
conditions	NNS	O
under	IN	O
which	WDT	O
an	DT	O
oligomeric	NN	O
compound	NN	O
will	MD	O
hybridize	VB	O
to	TO	O
its	PRP$	O
target	NN	O
sequence	NN	O
,	,	O
but	CC	O
to	TO	O
a	DT	O
minimal	JJ	O
number	NN	O
of	IN	O
other	JJ	O
sequences	NNS	O
.	.	O
Stringent	JJ	O
conditions	NNS	O
are	VBP	O
sequence-dependent	JJ	O
and	CC	O
will	MD	O
be	VB	O
different	JJ	O
in	IN	O
different	JJ	O
circumstances	NNS	O
,	,	O
and	CC	O
“	NNP	O
stringent	JJ	O
conditions	NNS	O
”	VBP	O
under	IN	O
which	WDT	O
oligomeric	JJ	O
compounds	NNS	O
hybridize	VBP	O
to	TO	O
a	DT	O
target	NN	O
sequence	NN	O
are	VBP	O
determined	VBN	O
by	IN	O
the	DT	O
nature	NN	O
and	CC	O
composition	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
assays	NNS	O
in	IN	O
which	WDT	O
they	PRP	O
are	VBP	O
being	VBG	O
investigated	VBN	O
.	.	O
Complementarity	NNP	O
“	NNP	O
Complementarity	NNP	O
,	,	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
the	DT	O
capacity	NN	O
for	IN	O
precise	JJ	O
pairing	VBG	O
between	IN	O
two	CD	O
nucleobases	NNS	O
on	IN	O
one	CD	O
or	CC	O
two	CD	O
oligomeric	JJ	O
compound	NN	O
strands	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
a	DT	O
nucleobase	NN	O
at	IN	O
a	DT	O
certain	JJ	O
position	NN	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
hydrogen	NN	O
bonding	VBG	O
with	IN	O
a	DT	O
nucleobase	NN	O
at	IN	O
a	DT	O
certain	JJ	O
position	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
,	,	O
then	RB	O
the	DT	O
position	NN	O
of	IN	O
hydrogen	NN	O
bonding	NN	O
between	IN	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
a	DT	O
complementary	JJ	O
position	NN	O
.	.	O
The	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
the	DT	O
further	JJ	O
DNA	NN	O
or	CC	O
RNA	NNP	O
are	VBP	O
complementary	JJ	O
to	TO	O
each	DT	O
other	JJ	O
when	WRB	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
complementary	JJ	O
positions	NNS	O
in	IN	O
each	DT	O
molecule	NN	O
are	VBP	O
occupied	VBN	O
by	IN	O
nucleobases	NNS	O
which	WDT	O
can	MD	O
hydrogen	VB	O
bond	NN	O
with	IN	O
each	DT	O
other	JJ	O
.	.	O
Thus	RB	O
,	,	O
“	NNP	O
specifically	RB	O
hybridizable	JJ	O
”	NN	O
and	CC	O
“	NNP	O
complementary	JJ	O
”	NNS	O
are	VBP	O
terms	NNS	O
which	WDT	O
are	VBP	O
used	VBN	O
to	TO	O
indicate	VB	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
precise	NN	O
pairing	NN	O
or	CC	O
complementarity	NN	O
over	IN	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
nucleobases	NNS	O
such	JJ	O
that	IN	O
stable	JJ	O
and	CC	O
specific	JJ	O
binding	VBG	O
occurs	NN	O
between	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
need	MD	O
not	RB	O
be	VB	O
100	CD	O
%	NN	O
complementary	JJ	O
to	TO	O
that	DT	O
of	IN	O
its	PRP$	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
specifically	RB	O
hybridizable	JJ	O
.	.	O
Moreover	RB	O
,	,	O
an	DT	O
oligonucleotide	NN	O
may	MD	O
hybridize	VB	O
over	RP	O
one	CD	O
or	CC	O
more	JJR	O
segments	NNS	O
such	JJ	O
that	IN	O
intervening	VBG	O
or	CC	O
adjacent	JJ	O
segments	NNS	O
are	VBP	O
not	RB	O
involved	VBN	O
in	IN	O
the	DT	O
hybridization	NN	O
event	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
loop	NN	O
structure	NN	O
,	,	O
mismatch	NN	O
or	CC	O
hairpin	NN	O
structure	NN	O
)	)	O
.	.	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
95	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
99	CD	O
%	NN	O
sequence	NN	O
complementarity	NN	O
to	TO	O
a	DT	O
target	NN	O
region	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
they	PRP	O
are	VBP	O
targeted	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
in	IN	O
which	WDT	O
18	CD	O
of	IN	O
20	CD	O
nucleobases	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
are	VBP	O
complementary	JJ	O
to	TO	O
a	DT	O
target	NN	O
region	NN	O
,	,	O
and	CC	O
would	MD	O
therefore	VB	O
specifically	RB	O
hybridize	JJ	O
,	,	O
would	MD	O
represent	VB	O
90	CD	O
percent	NN	O
complementarity	NN	O
.	.	O
In	IN	O
this	DT	O
example	NN	O
,	,	O
the	DT	O
remaining	VBG	O
noncomplementary	JJ	O
nucleobases	NNS	O
may	MD	O
be	VB	O
clustered	VBN	O
or	CC	O
interspersed	VBN	O
with	IN	O
complementary	JJ	O
nucleobases	NNS	O
and	CC	O
need	MD	O
not	RB	O
be	VB	O
contiguous	JJ	O
to	TO	O
each	DT	O
other	JJ	O
or	CC	O
to	TO	O
complementary	JJ	O
nucleobases	NNS	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
which	WDT	O
is	VBZ	O
18	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
having	VBG	O
4	CD	O
(	(	O
four	CD	O
)	)	O
noncomplementary	NN	O
nucleobases	NNS	O
which	WDT	O
are	VBP	O
flanked	VBN	O
by	IN	O
two	CD	O
regions	NNS	O
of	IN	O
complete	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
would	MD	O
have	VB	O
77.8	CD	O
%	NN	O
overall	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
would	MD	O
thus	RB	O
fall	VB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Percent	NNP	O
complementarity	NN	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
with	IN	O
a	DT	O
region	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
determined	VBN	O
routinely	RB	O
using	VBG	O
BLAST	NNP	O
programs	NNS	O
(	(	O
basic	JJ	O
local	JJ	O
alignment	NN	O
search	NN	O
tools	NNS	O
)	)	O
and	CC	O
PowerBLAST	NNP	O
programs	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
Altschul	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
1990	CD	I
,	,	I
215	CD	I
,	,	I
403-410	JJ	I
;	:	O
Zhang	NNP	B
and	CC	I
Madden	NNP	I
,	,	I
Genome	NNP	I
Res.	NNP	I
,	,	I
1997	CD	I
,	,	I
7	CD	I
,	,	I
649-656	JJ	I
)	)	O
.	.	O
Percent	NNP	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
Gap	NNP	O
program	NN	O
(	(	O
Wisconsin	NNP	O
Sequence	NNP	O
Analysis	NNP	O
Package	NNP	O
,	,	O
Version	NNP	O
8	CD	O
for	IN	O
Unix	NNP	O
,	,	O
Genetics	NNP	O
Computer	NNP	O
Group	NNP	O
,	,	O
University	NNP	O
Research	NNP	O
Park	NNP	O
,	,	O
Madison	NNP	O
Wis.	NNP	O
)	)	O
,	,	O
using	VBG	O
default	NN	O
settings	NNS	O
,	,	O
which	WDT	O
uses	VBZ	O
the	DT	O
algorithm	NN	O
of	IN	O
Smith	NNP	O
and	CC	O
Waterman	NNP	O
(	(	O
Adv	NNP	B
.	.	I
Appl	NNP	I
.	.	I
Math.	NNP	I
,	,	I
1981	CD	I
,	,	I
2	CD	I
,	,	I
482-489	JJ	I
)	)	O
.	.	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
also	RB	O
include	VBP	O
variants	NNS	O
in	IN	O
which	WDT	O
a	DT	O
different	JJ	O
base	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
nucleotide	JJ	O
positions	NNS	O
in	IN	O
the	DT	O
compound	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
first	JJ	O
nucleotide	NN	O
is	VBZ	O
an	DT	O
adenosine	NN	O
,	,	O
variants	NNS	O
may	MD	O
be	VB	O
produced	VBN	O
which	WDT	O
contain	VBP	O
thymidine	NN	O
,	,	O
guanosine	NN	O
or	CC	O
cytidine	NN	O
at	IN	O
this	DT	O
position	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
done	VBN	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
positions	NNS	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
.	.	O
These	DT	O
compounds	NNS	O
are	VBP	O
then	RB	O
tested	VBN	O
using	VBG	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
to	TO	O
determine	VB	O
their	PRP$	O
ability	NN	O
to	TO	O
inhibit	VB	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
mRNA	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
between	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
50	CD	O
%	NN	O
to	TO	O
about	RB	O
60	CD	O
%	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
from	IN	O
about	IN	O
60	CD	O
%	NN	O
to	TO	O
about	RB	O
70	CD	O
%	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
from	IN	O
about	IN	O
70	CD	O
%	NN	O
to	TO	O
about	RB	O
80	CD	O
%	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
from	IN	O
about	IN	O
80	CD	O
%	NN	O
to	TO	O
about	RB	O
90	CD	O
%	NN	O
.	.	O
In	IN	O
still	RB	O
other	JJ	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
about	IN	O
90	CD	O
%	NN	O
,	,	O
about	RB	O
92	CD	O
%	NN	O
,	,	O
about	RB	O
94	CD	O
%	NN	O
,	,	O
about	RB	O
95	CD	O
%	NN	O
,	,	O
about	RB	O
96	CD	O
%	NN	O
,	,	O
about	RB	O
97	CD	O
%	NN	O
,	,	O
about	RB	O
98	CD	O
%	NN	O
,	,	O
about	RB	O
99	CD	O
%	NN	O
or	CC	O
about	IN	O
100	CD	O
%	NN	O
.	.	O
Target	NNP	O
Nucleic	NNP	O
Acids	NNP	O
“	NNP	O
Targeting	NNP	O
”	NNP	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
a	DT	O
particular	JJ	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
molecule	NN	O
can	MD	O
be	VB	O
a	DT	O
multistep	NN	O
process	NN	O
.	.	O
The	DT	O
process	NN	O
usually	RB	O
begins	VBZ	O
with	IN	O
the	DT	O
identification	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
whose	WP$	O
expression	NN	O
is	VBZ	O
to	TO	O
be	VB	O
modulated	VBN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
”	NN	O
and	CC	O
“	NNP	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
”	NNP	O
encompass	NN	O
DNA	NNP	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
RNA	NNP	O
(	(	O
including	VBG	O
pre-mRNA	NN	O
and	CC	O
mRNA	NN	O
)	)	O
transcribed	VBD	O
from	IN	O
such	JJ	O
DNA	NNP	O
,	,	O
and	CC	O
also	RB	O
cDNA	VBP	O
derived	VBN	O
from	IN	O
such	JJ	O
RNA	NNP	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
a	DT	O
cellular	JJ	O
gene	NN	O
(	(	O
or	CC	O
mRNA	VB	O
transcribed	VBN	O
from	IN	O
the	DT	O
gene	NN	O
)	)	O
whose	WP$	O
expression	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
particular	JJ	O
disorder	NN	O
or	CC	O
disease	NN	O
state	NN	O
,	,	O
or	CC	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
from	IN	O
an	DT	O
infectious	JJ	O
agent	NN	O
.	.	O
As	IN	O
disclosed	VBN	O
herein	NN	O
,	,	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
encodes	VBZ	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Target	NN	O
Regions	NNP	O
,	,	O
Segments	NNP	O
,	,	O
and	CC	O
Sites	VBZ	O
The	DT	O
targeting	VBG	O
process	NN	O
usually	RB	O
also	RB	O
includes	VBZ	O
determination	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
target	NN	O
region	NN	O
,	,	O
segment	NN	O
,	,	O
or	CC	O
site	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
antisense	JJ	O
interaction	NN	O
to	TO	O
occur	VB	O
such	JJ	O
that	IN	O
the	DT	O
desired	JJ	O
effect	NN	O
,	,	O
e.g.	NN	O
,	,	O
modulation	NN	O
of	IN	O
expression	NN	O
,	,	O
will	MD	O
result	VB	O
.	.	O
“	JJ	O
Region	NNP	O
”	NNP	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
at	IN	O
least	JJS	O
one	CD	O
identifiable	JJ	O
structure	NN	O
,	,	O
function	NN	O
,	,	O
or	CC	O
characteristic	JJ	O
.	.	O
Within	IN	O
regions	NNS	O
of	IN	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
segments	NNS	O
.	.	O
“	JJ	O
Segments	NNS	O
”	WDT	O
are	VBP	O
defined	VBN	O
as	IN	O
smaller	JJR	O
or	CC	O
sub-portions	NNS	O
of	IN	O
regions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
“	NN	O
Sites	NNS	O
,	,	O
”	NN	O
as	IN	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
are	VBP	O
defined	VBN	O
as	IN	O
positions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Start	NNP	O
Codons	NNP	O
Since	IN	O
,	,	O
as	IN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
typically	RB	O
5′	CD	O
AUG	NNP	O
(	(	O
in	IN	O
transcribed	VBN	O
mRNA	NN	O
molecules	NNS	O
;	:	O
5′	CD	O
ATG	NNP	O
in	IN	O
the	DT	O
corresponding	JJ	O
DNA	NNP	O
molecule	NN	O
)	)	O
,	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
“	NNP	O
AUG	NNP	O
codon	NN	O
,	,	O
”	VBP	O
the	DT	O
“	NNP	O
start	NN	O
codon	NN	O
”	NN	O
or	CC	O
the	DT	O
“	JJ	O
AUG	NNP	O
start	NN	O
codon.	NN	O
”	VBP	O
A	DT	O
minority	NN	O
of	IN	O
genes	NNS	O
have	VBP	O
a	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
having	VBG	O
the	DT	O
RNA	NNP	O
sequence	NN	O
5′	CD	O
GUG	NNP	O
,	,	O
5′	CD	O
UUG	NNP	O
or	CC	O
5′	CD	O
CUG	NNP	O
,	,	O
and	CC	O
5′	CD	O
AUA	NNP	O
,	,	O
5′	CD	O
ACG	NNP	O
and	CC	O
5′	CD	O
CUG	NNP	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
function	NN	O
in	IN	O
vivo	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
translation	NN	O
initiation	NN	O
codon	NN	O
”	NN	O
and	CC	O
“	JJ	O
start	NN	O
codon	NN	O
”	NN	O
can	MD	O
encompass	VB	O
many	JJ	O
codon	NN	O
sequences	NNS	O
,	,	O
even	RB	O
though	IN	O
the	DT	O
initiator	NN	O
amino	NN	O
acid	NN	O
in	IN	O
each	DT	O
instance	NN	O
is	VBZ	O
typically	RB	O
methionine	JJ	O
(	(	O
in	IN	O
eukaryotes	NNS	O
)	)	O
or	CC	O
formylmethionine	NN	O
(	(	O
in	IN	O
prokaryotes	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
eukaryotic	JJ	O
and	CC	O
prokaryotic	JJ	O
genes	NNS	O
may	MD	O
have	VB	O
two	CD	O
or	CC	O
more	JJR	O
alternative	JJ	O
start	NN	O
codons	NNS	O
,	,	O
any	DT	O
one	CD	O
of	IN	O
which	WDT	O
may	MD	O
be	VB	O
preferentially	RB	O
utilized	JJ	O
for	IN	O
translation	NN	O
initiation	NN	O
in	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
type	NN	O
or	CC	O
tissue	NN	O
,	,	O
or	CC	O
under	IN	O
a	DT	O
particular	JJ	O
set	NN	O
of	IN	O
conditions	NNS	O
.	.	O
“	JJ	O
Start	NNP	O
codon	NN	O
”	NN	O
and	CC	O
“	JJ	O
translation	NN	O
initiation	NN	O
codon	NN	O
”	NNP	O
refer	NN	O
to	TO	O
the	DT	O
codon	NN	O
or	CC	O
codons	NNS	O
that	WDT	O
are	VBP	O
used	VBN	O
in	IN	O
vivo	NN	O
to	TO	O
initiate	VB	O
translation	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
transcribed	NN	O
from	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
protein	NN	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
sequence	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
such	JJ	O
codons	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
(	(	O
or	CC	O
“	VB	O
stop	JJ	O
codon	NN	O
”	NNP	O
)	)	O
of	IN	O
a	DT	O
gene	NN	O
may	MD	O
have	VB	O
one	CD	O
of	IN	O
three	CD	O
sequences	NNS	O
,	,	O
i.e.	NN	O
,	,	O
5′	CD	O
UAA	NNP	O
,	,	O
5′	CD	O
UAG	NNP	O
and	CC	O
5′	CD	O
UGA	NNP	O
(	(	O
the	DT	O
corresponding	NN	O
DNA	NN	O
sequences	NNS	O
are	VBP	O
5′	CD	O
TAA	NNP	O
,	,	O
5′	CD	O
TAG	NNP	O
and	CC	O
5′	CD	O
TGA	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O
The	DT	O
terms	NNS	O
“	VBP	O
start	VBP	O
codon	JJ	O
region	NN	O
”	NN	O
and	CC	O
“	JJ	O
translation	NN	O
initiation	NN	O
codon	NN	O
region	NN	O
”	NNP	O
refer	NN	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(	(	O
i.e.	JJ	O
,	,	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
from	IN	O
a	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
.	.	O
Similarly	RB	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
stop	JJ	O
codon	NN	O
region	NN	O
”	NNP	O
and	CC	O
“	NNP	O
translation	NN	O
termination	NN	O
codon	NN	O
region	NN	O
”	NNP	O
refer	NN	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(	(	O
i.e.	JJ	O
,	,	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
from	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
“	NNP	O
start	NN	O
codon	NN	O
region	NN	O
”	NNP	O
(	(	O
or	CC	O
“	VB	O
translation	NN	O
initiation	NN	O
codon	NN	O
region	NN	O
”	NNP	O
)	)	O
and	CC	O
the	DT	O
“	NNP	O
stop	NN	O
codon	NN	O
region	NN	O
”	NNP	O
(	(	O
or	CC	O
“	VB	O
translation	NN	O
termination	NN	O
codon	NN	O
region	NN	O
”	NN	O
)	)	O
are	VBP	O
all	DT	O
regions	NNS	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively	RB	O
with	IN	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Coding	VBG	O
Regions	NNPS	O
The	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(	(	O
ORF	NNP	O
)	)	O
or	CC	O
“	$	O
coding	VBG	O
region	NN	O
,	,	O
”	NNP	O
which	WDT	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
region	NN	O
between	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
and	CC	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
,	,	O
is	VBZ	O
also	RB	O
a	DT	O
region	NN	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively	RB	O
.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
one	CD	O
region	NN	O
is	VBZ	O
the	DT	O
intragenic	JJ	O
region	NN	O
encompassing	VBG	O
the	DT	O
translation	NN	O
initiation	NN	O
or	CC	O
termination	NN	O
codon	NN	O
of	IN	O
the	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(	(	O
ORF	NNP	O
)	)	O
of	IN	O
a	DT	O
gene	NN	O
.	.	O
Untranslated	VBN	O
Regions	NNPS	O
Other	JJ	O
target	NN	O
regions	NNS	O
include	VBP	O
the	DT	O
5′	CD	O
untranslated	JJ	O
region	NN	O
(	(	O
5′UTR	CD	O
)	)	O
,	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
5′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
5′	CD	O
cap	NN	O
site	NN	O
and	CC	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(	(	O
or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
3′	CD	O
untranslated	JJ	O
region	NN	O
(	(	O
3′UTR	CD	O
)	)	O
,	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
3′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
and	CC	O
3′	CD	O
end	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(	(	O
or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene	NN	O
)	)	O
.	.	O
The	DT	O
5′	CD	O
cap	NN	O
site	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
comprises	VBZ	O
an	DT	O
N7-methylated	JJ	O
guanosine	NN	O
residue	NN	O
joined	VBD	O
to	TO	O
the	DT	O
5′-most	JJ	O
residue	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
via	IN	O
a	DT	O
5′-5′	JJ	O
triphosphate	NN	O
linkage	NN	O
.	.	O
The	DT	O
5′	CD	O
cap	NN	O
region	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
include	VB	O
the	DT	O
5′	CD	O
cap	NN	O
structure	NN	O
itself	PRP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
first	JJ	O
50	CD	O
nucleotides	NNS	O
adjacent	JJ	O
to	TO	O
the	DT	O
cap	NN	O
site	NN	O
.	.	O
The	DT	O
5′	CD	O
cap	NN	O
region	NN	O
is	VBZ	O
also	RB	O
a	DT	O
target	NN	O
.	.	O
Introns	NNS	O
and	CC	O
Exons	NNP	O
Although	IN	O
some	DT	O
eukaryotic	JJ	O
mRNA	NN	O
transcripts	NNS	O
are	VBP	O
directly	RB	O
translated	VBN	O
,	,	O
many	JJ	O
contain	VBP	O
one	CD	O
or	CC	O
more	JJR	O
regions	NNS	O
,	,	O
known	VBN	O
as	IN	O
“	JJ	O
introns	NNS	O
,	,	O
”	NN	O
which	WDT	O
are	VBP	O
excised	VBN	O
from	IN	O
a	DT	O
transcript	NN	O
before	IN	O
it	PRP	O
is	VBZ	O
translated	VBN	O
.	.	O
The	DT	O
remaining	VBG	O
(	(	O
and	CC	O
therefore	RB	O
translated	VBD	O
)	)	O
regions	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
exons	NNS	O
”	NN	O
and	CC	O
are	VBP	O
spliced	VBN	O
together	RB	O
to	TO	O
form	VB	O
a	DT	O
continuous	JJ	O
mRNA	NN	O
sequence	NN	O
,	,	O
resulting	VBG	O
in	IN	O
exon-exon	JJ	O
junctions	NNS	O
at	IN	O
the	DT	O
site	NN	O
where	WRB	O
exons	NNS	O
are	VBP	O
joined	VBN	O
.	.	O
Targeting	VBG	O
exon-exon	JJ	O
junctions	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
aberrant	JJ	O
levels	NNS	O
of	IN	O
a	DT	O
normal	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
,	,	O
or	CC	O
where	WRB	O
aberrant	JJ	O
levels	NNS	O
of	IN	O
an	DT	O
aberrant	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
.	.	O
Targeting	VBG	O
splice	NN	O
sites	NNS	O
,	,	O
i.e.	FW	O
,	,	O
intron-exon	JJ	O
junctions	NNS	O
or	CC	O
exon-intron	JJ	O
junctions	NNS	O
can	MD	O
also	RB	O
be	VB	O
particularly	RB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
aberrant	JJ	O
splicing	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
,	,	O
or	CC	O
where	WRB	O
an	DT	O
overproduction	NN	O
of	IN	O
a	DT	O
particular	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
.	.	O
Aberrant	JJ	O
fusion	NN	O
junctions	NNS	O
due	JJ	O
to	TO	O
rearrangements	NNS	O
or	CC	O
deletions	NNS	O
are	VBP	O
also	RB	O
suitable	JJ	O
targets	NNS	O
.	.	O
mRNA	NN	O
transcripts	NNS	O
produced	VBD	O
via	IN	O
the	DT	O
process	NN	O
of	IN	O
splicing	VBG	O
of	IN	O
two	CD	O
(	(	O
or	CC	O
more	JJR	O
)	)	O
mRNAs	NN	O
from	IN	O
different	JJ	O
gene	NN	O
sources	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
fusion	NN	O
transcripts	NNS	O
”	CD	O
and	CC	O
are	VBP	O
also	RB	O
suitable	JJ	O
targets	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
that	IN	O
introns	NNS	O
can	MD	O
be	VB	O
effectively	RB	O
targeted	VBN	O
using	VBG	O
antisense	JJ	O
compounds	NNS	O
targeted	VBN	O
to	TO	O
,	,	O
for	IN	O
example	NN	O
,	,	O
DNA	NNP	O
or	CC	O
pre-mRNA	NN	O
.	.	O
Single-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
such	JJ	O
as	IN	O
oligonucleotide	JJ	O
compounds	NNS	O
that	WDT	O
work	VBP	O
via	IN	O
an	DT	O
RNase	NNP	O
H	NNP	O
mechanism	NN	O
are	VBP	O
effective	JJ	O
for	IN	O
targeting	VBG	O
pre-mRNA	NN	O
.	.	O
Antisense	NNP	O
compounds	VBZ	O
that	IN	O
function	NN	O
via	IN	O
an	DT	O
occupancy-based	JJ	O
mechanism	NN	O
are	VBP	O
effective	JJ	O
for	IN	O
redirecting	VBG	O
splicing	VBG	O
as	IN	O
they	PRP	O
do	VBP	O
not	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
elicit	JJ	O
RNase	NNP	O
H	NNP	O
cleavage	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
,	,	O
but	CC	O
rather	RB	O
leave	VBP	O
the	DT	O
mRNA	NN	O
intact	JJ	O
and	CC	O
promote	VB	O
the	DT	O
yield	NN	O
of	IN	O
desired	JJ	O
splice	NN	O
product	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O
Variants	NNS	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
alternative	JJ	O
RNA	NNP	O
transcripts	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
region	NN	O
of	IN	O
DNA	NNP	O
.	.	O
These	DT	O
alternative	JJ	O
transcripts	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
as	IN	O
“	JJ	O
variants.	NN	O
”	NNP	O
More	NNP	O
specifically	RB	O
,	,	O
“	JJ	O
pre-mRNA	JJ	O
variants	NNS	O
”	WDT	O
are	VBP	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
that	WDT	O
differ	VBP	O
from	IN	O
other	JJ	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
in	IN	O
either	CC	O
their	PRP$	O
start	NN	O
or	CC	O
stop	VB	O
position	NN	O
and	CC	O
contain	VB	O
both	DT	O
intronic	JJ	O
and	CC	O
exonic	JJ	O
sequence	NN	O
.	.	O
Upon	IN	O
excision	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
exon	NNS	O
or	CC	O
intron	NN	O
regions	NNS	O
,	,	O
or	CC	O
portions	NNS	O
thereof	VBP	O
during	IN	O
splicing	NN	O
,	,	O
pre-mRNA	JJ	O
variants	NNS	O
produce	VBP	O
smaller	JJR	O
“	NN	O
mRNA	NN	O
variants.	NN	O
”	NNP	O
Consequently	NNP	O
,	,	O
mRNA	NN	O
variants	NNS	O
are	VBP	O
processed	VBN	O
pre-mRNA	JJ	O
variants	NNS	O
and	CC	O
each	DT	O
unique	JJ	O
pre-mRNA	JJ	O
variant	NN	O
must	MD	O
always	RB	O
produce	VB	O
a	DT	O
unique	JJ	O
mRNA	NN	O
variant	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
splicing	NN	O
.	.	O
These	DT	O
mRNA	JJ	O
variants	NNS	O
are	VBP	O
also	RB	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
splice	NN	O
variants.	NN	O
”	NNP	O
If	IN	O
no	DT	O
splicing	NN	O
of	IN	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
occurs	VBZ	O
then	RB	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
is	VBZ	O
identical	JJ	O
to	TO	O
the	DT	O
mRNA	NN	O
variant	NN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
variants	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
alternative	JJ	O
signals	NNS	O
to	TO	O
start	VB	O
or	CC	O
stop	VB	O
transcription	NN	O
and	CC	O
that	IN	O
pre-mRNAs	JJ	O
and	CC	O
mRNAs	NN	O
can	MD	O
possess	VB	O
more	JJR	O
that	DT	O
one	CD	O
start	NN	O
codon	NN	O
or	CC	O
stop	VB	O
codon	NN	O
.	.	O
Variants	NNS	O
that	WDT	O
originate	VBP	O
from	IN	O
a	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
that	IN	O
use	NN	O
alternative	JJ	O
start	NN	O
codons	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
start	NN	O
variants	NNS	O
”	CD	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
.	.	O
Those	DT	O
transcripts	NNS	O
that	WDT	O
use	VBP	O
an	DT	O
alternative	JJ	O
stop	NN	O
codon	NN	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
stop	NN	O
variants	NNS	O
”	CD	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
.	.	O
One	CD	O
specific	JJ	O
type	NN	O
of	IN	O
alternative	JJ	O
stop	NN	O
variant	NN	O
is	VBZ	O
the	DT	O
“	JJ	O
polyA	NN	O
variant	NN	O
”	NN	O
in	IN	O
which	WDT	O
the	DT	O
multiple	NN	O
transcripts	NNS	O
produced	VBD	O
result	NN	O
from	IN	O
the	DT	O
alternative	JJ	O
selection	NN	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
“	NNP	O
polyA	NN	O
stop	NN	O
signals	NNS	O
”	VBN	O
by	IN	O
the	DT	O
transcription	NN	O
machinery	NN	O
,	,	O
thereby	RB	O
producing	VBG	O
transcripts	NNS	O
that	WDT	O
terminate	VBP	O
at	IN	O
unique	JJ	O
polyA	NN	O
sites	NNS	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
types	NNS	O
of	IN	O
variants	NNS	O
described	VBN	O
herein	NNS	O
are	VBP	O
also	RB	O
suitable	JJ	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
.	.	O
Target	NN	O
Names	NNP	O
,	,	O
Synonyms	NNP	O
,	,	O
Features	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
which	WDT	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
Table	JJ	O
1	CD	O
lists	VBZ	O
the	DT	O
gene	NN	O
target	NN	O
names	NNS	O
and	CC	O
their	PRP$	O
respective	JJ	O
synonyms	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
GenBank	NNP	O
accession	NN	O
numbers	NNS	O
used	VBN	O
to	TO	O
design	VB	O
oligomeric	JJ	O
compounds	NNS	O
targeted	VBN	O
to	TO	O
each	DT	O
gene	NN	O
.	.	O
Table	JJ	O
1	CD	O
also	RB	O
describes	JJ	O
features	NNS	O
contained	VBN	O
within	IN	O
the	DT	O
gene	NN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Representative	JJ	O
features	NNS	O
include	VBP	O
5′UTR	CD	O
,	,	O
start	NN	O
codon	NN	O
,	,	O
coding	VBG	O
sequence	NN	O
(	(	O
coding	VBG	O
)	)	O
,	,	O
stop	JJ	O
codon	NN	O
,	,	O
3′UTR	CD	O
,	,	O
exon	NN	O
,	,	O
intron	NN	O
,	,	O
exon	NN	O
:	:	O
exon	JJ	O
junction	NN	O
,	,	O
intron	NN	O
:	:	O
exon	JJ	O
junction	NN	O
and	CC	O
exon	NN	O
:	:	O
intron	NN	O
junction	NN	O
.	.	O
“	JJ	O
Feature	NNP	O
start	NN	O
site	NN	O
”	NN	O
and	CC	O
“	JJ	O
feature	NN	O
end	NN	O
site	NN	O
”	NN	O
refer	NN	O
to	TO	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
and	CC	O
last	JJ	O
(	(	O
3′-most	JJ	O
)	)	O
nucleotide	IN	O
numbers	NNS	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
the	DT	O
described	JJ	O
feature	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
designated	VBN	O
sequence	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
for	IN	O
a	DT	O
sequence	NN	O
containing	VBG	O
a	DT	O
start	NN	O
codon	NN	O
comprising	VBG	O
the	DT	O
first	JJ	O
three	CD	O
nucleotides	NNS	O
,	,	O
“	JJ	O
feature	JJ	O
start	NN	O
site	NN	O
”	NN	O
is	VBZ	O
“	JJ	O
1	CD	O
”	NN	O
and	CC	O
“	JJ	O
feature	NN	O
end	NN	O
site	NN	O
”	NN	O
is	VBZ	O
“	JJ	O
3	CD	O
”	NN	O
.	.	O
Small	JJ	O
Non-Coding	JJ	O
RNA-Regulated	JJ	O
Regions	NNPS	O
Small	NNP	O
non-coding	JJ	O
RNA	NNP	O
molecules	NNS	O
play	VBP	O
important	JJ	O
roles	NNS	O
in	IN	O
regulation	NN	O
of	IN	O
gene	NN	O
expression	NN	O
,	,	O
developmental	JJ	O
timing	NN	O
,	,	O
viral	JJ	O
surveillance	NN	O
,	,	O
and	CC	O
immunity	NN	O
.	.	O
Not	RB	O
only	RB	O
the	DT	O
classic	JJ	O
transfer	NN	O
RNAs	NNP	O
(	(	O
tRNAs	NN	O
)	)	O
and	CC	O
ribosomal	JJ	O
RNAs	NNP	O
(	(	O
rRNAs	NN	O
)	)	O
,	,	O
but	CC	O
also	RB	O
small	JJ	O
nuclear	JJ	O
RNAs	NNP	O
(	(	O
snRNAs	NN	O
)	)	O
,	,	O
small	JJ	O
nucleolar	JJ	O
RNAs	NNP	O
(	(	O
snoRNAs	NN	O
)	)	O
,	,	O
small	JJ	O
interfering	NN	O
RNAs	NNP	O
(	(	O
siRNAs	NN	O
)	)	O
,	,	O
tiny	JJ	O
non-coding	JJ	O
RNAs	NNP	O
(	(	O
tncRNAs	NN	O
)	)	O
and	CC	O
microRNAs	$	O
(	(	O
miRNAs	NN	O
)	)	O
are	VBP	O
now	RB	O
known	VBN	O
to	TO	O
act	VB	O
in	IN	O
diverse	JJ	O
cellular	JJ	O
processes	NNS	O
such	JJ	O
as	IN	O
chromosome	NN	O
maintenance	NN	O
,	,	O
gene	NN	O
imprinting	NN	O
,	,	O
pre-mRNA	JJ	O
splicing	NN	O
,	,	O
guiding	VBG	O
RNA	NNP	O
modifications	NNS	O
,	,	O
transcriptional	JJ	O
regulation	NN	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
of	IN	O
mRNA	JJ	O
translation	NN	O
(	(	O
Eddy	NNP	B
,	,	I
Nat	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2001	CD	I
,	,	I
2	CD	I
,	,	I
919-929	CD	I
;	:	O
Kawasaki	NNP	B
and	CC	I
Taira	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2003	CD	I
,	,	I
423	CD	I
,	,	I
838-842	JJ	I
)	)	O
.	.	O
RNA-mediated	JJ	O
processes	NNS	O
are	VBP	O
now	RB	O
also	RB	O
believed	VBN	O
to	TO	O
direct	VB	O
heterochromatin	NN	O
formation	NN	O
,	,	O
genome	JJ	O
rearrangements	NNS	O
,	,	O
and	CC	O
DNA	NNP	O
elimination	NN	O
(	(	O
Cerutti	NNP	B
,	,	I
Trends	NNP	I
Genet.	NNP	I
,	,	I
2003	CD	I
,	,	I
19	CD	I
,	,	I
39-46	CD	I
;	:	O
Couzin	NNP	B
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
298	CD	I
,	,	I
2296-2297	JJ	I
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
regions	NNS	O
of	IN	O
target	NN	O
genes	NNS	O
that	WDT	O
are	VBP	O
targets	NNS	O
of	IN	O
small	JJ	O
non-coding	JJ	O
RNAs	NNP	O
are	VBP	O
suitable	JJ	O
targets	NNS	O
for	IN	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
One	CD	O
class	NN	O
of	IN	O
small	JJ	O
non-coding	JJ	O
RNAs	NNP	O
known	VBN	O
as	IN	O
microRNAs	NN	O
(	(	O
miRNAs	NN	O
)	)	O
participates	VBZ	O
in	IN	O
regulation	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
Mature	NNP	O
miRNAs	NN	O
originate	NN	O
from	IN	O
long	RB	O
endogenous	JJ	O
primary	JJ	O
transcripts	NNS	O
(	(	O
pri-miRNAs	NN	O
)	)	O
that	WDT	O
are	VBP	O
often	RB	O
hundreds	NNS	O
of	IN	O
nucleotides	NNS	O
in	IN	O
length	NN	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
EMBO	NNP	I
J.	NNP	I
,	,	I
2002	CD	I
,	,	I
21	CD	I
,	,	I
4663-70	JJ	I
)	)	O
.	.	O
These	DT	O
pri-miRNAs	NNS	O
are	VBP	O
processed	VBN	O
by	IN	O
a	DT	O
nucleolar	JJ	O
enzyme	NN	O
in	IN	O
the	DT	O
RNase	NNP	O
III	NNP	O
family	NN	O
known	VBN	O
as	IN	O
Drosha	NNP	O
,	,	O
into	IN	O
approximately	RB	O
70	CD	O
nucleotide-long	JJ	O
pre-miRNAs	NN	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
stem-loop	NN	O
,	,	O
hairpin	NN	O
or	CC	O
foldback	NN	O
precursors	NNS	O
)	)	O
which	WDT	O
are	VBP	O
subsequently	RB	O
processed	VBN	O
by	IN	O
the	DT	O
Dicer	NNP	O
RNase	NNP	O
into	IN	O
mature	NN	O
miRNAs	NN	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
,	,	I
2003	CD	I
,	,	I
425	CD	I
,	,	I
415-419	JJ	I
)	)	O
.	.	O
The	DT	O
current	JJ	O
model	NN	O
is	VBZ	O
that	IN	O
the	DT	O
primary	JJ	O
miRNA	NN	O
transcript	NN	O
is	VBZ	O
processed	VBN	O
by	IN	O
Drosha	NNP	O
in	IN	O
the	DT	O
nucleus	NN	O
,	,	O
and	CC	O
the	DT	O
pre-miRNA	JJ	O
hairpin	NN	O
precursor	NN	O
is	VBZ	O
exported	VBN	O
from	IN	O
the	DT	O
nucleus	NN	O
through	IN	O
the	DT	O
action	NN	O
of	IN	O
the	DT	O
nuclear	JJ	O
export	NN	O
protein	IN	O
exportin-5	JJ	O
(	(	O
Bohnsack	NNP	B
et	RB	I
al.	RB	I
,	,	I
RNA	NNP	I
,	,	I
2004	CD	I
,	,	I
10	CD	I
,	,	I
185-191	CD	I
;	:	O
Lund	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
2004	CD	I
,	,	I
303	CD	I
,	,	I
95-98	CD	I
;	:	O
Yi	NNP	B
et	FW	I
al.	NN	I
,	,	I
Genes	NNP	I
Dev.	NNP	I
,	,	I
2003	CD	I
,	,	I
17	CD	I
,	,	I
3011-3016	JJ	I
)	)	O
.	.	O
Once	RB	O
in	IN	O
the	DT	O
cytoplasm	NN	O
,	,	O
the	DT	O
pre-miRNA	NN	O
is	VBZ	O
cleaved	VBN	O
by	IN	O
Dicer	NNP	O
to	TO	O
yield	VB	O
a	DT	O
double-stranded	JJ	O
intermediate	NN	O
,	,	O
but	CC	O
only	RB	O
one	CD	O
strand	NN	O
of	IN	O
this	DT	O
short-lived	JJ	O
intermediate	NN	O
accumulates	NNS	O
as	IN	O
the	DT	O
mature	NN	O
miRNA	NN	O
(	(	O
Ambros	NNP	B
et	RB	I
al.	RB	I
,	,	I
RNA	NNP	I
,	,	I
2003	CD	I
,	,	I
9	CD	I
,	,	I
277-279	JJ	I
;	:	O
Bartel	NNP	B
and	CC	I
Bartel	NNP	I
,	,	I
Plant	NNP	I
Physiol.	NNP	I
,	,	I
2003	CD	I
,	,	I
132	CD	I
,	,	I
709-717	CD	I
;	:	O
Shi	NNP	B
,	,	I
Trends	NNP	I
Genet.	NNP	I
,	,	I
2003	CD	I
,	,	I
19	CD	I
,	,	I
9-12	CD	I
)	)	O
.	.	O
miRNAs	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
primarily	RB	O
direct	VB	O
translation	NN	O
repression	NN	O
but	CC	O
have	VBP	O
recently	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
trigger	VB	O
cleavage	JJ	O
events	NNS	O
.	.	O
More	JJR	O
than	IN	O
200	CD	O
miRNA	NN	O
genes	NNS	O
have	VBP	O
been	VBN	O
detected	VBN	O
in	IN	O
the	DT	O
human	JJ	O
genome	NN	O
.	.	O
Naturally	RB	O
occurring	VBG	O
miRNAs	NNS	O
are	VBP	O
characterized	VBN	O
by	IN	O
imperfect	JJ	O
complementarity	NN	O
to	TO	O
their	PRP$	O
target	NN	O
sequences	NNS	O
.	.	O
Artificially	RB	O
modified	VBN	O
miRNAs	NN	O
with	IN	O
sequences	NNS	O
completely	RB	O
complementary	VBP	O
to	TO	O
their	PRP$	O
target	NN	O
RNAs	NNP	O
have	VBP	O
been	VBN	O
designed	VBN	O
and	CC	O
found	VBN	O
to	TO	O
function	VB	O
as	IN	O
siRNAs	NN	O
that	IN	O
inhibit	NN	O
gene	NN	O
expression	NN	O
by	IN	O
reducing	VBG	O
RNA	NNP	O
transcript	NN	O
levels	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
regions	NNS	O
of	IN	O
Gemin	NNP	O
Genes	NNP	O
targeted	VBN	O
by	IN	O
naturally	RB	O
occurring	VBG	O
or	CC	O
artificially	RB	O
modified	VBN	O
miRNAs	NN	O
are	VBP	O
contemplated	VBN	O
as	IN	O
suitable	JJ	O
target	NN	O
sites	NNS	O
for	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Modulation	NN	O
of	IN	O
Target	NNP	O
Expression	NNP	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	JJ	O
modulation	NN	O
”	NN	O
means	VBZ	O
a	DT	O
perturbation	NN	O
of	IN	O
function	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
either	DT	O
an	DT	O
increase	NN	O
(	(	O
stimulation	NN	O
or	CC	O
induction	NN	O
)	)	O
or	CC	O
a	DT	O
decrease	NN	O
(	(	O
inhibition	NN	O
or	CC	O
reduction	NN	O
)	)	O
in	IN	O
expression	NN	O
.	.	O
As	IN	O
another	DT	O
example	NN	O
,	,	O
modulation	NN	O
of	IN	O
expression	NN	O
can	MD	O
include	VB	O
perturbing	VBG	O
splice	JJ	O
site	NN	O
selection	NN	O
of	IN	O
pre-mRNA	JJ	O
processing	NN	O
.	.	O
“	JJ	O
Expression	NNP	O
”	NNP	O
includes	VBZ	O
all	PDT	O
the	DT	O
functions	NNS	O
by	IN	O
which	WDT	O
a	DT	O
gene	NN	O
's	POS	O
coded	VBN	O
information	NN	O
is	VBZ	O
converted	VBN	O
into	IN	O
structures	NNS	O
present	JJ	O
and	CC	O
operating	NN	O
in	IN	O
a	DT	O
cell	NN	O
and	CC	O
“	JJ	O
modulation	NN	O
of	IN	O
expression	NN	O
”	NN	O
means	VBZ	O
the	DT	O
perturbation	NN	O
of	IN	O
such	JJ	O
functions	NNS	O
.	.	O
The	DT	O
functions	NNS	O
of	IN	O
DNA	NN	O
to	TO	O
be	VB	O
modulated	VBN	O
can	MD	O
include	VB	O
replication	NN	O
and	CC	O
transcription	NN	O
.	.	O
Replication	NN	O
and	CC	O
transcription	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
can	MD	O
be	VB	O
from	IN	O
an	DT	O
endogenous	JJ	O
cellular	JJ	O
template	NN	O
,	,	O
a	DT	O
vector	NN	O
,	,	O
a	DT	O
plasmid	JJ	O
construct	NN	O
or	CC	O
otherwise	RB	O
.	.	O
The	DT	O
functions	NNS	O
of	IN	O
RNA	NNP	O
to	TO	O
be	VB	O
modulated	VBN	O
can	MD	O
include	VB	O
translocation	NN	O
functions	NNS	O
,	,	O
which	WDT	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
a	DT	O
site	NN	O
of	IN	O
protein	JJ	O
translation	NN	O
,	,	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
sites	NNS	O
within	IN	O
the	DT	O
cell	NN	O
which	WDT	O
are	VBP	O
distant	JJ	O
from	IN	O
the	DT	O
site	NN	O
of	IN	O
RNA	NNP	O
synthesis	NN	O
,	,	O
and	CC	O
translation	NN	O
of	IN	O
protein	NN	O
from	IN	O
the	DT	O
RNA	NNP	O
.	.	O
RNA	NNP	O
processing	NN	O
functions	NNS	O
that	WDT	O
can	MD	O
be	VB	O
modulated	VBN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
splicing	VBG	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
yield	VB	O
one	CD	O
or	CC	O
more	JJR	O
RNA	JJ	O
species	NNS	O
,	,	O
capping	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
,	,	O
3′	CD	O
maturation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
and	CC	O
catalytic	JJ	O
activity	NN	O
or	CC	O
complex	JJ	O
formation	NN	O
involving	VBG	O
the	DT	O
RNA	NNP	O
which	WDT	O
may	MD	O
be	VB	O
engaged	VBN	O
in	IN	O
or	CC	O
facilitated	VBN	O
by	IN	O
the	DT	O
RNA	NNP	O
.	.	O
Modulation	NN	O
of	IN	O
expression	NN	O
can	MD	O
result	VB	O
in	IN	O
the	DT	O
increased	JJ	O
level	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acid	NN	O
species	NNS	O
or	CC	O
the	DT	O
decreased	JJ	O
level	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acid	NN	O
species	NNS	O
,	,	O
either	CC	O
temporally	RB	O
or	CC	O
by	IN	O
net	JJ	O
steady	JJ	O
state	NN	O
level	NN	O
.	.	O
One	CD	O
result	NN	O
of	IN	O
such	JJ	O
interference	NN	O
with	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
function	NN	O
is	VBZ	O
modulation	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
one	CD	O
embodiment	JJ	O
modulation	NN	O
of	IN	O
expression	NN	O
can	MD	O
mean	VB	O
increase	NN	O
or	CC	O
decrease	NN	O
in	IN	O
target	NN	O
RNA	NNP	O
or	CC	O
protein	NN	O
levels	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	JJ	O
modulation	NN	O
of	IN	O
expression	NN	O
can	MD	O
mean	VB	O
an	DT	O
increase	NN	O
or	CC	O
decrease	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
RNA	NNP	O
splice	NN	O
products	NNS	O
,	,	O
or	CC	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
ratio	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
splice	JJ	O
products	NNS	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
on	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
can	MD	O
be	VB	O
tested	VBN	O
in	IN	O
any	DT	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
provided	VBD	O
that	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
measurable	JJ	O
levels	NNS	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
on	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
can	MD	O
be	VB	O
routinely	RB	O
determined	VBN	O
using	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
PCR	NNP	O
or	CC	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
.	.	O
Useful	NNP	O
cell	NN	O
lines	NNS	O
include	VBP	O
,	,	O
e.g.	JJ	O
,	,	O
1321rX3-7	JJ	O
;	:	O
3T3-L1	JJ	O
,	,	O
differentiated	VBD	O
;	:	O
3T3-L1	JJ	O
,	,	O
undifferentiated	JJ	O
;	:	O
70Z3	CD	O
;	:	O
7D4	CD	O
;	:	O
7F2	CD	O
(	(	O
osteoblast	NN	O
)	)	O
;	:	O
A10	NNP	O
;	:	O
A20	NNP	O
;	:	O
A375	NNP	O
;	:	O
A431	NNP	O
;	:	O
A549	NNP	O
;	:	O
AML-12	NNP	O
;	:	O
ARIP	NNP	O
;	:	O
differentiated	VBN	O
Adipocytes	NNPS	O
;	:	O
B104	NNP	O
;	:	O
B16-F10	NNP	O
;	:	O
B50	NNP	O
;	:	O
BALC	NNP	O
;	:	O
BB88	NNP	O
;	:	O
BC3H1	NNP	O
;	:	O
BCL	NNP	O
;	:	O
BEAS2B	NNP	O
;	:	O
BHK-21	NNP	O
(	(	O
fibroblast	NN	O
,	,	O
kidney	NN	O
)	)	O
;	:	O
BLO-11	NNP	O
(	(	O
skeletal	JJ	O
muscle	NN	O
)	)	O
;	:	O
BT-474	NNP	O
;	:	O
BW5147.3	NNP	O
(	(	O
ATCC	NNP	O
TIB-47	NNP	O
)	)	O
;	:	O
BaF3	NNP	O
;	:	O
Mouse	NNP	O
primary	JJ	O
bone	NN	O
marrow-derived	JJ	O
osteoclasts	NNS	O
;	:	O
C2C12	NNP	O
;	:	O
C3A	NNP	O
;	:	O
C3H/10T1/2	NNP	O
;	:	O
C58	NNP	O
;	:	O
C6	NNP	O
;	:	O
CHO	NNP	O
(	(	O
Ovary	NNP	O
)	)	O
;	:	O
CMT-93	JJ	O
;	:	O
COS-7	NNP	O
;	:	O
CT26.WT	NNP	O
;	:	O
Caco-2	NNP	O
;	:	O
ConA	NNP	O
;	:	O
D1	NNP	O
TNC1	NNP	O
;	:	O
D1B	NNP	O
;	:	O
DA-3	NNP	O
;	:	O
DDT1-MF2	NNP	O
;	:	O
DU	NNP	O
145	CD	O
(	(	O
prostate	NN	O
)	)	O
;	:	O
Peripheral	NNP	O
Blood	NNP	O
Monocyte	NNP	O
derived	VBD	O
Human	NNP	O
Primary	NNP	O
Dendritic	NNP	O
Cells	NNP	O
;	:	O
E14	NNP	O
;	:	O
EL4	NNP	O
;	:	O
EMT-6	NNP	O
;	:	O
F11	NNP	O
;	:	O
FAT	NNP	O
7	CD	O
(	(	O
epithelial	JJ	O
,	,	O
nasal	RB	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
)	)	O
;	:	O
Human	NNP	O
Primary	NNP	O
Dermal	NNP	O
Fibroblasts	NNP	O
;	:	O
Mouse	NNP	O
Embryonic	NNP	O
Primary	NNP	O
Fibroblasts	NNS	O
;	:	O
G-361	NNP	O
;	:	O
GH1	NNP	O
;	:	O
GH3	NNP	O
;	:	O
H-4-II-E	NNP	O
;	:	O
H2.35	NNP	O
;	:	O
H8	NNP	O
;	:	O
H9	NNP	O
(	(	O
Human	NNP	O
T	NNP	O
Lymphocyte	NNP	O
)	)	O
;	:	O
H9c2	NNP	O
(	(	O
2-1	JJ	O
)	)	O
;	:	O
HASMC	NNP	O
(	(	O
Human	NNP	O
Aortic	NNP	O
Smooth	NNP	O
Muscle	NNP	O
Cells	NNP	O
)	)	O
;	:	O
HC252	NNP	O
(	(	O
differentiated	VBN	O
rat	VBP	O
neuronal	JJ	O
progenitor	NN	O
cell	NN	O
line	NN	O
)	)	O
;	:	O
HC252	NNP	O
(	(	O
undifferentiated	JJ	O
rat	NN	O
neuronal	JJ	O
progenitor	NN	O
cell	NN	O
line	NN	O
)	)	O
;	:	O
HCT116	NNP	O
;	:	O
HEK	NNP	O
A-Z	NNP	O
(	(	O
rt-SLC	JJ	O
tx	NN	O
)	)	O
;	:	O
HEK-293	NNP	O
;	:	O
HEK-293	NNP	O
(	(	O
Rat	NNP	O
VR1	NNP	O
Transfected	NNP	O
)	)	O
;	:	O
HEPA1-6	NNP	O
;	:	O
HFN	NNP	O
36.3	CD	O
;	:	O
HK-2	NNP	O
(	(	O
human	JJ	O
HPV-16	NNP	O
transformed	VBD	O
proximal	JJ	O
tubule	NN	O
kidney	NN	O
)	)	O
;	:	O
HL-60	NNP	O
;	:	O
HMEC	NNP	O
(	(	O
Normal	NNP	O
Human	NNP	O
Mammary	NNP	O
Epithelial	NNP	O
Cells	NNP	O
)	)	O
;	:	O
HMVEC-L	NNP	O
(	(	O
Lung	NNP	O
Endothelial	NNP	O
)	)	O
;	:	O
HMVEC-d	JJ	O
Ad	NNP	O
(	(	O
Human	NNP	O
Adult	NNP	O
Dermal	NNP	O
Endothelial	NNP	O
)	)	O
;	:	O
HMVEC-d	JJ	O
Neo	NNP	O
(	(	O
Human	NNP	O
Neonatal	NNP	O
Dermal	NNP	O
Endothelial	NNP	O
)	)	O
;	:	O
HPAEC	NNP	O
(	(	O
Human	NNP	O
Pulmonary	NNP	O
Artery	NNP	O
Endothelial	NNP	O
Cells	NNP	O
)	)	O
;	:	O
HT-1080	NNP	O
;	:	O
HeLa	NNP	O
;	:	O
Hec-1A	NNP	O
;	:	O
HepB3	NNP	O
;	:	O
HepG2	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Hepatocytes	NNP	O
;	:	O
Mouse	NNP	O
Primary	NNP	O
Hepatocytes	NNP	O
;	:	O
Rabbit	NNP	O
Primary	NNP	O
Hepatocytes	NNP	O
;	:	O
Rat	NNP	O
Primary	NNP	O
Hepatocytes	NNP	O
;	:	O
HuT	NNP	O
78	CD	O
(	(	O
Human	NNP	O
cutaneous	JJ	O
T	NNP	O
lymphocyte	NN	O
)	)	O
;	:	O
HuVEC	NNP	O
;	:	O
Huh7	NNP	O
;	:	O
Human	NNP	O
H-ras	NNP	O
transformed	VBD	O
rat	JJ	O
intestinal	JJ	O
epithelial	JJ	O
cells	NNS	O
;	:	O
IC21	NNP	O
;	:	O
IEC-6	NNP	O
;	:	O
IW32	NNP	O
;	:	O
JAR	NNP	O
;	:	O
JEG-3	NNP	O
;	:	O
JUG-3	NNP	O
;	:	O
Jurkat	NNP	O
;	:	O
K-562	NNP	O
;	:	O
K204	NNP	O
;	:	O
Mouse	NNP	O
Primary	NNP	O
Keratinocytes	NNP	O
;	:	O
L2	NNP	O
(	(	O
lung	NN	O
)	)	O
;	:	O
L6	NNP	O
;	:	O
LA4	NNP	O
;	:	O
LBRM-33	NNP	O
;	:	O
LC-540	NNP	O
;	:	O
LL/6	NNP	O
;	:	O
LL2	NNP	O
;	:	O
LLC1	NNP	O
;	:	O
LNcAP	NNP	O
;	:	O
M-3	NNP	O
(	(	O
Mouse	NNP	O
melanoma	NN	O
;	:	O
skin	CC	O
;	:	O
melanocyte	NN	O
)	)	O
;	:	O
MCF7	NNP	O
(	(	O
breast	NN	O
adenocarcinoma	NN	O
,	,	O
w/t	WP	O
p53	NN	O
)	)	O
;	:	O
MDA	NNP	O
;	:	O
MDA	NNP	O
MB	NNP	O
468	CD	O
;	:	O
MDA	NNP	O
MB231	NNP	O
;	:	O
MEF	NNP	O
;	:	O
MH-S	NNP	O
;	:	O
MLE12	NNP	O
;	:	O
MLg2908	NNP	O
;	:	O
MMT	NNP	O
060562	CD	O
;	:	O
MRC-5	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Macrophages	NNP	O
;	:	O
Mouse	NNP	O
Peritoneal	NNP	O
Macrophages	NNP	O
;	:	O
Rat	NNP	O
Peritoneal	NNP	O
Macrophages	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Melanocytes	NNP	O
;	:	O
Mia	NNP	O
Paca	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Monocytes	NNP	O
;	:	O
N1S1	NNP	O
(	(	O
liver	NN	O
)	)	O
;	:	O
NBT-II	NNP	O
;	:	O
NCCIT	NNP	O
;	:	O
NCI-H292	NNP	O
;	:	O
NCTC	NNP	O
3749	CD	O
;	:	O
ND7/23	NNP	O
;	:	O
NG108-15	NNP	O
(	(	O
mouse	NN	O
)	)	O
;	:	O
NG108-15	NNP	O
(	(	O
rat	NN	O
)	)	O
;	:	O
NHDC	NNP	O
(	(	O
Dendritic	NNP	O
Cells	NNP	O
)	)	O
;	:	O
NHDF	NNP	O
;	:	O
NHEK	NNP	O
(	(	O
Human	NNP	O
Primary	NNP	O
Keratinocytes	NNP	O
)	)	O
;	:	O
NHEK-Ad	NNP	O
(	(	O
Human	NNP	O
Primary	NNP	O
Adult	NNP	O
Keratinocytes	NNP	O
)	)	O
;	:	O
NHEK-Neo	NNP	O
(	(	O
Human	NNP	O
Primary	NNP	O
Neonatal	NNP	O
Keratinocytes	NNP	O
)	)	O
;	:	O
NIH/3T3	NNP	O
(	(	O
mouse	IN	O
fibroblast	NN	O
)	)	O
;	:	O
NIT-1	JJ	O
;	:	O
NOR-10	NNP	O
(	(	O
Mouse	NNP	O
muscle	NN	O
)	)	O
;	:	O
NR-8383	NNP	O
;	:	O
NRK	NNP	O
;	:	O
NTERA-2	NNP	O
c1.D1	NN	O
;	:	O
Rat	NNP	O
Primary	NNP	O
Neurons	NNP	O
;	:	O
Mouse	NNP	O
primary	JJ	O
Osteoblasts	NNS	O
;	:	O
Rat	NNP	O
primary	JJ	O
Osteoblasts	NNS	O
;	:	O
P-19	NNP	O
;	:	O
P388D1	NNP	O
(	(	O
IL-1	NNP	O
)	)	O
adherent	NN	O
;	:	O
P388D1	NNP	O
suspension	NN	O
;	:	O
PANC-1	NNP	O
;	:	O
PC-12	NNP	O
;	:	O
PC-3	NNP	O
(	(	O
prostate	NN	O
)	)	O
;	:	O
White	NNP	O
Preadipocytes	NNPS	O
;	:	O
R2C	NNP	O
;	:	O
R6	NNP	O
;	:	O
RAW264.7	NNP	O
;	:	O
RB++	NNP	O
;	:	O
RBL-2H3	NNP	O
;	:	O
RFL-6	NNP	O
;	:	O
RK3E	NNP	O
;	:	O
RMC	NNP	O
;	:	O
ROS	NNP	O
17/2.8	CD	O
;	:	O
Raji	NNP	O
;	:	O
Rat	NNP	O
Tissue—Cerebellum	NNP	O
;	:	O
Rat	NNP	O
Tissue—Cerebrum	NNP	O
;	:	O
Rat	NNP	O
Tissue—Hippocampus	NNP	O
;	:	O
Rat-2	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Renal	NNP	O
Proximal	NNP	O
Tubule	NNP	O
Epithelial	NNP	O
Cell	NNP	O
;	:	O
Rin-5F	NNP	O
;	:	O
Rin-M	NNP	O
;	:	O
SK-MEL-28	NNP	O
;	:	O
SKBR	NNP	O
;	:	O
SMT/2A	NNP	O
LNM	NNP	O
;	:	O
SV40	NNP	O
MES	NNP	O
13	CD	O
;	:	O
SW480	NNP	O
;	:	O
SW97	NNP	O
;	:	O
Shionogi	NNP	O
;	:	O
Human	NNP	O
Primary	NNP	O
Smooth	NNP	O
Muscle	NNP	O
Bronchial	NNP	O
Cell	NNP	O
;	:	O
Mouse	NNP	O
Primary	NNP	O
Splenocytes	NNP	O
;	:	O
Human	NNP	O
Synoviocytes	NNPS	O
;	:	O
Mouse	NNP	O
Synoviocytes	NNPS	O
;	:	O
Rat	NNP	O
Synoviocytes	NNPS	O
;	:	O
T	NNP	O
cell	VBP	O
hybridoma	RB	O
2B4	CD	O
;	:	O
T-24	NNP	O
;	:	O
T-49	NNP	O
D	NNP	O
;	:	O
T3-3A1	NNP	O
;	:	O
T47D	NNP	O
(	(	O
breast	NN	O
adenocarcinoma	NN	O
,	,	O
mutant	JJ	O
p53	NN	O
)	)	O
;	:	O
T47D+p53	NNP	O
(	(	O
breast	NN	O
adenocarcinoma	NN	O
,	,	O
mutant	JJ	O
p53	NN	O
,	,	O
transfected	VBN	O
with	IN	O
wild-type	JJ	O
p53	NN	O
)	)	O
;	:	O
TCMK-1	NNP	O
(	(	O
kidney	NN	O
)	)	O
;	:	O
TF1.8	NNP	O
;	:	O
THLE-3	NNP	O
;	:	O
THP-1	NNP	O
;	:	O
TM-3	NNP	O
;	:	O
TM4	NNP	O
;	:	O
TRAMP-C1	NNP	O
;	:	O
U-20S	NNP	O
;	:	O
U-87	NNP	O
MG	NNP	O
;	:	O
U373	NNP	O
;	:	O
U937	NNP	O
;	:	O
UMR-106	NNP	O
(	(	O
osteosarcoma	NN	O
)	)	O
;	:	O
VERO	NNP	O
C1008	NNP	O
;	:	O
WEHI	NNP	O
231	CD	O
;	:	O
WISH	NNP	O
;	:	O
Y-1	JJ	O
;	:	O
Y13-238	NNP	O
(	(	O
spleen	JJ	O
)	)	O
;	:	O
Y13-259	NNP	O
(	(	O
spleen	JJ	O
)	)	O
;	:	O
YB2/0	NNP	O
(	(	O
spleen	JJ	O
)	)	O
;	:	O
Yac-1	JJ	O
;	:	O
b.END	NN	O
;	:	O
mIMCD-3	JJ	O
;	:	O
and	CC	O
sw872	NN	O
.	.	O
The	DT	O
culture	NN	O
of	IN	O
such	JJ	O
cells	NNS	O
is	VBZ	O
routine	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Other	JJ	O
cell	NN	O
types	NNS	O
well	RB	O
known	VBN	O
to	TO	O
one	CD	O
of	IN	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
can	MD	O
be	VB	O
routinely	RB	O
used	VBN	O
.	.	O
Many	JJ	O
cell	NN	O
lines	NNS	O
and	CC	O
instructions	NNS	O
for	IN	O
growing	VBG	O
them	PRP	O
are	VBP	O
obtainable	JJ	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
Assaying	VBG	O
Modulation	NNP	O
of	IN	O
Expression	NNP	O
Modulation	NNP	O
of	IN	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
can	MD	O
be	VB	O
assayed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Gemin	NNP	O
Gene	NNP	O
mRNA	NN	O
levels	NNS	O
can	MD	O
be	VB	O
quantitated	VBN	O
by	IN	O
,	,	O
e.g.	NN	O
,	,	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
,	,	O
competitive	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
,	,	O
or	CC	O
real-time	JJ	O
PCR	NNP	O
.	.	O
RNA	JJ	O
analysis	NN	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
total	JJ	O
cellular	JJ	O
RNA	NNP	O
or	CC	O
poly	NN	O
(	(	O
A	DT	O
)	)	O
+mRNA	NN	O
by	IN	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Methods	NNS	O
of	IN	O
RNA	NNP	O
isolation	NN	O
are	VBP	O
taught	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
1	CD	I
,	,	I
pp	NN	I
.	.	I
4.1.1-4.2.9	JJ	I
and	CC	I
4.5.1-4.5.3	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1993	CD	I
.	.	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
is	VBZ	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
is	VBZ	O
taught	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
1	CD	I
,	,	I
pp	NN	I
.	.	I
4.2.1-4.2.9	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1996	CD	I
.	.	O
Real-time	JJ	O
quantitative	NN	O
(	(	O
PCR	NNP	O
)	)	O
can	MD	O
be	VB	O
conveniently	RB	O
accomplished	VBN	O
using	VBG	O
the	DT	O
commercially	RB	O
available	JJ	O
ABI	NNP	O
PRISM™	NNP	O
7700	CD	O
Sequence	NNP	O
Detection	NNP	O
System	NNP	O
,	,	O
available	JJ	O
from	IN	O
PE-Applied	NNP	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
and	CC	O
used	VBD	O
according	VBG	O
to	TO	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Levels	NNS	O
of	IN	O
a	DT	O
protein	NN	O
encoded	VBN	O
by	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
can	MD	O
be	VB	O
quantitated	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
immunoprecipitation	NN	O
,	,	O
Western	JJ	O
blot	NN	O
analysis	NN	O
(	(	O
immunoblotting	VBG	O
)	)	O
,	,	O
ELISA	NNP	O
or	CC	O
fluorescence-activated	JJ	O
cell	NN	O
sorting	VBG	O
(	(	O
FACS	NNP	O
)	)	O
.	.	O
Antibodies	NNS	O
directed	VBD	O
to	TO	O
a	DT	O
protein	NN	O
encoded	VBN	O
by	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
can	MD	O
be	VB	O
identified	VBN	O
and	CC	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
MSRS	NNP	O
catalog	NN	O
of	IN	O
antibodies	NNS	O
(	(	O
Aerie	NNP	O
Corporation	NNP	O
,	,	O
Birmingham	NNP	O
,	,	O
Mich.	NNP	O
)	)	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
prepared	JJ	O
via	IN	O
conventional	JJ	O
antibody	NN	O
generation	NN	O
methods	NNS	O
.	.	O
Methods	NNS	O
for	IN	O
preparation	NN	O
of	IN	O
polyclonal	JJ	O
antisera	NN	O
are	VBP	O
taught	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
11.12.1-11.12.9	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1997	CD	I
.	.	O
Preparation	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
is	VBZ	O
taught	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
11.4.1-11.11.5	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1997	CD	I
.	.	O
Immunoprecipitation	NN	O
methods	NNS	O
are	VBP	O
standard	JJ	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
be	VB	O
found	VBN	O
at	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
10.16.1-10.16.11	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1998	CD	I
.	.	O
Western	JJ	O
blot	NN	O
(	(	O
immunoblot	NN	O
)	)	O
analysis	NN	O
is	VBZ	O
standard	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
be	VB	O
found	VBN	O
at	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
10.8.1-10.8.21	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1997	CD	I
.	.	O
Enzyme-linked	JJ	O
immunosorbent	NN	O
assays	NNS	O
(	(	O
ELISA	NNP	O
)	)	O
are	VBP	O
standard	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
be	VB	O
found	VBN	O
at	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Volume	NN	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
11.2.1-11.2.22	JJ	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
1991	CD	I
.	.	O
Suitable	JJ	O
Target	NNP	O
Regions	NNP	O
Once	NNP	O
one	CD	O
or	CC	O
more	JJR	O
target	NN	O
regions	NNS	O
,	,	O
segments	NNS	O
or	CC	O
sites	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
are	VBP	O
chosen	VBN	O
which	WDT	O
are	VBP	O
sufficiently	RB	O
complementary	JJ	O
to	TO	O
the	DT	O
target	NN	O
,	,	O
i.e.	FW	O
,	,	O
hybridize	VB	O
sufficiently	RB	O
well	RB	O
and	CC	O
with	IN	O
sufficient	JJ	O
specificity	NN	O
,	,	O
to	TO	O
give	VB	O
the	DT	O
desired	JJ	O
effect	NN	O
.	.	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
targeted	VBN	O
to	TO	O
features	NNS	O
of	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
All	DT	O
regions	NNS	O
of	IN	O
a	DT	O
nucleobase	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
targeted	VBN	O
,	,	O
wherein	VBZ	O
the	DT	O
regions	NNS	O
are	VBP	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases	NNS	O
,	,	O
are	VBP	O
described	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Let	VB	O
R	NNP	O
(	(	O
n	JJ	O
,	,	O
n+m−1	JJ	O
)	)	O
be	VB	O
a	DT	O
region	NN	O
from	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
where	WRB	O
“	NN	O
n	JJ	O
”	NN	O
is	VBZ	O
the	DT	O
5′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region	NN	O
,	,	O
where	WRB	O
“	NN	O
n+m−1	JJ	O
”	NN	O
is	VBZ	O
the	DT	O
3′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region	NN	O
and	CC	O
where	WRB	O
“	NNP	O
m	NN	O
”	NN	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
region	NN	O
.	.	O
A	DT	O
set	NN	O
“	NN	O
S	NNP	O
(	(	O
m	NN	O
)	)	O
”	NN	O
,	,	O
of	IN	O
regions	NNS	O
of	IN	O
length	NN	O
“	NNP	O
m	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
regions	NNS	O
where	WRB	O
n	JJ	O
ranges	NNS	O
from	IN	O
1	CD	O
to	TO	O
L−m+1	NNP	O
,	,	O
where	WRB	O
L	NNP	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
and	CC	O
L	NNP	O
>	NNP	O
m	NN	O
.	.	O
A	DT	O
set	NN	O
,	,	O
“	VB	O
A	NNP	O
”	NNP	O
,	,	O
of	IN	O
all	DT	O
regions	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
as	IN	O
a	DT	O
union	NN	O
of	IN	O
the	DT	O
sets	NNS	O
of	IN	O
regions	NNS	O
for	IN	O
each	DT	O
length	NN	O
from	IN	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
is	VBZ	O
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
.	.	O
This	DT	O
set	NN	O
of	IN	O
regions	NNS	O
can	MD	O
be	VB	O
represented	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
mathematical	JJ	O
notation	NN	O
:	:	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
for	IN	O
m	JJ	O
equal	JJ	O
to	TO	O
8	CD	O
,	,	O
20	CD	O
and	CC	O
80	CD	O
can	MD	O
be	VB	O
constructed	VBN	O
in	IN	O
the	DT	O
following	JJ	O
manner	NN	O
.	.	O
The	DT	O
set	NN	O
of	IN	O
regions	NNS	O
,	,	O
each	DT	O
8	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
S	NNP	O
(	(	O
m=8	NN	O
)	)	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
(	(	O
L=100	NNP	O
)	)	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
(	(	O
n=1	NN	O
)	)	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
created	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
8	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,8	CD	O
|nε	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
93	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-8	JJ	O
,	,	O
2-9	JJ	O
,	,	O
3-10	JJ	O
,	,	O
4-11	JJ	O
,	,	O
5-12	JJ	O
,	,	O
6-13	JJ	O
,	,	O
7-14	JJ	O
,	,	O
8-15	JJ	O
,	,	O
9-16	JJ	O
,	,	O
10-17	JJ	O
,	,	O
11-18	JJ	O
,	,	O
12-19	JJ	O
,	,	O
13-20	JJ	O
,	,	O
14-21	JJ	O
,	,	O
15-22	JJ	O
,	,	O
16-23	JJ	O
,	,	O
17-24	JJ	O
,	,	O
18-25	JJ	O
,	,	O
19-26	JJ	O
,	,	O
20-27	JJ	O
,	,	O
21-28	JJ	O
,	,	O
22-29	JJ	O
,	,	O
23-30	JJ	O
,	,	O
24-31	JJ	O
,	,	O
25-32	JJ	O
,	,	O
26-33	JJ	O
,	,	O
27-34	JJ	O
,	,	O
28-35	JJ	O
,	,	O
29-36	JJ	O
,	,	O
30-37	JJ	O
,	,	O
31-38	JJ	O
,	,	O
32-39	JJ	O
,	,	O
33-40	JJ	O
,	,	O
34-41	JJ	O
,	,	O
35-42	JJ	O
,	,	O
36-43	JJ	O
,	,	O
37-44	JJ	O
,	,	O
38-45	JJ	O
,	,	O
39-46	JJ	O
,	,	O
40-47	JJ	O
,	,	O
41-48	JJ	O
,	,	O
42-49	JJ	O
,	,	O
43-50	JJ	O
,	,	O
44-51	JJ	O
,	,	O
45-52	JJ	O
,	,	O
46-53	JJ	O
,	,	O
47-54	JJ	O
,	,	O
48-55	JJ	O
,	,	O
49-56	JJ	O
,	,	O
50-57	JJ	O
,	,	O
51-58	JJ	O
,	,	O
52-59	JJ	O
,	,	O
53-60	JJ	O
,	,	O
54-61	JJ	O
,	,	O
55-62	JJ	O
,	,	O
56-63	JJ	O
,	,	O
57-64	JJ	O
,	,	O
58-65	JJ	O
,	,	O
59-66	JJ	O
,	,	O
60-67	JJ	O
,	,	O
61-68	JJ	O
,	,	O
62-69	JJ	O
,	,	O
63-70	JJ	O
,	,	O
64-71	JJ	O
,	,	O
65-72	JJ	O
,	,	O
66-73	JJ	O
,	,	O
67-74	JJ	O
,	,	O
68-75	JJ	O
,	,	O
69-76	JJ	O
,	,	O
70-77	JJ	O
,	,	O
71-78	JJ	O
,	,	O
72-79	JJ	O
,	,	O
73-80	JJ	O
,	,	O
74-81	JJ	O
,	,	O
75-82	JJ	O
,	,	O
76-83	JJ	O
,	,	O
77-84	JJ	O
,	,	O
78-85	JJ	O
,	,	O
79-86	JJ	O
,	,	O
80-87	JJ	O
,	,	O
81-88	JJ	O
,	,	O
82-89	JJ	O
,	,	O
83-90	JJ	O
,	,	O
84-91	JJ	O
,	,	O
85-92	JJ	O
,	,	O
86-93	JJ	O
,	,	O
87-94	JJ	O
,	,	O
88-95	JJ	O
,	,	O
89-96	JJ	O
,	,	O
90-97	JJ	O
,	,	O
91-98	JJ	O
,	,	O
92-99	JJ	O
,	,	O
93-100	JJ	O
.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
20	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,20	CD	O
|n	NNP	O
ε	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
81	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-20	JJ	O
,	,	O
2-21	JJ	O
,	,	O
3-22	JJ	O
,	,	O
4-23	JJ	O
,	,	O
5-24	JJ	O
,	,	O
6-25	JJ	O
,	,	O
7-26	JJ	O
,	,	O
8-27	JJ	O
,	,	O
9-28	JJ	O
,	,	O
10-29	JJ	O
,	,	O
11-30	JJ	O
,	,	O
12-31	JJ	O
,	,	O
13-32	JJ	O
,	,	O
14-33	JJ	O
,	,	O
15-34	JJ	O
,	,	O
16-35	JJ	O
,	,	O
17-36	JJ	O
,	,	O
18-37	JJ	O
,	,	O
19-38	JJ	O
,	,	O
20-39	JJ	O
,	,	O
21-40	JJ	O
,	,	O
22-41	JJ	O
,	,	O
23-42	JJ	O
,	,	O
24-43	JJ	O
,	,	O
25-44	JJ	O
,	,	O
26-45	JJ	O
,	,	O
27-46	JJ	O
,	,	O
28-47	JJ	O
,	,	O
29-48	JJ	O
,	,	O
30-49	JJ	O
,	,	O
31-50	JJ	O
,	,	O
32-51	JJ	O
,	,	O
33-52	JJ	O
,	,	O
34-53	JJ	O
,	,	O
35-54	JJ	O
,	,	O
36-55	JJ	O
,	,	O
37-56	JJ	O
,	,	O
38-57	JJ	O
,	,	O
39-58	JJ	O
,	,	O
40-59	JJ	O
,	,	O
41-60	JJ	O
,	,	O
42-61	JJ	O
,	,	O
43-62	JJ	O
,	,	O
44-63	JJ	O
,	,	O
45-64	JJ	O
,	,	O
46-65	JJ	O
,	,	O
47-66	JJ	O
,	,	O
48-67	JJ	O
,	,	O
49-68	JJ	O
,	,	O
50-69	JJ	O
,	,	O
51-70	JJ	O
,	,	O
52-71	JJ	O
,	,	O
53-72	JJ	O
,	,	O
54-73	JJ	O
,	,	O
55-74	JJ	O
,	,	O
56-75	JJ	O
,	,	O
57-76	JJ	O
,	,	O
58-77	JJ	O
,	,	O
59-78	JJ	O
,	,	O
60-79	JJ	O
,	,	O
61-80	JJ	O
,	,	O
62-81	JJ	O
,	,	O
63-82	JJ	O
,	,	O
64-83	JJ	O
,	,	O
65-84	JJ	O
,	,	O
66-85	JJ	O
,	,	O
67-86	JJ	O
,	,	O
68-87	JJ	O
,	,	O
69-88	JJ	O
,	,	O
70-89	JJ	O
,	,	O
71-90	JJ	O
,	,	O
72-91	JJ	O
,	,	O
73-92	JJ	O
,	,	O
74-93	JJ	O
,	,	O
75-94	JJ	O
,	,	O
76-95	JJ	O
,	,	O
77-96	JJ	O
,	,	O
78-97	JJ	O
,	,	O
79-98	JJ	O
,	,	O
80-99	JJ	O
,	,	O
81-100	JJ	O
.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
80	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,80	CD	O
|n	NNP	O
ε	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
21	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-80	CD	O
,	,	O
2-81	CD	O
,	,	O
3-82	CD	O
,	,	O
4-83	CD	O
,	,	O
5-84	JJ	O
,	,	O
6-85	JJ	O
,	,	O
7-86	JJ	O
,	,	O
8-87	JJ	O
,	,	O
9-88	CD	O
,	,	O
10-89	CD	O
,	,	O
11-90	CD	O
,	,	O
12-91	CD	O
,	,	O
13-92	CD	O
,	,	O
14-93	CD	O
,	,	O
15-94	CD	O
,	,	O
16-95	CD	O
,	,	O
17-96	CD	O
,	,	O
18-97	CD	O
,	,	O
19-98	CD	O
,	,	O
20-99	CD	O
,	,	O
21-100	CD	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
this	DT	O
example	NN	O
,	,	O
A	NNP	O
would	MD	O
include	VB	O
regions	NNS	O
1-8	JJ	O
,	,	O
2-9	JJ	O
,	,	O
3-10	JJ	O
.	.	O
.	.	O
.	.	O
93-100	CD	O
,	,	O
1-20	CD	O
,	,	O
2-21	JJ	O
,	,	O
3-22	JJ	O
.	.	O
.	.	O
.	.	O
81-100	JJ	O
,	,	O
1-80	JJ	O
,	,	O
2-81	JJ	O
,	,	O
3-82	JJ	O
.	.	O
.	.	O
.	.	O
21-100	JJ	O
.	.	O
The	DT	O
union	NN	O
of	IN	O
these	DT	O
aforementioned	JJ	O
example	NN	O
sets	NNS	O
and	CC	O
other	JJ	O
sets	NNS	O
for	IN	O
lengths	NNS	O
from	IN	O
10	CD	O
to	TO	O
19	CD	O
and	CC	O
21	CD	O
to	TO	O
79	CD	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
mathematical	JJ	O
expression	NN	O
The	DT	O
mathematical	JJ	O
expressions	NNS	O
described	VBD	O
herein	JJ	O
defines	NNS	O
all	DT	O
possible	JJ	O
target	NN	O
regions	NNS	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
length	NN	O
L	NNP	O
,	,	O
where	WRB	O
the	DT	O
region	NN	O
is	VBZ	O
of	IN	O
length	NN	O
m	NN	O
,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases	NNS	O
and	CC	O
,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L	NNP	O
,	,	O
and	CC	O
where	WRB	O
n	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L−m+1	NNP	O
.	.	O
Validated	VBN	O
Target	NN	O
Segments	VBZ	O
The	DT	O
locations	NNS	O
on	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
suitable	JJ	O
oligomeric	JJ	O
compounds	NNS	O
hybridize	NNS	O
are	VBP	O
hereinbelow	JJ	O
referred	VBN	O
to	TO	O
as	IN	O
“	NNP	O
validated	VBD	O
target	NN	O
segments.	NN	O
”	NN	O
As	IN	O
used	VBN	O
herein	PDT	O
the	DT	O
term	NN	O
“	NNP	O
validated	VBD	O
target	NN	O
segment	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
a	DT	O
target	NN	O
region	NN	O
to	TO	O
which	WDT	O
an	DT	O
active	JJ	O
oligomeric	JJ	O
compound	NN	O
is	VBZ	O
targeted	VBN	O
.	.	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
theory	NN	O
,	,	O
it	PRP	O
is	VBZ	O
presently	RB	O
believed	VBN	O
that	IN	O
these	DT	O
target	NN	O
segments	NNS	O
represent	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
target	NN	O
nucleic	NN	O
acid	NN	O
which	WDT	O
are	VBP	O
accessible	JJ	O
for	IN	O
hybridization	NN	O
.	.	O
Target	NN	O
segments	NNS	O
can	MD	O
include	VB	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
a	DT	O
validated	JJ	O
target	NN	O
segment	NN	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
Similarly	RB	O
suitable	JJ	O
validated	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
a	DT	O
validated	JJ	O
target	NN	O
segment	NN	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
a	DT	O
validated	JJ	O
oligomeric	JJ	O
target	NN	O
segment	NN	O
can	MD	O
be	VB	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
a	DT	O
validated	JJ	O
target	NN	O
segment	NN	O
,	,	O
and	CC	O
can	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
about	IN	O
80	CD	O
nucleobases	NNS	O
.	.	O
Screening	VBG	O
for	IN	O
Modulator	NNP	O
Compounds	NNP	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
validated	JJ	O
target	NN	O
segments	NNS	O
identified	VBN	O
herein	NN	O
can	MD	O
be	VB	O
employed	VBN	O
in	IN	O
a	DT	O
screen	NN	O
for	IN	O
additional	JJ	O
compounds	NNS	O
that	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
“	JJ	O
Modulators	NNS	O
”	VBP	O
are	VBP	O
those	DT	O
compounds	NNS	O
that	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
and	CC	O
which	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
which	WDT	O
is	VBZ	O
complementary	JJ	O
to	TO	O
a	DT	O
validated	JJ	O
target	NN	O
segment	NN	O
.	.	O
The	DT	O
screening	NN	O
method	NN	O
comprises	VBZ	O
the	DT	O
steps	NNS	O
of	IN	O
contacting	VBG	O
a	DT	O
validated	JJ	O
target	NN	O
segment	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	JJ	O
modulators	NNS	O
,	,	O
and	CC	O
selecting	VBG	O
for	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	NN	O
modulators	NNS	O
which	WDT	O
perturb	VBP	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Once	IN	O
it	PRP	O
is	VBZ	O
shown	VBN	O
that	IN	O
the	DT	O
candidate	NN	O
modulator	NN	O
or	CC	O
modulators	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
the	DT	O
modulator	NN	O
can	MD	O
then	RB	O
be	VB	O
employed	VBN	O
in	IN	O
further	JJ	O
investigative	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
or	CC	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
research	NN	O
,	,	O
diagnostic	JJ	O
,	,	O
or	CC	O
therapeutic	JJ	O
agent	NN	O
.	.	O
The	DT	O
validated	JJ	O
target	NN	O
segments	NNS	O
can	MD	O
also	RB	O
be	VB	O
combined	VBN	O
with	IN	O
a	DT	O
second	JJ	O
strand	NN	O
as	IN	O
disclosed	VBN	O
herein	NN	O
to	TO	O
form	VB	O
stabilized	VBN	O
double-stranded	JJ	O
(	(	O
duplexed	JJ	O
)	)	O
oligonucleotides	NNS	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
research	NN	O
,	,	O
diagnostic	JJ	O
,	,	O
or	CC	O
therapeutic	JJ	O
agent	NN	O
.	.	O
Phenotypic	NNP	O
Assays	NNP	O
Once	NNP	O
modulator	NN	O
compounds	NNS	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
have	VBP	O
been	VBN	O
identified	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
disclosed	VBD	O
herein	NN	O
,	,	O
the	DT	O
compounds	NNS	O
can	MD	O
be	VB	O
further	RB	O
investigated	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
phenotypic	NN	O
assays	NNS	O
,	,	O
each	DT	O
having	VBG	O
measurable	JJ	O
endpoints	NNS	O
predictive	NN	O
of	IN	O
efficacy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
particular	JJ	O
disease	NN	O
state	NN	O
or	CC	O
condition	NN	O
.	.	O
Phenotypic	NNP	O
assays	NNS	O
,	,	O
kits	NNS	O
and	CC	O
reagents	NNS	O
for	IN	O
their	PRP$	O
use	NN	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
herein	NNS	O
used	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
and/or	NN	O
association	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
in	IN	O
health	NN	O
and	CC	O
disease	NN	O
.	.	O
Representative	JJ	O
phenotypic	NN	O
assays	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
purchased	VBN	O
from	IN	O
any	DT	O
one	CD	O
of	IN	O
several	JJ	O
commercial	JJ	O
vendors	NNS	O
,	,	O
include	VBP	O
those	DT	O
for	IN	O
determining	VBG	O
cell	NN	O
viability	NN	O
,	,	O
cytotoxicity	NN	O
,	,	O
proliferation	NN	O
or	CC	O
cell	NN	O
survival	NN	O
(	(	O
Molecular	JJ	O
Probes	NNP	O
,	,	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
;	:	O
PerkinElmer	NNP	O
,	,	O
Boston	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
,	,	O
protein-based	JJ	O
assays	NNS	O
including	VBG	O
enzymatic	JJ	O
assays	NNS	O
(	(	O
Panvera	NNP	O
,	,	O
LLC	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
;	:	O
BD	NNP	O
Biosciences	NNPS	O
,	,	O
Franklin	NNP	O
Lakes	NNP	O
,	,	O
N.J.	NNP	O
;	:	O
Oncogene	NNP	O
Research	NNP	O
Products	NNPS	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
cell	NN	O
regulation	NN	O
,	,	O
signal	JJ	O
transduction	NN	O
,	,	O
inflammation	NN	O
,	,	O
oxidative	JJ	O
processes	NNS	O
and	CC	O
apoptosis	NN	O
(	(	O
Assay	NNP	O
Designs	NNP	O
Inc.	NNP	O
,	,	O
Ann	NNP	O
Arbor	NNP	O
,	,	O
Mich.	NNP	O
)	)	O
,	,	O
triglyceride	JJ	O
accumulation	NN	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
,	,	O
angiogenesis	NN	O
assays	NNS	O
,	,	O
tube	NN	O
formation	NN	O
assays	NNS	O
,	,	O
cytokine	NN	O
and	CC	O
hormone	NN	O
assays	NNS	O
and	CC	O
metabolic	JJ	O
assays	NNS	O
(	(	O
Chemicon	NNP	O
International	NNP	O
Inc.	NNP	O
,	,	O
Temecula	NNP	O
,	,	O
Calif.	NNP	O
;	:	O
Amersham	NNP	O
Biosciences	NNPS	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
Phenotypic	NNP	O
endpoints	NNS	O
include	VBP	O
changes	NNS	O
in	IN	O
cell	NN	O
morphology	NN	O
over	IN	O
time	NN	O
or	CC	O
treatment	NN	O
dose	NN	O
as	RB	O
well	RB	O
as	IN	O
changes	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
cellular	JJ	O
components	NNS	O
such	JJ	O
as	IN	O
proteins	NNS	O
,	,	O
lipids	NNS	O
,	,	O
nucleic	JJ	O
acids	NNS	O
,	,	O
hormones	NNS	O
,	,	O
saccharides	NNS	O
or	CC	O
metals	NNS	O
.	.	O
Measurements	NNS	O
of	IN	O
cellular	JJ	O
status	NN	O
which	WDT	O
include	VBP	O
pH	NN	O
,	,	O
stage	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
,	,	O
intake	NN	O
or	CC	O
excretion	NN	O
of	IN	O
biological	JJ	O
indicators	NNS	O
by	IN	O
the	DT	O
cell	NN	O
,	,	O
are	VBP	O
also	RB	O
endpoints	NNS	O
of	IN	O
interest	NN	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
genotype	NN	O
of	IN	O
the	DT	O
cell	NN	O
(	(	O
measurement	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
genes	NNS	O
of	IN	O
the	DT	O
cell	NN	O
)	)	O
after	IN	O
treatment	NN	O
is	VBZ	O
also	RB	O
used	VBN	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
or	CC	O
potency	NN	O
of	IN	O
the	DT	O
Gemin	NNP	O
Gene	NNP	O
modulators	NNS	O
.	.	O
Hallmark	NNP	O
genes	NNS	O
,	,	O
or	CC	O
those	DT	O
genes	NNS	O
suspected	VBD	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
specific	JJ	O
disease	NN	O
state	NN	O
,	,	O
condition	NN	O
,	,	O
or	CC	O
phenotype	NN	O
,	,	O
are	VBP	O
measured	VBN	O
in	IN	O
both	DT	O
treated	JJ	O
and	CC	O
untreated	JJ	O
cells	NNS	O
.	.	O
The	DT	O
following	JJ	O
phenotypic	NN	O
assays	NNS	O
are	VBP	O
useful	JJ	O
in	IN	O
the	DT	O
study	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
and	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Cell	NNP	O
Proliferation	NNP	O
and	CC	O
Survival	NNP	O
Unregulated	NNP	O
cell	NN	O
proliferation	NN	O
is	VBZ	O
a	DT	O
characteristic	JJ	O
of	IN	O
cancer	NN	O
cells	NNS	O
,	,	O
thus	RB	O
most	JJS	O
current	JJ	O
chemotherapy	NN	O
agents	NNS	O
target	VB	O
dividing	VBG	O
cells	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
blocking	VBG	O
the	DT	O
synthesis	NN	O
of	IN	O
new	JJ	O
DNA	NNP	O
required	VBN	O
for	IN	O
cell	NN	O
division	NN	O
.	.	O
However	RB	O
,	,	O
cells	NNS	O
in	IN	O
healthy	JJ	O
tissues	NNS	O
are	VBP	O
also	RB	O
affected	VBN	O
by	IN	O
agents	NNS	O
that	WDT	O
modulate	VBP	O
cell	NN	O
proliferation	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
cell	NN	O
cycle	NN	O
inhibitor	NN	O
will	MD	O
cause	VB	O
apoptosis	NN	O
in	IN	O
cancer	NN	O
cells	NNS	O
,	,	O
but	CC	O
allow	IN	O
normal	JJ	O
cells	NNS	O
to	TO	O
undergo	VB	O
growth	NN	O
arrest	NN	O
and	CC	O
therefore	RB	O
remain	VBP	O
unaffected	JJ	O
(	(	O
Blagosklonny	NNP	B
,	,	I
Bioessays	NNP	I
,	,	I
1999	CD	I
,	,	I
21	CD	I
,	,	I
704-709	CD	I
;	:	O
Chen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1997	CD	I
,	,	I
57	CD	I
,	,	I
2013-2019	JJ	I
;	:	O
Evan	NNP	B
and	CC	I
Littlewood	NNP	I
,	,	I
Science	NNP	I
,	,	I
1998	CD	I
,	,	I
281	CD	I
,	,	I
1317-1322	CD	I
;	:	O
Lees	NNP	B
and	CC	I
Weinberg	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1999	CD	I
,	,	I
96	CD	I
,	,	I
4221-4223	JJ	I
)	)	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
sensitization	NN	O
to	TO	O
anti-cancer	JJ	O
agents	NNS	O
is	VBZ	O
observed	VBN	O
in	IN	O
cells	NNS	O
that	WDT	O
have	VBP	O
reduced	VBN	O
or	CC	O
absent	JJ	O
expression	NN	O
of	IN	O
the	DT	O
tumor	NN	O
suppressor	NN	O
genes	NNS	O
p53	NN	O
(	(	O
Bunz	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
,	,	I
1998	CD	I
,	,	I
282	CD	I
,	,	I
1497-1501	CD	I
;	:	O
Bunz	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
1999	CD	I
,	,	I
104	CD	I
,	,	I
263-269	JJ	I
;	:	O
Stewart	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1999	CD	I
,	,	I
59	CD	I
,	,	I
3831-3837	CD	I
;	:	O
Wahl	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Med.	NNP	I
,	,	I
1996	CD	I
,	,	I
2	CD	I
,	,	I
72-79	JJ	I
)	)	O
.	.	O
However	RB	O
,	,	O
cancer	NN	O
cells	NNS	O
often	RB	O
escape	VBP	O
apoptosis	NN	O
(	(	O
Lowe	NNP	B
and	CC	I
Lin	NNP	I
,	,	I
Carcinogenesis	NNP	I
,	,	I
2000	CD	I
,	,	I
21	CD	I
,	,	I
485-495	JJ	I
;	:	O
Reed	NNP	B
,	,	I
Cancer	NNP	I
J.	NNP	I
Sci	NNP	I
.	.	I
Am.	NNP	I
,	,	I
1998	CD	I
,	,	I
4	CD	I
Suppl	NNP	I
1	CD	I
,	,	I
S8-14	NNP	I
)	)	O
.	.	O
Further	JJ	O
disruption	NN	O
of	IN	O
cell	NN	O
cycle	NN	O
checkpoints	NNS	O
in	IN	O
cancer	NN	O
cells	NNS	O
can	MD	O
increase	VB	O
sensitivity	NN	O
to	TO	O
chemotherapy	VB	O
while	IN	O
allowing	VBG	O
normal	JJ	O
cells	NNS	O
to	TO	O
take	VB	O
refuge	NN	O
in	IN	O
G1	NNP	O
and	CC	O
remain	VBP	O
unaffected	JJ	O
.	.	O
Cell	NNP	O
cycle	NN	O
assays	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
to	TO	O
identify	VB	O
genes	NNS	O
,	,	O
such	JJ	O
as	IN	O
p53	NN	O
,	,	O
whose	WP$	O
inhibition	NN	O
will	MD	O
sensitize	VB	O
cells	NNS	O
to	TO	O
anti-cancer	JJ	O
agents	NNS	O
.	.	O
Caspase	NNP	O
Activity	NNP	O
Programmed	NNP	O
cell	NN	O
death	NN	O
,	,	O
or	CC	O
apoptosis	NN	O
,	,	O
is	VBZ	O
an	DT	O
important	JJ	O
aspect	NN	O
of	IN	O
various	JJ	O
biological	JJ	O
processes	NNS	O
,	,	O
including	VBG	O
normal	JJ	O
cell	NN	O
turnover	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
immune	NN	O
system	NN	O
and	CC	O
embryonic	JJ	O
development	NN	O
.	.	O
Apoptosis	NN	O
involves	VBZ	O
the	DT	O
activation	NN	O
of	IN	O
caspases	NNS	O
,	,	O
a	DT	O
family	NN	O
of	IN	O
intracellular	JJ	O
proteases	NNS	O
through	IN	O
which	WDT	O
a	DT	O
cascade	NN	O
of	IN	O
events	NNS	O
leads	VBZ	O
to	TO	O
the	DT	O
cleavage	NN	O
of	IN	O
a	DT	O
select	JJ	O
set	NN	O
of	IN	O
proteins	NNS	O
.	.	O
The	DT	O
caspase	NN	O
family	NN	O
can	MD	O
be	VB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
the	DT	O
initiator	NN	O
caspases	NNS	O
,	,	O
such	JJ	O
as	IN	O
caspase-8	NN	O
and	CC	O
-9	NN	O
,	,	O
and	CC	O
the	DT	O
executioner	NN	O
caspases	NNS	O
,	,	O
such	JJ	O
as	IN	O
caspase-3	NN	O
,	,	O
-6	NNP	O
and	CC	O
-7	NNP	O
,	,	O
which	WDT	O
are	VBP	O
activated	VBN	O
by	IN	O
the	DT	O
initiator	NN	O
caspases	NNS	O
.	.	O
The	DT	O
caspase	NN	O
family	NN	O
contains	VBZ	O
at	IN	O
least	JJS	O
14	CD	O
members	NNS	O
,	,	O
with	IN	O
differing	VBG	O
substrate	NN	O
preferences	NNS	O
(	(	O
Thornberry	NNP	B
and	CC	I
Lazebnik	NNP	I
,	,	I
Science	NNP	I
,	,	I
1998	CD	I
,	,	I
281	CD	I
,	,	I
1312-1316	JJ	I
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
caspase	NN	O
assay	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
genes	NNS	O
whose	WP$	O
inhibition	NN	O
selectively	RB	O
cause	JJ	O
apoptosis	NN	O
in	IN	O
breast	NN	O
carcinoma	NN	O
cell	NN	O
lines	NNS	O
,	,	O
without	IN	O
affecting	VBG	O
normal	JJ	O
cells	NNS	O
,	,	O
and	CC	O
to	TO	O
identify	VB	O
genes	NNS	O
whose	WP$	O
inhibition	NN	O
results	NNS	O
in	IN	O
cell	NN	O
death	NN	O
in	IN	O
p53-deficient	JJ	O
T47D	NNP	O
cells	NNS	O
,	,	O
and	CC	O
not	RB	O
in	IN	O
MCF7	NNP	O
cells	NNS	O
which	WDT	O
express	VBP	O
p53	NN	O
(	(	O
Ross	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2000	CD	I
,	,	I
24	CD	I
,	,	I
227-235	JJ	I
;	:	O
Scherf	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2000	CD	I
,	,	I
24	CD	I
,	,	I
236-244	JJ	I
)	)	O
.	.	O
Angiogenesis	NNP	O
Angiogenesis	NNP	O
is	VBZ	O
the	DT	O
growth	NN	O
of	IN	O
new	JJ	O
blood	NN	O
vessels	NNS	O
(	(	O
veins	NNS	O
and	CC	O
arteries	NNS	O
)	)	O
by	IN	O
endothelial	JJ	O
cells	NNS	O
.	.	O
This	DT	O
process	NN	O
is	VBZ	O
important	JJ	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
human	JJ	O
diseases	NNS	O
,	,	O
and	CC	O
is	VBZ	O
believed	VBN	O
to	TO	O
be	VB	O
particularly	RB	O
important	JJ	O
in	IN	O
regulating	VBG	O
the	DT	O
growth	NN	O
of	IN	O
solid	JJ	O
tumors	NNS	O
.	.	O
Without	IN	O
new	JJ	O
vessel	NN	O
formation	NN	O
it	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
tumors	NNS	O
will	MD	O
not	RB	O
grow	VB	O
beyond	IN	O
a	DT	O
few	JJ	O
millimeters	NNS	O
in	IN	O
size	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
their	PRP$	O
use	NN	O
as	IN	O
anti-cancer	JJ	O
agents	NNS	O
,	,	O
inhibitors	NNS	O
of	IN	O
angiogenesis	NN	O
have	VBP	O
potential	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetic	JJ	O
retinopathy	NN	O
,	,	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
psoriasis	NN	O
(	(	O
Carmeliet	NNP	B
and	CC	I
Jain	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2000	CD	I
,	,	I
407	CD	I
,	,	I
249-257	JJ	I
;	:	O
Freedman	NNP	B
and	CC	I
Isner	NNP	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Cardiol.	NNP	I
,	,	I
2001	CD	I
,	,	I
33	CD	I
,	,	I
379-393	CD	I
;	:	O
Jackson	NNP	B
et	FW	I
al.	NN	I
,	,	I
Faseb	NNP	I
J.	NNP	I
,	,	I
1997	CD	I
,	,	I
11	CD	I
,	,	I
457-465	JJ	I
;	:	O
Saaristo	NNP	B
et	FW	I
al.	NN	I
,	,	I
Oncogene	NNP	I
,	,	I
2000	CD	I
,	,	I
19	CD	I
,	,	I
6122-6129	JJ	I
;	:	O
Weber	NNP	B
and	CC	I
De	NNP	I
Bandt	NNP	I
,	,	I
Joint	NNP	I
Bone	NNP	I
Spine	NNP	I
,	,	I
2000	CD	I
,	,	I
67	CD	I
,	,	I
366-383	CD	I
;	:	O
Yoshida	NNP	B
et	FW	I
al.	NN	I
,	,	I
Histol	NNP	I
.	.	I
Histopathol.	NNP	I
,	,	I
1999	CD	I
,	,	I
14	CD	I
,	,	I
1287-1294	JJ	I
)	)	O
.	.	O
During	IN	O
the	DT	O
process	NN	O
of	IN	O
angiogenesis	NN	O
,	,	O
endothelial	JJ	O
cells	NNS	O
perform	JJ	O
several	JJ	O
distinct	JJ	O
functions	NNS	O
,	,	O
including	VBG	O
the	DT	O
degradation	NN	O
of	IN	O
the	DT	O
extracellular	JJ	O
matrix	NN	O
(	(	O
ECM	NNP	O
)	)	O
,	,	O
migration	NN	O
,	,	O
proliferation	NN	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
tube-like	JJ	O
structures	NNS	O
(	(	O
Liekens	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
2001	CD	I
,	,	I
61	CD	I
,	,	I
253-270	JJ	I
)	)	O
.	.	O
Endothelial	JJ	O
cells	NNS	O
must	MD	O
regulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
many	JJ	O
genes	NNS	O
in	IN	O
order	NN	O
to	TO	O
perform	VB	O
the	DT	O
functions	NNS	O
necessary	JJ	O
for	IN	O
angiogenesis	NN	O
.	.	O
This	DT	O
gene	NN	O
regulation	NN	O
has	VBZ	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
intense	JJ	O
scrutiny	NN	O
,	,	O
and	CC	O
many	JJ	O
genes	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
as	IN	O
being	VBG	O
important	JJ	O
for	IN	O
the	DT	O
angiogenic	JJ	O
phenotype	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
following	JJ	O
genes	NNS	O
,	,	O
previously	RB	O
identified	VBN	O
as	IN	O
being	VBG	O
highly	RB	O
expressed	VBN	O
in	IN	O
angiogenic	JJ	O
endothelial	JJ	O
cells	NNS	O
,	,	O
can	MD	O
be	VB	O
measured	VBN	O
as	IN	O
indicators	NNS	O
:	:	O
Integrin	NNP	O
beta3	NN	O
,	,	O
endoglin/CD105	NN	O
,	,	O
TEM5	NNP	O
and	CC	O
MMP-14/MT-MMP1	NNP	O
.	.	O
Integrin	NNP	O
beta3	NN	O
is	VBZ	O
part	NN	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
heterodimeric	JJ	O
transmembrane	NN	O
receptors	NNS	O
that	IN	O
consist	NN	O
of	IN	O
alpha	NN	O
and	CC	O
beta	NN	O
subunits	NNS	O
(	(	O
Brooks	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
1995	CD	I
,	,	I
96	CD	I
,	,	I
1815-1822	JJ	I
)	)	O
.	.	O
Each	DT	O
subunit	NN	O
recognizes	VBZ	O
a	DT	O
unique	JJ	O
set	NN	O
of	IN	O
ECM	NNP	O
ligands	NNS	O
,	,	O
thereby	RB	O
allowing	VBG	O
cells	NNS	O
to	TO	O
transmit	VB	O
angiogenic	JJ	O
signals	NNS	O
from	IN	O
the	DT	O
extracellular	JJ	O
matrix	NN	O
.	.	O
Integrin	NNP	O
beta3	NN	O
is	VBZ	O
prominently	RB	O
expressed	VBN	O
on	IN	O
proliferating	VBG	O
vascular	JJ	O
endothelial	JJ	O
cells	NNS	O
,	,	O
and	CC	O
it	PRP	O
plays	VBZ	O
roles	NNS	O
in	IN	O
allowing	VBG	O
new	JJ	O
blood	NN	O
vessels	NNS	O
to	TO	O
form	VB	O
at	IN	O
tumor	NN	O
sites	NNS	O
as	RB	O
well	RB	O
as	IN	O
allowing	VBG	O
the	DT	O
epithelial	JJ	O
cells	NNS	O
of	IN	O
breast	NN	O
tumors	NNS	O
to	TO	O
spread	VB	O
(	(	O
Brooks	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
1995	CD	I
,	,	I
96	CD	I
,	,	I
1815-1822	CD	I
;	:	O
Drake	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Sci.	NNP	I
,	,	I
1995	CD	I
,	,	I
108	CD	I
(	(	I
Pt	NNP	I
7	CD	I
)	)	I
,	,	I
2655-2661	JJ	I
)	)	O
.	.	O
Blockage	NN	O
of	IN	O
integrin	JJ	O
beta3	NN	O
with	IN	O
monoclonal	JJ	O
antibodies	NNS	O
or	CC	O
low	JJ	O
molecular	JJ	O
weight	NN	O
antagonists	NNS	O
inhibits	VBP	O
blood	NN	O
vessel	NN	O
formation	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
in-vivo	JJ	O
models	NNS	O
,	,	O
including	VBG	O
tumor	NN	O
angiogenesis	NN	O
and	CC	O
neovascularization	NN	O
during	IN	O
oxygen-induced	JJ	O
retinopathy	NN	O
(	(	O
Brooks	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
1994	CD	I
,	,	I
264	CD	I
,	,	I
569-571	JJ	I
;	:	O
Brooks	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
1995	CD	I
,	,	I
96	CD	I
,	,	I
1815-1822	CD	I
;	:	O
Hammes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Med.	NNP	I
,	,	I
1996	CD	I
,	,	I
2	CD	I
,	,	I
529-533	JJ	I
)	)	O
.	.	O
Endoglin	NNP	O
is	VBZ	O
a	DT	O
transforming	VBG	O
growth	NN	O
factor	NN	O
receptor-associated	JJ	O
protein	NN	O
highly	RB	O
expressed	VBN	O
on	IN	O
endothelial	JJ	O
cells	NNS	O
,	,	O
and	CC	O
present	NN	O
on	IN	O
some	DT	O
leukemia	NN	O
cells	NNS	O
and	CC	O
minor	JJ	O
subsets	NNS	O
of	IN	O
bone	NN	O
marrow	NN	O
cells	NNS	O
(	(	O
Burrows	NNP	B
et	FW	I
al.	NN	I
,	,	I
Clin	NNP	I
.	.	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1995	CD	I
,	,	I
1	CD	I
,	,	I
1623-1634	CD	I
;	:	O
Haruta	NNP	B
and	CC	I
Seon	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1986	CD	I
,	,	I
83	CD	I
,	,	I
7898-7902	JJ	I
)	)	O
.	.	O
Its	PRP$	O
expression	NN	O
is	VBZ	O
upregulated	VBN	O
in	IN	O
endothelial	JJ	O
cells	NNS	O
of	IN	O
angiogenic	JJ	O
tissues	NNS	O
and	CC	O
is	VBZ	O
therefore	RB	O
used	VBN	O
as	IN	O
a	DT	O
prognostic	JJ	O
indicator	NN	O
in	IN	O
various	JJ	O
tumors	NNS	O
(	(	O
Burrows	NNP	B
et	FW	I
al.	NN	I
,	,	I
Clin	NNP	I
.	.	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1995	CD	I
,	,	I
1	CD	I
,	,	I
1623-1634	JJ	I
)	)	O
.	.	O
Endoglin	NNP	O
functions	NNS	O
as	IN	O
an	DT	O
ancillary	JJ	O
receptor	NN	O
influencing	VBG	O
binding	NN	O
of	IN	O
the	DT	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
(	(	O
TGF-beta	NNP	O
)	)	O
family	NN	O
of	IN	O
ligands	NNS	O
to	TO	O
signaling	VBG	O
receptors	NNS	O
,	,	O
thus	RB	O
mediating	VBG	O
cell	NN	O
survival	NN	O
(	(	O
Massague	NNP	B
and	CC	I
Chen	NNP	I
,	,	I
Genes	NNP	I
Dev.	NNP	I
,	,	I
2000	CD	I
,	,	I
14	CD	I
,	,	I
627-644	JJ	I
)	)	O
.	.	O
Tumor	NNP	O
endothelial	JJ	O
marker	NN	O
5	CD	O
(	(	O
TEM5	NNP	O
)	)	O
is	VBZ	O
a	DT	O
putative	JJ	O
7-pass	JJ	O
transmembrane	NN	O
protein	NN	O
(	(	O
GPCR	NNP	O
)	)	O
(	(	O
Carson-Walter	JJ	B
et	NN	I
al.	NN	I
,	,	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
2001	CD	I
,	,	I
61	CD	I
,	,	I
6649-6655	JJ	I
)	)	O
.	.	O
The	DT	O
mRNA	NN	O
transcript	NN	O
,	,	O
designated	VBN	O
KIAA1531	NNP	O
,	,	O
encodes	VBZ	O
one	CD	O
of	IN	O
many	JJ	O
tumor	NN	O
endothelium	NN	O
markers	NNS	O
(	(	O
TEMs	NNP	O
)	)	O
that	IN	O
display	NN	O
elevated	VBN	O
expression	NN	O
(	(	O
greater	JJR	O
than	IN	O
10-fold	JJ	O
)	)	O
during	IN	O
tumor	NN	O
angiogenesis	NN	O
(	(	O
St	NNP	B
Croix	NNP	I
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
2000	CD	I
,	,	I
289	CD	I
,	,	I
1197-1202	JJ	I
)	)	O
.	.	O
TEM5	NNP	O
is	VBZ	O
coordinately	RB	O
expressed	VBN	O
with	IN	O
other	JJ	O
TEMs	NNP	O
on	IN	O
tumor	NN	O
endothelium	NN	O
in	IN	O
humans	NNS	O
and	CC	O
mice	NN	O
.	.	O
Matrix	NNP	O
metalloproteinase	NN	O
14	CD	O
(	(	O
MMP-14	NNP	O
)	)	O
,	,	O
a	DT	O
membrane-type	JJ	O
MMP	NNP	O
covalently	RB	O
linked	VBD	O
to	TO	O
the	DT	O
cell	NN	O
membrane	NN	O
,	,	O
is	VBZ	O
involved	VBN	O
in	IN	O
matrix	JJ	O
detachment	NN	O
and	CC	O
migration	NN	O
.	.	O
MMP-14	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
promote	VB	O
tumor	NN	O
angiogenesis	NN	O
;	:	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
catalytic	JJ	O
domain	NN	O
of	IN	O
MMP-14	NNP	O
block	NN	O
endothelial-cell	NN	O
migration	NN	O
,	,	O
invasion	NN	O
and	CC	O
capillary	JJ	O
tube	NN	O
formation	NN	O
in	IN	O
vitro	NN	O
(	(	O
Galvez	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
37491-37500	CD	I
)	)	O
.	.	O
MMP-14	NN	O
can	MD	O
degrade	VB	O
the	DT	O
fibrin	NN	O
matrix	NN	O
that	WDT	O
surrounds	VBZ	O
newly	RB	O
formed	VBN	O
vessels	NNS	O
potentially	RB	O
allowing	VBG	O
the	DT	O
endothelial	JJ	O
cells	NNS	O
to	TO	O
invade	VB	O
further	RB	O
into	IN	O
the	DT	O
tumor	NN	O
tissue	NN	O
(	(	O
Hotary	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med.	NNP	I
,	,	I
2002	CD	I
,	,	I
195	CD	I
,	,	I
295-308	JJ	I
)	)	O
.	.	O
MMP-14	JJ	O
null	NN	O
mice	NN	O
have	VBP	O
impaired	VBN	O
angiogenesis	NN	O
during	IN	O
development	NN	O
,	,	O
further	RB	O
demonstrating	VBG	O
the	DT	O
role	NN	O
of	IN	O
MMP-14	NNP	O
in	IN	O
angiogenesis	NN	O
(	(	O
Vu	NNP	B
and	CC	I
Werb	NNP	I
,	,	I
Genes	NNP	I
Dev.	NNP	I
,	,	I
2000	CD	I
,	,	I
14	CD	I
,	,	I
2123-2133	JJ	I
;	:	O
Zhou	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
4052-4057	JJ	I
)	)	O
.	.	O
Angiogenesis	NN	O
is	VBZ	O
stimulated	VBN	O
by	IN	O
numerous	JJ	O
factors	NNS	O
that	IN	O
promote	VBP	O
interaction	NN	O
of	IN	O
endothelial	JJ	O
cells	NNS	O
with	IN	O
each	DT	O
other	JJ	O
and	CC	O
with	IN	O
extracellular	JJ	O
matrix	NN	O
molecules	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
capillary	JJ	O
tubes	NNS	O
.	.	O
This	DT	O
morphogenic	JJ	O
process	NN	O
is	VBZ	O
necessary	JJ	O
for	IN	O
the	DT	O
delivery	NN	O
of	IN	O
oxygen	NN	O
to	TO	O
nearby	VB	O
tissues	NNS	O
and	CC	O
plays	VBZ	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
embryonic	JJ	O
development	NN	O
,	,	O
wound	IN	O
healing	NN	O
,	,	O
and	CC	O
tumor	NN	O
growth	NN	O
(	(	O
Carmeliet	NNP	B
and	CC	I
Jain	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2000	CD	I
,	,	I
407	CD	I
,	,	I
249-257	JJ	I
)	)	O
.	.	O
Moreover	RB	O
,	,	O
this	DT	O
process	NN	O
can	MD	O
be	VB	O
reproduced	VBN	O
in	IN	O
a	DT	O
tissue	NN	O
culture	NN	O
assay	VBP	O
that	WDT	O
evaluated	VBD	O
the	DT	O
formation	NN	O
of	IN	O
tube-like	JJ	O
structures	NNS	O
by	IN	O
endothelial	JJ	O
cells	NNS	O
.	.	O
There	EX	O
are	VBP	O
several	JJ	O
different	JJ	O
variations	NNS	O
of	IN	O
the	DT	O
assay	NN	O
that	WDT	O
use	VBP	O
different	JJ	O
matrices	NNS	O
,	,	O
such	JJ	O
as	IN	O
collagen	NN	O
I	PRP	O
(	(	O
Kanayasu	NNP	B
et	RB	I
al.	RB	I
,	,	I
Lipids	NNP	I
,	,	I
1991	CD	I
,	,	I
26	CD	I
,	,	I
271-276	JJ	I
)	)	O
,	,	O
Matrigel	NNP	O
(	(	O
Yamagishi	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1997	CD	I
,	,	I
272	CD	I
,	,	I
8723-8730	JJ	I
)	)	O
and	CC	O
fibrin	$	O
(	(	O
Bach	NNP	B
et	RB	I
al.	RB	I
,	,	I
Exp	NNP	I
.	.	I
Cell	NNP	I
Res.	NNP	I
,	,	I
1998	CD	I
,	,	I
238	CD	I
,	,	I
324-334	JJ	I
)	)	O
,	,	O
as	IN	O
growth	NN	O
substrates	NNS	O
for	IN	O
the	DT	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
HUVECs	NNP	O
can	MD	O
be	VB	O
plated	VBN	O
on	IN	O
a	DT	O
matrix	NN	O
derived	VBN	O
from	IN	O
the	DT	O
Engelbreth-Holm-Swarm	NNP	O
mouse	NN	O
tumor	NN	O
,	,	O
which	WDT	O
is	VBZ	O
very	RB	O
similar	JJ	O
to	TO	O
Matrigel	NNP	O
(	(	O
Kleinman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Biochemistry	NNP	I
,	,	I
1986	CD	I
,	,	I
25	CD	I
,	,	I
312-318	CD	I
;	:	O
Madri	NNP	B
and	CC	I
Pratt	NNP	I
,	,	I
J.	NNP	I
Histochem	NNP	I
.	.	I
Cytochem.	NNP	I
,	,	I
1986	CD	I
,	,	I
34	CD	I
,	,	I
85-91	JJ	I
)	)	O
.	.	O
Untreated	VBN	O
HUVECs	NNP	O
form	VB	O
tube-like	JJ	O
structures	NNS	O
when	WRB	O
grown	VBN	O
on	IN	O
this	DT	O
substrate	NN	O
.	.	O
Loss	NNP	O
of	IN	O
tube	NN	O
formation	NN	O
in	IN	O
vitro	NN	O
has	VBZ	O
been	VBN	O
correlated	VBN	O
with	IN	O
the	DT	O
inhibition	NN	O
of	IN	O
angiogenesis	NN	O
in	IN	O
vivo	NN	O
(	(	O
Carmeliet	NNP	B
and	CC	I
Jain	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2000	CD	I
,	,	I
407	CD	I
,	,	I
249-257	JJ	I
;	:	O
Zhang	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
2002	CD	I
,	,	I
62	CD	I
,	,	I
2034-2042	JJ	I
)	)	O
,	,	O
which	WDT	O
supports	VBZ	O
the	DT	O
use	NN	O
of	IN	O
in	IN	O
vitro	JJ	O
tube	NN	O
formation	NN	O
as	IN	O
an	DT	O
endpoint	NN	O
for	IN	O
angiogenesis	NN	O
.	.	O
Adipocyte	NNP	O
Differentiation	NNP	O
and	CC	O
Insulin	NNP	O
Signaling	NNP	O
Assays	NNP	O
Insulin	NNP	O
is	VBZ	O
an	DT	O
essential	JJ	O
signaling	NN	O
molecule	NN	O
throughout	IN	O
the	DT	O
body	NN	O
,	,	O
but	CC	O
its	PRP$	O
major	JJ	O
target	NN	O
organs	NNS	O
are	VBP	O
the	DT	O
liver	NN	O
,	,	O
skeletal	JJ	O
muscle	NN	O
and	CC	O
adipose	JJ	O
tissue	NN	O
.	.	O
Insulin	NNP	O
is	VBZ	O
the	DT	O
primary	JJ	O
modulator	NN	O
of	IN	O
glucose	JJ	O
homeostasis	NN	O
and	CC	O
helps	VBZ	O
maintain	VB	O
a	DT	O
balance	NN	O
of	IN	O
peripheral	JJ	O
glucose	JJ	O
utilization	NN	O
and	CC	O
hepatic	JJ	O
glucose	NN	O
production	NN	O
.	.	O
The	DT	O
reduced	JJ	O
ability	NN	O
of	IN	O
normal	JJ	O
circulating	VBG	O
concentrations	NNS	O
of	IN	O
insulin	NN	O
to	TO	O
maintain	VB	O
glucose	JJ	O
homeostasis	NN	O
manifests	NNS	O
in	IN	O
insulin	NN	O
resistance	NN	O
which	WDT	O
is	VBZ	O
often	RB	O
associated	VBN	O
with	IN	O
diabetes	NNS	O
,	,	O
central	JJ	O
obesity	NN	O
,	,	O
hypertension	NN	O
,	,	O
polycystic	JJ	O
ovarian	JJ	O
syndrome	NN	O
,	,	O
dyslipidemia	NN	O
and	CC	O
atherosclerosis	NN	O
(	(	O
Saltiel	NNP	B
,	,	I
Cell	NNP	I
,	,	I
2001	CD	I
,	,	I
104	CD	I
,	,	I
517-529	JJ	I
;	:	O
Saltiel	NNP	B
and	CC	I
Kahn	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
414	CD	I
,	,	I
799-806	JJ	I
)	)	O
.	.	O
Insulin	NNP	O
promotes	VBZ	O
the	DT	O
differentiation	NN	O
of	IN	O
preadipocytes	NNS	O
into	IN	O
adipocytes	NNS	O
.	.	O
The	DT	O
condition	NN	O
of	IN	O
obesity	NN	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
increases	NNS	O
in	IN	O
fat	NN	O
cell	NN	O
number	NN	O
,	,	O
occurs	VBZ	O
even	RB	O
in	IN	O
insulin-resistant	JJ	O
states	NNS	O
in	IN	O
which	WDT	O
glucose	JJ	O
transport	NN	O
is	VBZ	O
impaired	JJ	O
due	JJ	O
to	TO	O
the	DT	O
anti-lipolytic	JJ	O
effect	NN	O
of	IN	O
insulin	NN	O
.	.	O
Inhibition	NN	O
of	IN	O
triglyceride	JJ	O
breakdown	NN	O
requires	VBZ	O
much	RB	O
lower	JJR	O
insulin	NN	O
concentrations	NNS	O
than	IN	O
stimulation	NN	O
of	IN	O
glucose	JJ	O
transport	NN	O
,	,	O
resulting	VBG	O
in	IN	O
maintenance	NN	O
or	CC	O
expansion	NN	O
of	IN	O
adipose	JJ	O
stores	NNS	O
(	(	O
Kitamura	NNP	B
et	RB	I
al.	RB	I
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
1999	CD	I
,	,	I
19	CD	I
,	,	I
6286-6296	JJ	I
;	:	O
Kitamura	NNP	B
et	FW	I
al.	NN	I
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
1998	CD	I
,	,	I
18	CD	I
,	,	I
3708-3717	JJ	I
)	)	O
.	.	O
One	CD	O
of	IN	O
the	DT	O
hallmarks	NNS	O
of	IN	O
cellular	JJ	O
differentiation	NN	O
is	VBZ	O
the	DT	O
upregulation	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
During	IN	O
adipocyte	JJ	O
differentiation	NN	O
,	,	O
the	DT	O
gene	NN	O
expression	NN	O
patterns	NNS	O
in	IN	O
adipocytes	NNS	O
change	VBP	O
considerably	RB	O
.	.	O
Some	DT	O
genes	NNS	O
known	VBN	O
to	TO	O
be	VB	O
upregulated	JJ	O
during	IN	O
adipocyte	JJ	O
differentiation	NN	O
include	VBP	O
hormone-sensitive	JJ	O
lipase	NN	O
(	(	O
HSL	NNP	O
)	)	O
,	,	O
adipocyte	JJ	O
lipid	JJ	O
binding	NN	O
protein	NN	O
(	(	O
aP2	NN	O
)	)	O
,	,	O
glucose	JJ	O
transporter	NN	O
4	CD	O
(	(	O
Glut4	NNP	O
)	)	O
,	,	O
and	CC	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor	NN	O
gamma	NN	O
(	(	O
PPAR-gamma	NNP	O
)	)	O
.	.	O
Insulin	NNP	O
signaling	NN	O
is	VBZ	O
improved	VBN	O
by	IN	O
compounds	NNS	O
that	WDT	O
bind	VBP	O
and	CC	O
inactivate	JJ	O
PPAR-gamma	NNP	O
,	,	O
a	DT	O
key	JJ	O
regulator	NN	O
of	IN	O
adipocyte	JJ	O
differentiation	NN	O
(	(	O
Olefsky	NNP	B
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2000	CD	I
,	,	I
106	CD	I
,	,	I
467-472	JJ	I
)	)	O
.	.	O
Insulin	NNP	O
induces	VBZ	O
the	DT	O
translocation	NN	O
of	IN	O
GLUT4	NNP	O
to	TO	O
the	DT	O
adipocyte	NN	O
cell	NN	O
surface	NN	O
,	,	O
where	WRB	O
it	PRP	O
transports	VBZ	O
glucose	RB	O
into	IN	O
the	DT	O
cell	NN	O
,	,	O
an	DT	O
activity	NN	O
necessary	JJ	O
for	IN	O
triglyceride	JJ	O
synthesis	NN	O
.	.	O
In	IN	O
all	DT	O
forms	NNS	O
of	IN	O
obesity	NN	O
and	CC	O
diabetes	NNS	O
,	,	O
a	DT	O
major	JJ	O
factor	NN	O
contributing	VBG	O
to	TO	O
the	DT	O
impaired	JJ	O
insulin-stimulated	JJ	O
glucose	NN	O
transport	NN	O
in	IN	O
adipocytes	NNS	O
is	VBZ	O
the	DT	O
downregulation	NN	O
of	IN	O
GLUT4	NNP	O
.	.	O
Insulin	NNP	O
also	RB	O
induces	VBZ	O
hormone	NN	O
sensitive	JJ	O
lipase	NN	O
(	(	O
HSL	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
the	DT	O
predominant	JJ	O
lipase	NN	O
in	IN	O
adipocytes	NNS	O
that	IN	O
functions	NNS	O
to	TO	O
promote	VB	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
and	CC	O
lipogenesis	NN	O
(	(	O
Fredrikson	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1981	CD	I
,	,	I
256	CD	I
,	,	I
6311-6320	JJ	I
)	)	O
.	.	O
Adipocyte	NNP	O
fatty	JJ	O
acid	NN	O
binding	VBG	O
protein	NN	O
(	(	O
aP2	NN	O
)	)	O
belongs	VBZ	O
to	TO	O
a	DT	O
multi-gene	JJ	O
family	NN	O
of	IN	O
fatty	JJ	O
acid	NN	O
and	CC	O
retinoid	VB	O
transport	NN	O
proteins	NNS	O
.	.	O
aP2	NN	O
is	VBZ	O
postulated	VBN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
lipid	JJ	O
shuttle	NN	O
,	,	O
solubilizing	VBG	O
hydrophobic	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
delivering	VBG	O
them	PRP	O
to	TO	O
the	DT	O
appropriate	JJ	O
metabolic	NN	O
system	NN	O
for	IN	O
utilization	NN	O
(	(	O
Fu	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Lipid	NNP	I
Res.	NNP	I
,	,	I
2000	CD	I
,	,	I
41	CD	I
,	,	I
2017-2023	JJ	I
;	:	O
Pelton	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
1999	CD	I
,	,	I
261	CD	I
,	,	I
456-458	JJ	I
)	)	O
.	.	O
Together	RB	O
,	,	O
these	DT	O
genes	NNS	O
play	VBP	O
important	JJ	O
roles	NNS	O
in	IN	O
the	DT	O
uptake	NN	O
of	IN	O
glucose	NN	O
and	CC	O
the	DT	O
metabolism	NN	O
and	CC	O
utilization	NN	O
of	IN	O
fats	NNS	O
.	.	O
Leptin	NNP	O
secretion	NN	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
triglyceride	JJ	O
content	NN	O
are	VBP	O
also	RB	O
well-established	JJ	O
markers	NNS	O
of	IN	O
adipocyte	JJ	O
differentiation	NN	O
.	.	O
While	IN	O
it	PRP	O
serves	VBZ	O
as	IN	O
a	DT	O
marker	NN	O
for	IN	O
differentiated	JJ	O
adipocytes	NNS	O
,	,	O
leptin	NN	O
also	RB	O
regulates	VBZ	O
glucose	JJ	O
homeostasis	NN	O
through	IN	O
mechanisms	NNS	O
(	(	O
autocrine	NN	O
,	,	O
paracrine	NN	O
,	,	O
endocrine	NN	O
and	CC	O
neural	JJ	O
)	)	O
independent	JJ	O
of	IN	O
the	DT	O
adipocyte	NN	O
's	POS	O
role	NN	O
in	IN	O
energy	NN	O
storage	NN	O
and	CC	O
release	NN	O
.	.	O
As	IN	O
adipocytes	NNS	O
differentiate	VBP	O
,	,	O
insulin	NN	O
increases	NNS	O
triglyceride	IN	O
accumulation	NN	O
by	IN	O
both	DT	O
promoting	VBG	O
triglyceride	NN	O
synthesis	NN	O
and	CC	O
inhibiting	VBG	O
triglyceride	RB	O
breakdown	VBN	O
(	(	O
Spiegelman	NNP	B
and	CC	I
Flier	NNP	I
,	,	I
Cell	NNP	I
,	,	I
2001	CD	I
,	,	I
104	CD	I
,	,	I
531-543	JJ	I
)	)	O
.	.	O
As	IN	O
triglyceride	JJ	O
accumulation	NN	O
correlates	NNS	O
tightly	RB	O
with	IN	O
cell	NN	O
size	NN	O
and	CC	O
cell	NN	O
number	NN	O
,	,	O
it	PRP	O
is	VBZ	O
an	DT	O
excellent	JJ	O
indicator	NN	O
of	IN	O
differentiated	JJ	O
adipocytes	NNS	O
.	.	O
Insulin	NNP	O
mediates	VBZ	O
its	PRP$	O
effects	NNS	O
by	IN	O
suppressing	VBG	O
the	DT	O
RNA	NNP	O
expression	NN	O
levels	NNS	O
of	IN	O
enzymes	NNS	O
important	JJ	O
for	IN	O
gluconeogenesis	NN	O
and	CC	O
glycogenolysis	NN	O
,	,	O
and	CC	O
also	RB	O
by	IN	O
controlling	VBG	O
the	DT	O
activities	NNS	O
of	IN	O
some	DT	O
metabolic	JJ	O
enzymes	NNS	O
by	IN	O
post-translational	JJ	O
mechanisms	NNS	O
(	(	O
Hall	NNP	B
and	CC	I
Granner	NNP	I
,	,	I
J	NNP	I
.	.	I
Basic	NNP	I
Clin	NNP	I
.	.	I
Physiol	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1999	CD	I
,	,	I
10	CD	I
,	,	I
119-133	CD	I
;	:	O
Moller	NNP	B
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
414	CD	I
,	,	I
821-827	CD	I
;	:	O
Saltiel	NNP	B
and	CC	I
Kahn	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
414	CD	I
,	,	I
799-806	JJ	I
)	)	O
.	.	O
However	RB	O
,	,	O
the	DT	O
mechanisms	NNS	O
by	IN	O
which	WDT	O
insulin	NN	O
regulates	VBZ	O
these	DT	O
genes	NNS	O
are	VBP	O
not	RB	O
fully	RB	O
understood	JJ	O
.	.	O
Genes	NNS	O
in	IN	O
liver	NN	O
cells	NNS	O
cells	NNS	O
that	WDT	O
are	VBP	O
involved	VBN	O
in	IN	O
regulating	VBG	O
glucose	JJ	O
metabolism	NN	O
are	VBP	O
identified	VBN	O
by	IN	O
monitoring	VBG	O
changes	NNS	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
selective	JJ	O
insulin-responsive	JJ	O
genes	NNS	O
in	IN	O
a	DT	O
cell	NN	O
culture	NN	O
model	NN	O
.	.	O
Primary	JJ	O
human	JJ	O
hepatocytes	NNS	O
are	VBP	O
difficult	JJ	O
to	TO	O
obtain	VB	O
and	CC	O
work	VB	O
with	IN	O
in	IN	O
culture	NN	O
.	.	O
Therefore	RB	O
,	,	O
the	DT	O
insulin	NN	O
signaling	VBG	O
assay	NN	O
as	IN	O
used	VBN	O
in	IN	O
the	DT	O
Examples	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
the	DT	O
hepatocellular	JJ	O
carcinoma	NN	O
cell	NN	O
line	NN	O
HepG2	NNP	O
.	.	O
Insulin	NNP	O
responsive	JJ	O
genes	NNS	O
that	WDT	O
can	MD	O
be	VB	O
evaluated	VBN	O
in	IN	O
this	DT	O
assay	NN	O
are	VBP	O
phosphoenolpyruvate	JJ	O
carboxykinase	NN	O
(	(	O
PEPCK	NNP	O
)	)	O
,	,	O
insulin-like	JJ	O
growth	NN	O
factor	NN	O
binding	VBG	O
protein	NN	O
1	CD	O
(	(	O
IGFBP-1	NNP	O
)	)	O
and	CC	O
follistatin	NN	O
.	.	O
IGFBP-1	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
six	CD	O
secreted	JJ	O
proteins	NNS	O
that	WDT	O
bind	VBP	O
insulin-like	JJ	O
growth	NN	O
factor	NN	O
(	(	O
IGF	NNP	O
)	)	O
with	IN	O
high	JJ	O
affinity	NN	O
and	CC	O
thereby	RB	O
modulate	VB	O
IGFs	NNP	O
action	NN	O
in	IN	O
vivo	NN	O
(	(	O
Baxter	NNP	B
,	,	I
Am	NNP	I
.	.	I
J.	NNP	I
Physiol	NNP	I
.	.	I
Endocrinol	NNP	I
.	.	I
Metab.	NNP	I
,	,	I
2000	CD	I
,	,	I
278	CD	I
,	,	I
E967-976	NNP	I
;	:	O
Lee	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Soc	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Biol	NNP	I
.	.	I
Med.	NNP	I
,	,	I
1997	CD	I
,	,	I
216	CD	I
,	,	I
319-357	JJ	I
)	)	O
.	.	O
IGFBP-1	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
dynamic	JJ	O
variability	NN	O
of	IN	O
levels	NNS	O
in	IN	O
circulation	NN	O
due	JJ	O
to	TO	O
the	DT	O
regulation	NN	O
of	IN	O
its	PRP$	O
hepatic	JJ	O
secretion	NN	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Soc	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Biol	NNP	I
.	.	I
Med.	NNP	I
,	,	I
1997	CD	I
,	,	I
216	CD	I
,	,	I
319-357	JJ	I
)	)	O
.	.	O
The	DT	O
multi-hormonal	JJ	O
regulation	NN	O
of	IN	O
PEPCK	NNP	O
and	CC	O
IGFBP-1	NNP	O
are	VBP	O
similar	JJ	O
.	.	O
Glucocorticoids	NNS	O
and	CC	O
cyclic	JJ	O
AMP	NNP	O
(	(	O
cAMP	NN	O
)	)	O
stimulate	NN	O
transcription	NN	O
of	IN	O
the	DT	O
IGFBP-1	NNP	O
gene	NN	O
expression	NN	O
whereas	IN	O
insulin	NN	O
acts	NNS	O
in	IN	O
a	DT	O
dominant	JJ	O
manner	NN	O
to	TO	O
suppress	VB	O
both	DT	O
basal	NN	O
and	CC	O
cAMP	NN	O
or	CC	O
glucocorticoid-stimulated	JJ	O
IGFBP-1	JJ	O
gene	NN	O
transcription	NN	O
(	(	O
O'Brien	NNP	B
and	CC	I
Granner	NNP	I
,	,	I
Physiol	NNP	I
.	.	I
Rev.	NNP	I
,	,	I
1996	CD	I
,	,	I
76	CD	I
,	,	I
1109-1161	JJ	I
)	)	O
.	.	O
PEPCK	NNP	O
catalyzes	VBZ	O
the	DT	O
rate-limiting	JJ	O
step	NN	O
in	IN	O
gluconeogenesis	NN	O
,	,	O
and	CC	O
thereby	RB	O
contributes	NNS	O
to	TO	O
hepatic	JJ	O
glucose	NN	O
output	NN	O
(	(	O
Hall	NNP	B
and	CC	I
Granner	NNP	I
,	,	I
J	NNP	I
.	.	I
Basic	NNP	I
Clin	NNP	I
.	.	I
Physiol	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1999	CD	I
,	,	I
10	CD	I
,	,	I
119-133	CD	I
;	:	O
Moller	NNP	B
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
414	CD	I
,	,	I
821-827	CD	I
;	:	O
Saltiel	NNP	B
and	CC	I
Kahn	NNP	I
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
414	CD	I
,	,	I
799-806	JJ	I
)	)	O
.	.	O
In	IN	O
hepatoma	NN	O
cells	NNS	O
,	,	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
expression	NN	O
of	IN	O
PEPCK	NNP	O
is	VBZ	O
stimulated	VBN	O
by	IN	O
glucocorticoids	NNS	O
,	,	O
glucagon	NN	O
(	(	O
via	IN	O
cAMP	NN	O
)	)	O
,	,	O
and	CC	O
retinoic	JJ	O
acid	NN	O
.	.	O
Insulin	NNP	O
acts	VBZ	O
in	IN	O
a	DT	O
dominant	JJ	O
manner	NN	O
to	TO	O
suppress	VB	O
these	DT	O
stimulations	NNS	O
as	RB	O
well	RB	O
as	IN	O
basal	NN	O
transcription	NN	O
(	(	O
O'Brien	NNP	B
and	CC	I
Granner	NNP	I
,	,	I
Physiol	NNP	I
.	.	I
Rev.	NNP	I
,	,	I
1996	CD	I
,	,	I
76	CD	I
,	,	I
1109-1161	JJ	I
)	)	O
.	.	O
In	IN	O
HepG2	NNP	O
cells	NNS	O
,	,	O
prolonged	VBD	O
serum	JJ	O
starvation	NN	O
induces	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
PEPCK	NNP	O
and	CC	O
subsequent	JJ	O
insulin	NN	O
stimulation	NN	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
PEPCK	NNP	O
mRNA	NN	O
level	NN	O
.	.	O
Follistatin	NNP	O
is	VBZ	O
significantly	RB	O
stimulated	VBN	O
by	IN	O
insulin	NN	O
in	IN	O
HepG2	NNP	O
cells	NNS	O
.	.	O
Interestingly	RB	O
,	,	O
follistatin	NN	O
levels	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
higher	JJR	O
in	IN	O
women	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
(	(	O
Norman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Hum	NNP	I
.	.	I
Reprod.	NNP	I
,	,	I
2001	CD	I
,	,	I
16	CD	I
,	,	I
668-672	JJ	I
)	)	O
.	.	O
PCOS	NNP	O
is	VBZ	O
a	DT	O
metabolic	JJ	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
reproductive	JJ	O
disorder	NN	O
,	,	O
and	CC	O
an	DT	O
important	JJ	O
cause	NN	O
of	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
mellitus	VBP	O
in	IN	O
women	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
often	RB	O
associated	VBN	O
with	IN	O
profound	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
hyperinsulinemia	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
a	DT	O
defect	NN	O
in	IN	O
insulin	NN	O
secretion	NN	O
(	(	O
Dunaif	NNP	B
,	,	I
Endocr	NNP	I
.	.	I
Rev.	NNP	I
,	,	I
1997	CD	I
,	,	I
18	CD	I
,	,	I
774-800	CD	I
;	:	O
Nestler	NNP	B
et	FW	I
al.	NN	I
,	,	I
Fertil	NNP	I
.	.	I
Steril.	NNP	I
,	,	I
2002	CD	I
,	,	I
77	CD	I
,	,	I
209-215	JJ	I
)	)	O
.	.	O
Inflammation	NNP	O
Assays	NNP	O
Inflammation	NNP	O
assays	NNS	O
are	VBP	O
designed	VBN	O
to	TO	O
identify	VB	O
genes	NNS	O
that	WDT	O
regulate	VBP	O
the	DT	O
activation	NN	O
and	CC	O
effector	NN	O
phases	NNS	O
of	IN	O
the	DT	O
adaptive	JJ	O
immune	NN	O
response	NN	O
.	.	O
During	IN	O
the	DT	O
activation	NN	O
phase	NN	O
,	,	O
T	NNP	O
lymphocytes	VBZ	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
T-cells	NNP	O
)	)	O
receiving	VBG	O
signals	NNS	O
from	IN	O
the	DT	O
appropriate	JJ	O
antigens	NNS	O
undergo	JJ	O
clonal	JJ	O
expansion	NN	O
,	,	O
secrete	JJ	O
cytokines	NNS	O
,	,	O
and	CC	O
upregulate	VB	O
their	PRP$	O
receptors	NNS	O
for	IN	O
soluble	JJ	O
growth	NN	O
factors	NNS	O
,	,	O
cytokines	NNS	O
and	CC	O
co-stimulatory	JJ	O
molecules	NNS	O
(	(	O
Cantrell	NNP	B
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
1996	CD	I
,	,	I
14	CD	I
,	,	I
259-274	JJ	I
)	)	O
.	.	O
These	DT	O
changes	NNS	O
drive	VBP	O
T-cell	NNP	O
differentiation	NN	O
and	CC	O
effector	NN	O
function	NN	O
.	.	O
In	IN	O
the	DT	O
effector	NN	O
phase	NN	O
,	,	O
response	NN	O
to	TO	O
cytokines	NNS	O
by	IN	O
non-immune	JJ	O
effector	NN	O
cells	NNS	O
controls	VBZ	O
the	DT	O
production	NN	O
of	IN	O
inflammatory	JJ	O
mediators	NNS	O
that	WDT	O
can	MD	O
do	VB	O
extensive	JJ	O
damage	NN	O
to	TO	O
host	VB	O
tissues	NNS	O
.	.	O
The	DT	O
cells	NNS	O
of	IN	O
the	DT	O
adaptive	JJ	O
immune	NN	O
systems	NNS	O
,	,	O
their	PRP$	O
products	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
their	PRP$	O
interactions	NNS	O
with	IN	O
various	JJ	O
enzyme	JJ	O
cascades	NNS	O
involved	VBN	O
in	IN	O
inflammation	NN	O
(	(	O
e.g.	UH	O
,	,	O
the	DT	O
complement	NN	O
,	,	O
clotting	VBG	O
,	,	O
fibrinolytic	JJ	O
and	CC	O
kinin	VB	O
cascades	NNS	O
)	)	O
all	DT	O
represent	VBP	O
potential	JJ	O
points	NNS	O
for	IN	O
intervention	NN	O
in	IN	O
inflammatory	JJ	O
disease	NN	O
.	.	O
The	DT	O
inflammation	NN	O
assay	NN	O
measures	NNS	O
hallmarks	NNS	O
of	IN	O
the	DT	O
activation	NN	O
phase	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
Dendritic	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
regulators	NNS	O
of	IN	O
dendritic	JJ	O
cell-mediated	JJ	O
T-cell	NNP	O
costimulation	NN	O
.	.	O
The	DT	O
level	NN	O
of	IN	O
interleukin-2	JJ	O
(	(	O
IL-2	NNP	O
)	)	O
production	NN	O
by	IN	O
T-cells	NNP	O
,	,	O
a	DT	O
critical	JJ	O
consequence	NN	O
of	IN	O
T-cell	NNP	O
activation	NN	O
(	(	O
DeSilva	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
1991	CD	I
,	,	I
147	CD	I
,	,	I
3261-3267	CD	I
;	:	O
Salomon	NNP	B
and	CC	I
Bluestone	NNP	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
2001	CD	I
,	,	I
19	CD	I
,	,	I
225-252	JJ	I
)	)	O
,	,	O
is	VBZ	O
used	VBN	O
as	IN	O
an	DT	O
endpoint	NN	O
for	IN	O
T-cell	NNP	O
activation	NN	O
.	.	O
T	NNP	O
lymphocytes	NNS	O
are	VBP	O
important	JJ	O
immunoregulatory	NN	O
cells	NNS	O
that	WDT	O
mediate	VBP	O
pathological	JJ	O
inflammatory	NN	O
responses	NNS	O
.	.	O
Optimal	JJ	O
activation	NN	O
of	IN	O
T	NNP	O
lymphocytes	VBZ	O
requires	VBZ	O
both	DT	O
primary	JJ	O
antigen	NN	O
recognition	NN	O
events	NNS	O
as	RB	O
well	RB	O
as	IN	O
secondary	JJ	O
or	CC	O
costimulatory	JJ	O
signals	NNS	O
from	IN	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
(	(	O
APC	NNP	O
)	)	O
.	.	O
Dendritic	JJ	O
cells	NNS	O
are	VBP	O
the	DT	O
most	RBS	O
efficient	JJ	O
APCs	NNP	O
known	NN	O
and	CC	O
are	VBP	O
principally	RB	O
responsible	JJ	O
for	IN	O
antigen	JJ	O
presentation	NN	O
to	TO	O
T-cells	NNP	O
,	,	O
expression	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
costimulatory	NN	O
molecules	NNS	O
during	IN	O
infection	NN	O
and	CC	O
disease	NN	O
,	,	O
and	CC	O
the	DT	O
induction	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
immunological	JJ	O
memory	NN	O
(	(	O
Banchereau	NNP	B
and	CC	I
Steinman	NNP	I
,	,	I
Nature	NNP	I
,	,	I
1998	CD	I
,	,	I
392	CD	I
,	,	I
245-252	JJ	I
)	)	O
.	.	O
While	IN	O
a	DT	O
number	NN	O
of	IN	O
costimulatory	JJ	O
ligand-receptor	JJ	O
pairs	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
influence	VB	O
T-cell	NNP	O
activation	NN	O
,	,	O
a	DT	O
principal	JJ	O
signal	NN	O
is	VBZ	O
delivered	VBN	O
by	IN	O
engagement	NN	O
of	IN	O
CD28	NNP	O
on	IN	O
T-cells	NNP	O
by	IN	O
CD80	NNP	O
(	(	O
B7-1	NNP	O
)	)	O
and	CC	O
CD86	NNP	O
(	(	O
B7-2	NNP	O
)	)	O
on	IN	O
APCs	NNP	O
(	(	O
Boussiotis	NNP	B
et	RB	I
al.	RB	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
1994	CD	I
,	,	I
6	CD	I
,	,	I
797-807	CD	I
;	:	O
Lenschow	NNP	B
et	FW	I
al.	NN	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
1996	CD	I
,	,	I
14	CD	I
,	,	I
233-258	JJ	I
)	)	O
.	.	O
While	IN	O
not	RB	O
adhering	VBG	O
to	TO	O
a	DT	O
specific	JJ	O
mechanism	NN	O
,	,	O
inhibition	NN	O
of	IN	O
T-cell	NNP	O
co-stimulation	NN	O
by	IN	O
APCs	NNP	O
holds	VBZ	O
promise	NN	O
for	IN	O
novel	NN	O
and	CC	O
more	RBR	O
specific	JJ	O
strategies	NNS	O
of	IN	O
immune	JJ	O
suppression	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
blocking	VBG	O
costimulatory	JJ	O
signals	NNS	O
may	MD	O
lead	VB	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
long-term	JJ	O
immunological	JJ	O
anergy	NN	O
(	(	O
unresponsiveness	JJ	O
or	CC	O
tolerance	NN	O
)	)	O
that	WDT	O
would	MD	O
offer	VB	O
utility	NN	O
for	IN	O
promoting	VBG	O
transplantation	NN	O
or	CC	O
dampening	VBG	O
autoimmunity	NN	O
.	.	O
T-cell	NNP	O
anergy	NN	O
is	VBZ	O
the	DT	O
direct	JJ	O
consequence	NN	O
of	IN	O
failure	NN	O
of	IN	O
T-cells	NNP	O
to	TO	O
produce	VB	O
the	DT	O
growth	NN	O
factor	NN	O
IL-2	NNP	O
(	(	O
DeSilva	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
1991	CD	I
,	,	I
147	CD	I
,	,	I
3261-3267	CD	I
;	:	O
Salomon	NNP	B
and	CC	I
Bluestone	NNP	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
2001	CD	I
,	,	I
19	CD	I
,	,	I
225-252	JJ	I
)	)	O
.	.	O
The	DT	O
cytokine	NN	O
signaling	VBG	O
assay	JJ	O
identifies	NNS	O
genes	NNS	O
that	WDT	O
regulate	VBP	O
the	DT	O
responses	NNS	O
of	IN	O
non-immune	JJ	O
effector	NN	O
cells	NNS	O
(	(	O
initially	RB	O
endothelial	JJ	O
cells	NNS	O
)	)	O
to	TO	O
cytokines	NNS	O
such	JJ	O
as	IN	O
interferon-gamma	JJ	O
(	(	O
IFN-gamma	NNP	O
)	)	O
.	.	O
The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
on	IN	O
the	DT	O
regulation	NN	O
of	IN	O
the	DT	O
production	NN	O
of	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
(	(	O
ICAM-1	NNP	O
)	)	O
,	,	O
interferon	JJ	O
regulatory	JJ	O
factor	NN	O
1	CD	O
(	(	O
IRF1	NNP	O
)	)	O
and	CC	O
small	JJ	O
inducible	JJ	O
cytokine	NN	O
subfamily	RB	O
B	NNP	O
(	(	O
Cys-X-Cys	NNP	O
)	)	O
,	,	O
member	NN	O
11	CD	O
(	(	O
SCYB	NNP	O
11	CD	O
)	)	O
,	,	O
which	WDT	O
regulate	VBP	O
other	JJ	O
parameters	NNS	O
of	IN	O
the	DT	O
inflammatory	JJ	O
response	NN	O
,	,	O
can	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
response	NN	O
to	TO	O
cytokine	VB	O
treatment	NN	O
.	.	O
Kits	NNS	O
,	,	O
Research	NNP	O
Reagents	NNP	O
,	,	O
and	CC	O
Diagnostics	NNPS	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
for	IN	O
diagnostics	NNS	O
,	,	O
therapeutics	NNS	O
,	,	O
prophylaxis	NN	O
and	CC	O
as	IN	O
research	NN	O
reagents	NNS	O
and	CC	O
kits	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
antisense	JJ	O
compounds	NNS	O
,	,	O
which	WDT	O
are	VBP	O
able	JJ	O
to	TO	O
inhibit	VB	O
gene	NN	O
expression	NN	O
with	IN	O
exquisite	JJ	O
specificity	NN	O
,	,	O
are	VBP	O
often	RB	O
used	VBN	O
by	IN	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
to	TO	O
elucidate	VB	O
the	DT	O
function	NN	O
of	IN	O
particular	JJ	O
genes	NNS	O
or	CC	O
to	TO	O
distinguish	VB	O
between	IN	O
functions	NNS	O
of	IN	O
various	JJ	O
members	NNS	O
of	IN	O
a	DT	O
biological	JJ	O
pathway	NN	O
.	.	O
For	IN	O
use	NN	O
in	IN	O
kits	NNS	O
and	CC	O
diagnostics	NNS	O
,	,	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
compounds	NNS	O
or	CC	O
therapeutics	NNS	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
tools	NNS	O
in	IN	O
differential	JJ	O
and/or	JJ	O
combinatorial	JJ	O
analyses	NNS	O
to	TO	O
elucidate	VB	O
expression	NN	O
patterns	NNS	O
of	IN	O
a	DT	O
portion	NN	O
or	CC	O
the	DT	O
entire	JJ	O
complement	NN	O
of	IN	O
genes	NNS	O
expressed	VBN	O
within	IN	O
cells	NNS	O
and	CC	O
tissues	NNS	O
.	.	O
As	IN	O
one	CD	O
nonlimiting	VBG	O
example	NN	O
,	,	O
expression	NN	O
patterns	NNS	O
within	IN	O
cells	NNS	O
or	CC	O
tissues	NNS	O
treated	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
compared	VBN	O
to	TO	O
control	VB	O
cells	NNS	O
or	CC	O
tissues	NNS	O
not	RB	O
treated	VBN	O
with	IN	O
compounds	NNS	O
and	CC	O
the	DT	O
patterns	NNS	O
produced	VBN	O
are	VBP	O
analyzed	VBN	O
for	IN	O
differential	JJ	O
levels	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
as	IN	O
they	PRP	O
pertain	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
to	TO	O
disease	VB	O
association	NN	O
,	,	O
signaling	VBG	O
pathway	NN	O
,	,	O
cellular	JJ	O
localization	NN	O
,	,	O
expression	NN	O
level	NN	O
,	,	O
size	NN	O
,	,	O
structure	NN	O
or	CC	O
function	NN	O
of	IN	O
the	DT	O
genes	NNS	O
examined	VBD	O
.	.	O
These	DT	O
analyses	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
stimulated	JJ	O
or	CC	O
unstimulated	JJ	O
cells	NNS	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
other	JJ	O
compounds	NNS	O
which	WDT	O
affect	VBP	O
expression	NN	O
patterns	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
methods	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
analysis	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
include	VBP	O
DNA	NNP	O
arrays	NNS	O
or	CC	O
microarrays	NNS	O
(	(	O
Brazma	NNP	B
and	CC	I
Vilo	NNP	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
17-24	CD	I
;	:	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
)	)	O
,	,	O
SAGE	NNP	O
(	(	O
serial	JJ	O
analysis	NN	O
of	IN	O
gene	NN	O
expression	NN	O
)	)	O
(	(	O
Madden	NNP	B
,	,	I
et	FW	I
al.	RB	I
,	,	I
Drug	NNP	I
Discov	NNP	I
.	.	I
Today	NN	I
,	,	I
2000	CD	I
,	,	I
5	CD	I
,	,	I
415-425	JJ	I
)	)	O
,	,	O
READS	NNP	O
(	(	O
restriction	NN	O
enzyme	DT	O
amplification	NN	O
of	IN	O
digested	JJ	O
cDNAs	NN	O
)	)	O
(	(	O
Prashar	NNP	B
and	CC	I
Weissman	NNP	I
,	,	I
Methods	NNP	I
Enzymol.	NNP	I
,	,	I
1999	CD	I
,	,	I
303	CD	I
,	,	I
258-72	JJ	I
)	)	O
,	,	O
TOGA	NNP	O
(	(	O
total	JJ	O
gene	NN	O
expression	NN	O
analysis	NN	O
)	)	O
(	(	O
Sutcliffe	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
1976-81	JJ	I
)	)	O
,	,	O
protein	JJ	O
arrays	NNS	O
and	CC	O
proteomics	NNS	O
(	(	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
;	:	O
Jungblut	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Electrophoresis	NNP	I
,	,	I
1999	CD	I
,	,	I
20	CD	I
,	,	I
2100-10	JJ	I
)	)	O
,	,	O
expressed	VBD	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
sequencing	NN	O
(	(	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
;	:	O
Larsson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Biotechnol.	NNP	I
,	,	I
2000	CD	I
,	,	I
80	CD	I
,	,	I
143-57	JJ	I
)	)	O
,	,	O
subtractive	JJ	O
RNA	NNP	O
fingerprinting	NN	O
(	(	O
SuRF	NNP	O
)	)	O
(	(	O
Fuchs	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
2000	CD	I
,	,	I
286	CD	I
,	,	I
91-98	CD	I
;	:	O
Larson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Cytometry	NNP	I
,	,	I
2000	CD	I
,	,	I
41	CD	I
,	,	I
203-208	JJ	I
)	)	O
,	,	O
subtractive	JJ	O
cloning	NN	O
,	,	O
differential	JJ	O
display	NN	O
(	(	O
DD	NNP	O
)	)	O
(	(	O
Jurecic	NNP	B
and	CC	I
Belmont	NNP	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Microbiol.	NNP	I
,	,	I
2000	CD	I
,	,	I
3	CD	I
,	,	I
316-21	JJ	I
)	)	O
,	,	O
comparative	JJ	O
genomic	JJ	O
hybridization	NN	O
(	(	O
Carulli	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biochem	NNP	I
.	.	I
Suppl.	NNP	I
,	,	I
1998	CD	I
,	,	I
31	CD	I
,	,	I
286-96	JJ	I
)	)	O
,	,	O
FISH	NNP	O
(	(	O
fluorescent	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
)	)	O
techniques	NNS	O
(	(	O
Going	VBG	B
and	CC	I
Gusterson	NNP	I
,	,	I
Eur	NNP	I
.	.	I
J	NNP	I
.	.	I
Cancer	NN	I
,	,	I
1999	CD	I
,	,	I
35	CD	I
,	,	I
1895-904	JJ	I
)	)	O
and	CC	O
mass	$	O
spectrometry	NN	O
methods	NNS	O
(	(	O
To	TO	B
,	,	I
Comb	NNP	I
.	.	I
Chem	NNP	I
.	.	I
High	JJ	I
Throughput	NNP	I
Screen	NNP	I
,	,	I
2000	CD	I
,	,	I
3	CD	I
,	,	I
235-41	JJ	I
)	)	O
.	.	O
Therapeutics	NNS	O
The	DT	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
of	IN	O
antisense	NN	O
technology	NN	O
is	VBZ	O
also	RB	O
harnessed	VBN	O
by	IN	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
therapeutic	JJ	O
uses	NNS	O
.	.	O
Antisense	NNP	O
compounds	NNS	O
have	VBP	O
been	VBN	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
moieties	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disease	NN	O
states	NNS	O
in	IN	O
animals	NNS	O
,	,	O
including	VBG	O
humans	NNS	O
.	.	O
Antisense	NNP	O
drugs	NNS	O
have	VBP	O
been	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
administered	VBN	O
to	TO	O
humans	NNS	O
and	CC	O
numerous	JJ	O
clinical	JJ	O
trials	NNS	O
are	VBP	O
presently	RB	O
underway	RB	O
.	.	O
It	PRP	O
is	VBZ	O
thus	RB	O
established	VBN	O
that	IN	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
useful	JJ	O
therapeutic	JJ	O
modalities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
configured	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
treatment	NN	O
regimes	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cells	NNS	O
,	,	O
tissues	NNS	O
and	CC	O
animals	NNS	O
,	,	O
especially	RB	O
humans	NNS	O
.	.	O
For	IN	O
therapeutics	NNS	O
,	,	O
an	DT	O
animal	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
human	JJ	O
,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
having	VBG	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
which	WDT	O
can	MD	O
be	VB	O
treated	VBN	O
by	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
is	VBZ	O
treated	VBN	O
by	IN	O
administering	VBG	O
compounds	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
non-limiting	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
methods	NNS	O
comprise	VBP	O
the	DT	O
step	NN	O
of	IN	O
administering	VBG	O
to	TO	O
said	VBD	O
animal	NN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
that	IN	O
inhibits	VBZ	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
effectively	RB	O
inhibit	VB	O
the	DT	O
levels	NNS	O
or	CC	O
function	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
RNA	NNP	O
.	.	O
Because	IN	O
reduction	NN	O
in	IN	O
Gemin	NNP	O
Gene	NNP	O
mRNA	NN	O
levels	NNS	O
can	MD	O
lead	VB	O
to	TO	O
alteration	VB	O
in	IN	O
Gemin	NNP	O
Gene	NNP	O
protein	NN	O
products	NNS	O
of	IN	O
expression	NN	O
as	IN	O
well	RB	O
,	,	O
such	JJ	O
resultant	JJ	O
alterations	NNS	O
can	MD	O
also	RB	O
be	VB	O
measured	VBN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
inhibit	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
causing	VBG	O
a	DT	O
reduction	NN	O
of	IN	O
RNA	NNP	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
20	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
30	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
40	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
60	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
95	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
98	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
99	CD	O
%	NN	O
,	,	O
or	CC	O
by	IN	O
100	CD	O
%	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
can	MD	O
be	VB	O
measured	VBN	O
in	IN	O
a	DT	O
bodily	JJ	O
fluid	NN	O
,	,	O
tissue	NN	O
or	CC	O
organ	NN	O
of	IN	O
the	DT	O
animal	NN	O
.	.	O
Bodily	RB	O
fluids	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
blood	NN	O
(	(	O
serum	NN	O
or	CC	O
plasma	NN	O
)	)	O
,	,	O
lymphatic	JJ	O
fluid	NN	O
,	,	O
cerebrospinal	JJ	O
fluid	NN	O
,	,	O
semen	NNS	O
,	,	O
urine	NN	O
,	,	O
synovial	JJ	O
fluid	NN	O
and	CC	O
saliva	NN	O
and	CC	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
methods	NNS	O
routine	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Tissues	NNS	O
or	CC	O
organs	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
blood	NN	O
(	(	O
e.g.	JJ	O
,	,	O
hematopoietic	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
human	JJ	O
hematopoietic	JJ	O
progenitor	NN	O
cells	NNS	O
,	,	O
human	JJ	O
hematopoietic	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
CD34+	NNP	O
cells	NNS	O
CD4+	NNP	O
cells	NNS	O
)	)	O
,	,	O
lymphocytes	NNS	O
and	CC	O
other	JJ	O
blood	NN	O
lineage	NN	O
cells	NNS	O
,	,	O
skin	NN	O
,	,	O
bone	NN	O
marrow	NN	O
,	,	O
spleen	NN	O
,	,	O
thymus	NN	O
,	,	O
lymph	JJ	O
node	NN	O
,	,	O
brain	NN	O
,	,	O
spinal	JJ	O
cord	NN	O
,	,	O
heart	NN	O
,	,	O
skeletal	JJ	O
muscle	NN	O
,	,	O
liver	RB	O
,	,	O
pancreas	NNS	O
,	,	O
prostate	NN	O
,	,	O
kidney	NN	O
,	,	O
lung	NN	O
,	,	O
oral	JJ	O
mucosa	NN	O
,	,	O
esophagus	NN	O
,	,	O
stomach	NN	O
,	,	O
ilium	NN	O
,	,	O
small	JJ	O
intestine	NN	O
,	,	O
colon	NN	O
,	,	O
bladder	NN	O
,	,	O
cervix	NN	O
,	,	O
ovary	JJ	O
,	,	O
testis	NN	O
,	,	O
mammary	JJ	O
gland	NN	O
,	,	O
adrenal	JJ	O
gland	NN	O
,	,	O
and	CC	O
adipose	RB	O
(	(	O
white	JJ	O
and	CC	O
brown	JJ	O
)	)	O
.	.	O
Samples	NNS	O
of	IN	O
tissues	NNS	O
or	CC	O
organs	NNS	O
can	MD	O
be	VB	O
routinely	RB	O
obtained	VBN	O
by	IN	O
biopsy	NN	O
.	.	O
In	IN	O
some	DT	O
alternative	JJ	O
situations	NNS	O
,	,	O
samples	NNS	O
of	IN	O
tissues	NNS	O
or	CC	O
organs	NNS	O
can	MD	O
be	VB	O
recovered	VBN	O
from	IN	O
an	DT	O
animal	NN	O
after	IN	O
death	NN	O
.	.	O
The	DT	O
cells	NNS	O
contained	VBN	O
within	IN	O
said	VBD	O
fluids	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
organs	NNS	O
being	VBG	O
analyzed	VBN	O
can	MD	O
contain	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
protein	NN	O
and/or	VBZ	O
the	DT	O
Gemin	NNP	O
Gene-encoded	NNP	O
protein	NN	O
itself	PRP	O
For	IN	O
example	NN	O
,	,	O
tissues	NNS	O
or	CC	O
fluids	NNS	O
procured	VBN	O
from	IN	O
patients	NNS	O
can	MD	O
be	VB	O
evaluated	VBN	O
for	IN	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
or	CC	O
protein	NN	O
.	.	O
Additionally	RB	O
,	,	O
the	DT	O
mRNA	NN	O
or	CC	O
protein	JJ	O
expression	NN	O
levels	NNS	O
of	IN	O
other	JJ	O
genes	NNS	O
known	VBN	O
or	CC	O
suspected	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
state	NN	O
,	,	O
condition	NN	O
or	CC	O
phenotype	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
.	.	O
mRNA	NN	O
levels	NNS	O
can	MD	O
be	VB	O
measured	VBN	O
or	CC	O
evaluated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
,	,	O
Northern	NNP	O
blot	NN	O
,	,	O
in	IN	O
situ	JJ	O
hybridization	NN	O
or	CC	O
DNA	NNP	O
array	JJ	O
analysis	NN	O
.	.	O
Protein	NNP	O
levels	NNS	O
can	MD	O
be	VB	O
measured	VBN	O
or	CC	O
evaluated	VBN	O
by	IN	O
ELISA	NNP	O
,	,	O
immunoblotting	NN	O
,	,	O
quantitative	JJ	O
protein	NN	O
assays	NNS	O
,	,	O
protein	NN	O
activity	NN	O
assays	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
caspase	NN	O
activity	NN	O
assays	NNS	O
)	)	O
immunohistochemistry	NN	O
or	CC	O
immunocytochemistry	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
measuring	VBG	O
biomarkers	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
disease	NN	O
or	CC	O
condition	NN	O
in	IN	O
the	DT	O
aforementioned	JJ	O
tissues	NNS	O
and	CC	O
fluids	NNS	O
,	,	O
collected	VBN	O
from	IN	O
a	DT	O
patient	NN	O
or	CC	O
subject	JJ	O
receiving	NN	O
treatment	NN	O
,	,	O
by	IN	O
routine	JJ	O
clinical	JJ	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
These	DT	O
biomarkers	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
glucose	NN	O
,	,	O
cholesterol	NN	O
,	,	O
lipoproteins	VBZ	O
,	,	O
triglycerides	NNS	O
,	,	O
free	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
glucose	NN	O
and	CC	O
lipid	JJ	O
metabolism	NN	O
;	:	O
liver	CC	O
transaminases	NNS	O
,	,	O
bilirubin	NN	O
,	,	O
albumin	NN	O
,	,	O
blood	NN	O
urea	JJ	O
nitrogen	NN	O
,	,	O
creatine	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
kidney	NN	O
and	CC	O
liver	NN	O
function	NN	O
;	:	O
interleukins	NNS	O
,	,	O
tumor	NN	O
necrosis	NN	O
factors	NNS	O
,	,	O
intracellular	JJ	O
adhesion	NN	O
molecules	NNS	O
,	,	O
C-reactive	JJ	O
protein	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
inflammation	NN	O
;	:	O
testosterone	NN	O
,	,	O
estrogen	NN	O
and	CC	O
other	JJ	O
hormones	NNS	O
;	:	O
tumor	NN	O
markers	NNS	O
;	:	O
vitamins	NNS	O
,	,	O
minerals	NNS	O
and	CC	O
electrolytes	NNS	O
.	.	O
Pharmaceuticals	NNS	O
and	CC	O
Methods	NNS	O
of	IN	O
Treatment	NNP	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
by	IN	O
adding	VBG	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
to	TO	O
a	DT	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
diluent	NN	O
or	CC	O
carrier	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
inhibit	NN	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
compounds	NNS	O
are	VBP	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disorders	NNS	O
and	CC	O
diseases	NNS	O
related	VBN	O
to	TO	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
.	.	O
Use	NNP	O
of	IN	O
the	DT	O
compounds	NNS	O
,	,	O
compositions	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
prophylactically	RB	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diseases	NNS	O
and	CC	O
disorders	NNS	O
related	VBN	O
to	TO	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
.	.	O
Methods	NNS	O
whereby	WRB	O
bodily	RB	O
fluids	NNS	O
,	,	O
cells	NNS	O
or	CC	O
tissues	NNS	O
are	VBP	O
contacted	VBN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
contemplated	VBN	O
.	.	O
Bodily	NNP	O
fluids	NNS	O
,	,	O
cells	NNS	O
or	CC	O
tissues	NNS	O
can	MD	O
be	VB	O
contacted	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
resulting	VBG	O
in	IN	O
modulation	NN	O
of	IN	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
in	IN	O
the	DT	O
bodily	JJ	O
fluids	NNS	O
,	,	O
cells	NNS	O
or	CC	O
tissues	NNS	O
.	.	O
An	DT	O
effective	JJ	O
amount	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
monitoring	VBG	O
the	DT	O
modulatory	JJ	O
effect	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
or	CC	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
on	IN	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
or	CC	O
their	PRP$	O
products	NNS	O
by	IN	O
methods	NNS	O
routine	JJ	O
to	TO	O
the	DT	O
skilled	VBN	O
artisan	NN	O
.	.	O
Further	RB	O
contemplated	VBN	O
are	VBP	O
ex	JJ	O
vivo	JJ	O
methods	NNS	O
of	IN	O
treatment	NN	O
whereby	NN	O
cells	NNS	O
or	CC	O
tissues	NNS	O
are	VBP	O
isolated	VBN	O
from	IN	O
a	DT	O
subject	NN	O
,	,	O
contacted	VBN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
or	CC	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
and	CC	O
reintroduced	VBD	O
into	IN	O
the	DT	O
subject	NN	O
by	IN	O
routine	JJ	O
methods	NNS	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Further	RB	O
contemplated	VBN	O
herein	NN	O
is	VBZ	O
a	DT	O
method	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
subject	NN	O
suspected	VBN	O
of	IN	O
having	VBG	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
having	VBG	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
isolated	JJ	O
single	JJ	O
stranded	VBN	O
RNA	NNP	O
or	CC	O
double	RB	O
stranded	JJ	O
RNA	NNP	O
oligonucleotide	RB	O
directed	VBD	O
to	TO	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
.	.	O
The	DT	O
ssRNA	NN	O
or	CC	O
dsRNA	VB	O
oligonucleotide	NN	O
may	MD	O
be	VB	O
modified	VBN	O
or	CC	O
unmodified	VBN	O
.	.	O
That	DT	O
is	VBZ	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
an	DT	O
isolated	JJ	O
double	NN	O
stranded	VBD	O
RNA	NNP	O
oligonucleotide	RB	O
targeted	VBD	O
to	TO	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
,	,	O
or	CC	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
thereof	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
provided	VBN	O
are	VBP	O
uses	NNS	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
an	DT	O
isolated	JJ	O
double	NN	O
stranded	VBD	O
RNA	NNP	O
oligonucleotide	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
inhibiting	VBG	O
Gemin	NNP	O
Gene	NNP	O
expression	NN	O
or	CC	O
overexpression	NN	O
.	.	O
Thus	RB	O
,	,	O
provided	VBN	O
herein	NN	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
an	DT	O
isolated	JJ	O
double	NN	O
stranded	VBD	O
RNA	NNP	O
oligonucleotide	RB	O
targeted	VBD	O
to	TO	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
method	NN	O
described	VBN	O
above	IN	O
.	.	O
Salts	NNS	O
,	,	O
Prodrugs	NNP	O
and	CC	O
Bioequivalents	NNPS	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
any	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
,	,	O
esters	NNS	O
,	,	O
or	CC	O
salts	NNS	O
of	IN	O
such	JJ	O
esters	NNS	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
functional	JJ	O
chemical	NN	O
equivalent	NN	O
which	WDT	O
,	,	O
upon	IN	O
administration	NN	O
to	TO	O
an	DT	O
animal	JJ	O
including	VBG	O
a	DT	O
human	JJ	O
,	,	O
is	VBZ	O
capable	JJ	O
of	IN	O
providing	VBG	O
(	(	O
directly	RB	O
or	CC	O
indirectly	RB	O
)	)	O
the	DT	O
biologically	RB	O
active	JJ	O
metabolite	NN	O
or	CC	O
residue	JJ	O
thereof	NN	O
Accordingly	NNP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
disclosure	NN	O
is	VBZ	O
also	RB	O
drawn	VBN	O
to	TO	O
prodrugs	NNS	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
such	JJ	O
prodrugs	NNS	O
,	,	O
and	CC	O
other	JJ	O
bioequivalents	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
prodrug	NN	O
”	NNP	O
indicates	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
that	WDT	O
is	VBZ	O
prepared	VBN	O
in	IN	O
an	DT	O
inactive	JJ	O
or	CC	O
less	RBR	O
active	JJ	O
form	NN	O
that	WDT	O
is	VBZ	O
converted	VBN	O
to	TO	O
an	DT	O
active	JJ	O
form	NN	O
(	(	O
i.e.	JJ	O
,	,	O
drug	NN	O
)	)	O
within	IN	O
the	DT	O
body	NN	O
or	CC	O
cells	NNS	O
thereof	VBN	O
by	IN	O
the	DT	O
action	NN	O
of	IN	O
endogenous	JJ	O
enzymes	NNS	O
or	CC	O
other	JJ	O
chemicals	NNS	O
and/or	JJ	O
conditions	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
prodrug	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
prepared	VBN	O
as	IN	O
SATE	NNP	O
(	(	O
(	(	O
S-acetyl-2-thioethyl	NNP	O
)	)	O
phosphate	NN	O
)	)	O
derivatives	VBZ	O
according	VBG	O
to	TO	O
the	DT	O
methods	NNS	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
93/24510	CD	O
or	CC	O
WO	NNP	O
94/26764	CD	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
”	JJ	O
refers	NNS	O
to	TO	O
physiologically	RB	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
:	:	O
i.e.	NN	O
,	,	O
salts	NNS	O
that	WDT	O
retain	VBP	O
the	DT	O
desired	JJ	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
parent	NN	O
compound	NN	O
and	CC	O
do	VBP	O
not	RB	O
impart	VB	O
undesired	JJ	O
toxicological	JJ	O
effects	NNS	O
thereto	NN	O
.	.	O
Pharmaceutically	RB	O
acceptable	JJ	O
base	NN	O
addition	NN	O
salts	NNS	O
are	VBP	O
formed	VBN	O
with	IN	O
metals	NNS	O
or	CC	O
amines	NNS	O
,	,	O
such	JJ	O
as	IN	O
alkali	NN	O
and	CC	O
alkaline	JJ	O
earth	NN	O
metals	NNS	O
or	CC	O
organic	JJ	O
amines	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
metals	NNS	O
used	VBN	O
as	IN	O
cations	NNS	O
are	VBP	O
sodium	JJ	O
,	,	O
potassium	NN	O
,	,	O
magnesium	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Examples	NNS	O
of	IN	O
suitable	JJ	O
amines	NNS	O
are	VBP	O
N	NNP	O
,	,	O
N′-dibenzylethylenediamine	NNP	O
,	,	O
chloroprocaine	NN	O
,	,	O
choline	NN	O
,	,	O
diethanolamine	NN	O
,	,	O
dicyclohexylamine	NN	O
,	,	O
ethylenediamine	NN	O
,	,	O
N-methylglucamine	NNP	O
,	,	O
and	CC	O
procaine	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Berge	NNP	B
et	FW	I
al.	NN	I
,	,	I
“	NNP	I
Pharmaceutical	NNP	I
Salts	NNP	I
,	,	I
”	NNP	I
J.	NNP	I
of	IN	I
Pharma	NNP	I
Sci.	NNP	I
,	,	I
1977	CD	I
,	,	I
66	CD	I
,	,	I
1-19	JJ	I
)	)	O
.	.	O
The	DT	O
base	NN	O
addition	NN	O
salts	NNS	O
of	IN	O
said	VBD	O
acidic	JJ	O
compounds	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
contacting	VBG	O
the	DT	O
free	JJ	O
acid	NN	O
form	NN	O
with	IN	O
a	DT	O
sufficient	JJ	O
amount	NN	O
of	IN	O
the	DT	O
desired	JJ	O
base	NN	O
to	TO	O
produce	VB	O
the	DT	O
salt	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
manner	NN	O
.	.	O
The	DT	O
free	JJ	O
acid	NN	O
form	NN	O
may	MD	O
be	VB	O
regenerated	VBN	O
by	IN	O
contacting	VBG	O
the	DT	O
salt	NN	O
form	NN	O
with	IN	O
an	DT	O
acid	NN	O
and	CC	O
isolating	VBG	O
the	DT	O
free	JJ	O
acid	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
manner	NN	O
.	.	O
The	DT	O
free	JJ	O
acid	NN	O
forms	NNS	O
differ	VBP	O
from	IN	O
their	PRP$	O
respective	JJ	O
salt	NN	O
forms	NNS	O
somewhat	RB	O
in	IN	O
certain	JJ	O
physical	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
solubility	NN	O
in	IN	O
polar	JJ	O
solvents	NNS	O
,	,	O
but	CC	O
otherwise	RB	O
the	DT	O
salts	NNS	O
are	VBP	O
equivalent	JJ	O
to	TO	O
their	PRP$	O
respective	JJ	O
free	JJ	O
acid	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
a	DT	O
“	JJ	O
pharmaceutical	JJ	O
addition	NN	O
salt	NN	O
”	NNP	O
includes	VBZ	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
salt	NN	O
of	IN	O
an	DT	O
acid	JJ	O
form	NN	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
These	DT	O
include	VBP	O
organic	JJ	O
or	CC	O
inorganic	JJ	O
acid	NN	O
salts	NNS	O
of	IN	O
the	DT	O
amines	NNS	O
.	.	O
Acid	NNP	O
salts	NNS	O
are	VBP	O
the	DT	O
hydrochlorides	NNS	O
,	,	O
acetates	NNS	O
,	,	O
salicylates	NNS	O
,	,	O
nitrates	NNS	O
and	CC	O
phosphates	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
basic	JJ	O
salts	NNS	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
inorganic	JJ	O
and	CC	O
organic	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
with	IN	O
inorganic	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
hydrochloric	JJ	O
acid	NN	O
,	,	O
hydrobromic	JJ	O
acid	NN	O
,	,	O
sulfuric	JJ	O
acid	NN	O
or	CC	O
phosphoric	JJ	O
acid	NN	O
;	:	O
with	IN	O
organic	JJ	O
carboxylic	NN	O
,	,	O
sulfonic	JJ	O
,	,	O
sulfo	JJ	O
or	CC	O
phospho	JJ	O
acids	NNS	O
or	CC	O
N-substituted	JJ	O
sulfamic	JJ	O
acids	NNS	O
,	,	O
for	IN	O
example	NN	O
acetic	JJ	O
acid	NN	O
,	,	O
propionic	JJ	O
acid	NN	O
,	,	O
glycolic	JJ	O
acid	NN	O
,	,	O
succinic	JJ	O
acid	NN	O
,	,	O
maleic	JJ	O
acid	NN	O
,	,	O
hydroxymaleic	JJ	O
acid	NN	O
,	,	O
methylmaleic	JJ	O
acid	NN	O
,	,	O
fumaric	JJ	O
acid	NN	O
,	,	O
malic	JJ	O
acid	NN	O
,	,	O
tartaric	JJ	O
acid	NN	O
,	,	O
lactic	JJ	O
acid	NN	O
,	,	O
oxalic	JJ	O
acid	NN	O
,	,	O
gluconic	JJ	O
acid	NN	O
,	,	O
glucaric	JJ	O
acid	NN	O
,	,	O
glucuronic	JJ	O
acid	NN	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
benzoic	NN	O
acid	NN	O
,	,	O
cinnamic	JJ	O
acid	NN	O
,	,	O
mandelic	JJ	O
acid	NN	O
,	,	O
salicylic	JJ	O
acid	NN	O
,	,	O
4-aminosalicylic	JJ	O
acid	NN	O
,	,	O
2-phenoxybenzoic	JJ	O
acid	NN	O
,	,	O
2-acetoxybenzoic	JJ	O
acid	NN	O
,	,	O
embonic	JJ	O
acid	NN	O
,	,	O
nicotinic	JJ	O
acid	NN	O
or	CC	O
isonicotinic	JJ	O
acid	NN	O
;	:	O
and	CC	O
with	IN	O
amino	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
22	CD	O
alpha-amino	JJ	O
acids	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
proteins	NNS	O
in	IN	O
nature	NN	O
,	,	O
for	IN	O
example	NN	O
glutamic	JJ	O
acid	NN	O
or	CC	O
aspartic	JJ	O
acid	NN	O
,	,	O
and	CC	O
also	RB	O
with	IN	O
phenylacetic	JJ	O
acid	NN	O
,	,	O
methanesulfonic	JJ	O
acid	NN	O
,	,	O
ethanesulfonic	JJ	O
acid	NN	O
,	,	O
2-hydroxyethanesulfonic	JJ	O
acid	NN	O
,	,	O
ethane-1,2-disulfonic	JJ	O
acid	NN	O
,	,	O
benzenesulfonic	JJ	O
acid	NN	O
,	,	O
4-methylbenzenesulfoc	JJ	O
acid	NN	O
,	,	O
naphthalene-2-sulfonic	JJ	O
acid	NN	O
,	,	O
naphthalene-1,5-disulfonic	JJ	O
acid	NN	O
,	,	O
2-	JJ	O
or	CC	O
3-phosphoglycerate	JJ	O
,	,	O
glucose-6-phosphate	JJ	O
,	,	O
N-cyclohexylsulfamic	JJ	O
acid	NN	O
(	(	O
with	IN	O
the	DT	O
formation	NN	O
of	IN	O
cyclamates	NNS	O
)	)	O
,	,	O
or	CC	O
with	IN	O
other	JJ	O
acid	JJ	O
organic	JJ	O
compounds	NNS	O
,	,	O
such	JJ	O
as	IN	O
ascorbic	JJ	O
acid	NN	O
.	.	O
Pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
compounds	NNS	O
may	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
with	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
cation	NN	O
.	.	O
Suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
cations	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
alkaline	NN	O
,	,	O
alkaline	JJ	O
earth	NN	O
,	,	O
ammonium	NN	O
and	CC	O
quaternary	JJ	O
ammonium	NN	O
cations	NNS	O
.	.	O
Carbonates	NNS	O
or	CC	O
hydrogen	NN	O
carbonates	NNS	O
are	VBP	O
also	RB	O
possible	JJ	O
.	.	O
For	IN	O
oligonucleotides	NNS	O
,	,	O
examples	NNS	O
of	IN	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
salts	NNS	O
formed	VBN	O
with	IN	O
cations	NNS	O
such	JJ	O
as	IN	O
sodium	NN	O
,	,	O
potassium	NN	O
,	,	O
ammonium	NN	O
,	,	O
magnesium	NN	O
,	,	O
calcium	NN	O
,	,	O
polyamines	NNS	O
such	JJ	O
as	IN	O
spermine	NN	O
and	CC	O
spermidine	NN	O
,	,	O
etc	FW	O
.	.	O
;	:	O
(	(	O
b	NN	O
)	)	O
acid	NN	O
addition	NN	O
salts	NNS	O
formed	VBN	O
with	IN	O
inorganic	JJ	O
acids	NNS	O
,	,	O
for	IN	O
example	NN	O
hydrochloric	JJ	O
acid	NN	O
,	,	O
hydrobromic	JJ	O
acid	NN	O
,	,	O
sulfuric	JJ	O
acid	NN	O
,	,	O
phosphoric	JJ	O
acid	NN	O
,	,	O
nitric	JJ	O
acid	NN	O
and	CC	O
the	DT	O
like	JJ	O
;	:	O
(	(	O
c	NN	O
)	)	O
salts	NNS	O
formed	VBN	O
with	IN	O
organic	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
acetic	JJ	O
acid	NN	O
,	,	O
oxalic	JJ	O
acid	NN	O
,	,	O
tartaric	JJ	O
acid	NN	O
,	,	O
succinic	JJ	O
acid	NN	O
,	,	O
maleic	JJ	O
acid	NN	O
,	,	O
fumaric	JJ	O
acid	NN	O
,	,	O
gluconic	JJ	O
acid	NN	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
malic	JJ	O
acid	NN	O
,	,	O
ascorbic	JJ	O
acid	NN	O
,	,	O
benzoic	NN	O
acid	NN	O
,	,	O
tannic	JJ	O
acid	NN	O
,	,	O
palmitic	JJ	O
acid	NN	O
,	,	O
alginic	JJ	O
acid	NN	O
,	,	O
polyglutamic	JJ	O
acid	NN	O
,	,	O
naphthalenesulfonic	JJ	O
acid	NN	O
,	,	O
methanesulfonic	JJ	O
acid	NN	O
,	,	O
p-toluenesulfonic	JJ	O
acid	NN	O
,	,	O
naphthalenedisulfonic	JJ	O
acid	NN	O
,	,	O
polygalacturonic	JJ	O
acid	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
;	:	O
and	CC	O
(	(	O
d	NN	O
)	)	O
salts	NNS	O
formed	VBN	O
from	IN	O
elemental	JJ	O
anions	NNS	O
such	JJ	O
as	IN	O
chlorine	NN	O
,	,	O
bromine	NN	O
,	,	O
and	CC	O
iodine	NN	O
.	.	O
Sodium	NN	O
salts	NNS	O
of	IN	O
antisense	NN	O
oligonucleotides	NNS	O
are	VBP	O
useful	JJ	O
and	CC	O
are	VBP	O
well	RB	O
accepted	VBN	O
for	IN	O
therapeutic	JJ	O
administration	NN	O
to	TO	O
humans	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
sodium	NN	O
salts	NNS	O
of	IN	O
dsRNA	NN	O
compounds	NNS	O
are	VBP	O
also	RB	O
provided	VBN	O
.	.	O
Formulations	NNS	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
admixed	VBN	O
,	,	O
encapsulated	VBN	O
,	,	O
conjugated	VBD	O
or	CC	O
otherwise	RB	O
associated	VBN	O
with	IN	O
other	JJ	O
molecules	NNS	O
,	,	O
molecule	NN	O
structures	NNS	O
or	CC	O
mixtures	NNS	O
of	IN	O
compounds	NNS	O
,	,	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
liposomes	RB	O
,	,	O
receptor-targeted	JJ	O
molecules	NNS	O
,	,	O
oral	JJ	O
,	,	O
rectal	JJ	O
,	,	O
topical	JJ	O
or	CC	O
other	JJ	O
formulations	NNS	O
,	,	O
for	IN	O
assisting	VBG	O
in	IN	O
uptake	NN	O
,	,	O
distribution	NN	O
and/or	NN	O
absorption	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
uptake	JJ	O
,	,	O
distribution	NN	O
and/or	IN	O
absorption-assisting	JJ	O
formulations	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,108,921	CD	O
;	:	O
5,354,844	CD	O
;	:	O
5,416,016	CD	O
;	:	O
5,459,127	CD	O
;	:	O
5,521,291	CD	O
;	:	O
5,543,158	CD	O
;	:	O
5,547,932	CD	O
;	:	O
5,583,020	CD	O
;	:	O
5,591,721	CD	O
;	:	O
4,426,330	CD	O
;	:	O
4,534,899	CD	O
;	:	O
5,013,556	CD	O
;	:	O
5,108,921	CD	O
;	:	O
5,213,804	CD	O
;	:	O
5,227,170	CD	O
;	:	O
5,264,221	CD	O
;	:	O
5,356,633	CD	O
;	:	O
5,395,619	CD	O
;	:	O
5,416,016	CD	O
;	:	O
5,417,978	CD	O
;	:	O
5,462,854	CD	O
;	:	O
5,469,854	CD	O
;	:	O
5,512,295	CD	O
;	:	O
5,527,528	CD	O
;	:	O
5,534,259	CD	O
;	:	O
5,543,152	CD	O
;	:	O
5,556,948	CD	O
;	:	O
5,580,575	CD	O
;	:	O
and	CC	O
5,595,756	CD	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
includes	VBZ	O
pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
which	WDT	O
include	VBP	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
ways	NNS	O
depending	VBG	O
upon	IN	O
whether	IN	O
local	JJ	O
or	CC	O
systemic	JJ	O
treatment	NN	O
is	VBZ	O
desired	VBN	O
and	CC	O
upon	IN	O
the	DT	O
area	NN	O
to	TO	O
be	VB	O
treated	VBN	O
.	.	O
Administration	NN	O
may	MD	O
be	VB	O
topical	JJ	O
(	(	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
ophthalmic	VB	O
and	CC	O
to	TO	O
mucous	JJ	O
membranes	NNS	O
including	VBG	O
vaginal	JJ	O
and	CC	O
rectal	JJ	O
delivery	NN	O
)	)	O
,	,	O
pulmonary	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
by	IN	O
inhalation	NN	O
or	CC	O
insufflation	NN	O
of	IN	O
powders	NNS	O
or	CC	O
aerosols	NNS	O
,	,	O
including	VBG	O
by	IN	O
nebulizer	NN	O
(	(	O
intratracheal	JJ	O
,	,	O
intranasal	JJ	O
,	,	O
epidermal	JJ	O
and	CC	O
transdermal	JJ	O
)	)	O
,	,	O
oral	JJ	O
or	CC	O
parenteral	JJ	O
.	.	O
Parenteral	JJ	O
administration	NN	O
includes	VBZ	O
intravenous	JJ	O
,	,	O
intraarterial	JJ	O
,	,	O
subcutaneous	JJ	O
,	,	O
intraperitoneal	JJ	O
or	CC	O
intramuscular	JJ	O
injection	NN	O
or	CC	O
infusion	NN	O
;	:	O
or	CC	O
intracranial	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
intrathecal	JJ	O
or	CC	O
intraventricular	JJ	O
,	,	O
administration	NN	O
.	.	O
Sites	NNS	O
of	IN	O
administration	NN	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Oligonucleotides	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
2′-O-methoxyethyl	JJ	O
modification	NN	O
are	VBP	O
believed	VBN	O
to	TO	O
be	VB	O
particularly	RB	O
useful	JJ	O
for	IN	O
oral	JJ	O
administration	NN	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
for	IN	O
topical	JJ	O
administration	NN	O
may	MD	O
include	VB	O
transdermal	JJ	O
patches	NNS	O
,	,	O
ointments	NNS	O
,	,	O
lotions	NNS	O
,	,	O
creams	NNS	O
,	,	O
gels	NNS	O
,	,	O
drops	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
sprays	NNS	O
,	,	O
liquids	NNS	O
and	CC	O
powders	NNS	O
.	.	O
Conventional	JJ	O
pharmaceutical	JJ	O
carriers	NNS	O
,	,	O
aqueous	JJ	O
,	,	O
powder	NN	O
or	CC	O
oily	RB	O
bases	NNS	O
,	,	O
thickeners	NNS	O
and	CC	O
the	DT	O
like	JJ	O
may	MD	O
be	VB	O
necessary	JJ	O
or	CC	O
desirable	JJ	O
.	.	O
Coated	VBN	O
condoms	NNS	O
,	,	O
gloves	NNS	O
and	CC	O
the	DT	O
like	JJ	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
which	WDT	O
may	MD	O
conveniently	RB	O
be	VB	O
presented	VBN	O
in	IN	O
unit	NN	O
dosage	NN	O
form	NN	O
,	,	O
may	MD	O
be	VB	O
prepared	VBN	O
according	VBG	O
to	TO	O
conventional	JJ	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
pharmaceutical	JJ	O
industry	NN	O
.	.	O
Such	JJ	O
techniques	NNS	O
include	VBP	O
the	DT	O
step	NN	O
of	IN	O
bringing	VBG	O
into	IN	O
association	NN	O
the	DT	O
active	JJ	O
ingredients	NNS	O
with	IN	O
the	DT	O
pharmaceutical	JJ	O
carrier	NN	O
(	(	O
s	NN	O
)	)	O
or	CC	O
excipient	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
formulations	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
uniformly	JJ	O
and	CC	O
intimately	RB	O
bringing	VBG	O
into	IN	O
association	NN	O
the	DT	O
active	JJ	O
ingredients	NNS	O
with	IN	O
liquid	JJ	O
carriers	NNS	O
or	CC	O
finely	RB	O
divided	VBN	O
solid	JJ	O
carriers	NNS	O
or	CC	O
both	DT	O
,	,	O
and	CC	O
then	RB	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
shaping	VBG	O
the	DT	O
product	NN	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
formulated	VBN	O
into	IN	O
any	DT	O
of	IN	O
many	JJ	O
possible	JJ	O
dosage	NN	O
forms	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
tablets	NNS	O
,	,	O
capsules	NNS	O
,	,	O
gel	NN	O
capsules	NNS	O
,	,	O
liquid	NN	O
syrups	NNS	O
,	,	O
soft	JJ	O
gels	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
and	CC	O
enemas	NN	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
formulated	VBN	O
as	IN	O
suspensions	NNS	O
in	IN	O
aqueous	JJ	O
,	,	O
non-aqueous	JJ	O
or	CC	O
mixed	JJ	O
media	NNS	O
.	.	O
Aqueous	JJ	O
suspensions	NNS	O
may	MD	O
further	RB	O
contain	VB	O
substances	NNS	O
which	WDT	O
increase	VBP	O
the	DT	O
viscosity	NN	O
of	IN	O
the	DT	O
suspension	NN	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
sodium	NN	O
carboxymethylcellulose	NN	O
,	,	O
sorbitol	JJ	O
and/or	NN	O
dextran	NN	O
.	.	O
The	DT	O
suspension	NN	O
may	MD	O
also	RB	O
contain	VB	O
stabilizers	NNS	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
solutions	NNS	O
,	,	O
emulsions	NNS	O
,	,	O
foams	NNS	O
and	CC	O
liposome-containing	JJ	O
formulations	NNS	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
comprise	VB	O
one	CD	O
or	CC	O
more	JJR	O
penetration	NN	O
enhancers	NNS	O
,	,	O
carriers	NNS	O
,	,	O
excipients	NNS	O
or	CC	O
other	JJ	O
active	JJ	O
or	CC	O
inactive	JJ	O
ingredients	NNS	O
.	.	O
Emulsions	NNS	O
are	VBP	O
typically	RB	O
heterogenous	JJ	O
systems	NNS	O
of	IN	O
one	CD	O
liquid	NN	O
dispersed	VBN	O
in	IN	O
another	DT	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
droplets	NNS	O
usually	RB	O
exceeding	VBG	O
0.1	CD	O
μm	NN	O
in	IN	O
diameter	NN	O
.	.	O
Emulsions	NNS	O
may	MD	O
contain	VB	O
additional	JJ	O
components	NNS	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
dispersed	JJ	O
phases	NNS	O
,	,	O
and	CC	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
which	WDT	O
may	MD	O
be	VB	O
present	JJ	O
as	IN	O
a	DT	O
solution	NN	O
in	IN	O
the	DT	O
aqueous	JJ	O
phase	NN	O
,	,	O
oily	RB	O
phase	NN	O
or	CC	O
itself	PRP	O
as	IN	O
a	DT	O
separate	JJ	O
phase	NN	O
.	.	O
Microemulsions	NNS	O
are	VBP	O
included	VBN	O
as	IN	O
an	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Emulsions	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
Formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
liposomal	JJ	O
formulations	NNS	O
.	.	O
As	IN	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
liposome	VBZ	O
”	NNP	O
means	VBZ	O
a	DT	O
vesicle	NN	O
composed	VBN	O
of	IN	O
amphiphilic	JJ	O
lipids	NNS	O
arranged	VBN	O
in	IN	O
a	DT	O
spherical	JJ	O
bilayer	NN	O
or	CC	O
bilayers	NNS	O
.	.	O
Liposomes	NNS	O
are	VBP	O
unilamellar	JJ	O
or	CC	O
multilamellar	JJ	O
vesicles	NNS	O
which	WDT	O
have	VBP	O
a	DT	O
membrane	NN	O
formed	VBN	O
from	IN	O
a	DT	O
lipophilic	JJ	O
material	NN	O
and	CC	O
an	DT	O
aqueous	JJ	O
interior	NN	O
that	WDT	O
contains	VBZ	O
the	DT	O
composition	NN	O
to	TO	O
be	VB	O
delivered	VBN	O
.	.	O
Cationic	JJ	O
liposomes	NNS	O
are	VBP	O
positively	RB	O
charged	VBN	O
liposomes	NNS	O
which	WDT	O
are	VBP	O
believed	VBN	O
to	TO	O
interact	VB	O
with	IN	O
negatively	RB	O
charged	VBN	O
DNA	NNP	O
molecules	NNS	O
to	TO	O
form	VB	O
a	DT	O
stable	JJ	O
complex	NN	O
.	.	O
Liposomes	NNS	O
that	WDT	O
are	VBP	O
pH-sensitive	JJ	O
or	CC	O
negatively-charged	JJ	O
are	VBP	O
believed	VBN	O
to	TO	O
entrap	VB	O
DNA	NNP	O
rather	RB	O
than	IN	O
complex	JJ	O
with	IN	O
it	PRP	O
.	.	O
Both	DT	O
cationic	JJ	O
and	CC	O
noncationic	JJ	O
liposomes	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
deliver	VB	O
DNA	NNP	O
to	TO	O
cells	NNS	O
.	.	O
Liposomes	NNS	O
also	RB	O
include	VBP	O
“	NNP	O
sterically	RB	O
stabilized	VBD	O
”	JJ	O
liposomes	NNS	O
,	,	O
a	DT	O
term	NN	O
which	WDT	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
liposomes	VB	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
specialized	JJ	O
lipids	NNS	O
that	IN	O
,	,	O
when	WRB	O
incorporated	VBN	O
into	IN	O
liposomes	NNS	O
,	,	O
result	NN	O
in	IN	O
enhanced	JJ	O
circulation	NN	O
lifetimes	NNS	O
relative	VBP	O
to	TO	O
liposomes	VB	O
lacking	VBG	O
such	JJ	O
specialized	JJ	O
lipids	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
sterically	RB	O
stabilized	VBN	O
liposomes	NNS	O
are	VBP	O
those	DT	O
in	IN	O
which	WDT	O
part	NN	O
of	IN	O
the	DT	O
vesicle-forming	JJ	O
lipid	JJ	O
portion	NN	O
of	IN	O
the	DT	O
liposome	JJ	O
comprises	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
glycolipids	NNS	O
or	CC	O
is	VBZ	O
derivatized	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
hydrophilic	JJ	O
polymers	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
moiety	NN	O
.	.	O
Liposomes	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
Formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
dendrimers	NNS	O
,	,	O
which	WDT	O
are	VBP	O
hyperbranched	VBN	O
polymers	NNS	O
.	.	O
Dendrimers	NNS	O
are	VBP	O
built	VBN	O
around	IN	O
a	DT	O
central	JJ	O
core	NN	O
to	TO	O
which	WDT	O
the	DT	O
branch	NN	O
points	NNS	O
are	VBP	O
attached	VBN	O
.	.	O
Thus	RB	O
the	DT	O
core	NN	O
is	VBZ	O
encapsulated	VBN	O
in	IN	O
a	DT	O
web	NN	O
of	IN	O
branch	NN	O
points	NNS	O
.	.	O
Dendrimers	NNS	O
form	VBP	O
a	DT	O
monodisperse	JJ	O
material	NN	O
of	IN	O
uniform	JJ	O
molecular	JJ	O
weight	NN	O
providing	VBG	O
more	RBR	O
predictable	JJ	O
pK	NN	O
and	CC	O
biodistribution	NN	O
properties	NNS	O
.	.	O
Hyperbranched	VBN	O
dendrimers	NNS	O
offer	VBP	O
a	DT	O
unique	JJ	O
opportunity	NN	O
of	IN	O
polyfunctionalization	NN	O
with	IN	O
desired	VBN	O
carrier	NN	O
or	CC	O
targeting	NN	O
molecules	NNS	O
for	IN	O
targeted	JJ	O
drug	NN	O
delivery	NN	O
.	.	O
Short	JJ	O
dendrimers	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
attach	VB	O
multiple	JJ	O
carriers	NNS	O
to	TO	O
a	DT	O
single	JJ	O
oligomeric	JJ	O
compound	NN	O
thus	RB	O
increasing	VBG	O
chances	NNS	O
of	IN	O
uptake	NN	O
by	IN	O
the	DT	O
cluster	NN	O
effect	NN	O
.	.	O
Dendrimers	NNS	O
can	MD	O
be	VB	O
attached	VBN	O
to	TO	O
oligomeric	VB	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
target	VB	O
solid	JJ	O
tumors	NNS	O
which	WDT	O
have	VBP	O
a	DT	O
leaky	JJ	O
vasculature	NN	O
while	IN	O
avoiding	VBG	O
glomelular	JJ	O
filtration	NN	O
by	IN	O
virtue	NN	O
of	IN	O
their	PRP$	O
large	JJ	O
size	NN	O
.	.	O
Due	JJ	O
to	TO	O
dendrimers	NNS	O
'	POS	O
cage	NN	O
like	IN	O
structure	NN	O
they	PRP	O
protect	VBP	O
their	PRP$	O
core	NN	O
and	CC	O
thus	RB	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
protected	VBN	O
from	IN	O
degradation	NN	O
by	IN	O
encapsulating	VBG	O
it	PRP	O
within	IN	O
a	DT	O
dendrimer	NN	O
.	.	O
Dendrimers	NNS	O
can	MD	O
be	VB	O
programmed	VBN	O
to	TO	O
self-destruct	NN	O
under	IN	O
certain	JJ	O
pH	NN	O
,	,	O
oxidative	JJ	O
and	CC	O
enzymatic	JJ	O
conditions	NNS	O
and	CC	O
thus	RB	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
osmotic	JJ	O
bombs	NNS	O
attached	VBN	O
to	TO	O
oligomeric	VB	O
compounds	NNS	O
to	TO	O
disrupt	VB	O
lysosomal	JJ	O
membranes	NNS	O
and	CC	O
release	NN	O
attached	VBN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
Dendrimers	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
used	VBN	O
to	TO	O
target	VB	O
molecules	NNS	O
to	TO	O
specific	JJ	O
organs	NNS	O
and	CC	O
intracellular	JJ	O
compartments	NNS	O
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
uses	NNS	O
can	MD	O
be	VB	O
applied	VBN	O
to	TO	O
oligomeric	VB	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Dendrimers	NNS	O
can	MD	O
also	RB	O
serve	VB	O
as	IN	O
biocompatible	JJ	O
carriers	NNS	O
for	IN	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
increase	VB	O
their	PRP$	O
plasma	JJ	O
circulation	NN	O
time	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
formulations	NNS	O
and	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
include	VB	O
surfactants	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
surfactants	NNS	O
in	IN	O
drug	NN	O
products	NNS	O
,	,	O
formulations	NNS	O
and	CC	O
in	IN	O
emulsions	NNS	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Surfactants	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
employs	VBZ	O
various	JJ	O
penetration	NN	O
enhancers	NNS	O
to	TO	O
effect	NN	O
the	DT	O
efficient	JJ	O
delivery	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
particularly	RB	O
oligonucleotides	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
aiding	VBG	O
the	DT	O
diffusion	NN	O
of	IN	O
non-lipophilic	JJ	O
compounds	NNS	O
across	IN	O
cell	NN	O
membranes	NNS	O
,	,	O
penetration	NN	O
enhancers	NNS	O
also	RB	O
enhance	VBP	O
the	DT	O
permeability	NN	O
of	IN	O
lipophilic	JJ	O
compounds	NNS	O
.	.	O
Penetration	NN	O
enhancers	NNS	O
may	MD	O
be	VB	O
classified	VBN	O
as	IN	O
belonging	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
broad	JJ	O
categories	NNS	O
,	,	O
i.e.	FW	O
,	,	O
surfactants	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
bile	NN	O
salts	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
,	,	O
and	CC	O
non-chelating	JJ	O
non-surfactants	NNS	O
.	.	O
Penetration	NN	O
enhancers	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
a	DT	O
composition	NN	O
's	POS	O
bioavailability	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
“	RB	O
enhanced	VBN	O
”	NN	O
when	WRB	O
its	PRP$	O
relative	JJ	O
bioavailability	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
a	DT	O
composition	NN	O
substantially	RB	O
consisting	VBG	O
of	IN	O
pure	NN	O
oligomeric	JJ	O
compound	NN	O
,	,	O
i.e	NN	O
.	.	O
oligomeric	JJ	O
compound	NN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
penetration	NN	O
enhancer	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
refers	NNS	O
to	TO	O
the	DT	O
concentration	NN	O
of	IN	O
compound	NN	O
in	IN	O
an	DT	O
organ	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
may	MD	O
be	VB	O
measured	VBN	O
in	IN	O
test	NN	O
subjects	NNS	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
means	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
whole-body	NN	O
radiography	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
may	MD	O
be	VB	O
modified	VBN	O
,	,	O
e.g	NN	O
.	.	O
enhanced	VBN	O
,	,	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
to	TO	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
,	,	O
by	IN	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
carrier	NN	O
compounds	NNS	O
or	CC	O
excipients	NNS	O
,	,	O
etc	FW	O
.	.	O
as	IN	O
discussed	VBN	O
in	IN	O
more	JJR	O
detail	NN	O
herein	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
an	DT	O
increase	NN	O
in	IN	O
bioavailability	NN	O
will	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
organ	JJ	O
bioavailability	NN	O
.	.	O
Suitable	JJ	O
embodiments	NNS	O
provided	VBN	O
herein	NNS	O
are	VBP	O
compositions	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
pharmaceutically	RB	O
acceptable	JJ	O
penetration	NN	O
enhancers	NNS	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
such	JJ	O
compositions	NNS	O
,	,	O
which	WDT	O
result	VBP	O
in	IN	O
the	DT	O
improved	JJ	O
bioavailability	NN	O
of	IN	O
oligonucleotides	NNS	O
administered	VBN	O
via	IN	O
non-parenteral	JJ	O
modes	NNS	O
of	IN	O
administration	NN	O
.	.	O
Heretofore	NNP	O
,	,	O
certain	JJ	O
penetration	NN	O
enhancers	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
improve	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
certain	JJ	O
drugs	NNS	O
.	.	O
See	NNP	O
Muranishi	NNP	B
,	,	I
Crit	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Ther	DT	I
.	.	I
Drug	NN	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
and	CC	O
Lee	NNP	B
et	NNP	I
al.	NN	I
,	,	I
Crit	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Ther	DT	I
.	.	I
Drug	NN	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
8	CD	I
,	,	I
91	CD	I
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
found	VBN	O
that	IN	O
the	DT	O
uptake	NN	O
and	CC	O
delivery	NN	O
of	IN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
greatly	RB	O
improved	VBN	O
even	RB	O
when	WRB	O
administered	VBN	O
by	IN	O
non-parenteral	JJ	O
means	NNS	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
classes	NNS	O
of	IN	O
penetration	NN	O
enhancers	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
compositions	NNS	O
for	IN	O
non-parenteral	JJ	O
administration	NN	O
include	VBP	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
from	IN	O
naturally-occurring	JJ	O
oligonucleotides	NNS	O
(	(	O
i.e	NN	O
.	.	O
full-phosphodiester	JJ	O
deoxyribosyl	NN	O
or	CC	O
full-phosphodiester	JJ	O
ribosyl	NN	O
oligonucleotides	NNS	O
)	)	O
.	.	O
Such	JJ	O
modifications	NNS	O
may	MD	O
increase	VB	O
binding	VBG	O
affinity	NN	O
,	,	O
nuclease	JJ	O
stability	NN	O
,	,	O
cell	NN	O
or	CC	O
tissue	NN	O
permeability	NN	O
,	,	O
tissue	NN	O
distribution	NN	O
,	,	O
or	CC	O
other	JJ	O
biological	JJ	O
or	CC	O
pharmacokinetic	JJ	O
property	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
compositions	NNS	O
for	IN	O
administration	NN	O
to	TO	O
a	DT	O
subject	NN	O
,	,	O
and	CC	O
in	IN	O
particular	JJ	O
oral	JJ	O
compositions	NNS	O
for	IN	O
administration	NN	O
to	TO	O
an	DT	O
animal	NN	O
or	CC	O
human	JJ	O
subject	NN	O
,	,	O
will	MD	O
comprise	VB	O
modified	VBN	O
oligomeric	JJ	O
compounds	NNS	O
having	VBG	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
for	IN	O
enhancing	VBG	O
affinity	NN	O
,	,	O
stability	NN	O
,	,	O
tissue	NN	O
distribution	NN	O
,	,	O
or	CC	O
other	JJ	O
biological	JJ	O
property	NN	O
.	.	O
Oral	JJ	O
compositions	NNS	O
for	IN	O
administration	NN	O
of	IN	O
non-parenteral	JJ	O
oligomeric	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
various	JJ	O
dosage	NN	O
forms	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
tablets	NNS	O
,	,	O
capsules	NNS	O
,	,	O
liquid	NN	O
syrups	NNS	O
,	,	O
soft	JJ	O
gels	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
and	CC	O
enemas	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
alimentary	JJ	O
delivery	NN	O
”	NN	O
encompasses	VBZ	O
e.g	NN	O
.	.	O
oral	JJ	O
,	,	O
rectal	JJ	O
,	,	O
endoscopic	NN	O
and	CC	O
sublingual/buccal	JJ	O
administration	NN	O
.	.	O
A	DT	O
common	JJ	O
requirement	NN	O
for	IN	O
these	DT	O
modes	NNS	O
of	IN	O
administration	NN	O
is	VBZ	O
absorption	NN	O
over	IN	O
some	DT	O
portion	NN	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
alimentary	JJ	O
tract	NN	O
and	CC	O
a	DT	O
need	NN	O
for	IN	O
efficient	JJ	O
mucosal	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
(	(	O
s	PRP	O
)	)	O
so	RB	O
administered	VBN	O
.	.	O
Consequently	RB	O
,	,	O
such	JJ	O
oral	JJ	O
oligomeric	JJ	O
compound	NN	O
compositions	NNS	O
can	MD	O
be	VB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
mucosal	NN	O
penetration	NN	O
enhancers.	FW	O
”	JJ	O
Delivery	NNP	O
of	IN	O
a	DT	O
drug	NN	O
via	IN	O
the	DT	O
oral	JJ	O
mucosa	NN	O
,	,	O
as	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
buccal	JJ	O
and	CC	O
sublingual	JJ	O
administration	NN	O
,	,	O
has	VBZ	O
several	JJ	O
desirable	JJ	O
features	NNS	O
,	,	O
including	VBG	O
,	,	O
in	IN	O
many	JJ	O
instances	NNS	O
,	,	O
a	DT	O
more	RBR	O
rapid	JJ	O
rise	NN	O
in	IN	O
plasma	JJ	O
concentration	NN	O
of	IN	O
the	DT	O
drug	NN	O
than	IN	O
via	IN	O
oral	JJ	O
delivery	NN	O
(	(	O
Harvey	NNP	B
,	,	I
Chapter	NNP	I
35	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
page	VB	I
711	CD	I
)	)	O
.	.	O
Oligomeric	NNP	O
compounds	NNS	O
,	,	O
such	JJ	O
as	IN	O
oligonucleotides	NNS	O
,	,	O
may	MD	O
be	VB	O
delivered	VBN	O
orally	RB	O
,	,	O
in	IN	O
granular	JJ	O
form	NN	O
including	VBG	O
sprayed	VBN	O
dried	JJ	O
particles	NNS	O
,	,	O
or	CC	O
complexed	VBN	O
to	TO	O
form	VB	O
micro	NN	O
or	CC	O
nanoparticles	NNS	O
.	.	O
Oligonucleotide	IN	O
complexing	VBG	O
agents	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
Oral	JJ	O
formulations	NNS	O
for	IN	O
oligonucleotides	NNS	O
and	CC	O
their	PRP$	O
preparation	NN	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/108,673	CD	O
(	(	O
filed	VBN	O
Jul	NNP	O
.	.	O
1	CD	O
,	,	O
1998	CD	O
)	)	O
,	,	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/315,298	CD	O
(	(	O
filed	VBN	O
May	NNP	O
20	CD	O
,	,	O
1999	CD	O
)	)	O
and	CC	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/071,822	CD	O
,	,	O
filed	VBD	O
Feb.	NNP	O
8	CD	O
,	,	O
2002	CD	O
.	.	O
Endoscopy	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
drug	NN	O
delivery	NN	O
directly	RB	O
to	TO	O
an	DT	O
interior	JJ	O
portion	NN	O
of	IN	O
the	DT	O
alimentary	JJ	O
tract	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
endoscopic	FW	O
retrograde	NN	O
cystopancreatography	NN	O
(	(	O
ERCP	NNP	O
)	)	O
takes	VBZ	O
advantage	NN	O
of	IN	O
extended	VBN	O
gastroscopy	NN	O
and	CC	O
permits	NNS	O
selective	JJ	O
access	NN	O
to	TO	O
the	DT	O
biliary	JJ	O
tract	NN	O
and	CC	O
the	DT	O
pancreatic	JJ	O
duct	NN	O
(	(	O
Hirahata	NNP	B
et	RB	I
al.	RB	I
,	,	I
Gan	NNP	I
To	TO	I
Kagaku	NNP	I
Ryoho	NNP	I
,	,	I
1992	CD	I
,	,	I
19	CD	I
(	(	I
10	CD	I
Suppl	NNP	I
.	.	I
)	)	I
,	,	I
1591	CD	I
)	)	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
including	VBG	O
liposomal	JJ	O
formulations	NNS	O
,	,	O
can	MD	O
be	VB	O
delivered	VBN	O
directly	RB	O
into	IN	O
portions	NNS	O
of	IN	O
the	DT	O
alimentary	JJ	O
canal	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
e.g.	UH	O
,	,	O
the	DT	O
duodenum	NN	O
(	(	O
Somogyi	NNP	B
et	RB	I
al.	RB	I
,	,	I
Pharm	NNP	I
.	.	I
Res.	NNP	I
,	,	I
1995	CD	I
,	,	I
12	CD	I
,	,	I
149	CD	I
)	)	O
or	CC	O
the	DT	O
gastric	JJ	O
submucosa	NN	O
(	(	O
Akamo	NNP	B
et	RB	I
al.	RB	I
,	,	I
Japanese	JJ	I
J	NNP	I
.	.	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1994	CD	I
,	,	I
85	CD	I
,	,	I
652	CD	I
)	)	O
via	IN	O
endoscopic	NN	O
means	NNS	O
.	.	O
Gastric	NNP	O
lavage	NN	O
devices	NNS	O
(	(	O
Inoue	NNP	B
et	RB	I
al.	RB	I
,	,	I
Artif	NNP	I
.	.	I
Organs	NNS	I
,	,	I
1997	CD	I
,	,	I
21	CD	I
,	,	I
28	CD	I
)	)	O
and	CC	O
percutaneous	JJ	O
endoscopic	NN	O
feeding	VBG	O
devices	NNS	O
(	(	O
Pennington	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Ailment	NNP	I
Pharmacol	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
1995	CD	I
,	,	I
9	CD	I
,	,	I
471	CD	I
)	)	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
direct	JJ	O
alimentary	JJ	O
delivery	NN	O
of	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
oligomeric	JJ	O
compound	NN	O
formulations	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
through	IN	O
the	DT	O
anus	NN	O
into	IN	O
the	DT	O
rectum	NN	O
or	CC	O
lower	JJR	O
intestine	NN	O
.	.	O
Rectal	JJ	O
suppositories	NNS	O
,	,	O
retention	NN	O
enemas	NN	O
or	CC	O
rectal	JJ	O
catheters	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
and	CC	O
may	MD	O
be	VB	O
preferred	VBN	O
when	WRB	O
patient	JJ	O
compliance	NN	O
might	MD	O
otherwise	RB	O
be	VB	O
difficult	JJ	O
to	TO	O
achieve	VB	O
(	(	O
e.g.	NN	O
,	,	O
in	IN	O
pediatric	JJ	O
and	CC	O
geriatric	JJ	O
applications	NNS	O
,	,	O
or	CC	O
when	WRB	O
the	DT	O
patient	NN	O
is	VBZ	O
vomiting	VBG	O
or	CC	O
unconscious	JJ	O
)	)	O
.	.	O
Rectal	JJ	O
administration	NN	O
can	MD	O
result	VB	O
in	IN	O
more	JJR	O
prompt	NN	O
and	CC	O
higher	JJR	O
blood	NN	O
levels	NNS	O
than	IN	O
the	DT	O
oral	JJ	O
route	NN	O
(	(	O
Harvey	NNP	B
,	,	I
Chapter	NNP	I
35	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
page	VB	I
711	CD	I
)	)	O
.	.	O
Because	IN	O
about	RB	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
drug	NN	O
that	WDT	O
is	VBZ	O
absorbed	VBN	O
from	IN	O
the	DT	O
rectum	NN	O
will	MD	O
bypass	VB	O
the	DT	O
liver	NN	O
,	,	O
administration	NN	O
by	IN	O
this	DT	O
route	NN	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
potential	JJ	O
for	IN	O
first-pass	JJ	O
metabolism	NN	O
(	(	O
Benet	NNP	B
et	RB	I
al.	RB	I
,	,	I
Chapter	NNP	I
1	CD	I
In	IN	I
:	:	I
Goodman	NNP	I
&	CC	I
Gilman	NNP	I
's	POS	I
The	DT	I
Pharmacological	JJ	I
Basis	NNP	I
of	IN	I
Therapeutics	NNP	I
,	,	I
9th	CD	I
Ed.	NNP	I
,	,	I
Hardman	NNP	I
et	VBZ	I
al.	NN	I
,	,	I
eds.	NN	I
,	,	I
McGraw-Hill	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1996	CD	I
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
oral	JJ	O
oligomeric	JJ	O
compound	NN	O
compositions	NNS	O
comprise	VBP	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
of	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
surfactants	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
bile	NN	O
salts	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
,	,	O
and	CC	O
non-chelating	JJ	O
surfactants	NNS	O
.	.	O
Further	JJ	O
embodiments	NNS	O
comprise	VB	O
oral	JJ	O
oligomeric	JJ	O
compound	NN	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
fatty	JJ	O
acid	NN	O
,	,	O
e.g	NN	O
.	.	O
capric	NN	O
or	CC	O
lauric	JJ	O
acid	NN	O
,	,	O
or	CC	O
combinations	NNS	O
or	CC	O
salts	NNS	O
thereof	NNS	O
.	.	O
One	CD	O
combination	NN	O
is	VBZ	O
the	DT	O
sodium	NN	O
salt	NN	O
of	IN	O
lauric	JJ	O
acid	NN	O
,	,	O
capric	JJ	O
acid	NN	O
and	CC	O
UDCA	NNP	O
.	.	O
Other	JJ	O
embodiments	NNS	O
comprise	VBP	O
methods	NNS	O
of	IN	O
enhancing	VBG	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
co-administering	VBG	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
Other	JJ	O
excipients	NNS	O
that	WDT	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
oral	JJ	O
oligomeric	JJ	O
compound	NN	O
compositions	NNS	O
include	VBP	O
surfactants	NNS	O
(	(	O
or	CC	O
“	VB	O
surface-active	JJ	O
agents	NNS	O
”	MD	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
chemical	JJ	O
entities	NNS	O
which	WDT	O
,	,	O
when	WRB	O
dissolved	VBN	O
in	IN	O
an	DT	O
aqueous	JJ	O
solution	NN	O
,	,	O
reduce	VB	O
the	DT	O
surface	NN	O
tension	NN	O
of	IN	O
the	DT	O
solution	NN	O
or	CC	O
the	DT	O
interfacial	JJ	O
tension	NN	O
between	IN	O
the	DT	O
aqueous	JJ	O
solution	NN	O
and	CC	O
another	DT	O
liquid	NN	O
,	,	O
with	IN	O
the	DT	O
result	NN	O
that	IN	O
absorption	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
through	IN	O
the	DT	O
alimentary	JJ	O
mucosa	NN	O
and	CC	O
other	JJ	O
epithelial	JJ	O
membranes	NNS	O
is	VBZ	O
enhanced	VBN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
bile	VB	O
salts	NNS	O
and	CC	O
fatty	JJ	O
acids	NNS	O
,	,	O
surfactants	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
sodium	NN	O
lauryl	NN	O
sulfate	NN	O
,	,	O
polyoxyethylene-9-lauryl	JJ	O
ether	NN	O
and	CC	O
polyoxyethylene-20-cetyl	NN	O
ether	NN	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	VB	I
92	CD	I
)	)	O
;	:	O
and	CC	O
perfluorochemical	JJ	O
emulsions	NNS	O
,	,	O
such	JJ	O
as	IN	O
FC-43	NNP	O
(	(	O
Takahashi	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Phamacol.	NNP	I
,	,	I
1988	CD	I
,	,	I
40	CD	I
,	,	I
252	CD	I
)	)	O
.	.	O
Fatty	NNP	O
acids	NNS	O
and	CC	O
their	PRP$	O
derivatives	NNS	O
which	WDT	O
act	VBP	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
compositions	NNS	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
oleic	JJ	O
acid	NN	O
,	,	O
lauric	JJ	O
acid	NN	O
,	,	O
capric	JJ	O
acid	NN	O
(	(	O
n-decanoic	JJ	O
acid	NN	O
)	)	O
,	,	O
myristic	JJ	O
acid	NN	O
,	,	O
palmitic	JJ	O
acid	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
linoleic	JJ	O
acid	NN	O
,	,	O
linolenic	JJ	O
acid	NN	O
,	,	O
dicaprate	NN	O
,	,	O
tricaprate	NN	O
,	,	O
monoolein	NN	O
(	(	O
1-monooleoyl-rac-glycerol	JJ	O
)	)	O
,	,	O
dilaurin	UH	O
,	,	O
caprylic	JJ	O
acid	NN	O
,	,	O
arachidonic	JJ	O
acid	NN	O
,	,	O
glyceryl	JJ	O
1-monocaprate	JJ	O
,	,	O
1-dodecylazacycloheptan-2-one	JJ	O
,	,	O
acylcarnitines	NNS	O
,	,	O
acylcholines	NNS	O
and	CC	O
mono-	JJ	O
and	CC	O
di-glycerides	JJ	O
thereof	NN	O
and/or	NN	O
physiologically	RB	O
acceptable	JJ	O
salts	NNS	O
thereof	NN	O
(	(	O
i.e.	FW	O
,	,	O
oleate	NN	O
,	,	O
laurate	NN	O
,	,	O
caprate	NN	O
,	,	O
myristate	NN	O
,	,	O
palmitate	NN	O
,	,	O
stearate	NN	O
,	,	O
linoleate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
8:2	CD	I
,	,	I
91-192	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7:1	CD	I
,	,	I
1-33	JJ	I
;	:	O
El-Hariri	JJ	B
et	NN	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1992	CD	I
,	,	I
44	CD	I
,	,	I
651-654	JJ	I
)	)	O
.	.	O
Examples	NNS	O
of	IN	O
some	DT	O
fatty	JJ	O
acids	NNS	O
are	VBP	O
sodium	JJ	O
caprate	NN	O
(	(	O
C10	NNP	O
)	)	O
and	CC	O
sodium	JJ	O
laurate	NN	O
(	(	O
C12	NNP	O
)	)	O
,	,	O
used	VBN	O
singly	RB	O
or	CC	O
in	IN	O
combination	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.5	CD	O
to	TO	O
5	CD	O
%	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
oligomeric	JJ	O
compound	NN	O
compositions	NNS	O
for	IN	O
oral	JJ	O
delivery	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
two	CD	O
discrete	JJ	O
phases	NNS	O
,	,	O
which	WDT	O
phases	VBZ	O
may	MD	O
comprise	VB	O
particles	NNS	O
,	,	O
capsules	NNS	O
,	,	O
gel-capsules	NNS	O
,	,	O
microspheres	NNS	O
,	,	O
etc	FW	O
.	.	O
Each	DT	O
phase	NN	O
may	MD	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
penetration	NN	O
enhancers	NNS	O
,	,	O
surfactants	NNS	O
,	,	O
bioadhesives	NNS	O
,	,	O
effervescent	JJ	O
agents	NNS	O
,	,	O
or	CC	O
other	JJ	O
adjuvant	NN	O
,	,	O
excipient	NN	O
or	CC	O
diluent	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
one	CD	O
phase	NN	O
comprises	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
and	CC	O
substantially	RB	O
no	DT	O
oligomeric	JJ	O
compound	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
phase	NN	O
is	VBZ	O
compounded	VBN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
degradation	NN	O
retardant	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
coating	NN	O
or	CC	O
a	DT	O
matrix	NN	O
,	,	O
which	WDT	O
delays	VBZ	O
release	NN	O
of	IN	O
the	DT	O
contents	NNS	O
of	IN	O
that	DT	O
phase	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
and	CC	O
a	DT	O
release-retardant	JJ	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
,	,	O
an	DT	O
oral	JJ	O
oligomeric	JJ	O
compound	NN	O
comprises	VBZ	O
a	DT	O
first	JJ	O
phase	NN	O
comprising	VBG	O
particles	NNS	O
containing	VBG	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
a	DT	O
penetration	NN	O
enhancer	NN	O
,	,	O
and	CC	O
a	DT	O
second	JJ	O
phase	NN	O
comprising	VBG	O
particles	NNS	O
coated	VBN	O
with	IN	O
a	DT	O
release-retarding	JJ	O
agent	NN	O
and	CC	O
containing	VBG	O
penetration	NN	O
enhancer	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
bile	NN	O
salts	NNS	O
also	RB	O
function	VBP	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
to	TO	O
facilitate	VB	O
the	DT	O
uptake	NN	O
and	CC	O
bioavailability	NN	O
of	IN	O
drugs	NNS	O
.	.	O
The	DT	O
physiological	JJ	O
roles	NNS	O
of	IN	O
bile	NN	O
include	VBP	O
the	DT	O
facilitation	NN	O
of	IN	O
dispersion	NN	O
and	CC	O
absorption	NN	O
of	IN	O
lipids	NNS	O
and	CC	O
fat-soluble	JJ	O
vitamins	NNS	O
(	(	O
Brunton	NNP	B
,	,	I
Chapter	NNP	I
38	CD	I
In	IN	I
:	:	I
Goodman	NNP	I
&	CC	I
Gilman	NNP	I
's	POS	I
The	DT	I
Pharmacological	JJ	I
Basis	NNP	I
of	IN	I
Therapeutics	NNP	I
,	,	I
9th	CD	I
Ed.	NNP	I
,	,	I
Hardman	NNP	I
et	VBZ	I
al.	NN	I
,	,	I
eds.	NN	I
,	,	I
McGraw-Hill	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1996	CD	I
,	,	I
pages	VBZ	I
934-935	CD	I
)	)	O
.	.	O
Various	JJ	O
natural	JJ	O
bile	NN	O
salts	NNS	O
,	,	O
and	CC	O
their	PRP$	O
synthetic	JJ	O
derivatives	NNS	O
,	,	O
act	NN	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
bile	NN	O
salt	NN	O
”	NNP	O
includes	VBZ	O
any	DT	O
of	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
components	NNS	O
of	IN	O
bile	NN	O
as	RB	O
well	RB	O
as	IN	O
any	DT	O
of	IN	O
their	PRP$	O
synthetic	JJ	O
derivatives	NNS	O
.	.	O
Bile	NNP	O
salts	NNS	O
contemplated	VBD	O
herein	JJ	O
include	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
cholic	JJ	O
acid	NN	O
(	(	O
or	CC	O
its	PRP$	O
sodium	NN	O
salt	NN	O
,	,	O
sodium	NN	O
cholate	NN	O
,	,	O
or	CC	O
other	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
)	)	O
,	,	O
dehydrocholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
dehydrocholate	NN	O
)	)	O
,	,	O
deoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
deoxycholate	NN	O
)	)	O
,	,	O
glucholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glucholate	NN	O
)	)	O
,	,	O
glycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glycocholate	NN	O
)	)	O
,	,	O
glycodeoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glycodeoxycholate	NN	O
)	)	O
,	,	O
taurocholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
taurocholate	NN	O
)	)	O
,	,	O
taurodeoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
taurodeoxycholate	NN	O
)	)	O
,	,	O
chenodeoxycholic	JJ	O
acid	NN	O
(	(	O
CDCA	NNP	O
,	,	O
sodium	NN	O
chenodeoxycholate	NN	O
)	)	O
,	,	O
ursodeoxycholic	JJ	O
acid	NN	O
(	(	O
UDCA	NNP	O
)	)	O
,	,	O
sodium	JJ	O
tauro-24,25-dihydro-fusidate	NN	O
(	(	O
STDHF	NNP	O
)	)	O
,	,	O
sodium	JJ	O
glycodihydrofusidate	NN	O
and	CC	O
polyoxyethylene-9-lauryl	NN	O
ether	NN	O
(	(	O
POE	NNP	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	NN	I
92	CD	I
;	:	O
Swinyard	NNP	B
,	,	I
Chapter	NNP	I
39	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
pages	VBZ	I
782-783	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1-33	CD	I
;	:	O
Yamamoto	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
1992	CD	I
,	,	I
263	CD	I
,	,	I
25	CD	I
;	:	O
Yamashita	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1990	CD	I
,	,	I
79	CD	I
,	,	I
579-583	JJ	I
)	)	O
.	.	O
UDCA	NNP	O
and	CC	O
CDCA	NNP	O
have	VBP	O
been	VBN	O
used	VBN	O
effectively	RB	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
for	IN	O
oligonucleotides	NNS	O
,	,	O
and	CC	O
even	RB	O
more	RBR	O
effectively	RB	O
when	WRB	O
combined	VBN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
penetration	NN	O
enhancers	NNS	O
useful	JJ	O
in	IN	O
some	DT	O
embodiments	NNS	O
are	VBP	O
mixtures	NNS	O
of	IN	O
penetration	NN	O
enhancing	VBG	O
compounds	NNS	O
.	.	O
One	CD	O
such	JJ	O
penetration	NN	O
enhancer	NN	O
is	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
UDCA	NNP	O
(	(	O
and/or	JJ	O
CDCA	NNP	O
)	)	O
with	IN	O
capric	JJ	O
and/or	NN	O
lauric	JJ	O
acids	NNS	O
or	CC	O
salts	NNS	O
thereof	JJ	O
e.g	NN	O
.	.	O
sodium	NN	O
.	.	O
Such	JJ	O
mixtures	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
enhancing	VBG	O
the	DT	O
delivery	NN	O
of	IN	O
biologically	RB	O
active	JJ	O
substances	NNS	O
across	IN	O
mucosal	NN	O
membranes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
intestinal	JJ	O
mucosa	NN	O
.	.	O
Other	JJ	O
penetration	NN	O
enhancer	NN	O
mixtures	NNS	O
comprise	VBP	O
about	IN	O
5-95	CD	O
%	NN	O
of	IN	O
bile	JJ	O
acid	NN	O
or	CC	O
salt	NN	O
(	(	O
s	PRP	O
)	)	O
UDCA	NNP	O
and/or	VBZ	O
CDCA	NNP	O
with	IN	O
5-95	JJ	O
%	NN	O
capric	JJ	O
and/or	NN	O
lauric	JJ	O
acid	NN	O
.	.	O
Particular	JJ	O
penetration	NN	O
enhancers	NNS	O
are	VBP	O
mixtures	NNS	O
of	IN	O
the	DT	O
sodium	NN	O
salts	NNS	O
of	IN	O
UDCA	NNP	O
,	,	O
capric	JJ	O
acid	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
in	IN	O
a	DT	O
ratio	NN	O
of	IN	O
about	IN	O
1:2:2	CD	O
respectively	RB	O
.	.	O
Anther	DT	O
such	JJ	O
penetration	NN	O
enhancer	NN	O
is	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
capric	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
(	(	O
or	CC	O
salts	VB	O
thereof	NN	O
)	)	O
in	IN	O
a	DT	O
0.01:1	CD	O
to	TO	O
1:0.01	CD	O
ratio	NN	O
(	(	O
mole	JJ	O
basis	NN	O
)	)	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
capric	JJ	O
acid	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
are	VBP	O
present	JJ	O
in	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
e.g	NN	O
.	.	O
about	RB	O
0.1:1	CD	O
to	TO	O
about	IN	O
1:0.1	CD	O
,	,	O
in	IN	O
particular	JJ	O
about	IN	O
0.5:1	CD	O
to	TO	O
about	IN	O
1:0.5	CD	O
.	.	O
Other	JJ	O
excipients	NNS	O
include	VBP	O
chelating	VBG	O
agents	NNS	O
,	,	O
i.e	NN	O
.	.	O
compounds	NNS	O
that	WDT	O
remove	VBP	O
metallic	JJ	O
ions	NNS	O
from	IN	O
solution	NN	O
by	IN	O
forming	VBG	O
complexes	NNS	O
therewith	NN	O
,	,	O
with	IN	O
the	DT	O
result	NN	O
that	IN	O
absorption	NN	O
of	IN	O
oligomeric	JJ	O
compound	NN	O
through	IN	O
the	DT	O
alimentary	JJ	O
and	CC	O
other	JJ	O
mucosa	NN	O
is	VBZ	O
enhanced	VBN	O
.	.	O
With	IN	O
regards	NNS	O
to	TO	O
their	PRP$	O
use	NN	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
chelating	VBG	O
agents	NNS	O
have	VBP	O
the	DT	O
added	JJ	O
advantage	NN	O
of	IN	O
also	RB	O
serving	VBG	O
as	IN	O
DNase	NNP	O
inhibitors	NNS	O
,	,	O
as	IN	O
most	JJS	O
characterized	JJ	O
DNA	NN	O
nucleases	NNS	O
require	VBP	O
a	DT	O
divalent	NN	O
metal	NN	O
ion	NN	O
for	IN	O
catalysis	NN	O
and	CC	O
are	VBP	O
thus	RB	O
inhibited	VBN	O
by	IN	O
chelating	VBG	O
agents	NNS	O
(	(	O
Jarrett	NNP	B
,	,	I
J	NNP	I
.	.	I
Chromatogr.	NNP	I
,	,	I
1993	CD	I
,	,	I
618	CD	I
,	,	I
315	CD	I
)	)	O
.	.	O
Chelating	VBG	O
agents	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
disodium	NN	O
ethylenediaminetetraacetate	NN	O
(	(	O
EDTA	NNP	O
)	)	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
salicylates	NNS	O
(	(	O
e.g.	NN	O
,	,	O
sodium	NN	O
salicylate	NN	O
,	,	O
5-methoxysalicylate	JJ	O
and	CC	O
homovanilate	NN	O
)	)	O
,	,	O
N-acyl	JJ	O
derivatives	NNS	O
of	IN	O
collagen	NN	O
,	,	O
laureth-9	JJ	O
and	CC	O
N-amino	JJ	O
acyl	NN	O
derivatives	NNS	O
of	IN	O
beta-diketones	NNS	O
(	(	O
enamines	NNS	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	NN	I
92	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
;	:	O
Buur	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Control	NNP	I
Rel.	NNP	I
,	,	I
1990	CD	I
,	,	I
14	CD	I
,	,	I
43	CD	I
)	)	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
non-chelating	JJ	O
non-surfactant	JJ	O
penetration	NN	O
enhancers	NNS	O
may	MD	O
be	VB	O
defined	VBN	O
as	IN	O
compounds	NNS	O
that	WDT	O
demonstrate	VBP	O
insignificant	JJ	O
activity	NN	O
as	IN	O
chelating	VBG	O
agents	NNS	O
or	CC	O
as	IN	O
surfactants	NNS	O
but	CC	O
that	DT	O
nonetheless	RB	O
enhance	JJ	O
absorption	NN	O
of	IN	O
oligonucelotides	NNS	O
through	IN	O
the	DT	O
alimentary	JJ	O
and	CC	O
other	JJ	O
mucosal	NN	O
membranes	NNS	O
(	(	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
)	)	O
.	.	O
This	DT	O
class	NN	O
of	IN	O
penetration	NN	O
enhancers	NNS	O
includes	VBZ	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
unsaturated	JJ	O
cyclic	JJ	O
ureas	NNS	O
,	,	O
1-alkyl-	JJ	O
and	CC	O
1-alkenylazacyclo-alkanone	JJ	O
derivatives	NNS	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	VB	I
92	CD	I
)	)	O
;	:	O
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
diclofenac	JJ	O
sodium	NN	O
,	,	O
indomethacin	NN	O
and	CC	O
phenylbutazone	NN	O
(	(	O
Yamashita	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1987	CD	I
,	,	I
39	CD	I
,	,	I
621	CD	I
)	)	O
.	.	O
Some	DT	O
oral	JJ	O
oligonucleotide	JJ	O
compositions	NNS	O
also	RB	O
incorporate	VBP	O
carrier	NN	O
compounds	NNS	O
in	IN	O
the	DT	O
formulation	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	NNP	O
carrier	NN	O
compound	NN	O
”	NN	O
or	CC	O
“	NN	O
carrier	NN	O
”	NNS	O
can	MD	O
refer	VB	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
or	CC	O
analog	NN	O
thereof	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
inert	JJ	O
(	(	O
i.e.	FW	O
,	,	O
does	VBZ	O
not	RB	O
possess	VB	O
biological	JJ	O
activity	NN	O
per	IN	O
se	NN	O
)	)	O
or	CC	O
may	MD	O
be	VB	O
necessary	JJ	O
for	IN	O
transport	NN	O
,	,	O
recognition	NN	O
or	CC	O
pathway	JJ	O
activation	NN	O
or	CC	O
mediation	NN	O
,	,	O
or	CC	O
is	VBZ	O
recognized	VBN	O
as	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
by	IN	O
in	IN	O
vivo	NN	O
processes	NNS	O
that	WDT	O
reduce	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
biological	JJ	O
activity	NN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
degrading	VBG	O
the	DT	O
biologically	RB	O
active	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
promoting	VBG	O
its	PRP$	O
removal	NN	O
from	IN	O
circulation	NN	O
.	.	O
The	DT	O
coadministration	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
and	CC	O
a	DT	O
carrier	NN	O
compound	NN	O
,	,	O
typically	RB	O
with	IN	O
an	DT	O
excess	NN	O
of	IN	O
the	DT	O
latter	JJ	O
substance	NN	O
,	,	O
can	MD	O
result	VB	O
in	IN	O
a	DT	O
substantial	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
amount	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
recovered	VBN	O
in	IN	O
the	DT	O
liver	NN	O
,	,	O
kidney	NN	O
or	CC	O
other	JJ	O
extracirculatory	JJ	O
reservoirs	NNS	O
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
competition	NN	O
between	IN	O
the	DT	O
carrier	NN	O
compound	NN	O
and	CC	O
the	DT	O
nucleic	JJ	O
acid	NN	O
for	IN	O
a	DT	O
common	JJ	O
receptor	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
recovery	NN	O
of	IN	O
a	DT	O
partially	RB	O
phosphorothioate	JJ	O
oligonucleotide	NN	O
in	IN	O
hepatic	JJ	O
tissue	NN	O
can	MD	O
be	VB	O
reduced	VBN	O
when	WRB	O
it	PRP	O
is	VBZ	O
coadministered	VBN	O
with	IN	O
polyinosinic	JJ	O
acid	NN	O
,	,	O
dextran	NN	O
sulfate	NN	O
,	,	O
polycytidic	JJ	O
acid	NN	O
or	CC	O
4-acetamido-4′isothiocyano-stilbene-2,2′-disulfonic	JJ	O
acid	NN	O
(	(	O
Miyao	NNP	B
et	RB	I
al.	RB	I
,	,	I
Antisense	NNP	I
Res	NNP	I
.	.	I
Dev.	NNP	I
,	,	I
1995	CD	I
,	,	I
5	CD	I
,	,	I
115	CD	I
;	:	O
Takakura	NNP	B
et	FW	I
al.	NN	I
,	,	I
Antisense	NNP	I
&	CC	I
Nucl	NNP	I
.	.	I
Acid	NNP	I
Drug	NNP	I
Dev.	NNP	I
,	,	I
1996	CD	I
,	,	I
6	CD	I
,	,	I
177	CD	I
)	)	O
.	.	O
A	DT	O
“	JJ	O
pharmaceutical	JJ	O
carrier	NN	O
”	NN	O
or	CC	O
“	JJ	O
excipient	JJ	O
”	NN	O
may	MD	O
be	VB	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
solvent	NN	O
,	,	O
suspending	VBG	O
agent	NN	O
or	CC	O
any	DT	O
other	JJ	O
pharmacologically	RB	O
inert	JJ	O
vehicle	NN	O
for	IN	O
delivering	VBG	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
to	TO	O
an	DT	O
animal	NN	O
.	.	O
The	DT	O
excipient	NN	O
may	MD	O
be	VB	O
liquid	JJ	O
or	CC	O
solid	JJ	O
and	CC	O
is	VBZ	O
selected	VBN	O
,	,	O
with	IN	O
the	DT	O
planned	JJ	O
manner	NN	O
of	IN	O
administration	NN	O
in	IN	O
mind	NN	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
provide	VB	O
for	IN	O
the	DT	O
desired	JJ	O
bulk	NN	O
,	,	O
consistency	NN	O
,	,	O
etc.	FW	O
,	,	O
when	WRB	O
combined	VBN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
and	CC	O
the	DT	O
other	JJ	O
components	NNS	O
of	IN	O
a	DT	O
given	VBN	O
pharmaceutical	JJ	O
composition	NN	O
.	.	O
Typical	JJ	O
pharmaceutical	JJ	O
carriers	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
binding	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
pregelatinised	VBD	O
maize	NN	O
starch	NN	O
,	,	O
polyvinylpyrrolidone	NN	O
or	CC	O
hydroxypropyl	NN	O
methylcellulose	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
fillers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
lactose	JJ	O
and	CC	O
other	JJ	O
sugars	NNS	O
,	,	O
microcrystalline	NN	O
cellulose	NN	O
,	,	O
pectin	NN	O
,	,	O
gelatin	NN	O
,	,	O
calcium	NN	O
sulfate	NN	O
,	,	O
ethyl	FW	O
cellulose	NN	O
,	,	O
polyacrylates	VBZ	O
or	CC	O
calcium	NN	O
hydrogen	NN	O
phosphate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
lubricants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
magnesium	NN	O
stearate	NN	O
,	,	O
talc	NN	O
,	,	O
silica	NN	O
,	,	O
colloidal	JJ	O
silicon	NN	O
dioxide	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
metallic	JJ	O
stearates	NNS	O
,	,	O
hydrogenated	VBD	O
vegetable	JJ	O
oils	NNS	O
,	,	O
corn	NN	O
starch	NN	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
,	,	O
sodium	NN	O
benzoate	NN	O
,	,	O
sodium	NN	O
acetate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
disintegrants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
starch	NN	O
,	,	O
sodium	NN	O
starch	NN	O
glycolate	NN	O
,	,	O
EXPLOTAB	NNP	O
)	)	O
;	:	O
and	CC	O
wetting	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
sodium	NN	O
lauryl	NN	O
sulphate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Oral	NNP	O
oligomeric	JJ	O
compositions	NNS	O
may	MD	O
additionally	RB	O
contain	VB	O
other	JJ	O
adjunct	JJ	O
components	NNS	O
conventionally	RB	O
found	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
at	IN	O
their	PRP$	O
art-established	JJ	O
usage	NN	O
levels	NNS	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
compositions	NNS	O
may	MD	O
contain	VB	O
additional	JJ	O
,	,	O
compatible	JJ	O
,	,	O
pharmaceutically-active	JJ	O
materials	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
antipruritics	NNS	O
,	,	O
astringents	NNS	O
,	,	O
local	JJ	O
anesthetics	NNS	O
or	CC	O
anti-inflammatory	JJ	O
agents	NNS	O
,	,	O
or	CC	O
may	MD	O
contain	VB	O
additional	JJ	O
materials	NNS	O
useful	JJ	O
in	IN	O
physically	RB	O
formulating	VBG	O
various	JJ	O
dosage	NN	O
forms	NNS	O
of	IN	O
the	DT	O
composition	NN	O
of	IN	O
present	JJ	O
invention	NN	O
,	,	O
such	JJ	O
as	IN	O
dyes	NNS	O
,	,	O
flavoring	VBG	O
agents	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
antioxidants	NNS	O
,	,	O
opacifiers	NNS	O
,	,	O
thickening	VBG	O
agents	NNS	O
and	CC	O
stabilizers	NNS	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
that	IN	O
formulations	NNS	O
are	VBP	O
routinely	RB	O
designed	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
intended	VBN	O
use	NN	O
,	,	O
i.e	NN	O
.	.	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O
Formulations	NNS	O
for	IN	O
topical	JJ	O
administration	NN	O
include	VBP	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
in	IN	O
admixture	NN	O
with	IN	O
a	DT	O
topical	JJ	O
delivery	NN	O
agent	NN	O
such	JJ	O
as	IN	O
lipids	NNS	O
,	,	O
liposomes	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
steroids	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
and	CC	O
surfactants	NNS	O
.	.	O
Lipids	NNS	O
and	CC	O
liposomes	NNS	O
include	VBP	O
neutral	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoylphosphatidyl	NNS	O
DOPE	NNP	O
ethanolamine	NN	O
,	,	O
dimyristoylphosphatidyl	JJ	O
choline	NN	O
DMPC	NNP	O
,	,	O
distearolyphosphatidyl	JJ	O
choline	NN	O
)	)	O
negative	NN	O
(	(	O
e.g	NN	O
.	.	O
dimyristoylphosphatidyl	NN	O
glycerol	NN	O
DMPG	NNP	O
)	)	O
and	CC	O
cationic	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoyltetramethylaminopropyl	NN	O
DOTAP	NNP	O
and	CC	O
dioleoylphosphatidyl	JJ	O
ethanolamine	NN	O
DOTMA	NNP	O
)	)	O
.	.	O
For	IN	O
topical	JJ	O
or	CC	O
other	JJ	O
administration	NN	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
encapsulated	VBN	O
within	IN	O
liposomes	NNS	O
or	CC	O
may	MD	O
form	VB	O
complexes	NNS	O
thereto	NN	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
liposomes	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
complexed	VBN	O
to	TO	O
lipids	NNS	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
lipids	NNS	O
.	.	O
Fatty	NNP	O
acids	NNS	O
and	CC	O
esters	NNS	O
,	,	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
thereof	NN	O
,	,	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
.	.	O
Topical	JJ	O
formulations	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/315,298	CD	O
filed	VBN	O
on	IN	O
May	NNP	O
20	CD	O
,	,	O
1999	CD	O
.	.	O
Combinations	NNS	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
certain	JJ	O
pharmaceutical	JJ	O
compositions	NNS	O
contain	VBP	O
one	CD	O
or	CC	O
more	JJR	O
antisense	JJ	O
compounds	NNS	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
agents	NNS	O
which	WDT	O
function	NN	O
by	IN	O
a	DT	O
non-antisense	JJ	O
mechanism	NN	O
.	.	O
Selection	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
agents	NNS	O
for	IN	O
use	NN	O
in	IN	O
combination	NN	O
therapy	NN	O
may	MD	O
be	VB	O
made	VBN	O
by	IN	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
according	VBG	O
to	TO	O
conventional	JJ	O
pharmaceutical	JJ	O
principles	NNS	O
.	.	O
The	DT	O
combination	NN	O
of	IN	O
therapeutic	JJ	O
agents	NNS	O
may	MD	O
act	VB	O
synergistically	RB	O
to	TO	O
effect	NN	O
the	DT	O
treatment	NN	O
or	CC	O
prevention	NN	O
of	IN	O
the	DT	O
various	JJ	O
disorders	NNS	O
described	VBN	O
above	IN	O
.	.	O
Using	VBG	O
this	DT	O
approach	NN	O
,	,	O
one	CD	O
can	MD	O
achieve	VB	O
therapeutic	JJ	O
efficacy	NN	O
with	IN	O
lower	JJR	O
dosages	NNS	O
of	IN	O
each	DT	O
agent	NN	O
,	,	O
thus	RB	O
reducing	VBG	O
the	DT	O
potential	NN	O
for	IN	O
adverse	JJ	O
side	NN	O
effects	NNS	O
.	.	O
Chemotherapeutic	JJ	O
Agents	NNS	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cancer	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
agents	NNS	O
can	MD	O
be	VB	O
chemotherapeutic	JJ	O
agents	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
cancer	NN	O
chemotherapeutic	JJ	O
drugs	NNS	O
such	JJ	O
as	IN	O
daunorubicin	NN	O
,	,	O
daunomycin	NN	O
,	,	O
dactinomycin	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
epirubicin	NN	O
,	,	O
idarubicin	NN	O
,	,	O
esorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
mafosfamide	NN	O
,	,	O
ifosfamide	NN	O
,	,	O
cytosine	NN	O
arabinoside	NN	O
,	,	O
bis-chloroethylnitrosurea	JJ	O
,	,	O
busulfan	NN	O
,	,	O
mitomycin	FW	O
C	NNP	O
,	,	O
actinomycin	JJ	O
D	NNP	O
,	,	O
mithramycin	NN	O
,	,	O
prednisone	NN	O
,	,	O
hydroxyprogesterone	NN	O
,	,	O
testosterone	NN	O
,	,	O
tamoxifen	NN	O
,	,	O
dacarbazine	NN	O
,	,	O
procarbazine	NN	O
,	,	O
hexamethylmelamine	NN	O
,	,	O
pentamethylmelamine	NN	O
,	,	O
mitoxantrone	NN	O
,	,	O
amsacrine	NN	O
,	,	O
chlorambucil	NN	O
,	,	O
methylcyclohexylnitrosurea	NN	O
,	,	O
nitrogen	NN	O
mustards	NNS	O
,	,	O
melphalan	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
6-mercaptopurine	JJ	O
,	,	O
6-thioguanine	JJ	O
,	,	O
cytarabine	JJ	O
,	,	O
5-azacytidine	JJ	O
,	,	O
hydroxyurea	JJ	O
,	,	O
deoxycoformycin	JJ	O
,	,	O
4-hydroxyperoxycyclophosphoramide	JJ	O
,	,	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
,	,	O
5-fluorodeoxyuridine	JJ	O
(	(	O
5-FUdR	JJ	O
)	)	O
,	,	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
,	,	O
colchicine	NN	O
,	,	O
taxol	NN	O
,	,	O
vincristine	NN	O
,	,	O
vinblastine	NN	O
,	,	O
etoposide	RB	O
(	(	O
VP-16	NNP	O
)	)	O
,	,	O
trimetrexate	NN	O
,	,	O
irinotecan	JJ	O
,	,	O
topotecan	JJ	O
,	,	O
gemcitabine	NN	O
,	,	O
teniposide	NN	O
,	,	O
cisplatin	NN	O
,	,	O
pemetrexed	NN	O
and	CC	O
diethylstilbestrol	NN	O
(	(	O
DES	NNP	O
)	)	O
.	.	O
When	WRB	O
used	VBN	O
with	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
used	VBN	O
individually	RB	O
(	(	O
e.g.	UH	O
,	,	O
5-FU	JJ	O
and	CC	O
oligonucleotide	NN	O
)	)	O
,	,	O
sequentially	RB	O
(	(	O
e.g.	UH	O
,	,	O
5-FU	JJ	O
and	CC	O
oligonucleotide	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
followed	VBN	O
by	IN	O
MTX	NNP	O
and	CC	O
oligonucleotide	RB	O
)	)	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
5-FU	JJ	O
,	,	O
MTX	NNP	O
and	CC	O
oligonucleotide	RB	O
,	,	O
or	CC	O
5-FU	JJ	O
,	,	O
radiotherapy	NN	O
and	CC	O
oligonucleotide	NN	O
)	)	O
.	.	O
Anti-inflammatory	JJ	O
drugs	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
nonsteroidal	VB	O
anti-inflammatory	JJ	O
drugs	NNS	O
and	CC	O
corticosteroids	NNS	O
,	,	O
and	CC	O
antiviral	JJ	O
drugs	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
ribivirin	VB	O
,	,	O
vidarabine	NN	O
,	,	O
acyclovir	NN	O
and	CC	O
ganciclovir	NN	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
combined	VBN	O
in	IN	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
NONLIMITING	NN	O
DISCLOSURE	NNP	O
AND	CC	O
INCORPORATION	NNP	O
BY	NNP	O
REFERENCE	NNP	O
While	IN	O
certain	JJ	O
compounds	NNS	O
,	,	O
compositions	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
have	VBP	O
been	VBN	O
described	VBN	O
with	IN	O
specificity	NN	O
in	IN	O
accordance	NN	O
with	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
following	JJ	O
examples	NNS	O
serve	VBP	O
only	RB	O
to	TO	O
illustrate	VB	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
are	VBP	O
not	RB	O
intended	VBN	O
to	TO	O
limit	VB	O
the	DT	O
same	JJ	O
.	.	O
Each	DT	O
of	IN	O
the	DT	O
references	NNS	O
,	,	O
GenBank	NNP	O
accession	NN	O
numbers	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
recited	VBN	O
in	IN	O
the	DT	O
present	JJ	O
application	NN	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Example	RB	O
1	CD	O
The	DT	O
effect	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
on	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
was	VBD	O
tested	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	VBG	O
cell	NN	O
types	NNS	O
.	.	O
3T3-L1	JJ	O
cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
embryonic	JJ	O
adipocyte-like	JJ	O
cell	NN	O
line	NN	O
3T3-L1	CD	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
3T3-L1	JJ	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
80	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
4000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
A10	NNP	O
cells	NNS	O
:	:	O
The	DT	O
rat	NN	O
aortic	JJ	O
smooth	JJ	O
muscle	NN	O
cell	NN	O
line	NN	O
A10	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
A10	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
80	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
2500	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
A549	NNP	O
cells	NNS	O
:	:	O
The	DT	O
human	JJ	O
lung	NN	O
carcinoma	NN	O
cell	NN	O
line	NN	O
A549	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
A549	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
100	CD	O
units	NNS	O
per	IN	O
ml	NN	O
penicillin	NN	O
,	,	O
and	CC	O
100	CD	O
micrograms	NNS	O
per	IN	O
ml	NN	O
streptomycin	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
5000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
AML-12	JJ	O
cells	NNS	O
:	:	O
AML12	NNP	O
(	(	O
alpha	JJ	O
mouse	NN	O
liver	RB	O
12	CD	O
)	)	O
cell	NN	O
line	NN	O
was	VBD	O
established	VBN	O
from	IN	O
hepatocytes	NNS	O
from	IN	O
a	DT	O
mouse	NN	O
(	(	O
CD	NN	O
1	CD	O
strain	NN	O
,	,	O
line	NN	O
MT42	NNP	O
)	)	O
transgenic	NN	O
for	IN	O
human	JJ	O
TGF	NNP	O
alpha	NN	O
.	.	O
Cells	NNS	O
are	VBP	O
cultured	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
mixture	NN	O
of	IN	O
DMEM	NNP	O
and	CC	O
Ham	NNP	O
's	POS	O
F12	NNP	O
medium	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
0.005	CD	O
mg/ml	NN	O
insulin	NN	O
,	,	O
0.005	CD	O
mg/ml	NN	O
transferrin	NN	O
,	,	O
5	CD	O
ng/ml	JJ	O
selenium	NN	O
,	,	O
and	CC	O
40	CD	O
ng/ml	NN	O
dexamethasone	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
5000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
b.END	NN	O
cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
brain	NN	O
endothelial	JJ	O
cell	NN	O
line	NN	O
b.END	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
Dr.	NNP	O
Werner	NNP	O
Risau	NNP	O
at	IN	O
the	DT	O
Max	NNP	O
Plank	NNP	O
Institute	NNP	O
(	(	O
Bad	NNP	O
Nauheim	NNP	O
,	,	O
Germany	NNP	O
)	)	O
.	.	O
b.END	NN	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
3000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
B16-F10	JJ	O
cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
melanoma	NN	O
cell	NN	O
line	NN	O
B16-F10	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
B16-F10	JJ	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
Cells	NNP	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
7000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
CHO	NNP	O
cells	NNS	O
:	:	O
The	DT	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
cell	NN	O
line	NN	O
CHO	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
CHO	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
Ham	NNP	O
's	POS	O
F12K	NNP	O
media	NNS	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
and	CC	O
2	CD	O
mM	NN	O
L-glutamine	NNP	O
,	,	O
which	WDT	O
was	VBD	O
adjusted	VBN	O
to	TO	O
contain	VB	O
1.5	CD	O
g/L	JJ	O
sodium	NN	O
bicarbonate	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
6000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
HEPA	NNP	O
1-6	JJ	O
cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
hepatoma	NN	O
cell	NN	O
line	NN	O
HEPA	NNP	O
1-6	CD	O
is	VBZ	O
a	DT	O
derivative	JJ	O
of	IN	O
the	DT	O
BW7756	NNP	O
mouse	NN	O
hepatoma	NN	O
that	WDT	O
arose	VBD	O
in	IN	O
a	DT	O
C57/L	NNP	O
mouse	NN	O
and	CC	O
is	VBZ	O
supplied	VBN	O
by	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
propagated	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
,	,	O
supplemented	VBN	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
and	CC	O
1	CD	O
%	NN	O
penicillin/streptomycin	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
80	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
4000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
:	:	O
Primary	NNP	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
prepared	VBN	O
from	IN	O
CD-1	NNP	O
mice	NNS	O
purchased	VBD	O
from	IN	O
Charles	NNP	O
River	NNP	O
Labs	NNP	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
Hepatocyte	NNP	O
Attachment	NNP	O
Media	NNP	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
1	CD	O
%	NN	O
penicillin/streptomycin	NN	O
,	,	O
1	CD	O
%	NN	O
antibiotic-antimitotic	JJ	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
10	CD	O
nM	JJ	O
bovine	NN	O
insulin	NN	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
coated	VBN	O
with	IN	O
0.1	CD	O
mg/ml	NNS	O
collagen	NN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
10,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
HepG2	NNP	O
cells	NNS	O
:	:	O
The	DT	O
human	JJ	O
hepatoblastoma	NN	O
cell	NN	O
line	NN	O
HepG2	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
HepG2	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
Eagle	NNP	O
's	POS	O
MEM	NNP	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
1	CD	O
mM	JJ	O
non-essential	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
and	CC	O
1	CD	O
mM	NN	O
sodium	NN	O
pyruvate	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Multiwell	NNP	O
culture	NN	O
plates	NNS	O
are	VBP	O
prepared	JJ	O
for	IN	O
cell	NN	O
culture	NN	O
by	IN	O
coating	VBG	O
with	IN	O
a	DT	O
1:100	CD	O
dilution	NN	O
of	IN	O
type	NN	O
1	CD	O
rat	NN	O
tail	NN	O
collagen	NN	O
(	(	O
BD	NNP	O
Biosciences	NNP	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
in	IN	O
phosphate-buffered	JJ	O
saline	NN	O
.	.	O
The	DT	O
collagen-containing	JJ	O
plates	NNS	O
were	VBD	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
for	IN	O
approximately	RB	O
1	CD	O
hour	NN	O
,	,	O
after	IN	O
which	WDT	O
the	DT	O
collagen	NN	O
was	VBD	O
removed	VBN	O
and	CC	O
the	DT	O
wells	NNS	O
were	VBD	O
washed	VBN	O
twice	RB	O
with	IN	O
phosphate-buffered	JJ	O
saline	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
8,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
HUVEC	NNP	O
cells	NNS	O
:	:	O
The	DT	O
human	JJ	O
umbilical	JJ	O
vein	NN	O
endothilial	JJ	O
cell	NN	O
line	NN	O
HuVEC	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
HuVEC	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
EBM	NNP	O
(	(	O
Cambrex	NNP	O
Bio	NNP	O
Science	NNP	O
,	,	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
supplemented	VBN	O
with	IN	O
SingleQuots	NNP	O
supplements	NNS	O
(	(	O
Cambrex	NNP	O
Bio	NNP	O
Science	NNP	O
,	,	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
were	VBD	O
maintained	VBN	O
for	IN	O
up	RB	O
to	TO	O
15	CD	O
passages	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
10000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
MLg2908	NNP	O
cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
lung	NN	O
cell	NN	O
line	NN	O
MLg2908	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
MLg2908	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
MEM	NNP	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
2	CD	O
mM	NN	O
L-glutamine	NNP	O
,	,	O
Earle	NNP	O
's	POS	O
BSS	NNP	O
adjusted	VBD	O
to	TO	O
contain	VB	O
1.5	CD	O
g/L	JJ	O
sodium	NN	O
bicarbonate	NN	O
,	,	O
0.1	CD	O
mM	JJ	O
non-essential	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
and	CC	O
1.0	CD	O
mM	NN	O
sodium	NN	O
pyruvate	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
3000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
P388D1	NNP	O
cells	NNS	O
:	:	O
The	DT	O
murine	NN	O
macrophage	NN	O
cell	NN	O
line	NN	O
P388D1	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
P388D1	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
RPMI	NNP	O
1640	CD	O
media	NNS	O
supplemented	VBN	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
2	CD	O
mM	NN	O
L-glutamine	NNP	O
and	CC	O
1	CD	O
%	NN	O
sodium	NN	O
pyruvate	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
65-75	JJ	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
15,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
T-24	JJ	O
cells	NNS	O
:	:	O
The	DT	O
transitional	JJ	O
cell	NN	O
bladder	NN	O
carcinoma	NN	O
cell	NN	O
line	NN	O
T-24	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
T-24	JJ	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
complete	JJ	O
McCoy	NNP	O
's	POS	O
5A	CD	O
basal	JJ	O
media	NNS	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
approximately	RB	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
4000-6000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
Treatment	NN	O
with	IN	O
antisense	JJ	O
compounds	NNS	O
:	:	O
When	WRB	O
cells	NNS	O
reached	VBD	O
approximately	RB	O
65-75	JJ	O
%	NN	O
confluency	NN	O
,	,	O
they	PRP	O
were	VBD	O
treated	VBN	O
with	IN	O
oligonucleotide	NN	O
.	.	O
Oligonucleotide	NNP	O
was	VBD	O
mixed	JJ	O
with	IN	O
LIPOFECTIN™	NNP	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
achieve	VB	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
3	CD	O
μg/mL	JJ	O
LIPOFECTIN™	NNP	O
per	IN	O
100	CD	O
nM	JJ	O
oligonucleotide	NN	O
in	IN	O
1	CD	O
mL	JJ	O
OPTI-MEM™-1	NNP	O
or	CC	O
Eagle	NNP	O
's	POS	O
MEM	NNP	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
For	IN	O
cells	NNS	O
grown	VBN	O
in	IN	O
96-well	CD	O
plates	NNS	O
,	,	O
wells	NNS	O
were	VBD	O
washed	VBN	O
once	RB	O
with	IN	O
100	CD	O
μL	JJ	O
OPTI-MEM™-1	NNP	O
,	,	O
Eagle	NNP	O
's	POS	O
MEM	NNP	O
or	CC	O
serum-free	JJ	O
culture	NN	O
medium	NN	O
and	CC	O
then	RB	O
treated	VBD	O
with	IN	O
130	CD	O
μL	NNS	O
of	IN	O
the	DT	O
oligonucleotide/OPTI-MEM™-1	JJ	O
or	CC	O
Eagle	NNP	O
's	POS	O
MEM/LIPOFECTIN™	NNP	O
cocktail	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
treated	VBN	O
and	CC	O
data	NNS	O
were	VBD	O
obtained	VBN	O
in	IN	O
duplicate	NN	O
or	CC	O
triplicate	NN	O
.	.	O
After	IN	O
4-7	JJ	O
hours	NNS	O
of	IN	O
treatment	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
the	DT	O
medium	NN	O
was	VBD	O
replaced	VBN	O
with	IN	O
fresh	JJ	O
medium	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
16-24	JJ	O
hours	NNS	O
after	IN	O
oligonucleotide	JJ	O
treatment	NN	O
.	.	O
Control	NNP	O
oligonucleotides	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
oligomeric	JJ	O
compound	NN	O
concentration	NN	O
for	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
line	NN	O
.	.	O
Furthermore	RB	O
,	,	O
when	WRB	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
tested	VBN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
screening	VBG	O
experiments	NNS	O
or	CC	O
phenotypic	NN	O
assays	NNS	O
,	,	O
control	NN	O
oligonucleotides	NNS	O
are	VBP	O
tested	VBN	O
in	IN	O
parallel	NN	O
with	IN	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
control	NN	O
oligonucleotides	NNS	O
are	VBP	O
used	VBN	O
as	IN	O
negative	JJ	O
control	NN	O
oligonucleotides	NNS	O
,	,	O
i.e.	FW	O
,	,	O
as	IN	O
a	DT	O
means	NN	O
for	IN	O
measuring	VBG	O
the	DT	O
absence	NN	O
of	IN	O
an	DT	O
effect	NN	O
on	IN	O
gene	NN	O
expression	NN	O
or	CC	O
phenotype	NN	O
.	.	O
In	IN	O
alternative	JJ	O
embodiments	NNS	O
,	,	O
control	NN	O
oligonucleotides	NNS	O
are	VBP	O
used	VBN	O
as	IN	O
positive	JJ	O
control	NN	O
oligonucleotides	NNS	O
,	,	O
i.e.	FW	O
,	,	O
as	IN	O
oligonucleotides	NNS	O
known	VBN	O
to	TO	O
affect	VB	O
gene	NN	O
expression	NN	O
or	CC	O
phenotype	NN	O
.	.	O
Control	NNP	O
oligonucleotides	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O
“	JJ	O
Target	NNP	O
Name	NNP	O
”	NNP	O
indicates	VBZ	O
the	DT	O
gene	NN	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
targeted	VBN	O
.	.	O
“	JJ	O
Species	NNS	O
of	IN	O
Target	NNP	O
”	NNP	O
indicates	VBZ	O
species	NNS	O
in	IN	O
which	WDT	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
perfectly	RB	O
complementary	JJ	O
to	TO	O
the	DT	O
target	NN	O
mRNA	NN	O
.	.	O
“	JJ	O
Motif	NNP	O
”	NNP	O
is	VBZ	O
indicative	JJ	O
of	IN	O
chemically	RB	O
distinct	JJ	O
regions	NNS	O
comprising	VBG	O
the	DT	O
oligonucleotide	NN	O
.	.	O
Certain	NNP	O
compounds	NNS	O
in	IN	O
Table	JJ	O
2	CD	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
nucleotides	NNS	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-MOE	JJ	O
nucleotides	NNS	O
,	,	O
and	CC	O
designated	VBD	O
as	IN	O
“	JJ	O
Uniform	NNP	O
MOE	NNP	O
”	NNP	O
.	.	O
Certain	NNP	O
compounds	NNS	O
in	IN	O
Table	JJ	O
2	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
)	)	O
by	IN	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
nucleotides	NNS	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-MOE	JJ	O
nucleotides	NNS	O
.	.	O
The	DT	O
“	NNP	O
motif	NNP	O
”	NNP	O
of	IN	O
each	DT	O
gapmer	NN	O
oligonucleotide	NN	O
is	VBZ	O
illustrated	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
and	CC	O
indicates	VBZ	O
the	DT	O
number	NN	O
of	IN	O
nucleotides	NNS	O
in	IN	O
each	DT	O
gap	NN	O
region	NN	O
and	CC	O
wing	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
“	VB	O
5-10-5	JJ	O
”	NNP	O
indicates	VBZ	O
a	DT	O
gapmer	NN	O
having	VBG	O
a	DT	O
10-nucleotide	JJ	O
gap	NN	O
region	NN	O
flanked	VBN	O
by	IN	O
5-nucleotide	JJ	O
wings	NNS	O
.	.	O
Similarly	RB	O
,	,	O
the	DT	O
motif	NN	O
“	NNP	O
5-9-6	JJ	O
”	NNP	O
indicates	VBZ	O
a	DT	O
9-nucleotide	JJ	O
gap	NN	O
region	NN	O
flanked	VBN	O
by	IN	O
5-nucleotide	JJ	O
wing	NN	O
on	IN	O
the	DT	O
5′	CD	O
side	NN	O
and	CC	O
a	DT	O
6-nucleotide	JJ	O
wing	NN	O
on	IN	O
the	DT	O
3′	CD	O
side	NN	O
.	.	O
ISIS	NNP	O
15839	CD	O
is	VBZ	O
a	DT	O
“	JJ	O
hemimer	NN	O
”	NNP	O
composed	VBD	O
of	IN	O
two	CD	O
regions	NNS	O
of	IN	O
distinct	JJ	O
chemistry	NN	O
,	,	O
wherein	WP	O
the	DT	O
first	JJ	O
12-nucleotides	NNS	O
are	VBP	O
2′-deoxynucleotides	JJ	O
and	CC	O
the	DT	O
last	JJ	O
8	CD	O
nucleotides	NNS	O
are	VBP	O
2′-MOE	JJ	O
nucleotides	NNS	O
.	.	O
ISIS	NNP	O
15344	CD	O
is	VBZ	O
a	DT	O
“	JJ	O
hemimer	NN	O
”	NNP	O
composed	VBD	O
of	IN	O
two	CD	O
regions	NNS	O
of	IN	O
distinct	JJ	O
chemistry	NN	O
,	,	O
wherein	WP	O
the	DT	O
first	JJ	O
9	CD	O
nucleotides	NNS	O
are	VBP	O
2′-deoxynucleotides	JJ	O
and	CC	O
the	DT	O
last	JJ	O
11	CD	O
are	VBP	O
2′-MOE	JJ	O
nucleotides	NNS	O
.	.	O
ISIS	NNP	O
13513	CD	O
is	VBZ	O
a	DT	O
chimeric	JJ	O
oligonucleotide	NN	O
composed	VBD	O
of	IN	O
multiple	JJ	O
regions	NNS	O
of	IN	O
distinct	JJ	O
chemistry	NN	O
,	,	O
denoted	VBN	O
with	IN	O
a	DT	O
motif	NN	O
of	IN	O
“	JJ	O
6-8-5-1	JJ	O
”	NN	O
and	CC	O
comprised	VBN	O
of	IN	O
a	DT	O
6-nucleotide	JJ	O
wing	NN	O
flanking	VBG	O
an	DT	O
8-nucleotide	JJ	O
gap	NN	O
region	NN	O
followed	VBN	O
by	IN	O
5	CD	O
2′-MOE	JJ	O
nucleotides	NNS	O
and	CC	O
terminating	VBG	O
with	IN	O
a	DT	O
2′-deoxynucleotide	JJ	O
at	IN	O
the	DT	O
3′	CD	O
end	NN	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
throughout	IN	O
the	DT	O
oligonucleotides	NNS	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O
Unmodified	VBN	O
cytosines	NNS	O
are	VBP	O
indicated	VBN	O
by	IN	O
“	NNP	O
uC	JJ	O
”	NN	O
in	IN	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
;	:	O
all	DT	O
other	JJ	O
cytosines	NNS	O
are	VBP	O
5-methylcytosines	JJ	O
.	.	O
The	DT	O
concentration	NN	O
of	IN	O
oligonucleotide	NN	O
used	VBN	O
varies	NNS	O
from	IN	O
cell	NN	O
line	NN	O
to	TO	O
cell	VB	O
line	NN	O
.	.	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
oligonucleotide	JJ	O
concentration	NN	O
for	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
line	NN	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
treated	VBN	O
with	IN	O
a	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
at	IN	O
a	DT	O
range	NN	O
of	IN	O
concentrations	NNS	O
.	.	O
Positive	JJ	O
controls	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O
For	IN	O
human	JJ	O
and	CC	O
non-human	JJ	O
primate	NN	O
cells	NNS	O
,	,	O
the	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
is	VBZ	O
selected	VBN	O
from	IN	O
either	CC	O
ISIS	NNP	O
13650	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
51	CD	O
)	)	O
,	,	O
ISIS	NNP	O
336806	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
52	CD	O
)	)	O
or	CC	O
ISIS	$	O
18078	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
38	CD	O
)	)	O
.	.	O
For	IN	O
mouse	NN	O
or	CC	O
rat	NN	O
cells	NNS	O
the	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
is	VBZ	O
ISIS	NNP	O
15770	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
53	CD	O
)	)	O
or	CC	O
ISIS	$	O
15346	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
36	CD	O
)	)	O
.	.	O
The	DT	O
concentration	NN	O
of	IN	O
positive	JJ	O
control	NN	O
oligonucleotide	IN	O
that	DT	O
results	NNS	O
in	IN	O
80	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
human	JJ	O
Raf	NNP	O
kinase	NN	O
C	NNP	O
for	IN	O
ISIS	NNP	O
13650	CD	O
,	,	O
is	VBZ	O
then	RB	O
utilized	JJ	O
as	IN	O
the	DT	O
screening	NN	O
concentration	NN	O
for	IN	O
new	JJ	O
oligonucleotides	NNS	O
in	IN	O
subsequent	JJ	O
experiments	NNS	O
for	IN	O
that	DT	O
cell	NN	O
line	NN	O
.	.	O
If	IN	O
80	CD	O
%	NN	O
inhibition	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
,	,	O
the	DT	O
lowest	JJS	O
concentration	NN	O
of	IN	O
positive	JJ	O
control	NN	O
oligonucleotide	IN	O
that	DT	O
results	NNS	O
in	IN	O
60	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
is	VBZ	O
then	RB	O
utilized	JJ	O
as	IN	O
the	DT	O
oligonucleotide	NN	O
screening	VBG	O
concentration	NN	O
in	IN	O
subsequent	JJ	O
experiments	NNS	O
for	IN	O
that	DT	O
cell	NN	O
line	NN	O
.	.	O
If	IN	O
60	CD	O
%	NN	O
inhibition	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
,	,	O
that	IN	O
particular	JJ	O
cell	NN	O
line	NN	O
is	VBZ	O
deemed	VBN	O
as	IN	O
unsuitable	JJ	O
for	IN	O
oligonucleotide	JJ	O
transfection	NN	O
experiments	NNS	O
.	.	O
The	DT	O
concentrations	NNS	O
of	IN	O
antisense	NN	O
oligonucleotides	NNS	O
used	VBN	O
herein	NNS	O
are	VBP	O
from	IN	O
50	CD	O
nM	NNS	O
to	TO	O
300	CD	O
nM	NNS	O
.	.	O
Example	JJ	O
2	CD	O
Real-Time	JJ	O
Quantitative	NNP	O
PCR	NNP	O
Analysis	NNP	O
of	IN	O
Target	NNP	O
Gene	NNP	O
mRNA	NN	O
Levels	NNP	O
Quantitation	NNP	O
of	IN	O
Gemin	NNP	O
Gene	NNP	O
mRNA	NN	O
levels	NNS	O
was	VBD	O
accomplished	VBN	O
by	IN	O
real-time	JJ	O
quantitative	JJ	O
PCR	NNP	O
using	VBG	O
the	DT	O
ABI	NNP	O
PRISM™	NNP	O
7600	CD	O
,	,	O
7700	CD	O
,	,	O
or	CC	O
7900	CD	O
Sequence	NNP	O
Detection	NNP	O
System	NNP	O
(	(	O
PE-Applied	JJ	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
according	VBG	O
to	TO	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Prior	RB	O
to	TO	O
quantitative	VB	O
PCR	NNP	O
analysis	NN	O
,	,	O
primer-probe	JJ	O
sets	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
target	NN	O
gene	NN	O
being	VBG	O
measured	VBN	O
were	VBD	O
evaluated	VBN	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
be	VB	O
“	JJ	O
multiplexed	JJ	O
”	NN	O
with	IN	O
a	DT	O
GAPDH	NNP	O
amplification	NN	O
reaction	NN	O
.	.	O
After	IN	O
isolation	NN	O
the	DT	O
RNA	NNP	O
is	VBZ	O
subjected	VBN	O
to	TO	O
sequential	JJ	O
reverse	NN	O
transcriptase	NN	O
(	(	O
RT	NNP	O
)	)	O
reaction	NN	O
and	CC	O
real-time	JJ	O
PCR	NNP	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
performed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
well	NN	O
.	.	O
RT	NNP	O
and	CC	O
PCR	NNP	O
reagents	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
(	(	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
RT	NNP	O
,	,	O
real-time	JJ	O
PCR	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
the	DT	O
same	JJ	O
by	IN	O
adding	VBG	O
20	CD	O
μL	JJ	O
PCR	NNP	O
cocktail	NN	O
(	(	O
2.5×PCR	CD	O
buffer	NN	O
minus	NN	O
MgCl2	NNP	O
,	,	O
6.6	CD	O
mM	NN	O
MgCl2	NNP	O
,	,	O
375	CD	O
μM	JJ	O
each	DT	O
of	IN	O
dATP	NN	O
,	,	O
dCTP	NN	O
,	,	O
dCTP	NN	O
and	CC	O
dGTP	NN	O
,	,	O
375	CD	O
nM	JJ	O
each	DT	O
of	IN	O
forward	RB	O
primer	NN	O
and	CC	O
reverse	VB	O
primer	NN	O
,	,	O
125	CD	O
nM	NN	O
of	IN	O
probe	NN	O
,	,	O
4	CD	O
Units	NNS	O
RNAse	NNP	O
inhibitor	NN	O
,	,	O
1.25	CD	O
Units	NNS	O
PLATINUM®	NNP	O
Taq	NNP	O
,	,	O
5	CD	O
Units	NNS	O
MuLV	NNP	O
reverse	NN	O
transcriptase	NN	O
,	,	O
and	CC	O
2.5×	CD	O
ROX	NNP	O
dye	NN	O
)	)	O
to	TO	O
96-well	CD	O
plates	NNS	O
containing	VBG	O
30	CD	O
μL	JJ	O
total	JJ	O
RNA	NNP	O
solution	NN	O
(	(	O
20-200	JJ	O
ng	NN	O
)	)	O
.	.	O
The	DT	O
RT	NNP	O
reaction	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
incubation	NN	O
for	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
48°	CD	O
C.	NNP	O
Following	VBG	O
a	DT	O
10	CD	O
minute	NN	O
incubation	NN	O
at	IN	O
95°	CD	O
C.	NNP	O
to	TO	O
activate	VB	O
the	DT	O
PLATINUM®	NNP	O
Taq	NNP	O
,	,	O
40	CD	O
cycles	NNS	O
of	IN	O
a	DT	O
two-step	JJ	O
PCR	NNP	O
protocol	NN	O
were	VBD	O
carried	VBN	O
out	IN	O
:	:	O
95°	CD	O
C.	NNP	O
for	IN	O
15	CD	O
seconds	NNS	O
(	(	O
denaturation	NN	O
)	)	O
followed	VBN	O
by	IN	O
60°	CD	O
C.	NNP	O
for	IN	O
1.5	CD	O
minutes	NNS	O
(	(	O
annealing/extension	NN	O
)	)	O
.	.	O
Gene	NNP	O
target	NN	O
quantities	NNS	O
obtained	VBN	O
by	IN	O
RT	NNP	O
,	,	O
real-time	JJ	O
PCR	NNP	O
were	VBD	O
normalized	VBN	O
using	VBG	O
either	CC	O
the	DT	O
expression	NN	O
level	NN	O
of	IN	O
GAPDH	NNP	O
,	,	O
a	DT	O
gene	NN	O
whose	WP$	O
expression	NN	O
is	VBZ	O
constant	JJ	O
,	,	O
or	CC	O
by	IN	O
quantifying	VBG	O
total	JJ	O
RNA	NNP	O
using	VBG	O
RiboGreen™	NNP	O
(	(	O
Molecular	NNP	O
Probes	NNP	O
,	,	O
Inc.	NNP	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
)	)	O
.	.	O
GAPDH	NNP	O
expression	NN	O
was	VBD	O
quantified	VBN	O
by	IN	O
RT	NNP	O
,	,	O
real-time	JJ	O
PCR	NNP	O
,	,	O
by	IN	O
being	VBG	O
run	VBN	O
simultaneously	RB	O
with	IN	O
the	DT	O
target	NN	O
,	,	O
multiplexing	NN	O
,	,	O
or	CC	O
separately	RB	O
.	.	O
Total	JJ	O
RNA	NNP	O
was	VBD	O
quantified	VBN	O
using	VBG	O
RiboGreen™	NNP	O
RNA	NNP	O
quantification	NN	O
reagent	NN	O
(	(	O
Molecular	JJ	O
Probes	NNP	O
,	,	O
Inc.	NNP	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
)	)	O
.	.	O
170	CD	O
μL	NN	O
of	IN	O
RiboGreen™	NNP	O
working	VBG	O
reagent	NN	O
(	(	O
RiboGreen™	NNP	O
reagent	NN	O
diluted	VBD	O
1:350	CD	O
in	IN	O
10	CD	O
mM	JJ	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
pH	RB	O
7.5	CD	O
)	)	O
was	VBD	O
pipetted	VBN	O
into	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
containing	VBG	O
30	CD	O
μL	JJ	O
purified	VBN	O
cellular	JJ	O
RNA	NNP	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
read	VBN	O
in	IN	O
a	DT	O
CytoFluor	NN	O
4000	CD	O
(	(	O
PE	NNP	O
Applied	NNP	O
Biosystems	NNP	O
)	)	O
with	IN	O
excitation	NN	O
at	IN	O
485	CD	O
nm	NNS	O
and	CC	O
emission	NN	O
at	IN	O
530	CD	O
nm	NNS	O
.	.	O
Presented	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
are	VBP	O
primers	NNS	O
and	CC	O
probes	NNS	O
used	VBN	O
to	TO	O
measure	VB	O
GAPDH	NNP	O
expression	NN	O
in	IN	O
the	DT	O
cell	NN	O
types	NNS	O
described	VBD	O
herein	NN	O
.	.	O
The	DT	O
GAPDH	NNP	O
PCR	NNP	O
probes	NNS	O
have	VBP	O
JOE	NNP	O
covalently	RB	O
linked	VBD	O
to	TO	O
the	DT	O
5′	CD	O
end	NN	O
and	CC	O
TAMRA	NNP	O
covalently	RB	O
linked	VBD	O
to	TO	O
the	DT	O
3′	CD	O
end	NN	O
,	,	O
where	WRB	O
JOE	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
reporter	NN	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
In	IN	O
some	DT	O
cell	NN	O
types	NNS	O
,	,	O
primers	NNS	O
and	CC	O
probe	NN	O
designed	VBN	O
to	TO	O
a	DT	O
GAPDH	NNP	O
sequence	NN	O
from	IN	O
a	DT	O
different	JJ	O
species	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
measure	VB	O
GAPDH	NNP	O
expression	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
human	JJ	O
GAPDH	NNP	O
primer	NN	O
and	CC	O
probe	NN	O
set	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
measure	VB	O
GAPDH	NNP	O
expression	NN	O
in	IN	O
monkey-derived	JJ	O
cells	NNS	O
and	CC	O
cell	NN	O
lines	NNS	O
.	.	O
Probes	NNS	O
and	CC	O
primers	NNS	O
for	IN	O
use	NN	O
in	IN	O
real-time	JJ	O
PCR	NNP	O
were	VBD	O
designed	VBN	O
to	TO	O
hybridize	VB	O
to	TO	O
target-specific	JJ	O
sequences	NNS	O
.	.	O
The	DT	O
primers	NNS	O
and	CC	O
probes	NNS	O
and	CC	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
to	TO	O
which	WDT	O
they	PRP	O
hybridize	VBP	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
.	.	O
The	DT	O
target-specific	JJ	O
PCR	NNP	O
probes	NNS	O
have	VBP	O
FAM	NNP	O
covalently	RB	O
linked	VBD	O
to	TO	O
the	DT	O
5′	CD	O
end	NN	O
and	CC	O
TAMRA	NNP	O
covalently	RB	O
linked	VBD	O
to	TO	O
the	DT	O
3′	CD	O
end	NN	O
,	,	O
where	WRB	O
FAM	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
Example	JJ	O
3	CD	O
Treatment	NN	O
of	IN	O
Cultured	NNP	O
Cells	NNP	O
with	IN	O
Oligomeric	NNP	O
Compounds	NNP	O
Oligomeric	NNP	O
compounds	VBZ	O
targeted	VBN	O
to	TO	O
Gemin	NNP	O
Genes	NNP	O
presented	VBD	O
in	IN	O
Table	JJ	O
1	CD	O
were	VBD	O
tested	VBN	O
for	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
gene	NN	O
target	NN	O
expression	NN	O
in	IN	O
cultured	JJ	O
cells	NNS	O
.	.	O
Table	JJ	O
5	CD	O
shows	VBZ	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
including	VBG	O
cell	NN	O
type	NN	O
,	,	O
transfection	NN	O
method	NN	O
,	,	O
dose	NN	O
of	IN	O
oligonucleotide	JJ	O
and	CC	O
control	VB	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
used	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression	NN	O
by	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
control	NN	O
oligonucleotide	NN	O
was	VBD	O
chosen	VBN	O
from	IN	O
the	DT	O
group	NN	O
presented	VBD	O
in	IN	O
Table	NNP	O
2	CD	O
,	,	O
and	CC	O
in	IN	O
these	DT	O
experiments	NNS	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
Each	DT	O
cell	NN	O
type	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
indicated	VBN	O
dose	NN	O
of	IN	O
oligonucleotide	NN	O
as	IN	O
described	VBN	O
by	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
Example	RB	O
4	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Gene	NNP	O
Targets	NNP	O
by	IN	O
Oligomeric	NNP	O
Compounds	NNP	O
A	NNP	O
series	NN	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
Gemin	NNP	O
Genes	NNP	O
,	,	O
using	VBG	O
sequences	NNS	O
cited	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
data	NN	O
describing	VBG	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
they	PRP	O
inhibit	VBP	O
gene	NN	O
expression	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
.	.	O
All	DT	O
oligomeric	JJ	O
compounds	NNS	O
in	IN	O
Table	JJ	O
6	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
10	CD	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-0-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
nucleotides	NNS	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-MOE	JJ	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
The	DT	O
oligomeric	JJ	O
compounds	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
gene	NN	O
target	NN	O
mRNA	NN	O
levels	NNS	O
by	IN	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
Data	NNS	O
are	VBP	O
averages	NNS	O
from	IN	O
experiments	NNS	O
in	IN	O
which	WDT	O
cultured	VBD	O
cells	NNS	O
,	,	O
as	IN	O
indicated	VBN	O
for	IN	O
each	DT	O
target	NN	O
in	IN	O
Table	JJ	O
5	CD	O
,	,	O
were	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
disclosed	VBN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
A	DT	O
reduction	NN	O
in	IN	O
expression	NN	O
is	VBZ	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
in	IN	O
Table	JJ	O
6	CD	O
.	.	O
If	IN	O
the	DT	O
target	NN	O
expression	NN	O
level	NN	O
of	IN	O
oligomeric	JJ	O
compound-treated	JJ	O
cell	NN	O
was	VBD	O
higher	JJR	O
than	IN	O
control	NN	O
,	,	O
percent	NN	O
inhibition	NN	O
is	VBZ	O
expressed	VBN	O
as	IN	O
zero	CD	O
inhibition	NN	O
.	.	O
If	IN	O
present	JJ	O
,	,	O
“	JJ	O
N.D.	NNP	O
”	NNP	O
indicates	VBZ	O
“	MD	O
not	RB	O
determined	VB	O
”	NN	O
.	.	O
The	DT	O
target	NN	O
regions	NNS	O
to	TO	O
which	WDT	O
these	DT	O
oligomeric	IN	O
compounds	NNS	O
are	VBP	O
inhibitory	JJ	O
are	VBP	O
herein	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	NNP	O
validated	VBD	O
target	NN	O
segments.	NN	O
”	NN	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NOs	NNP	O
87	CD	O
,	,	O
89	CD	O
,	,	O
90	CD	O
,	,	O
91	CD	O
,	,	O
92	CD	O
,	,	O
94	CD	O
,	,	O
103	CD	O
,	,	O
104	CD	O
,	,	O
105	CD	O
,	,	O
106	CD	O
,	,	O
109	CD	O
,	,	O
110	CD	O
,	,	O
111	CD	O
,	,	O
112	CD	O
,	,	O
113	CD	O
,	,	O
114	CD	O
,	,	O
115	CD	O
,	,	O
116	CD	O
,	,	O
117	CD	O
,	,	O
118	CD	O
,	,	O
119	CD	O
,	,	O
121	CD	O
,	,	O
122	CD	O
,	,	O
123	CD	O
,	,	O
125	CD	O
,	,	O
127	CD	O
,	,	O
128	CD	O
,	,	O
129	CD	O
,	,	O
130	CD	O
,	,	O
131	CD	O
,	,	O
132	CD	O
,	,	O
135	CD	O
,	,	O
136	CD	O
,	,	O
137	CD	O
,	,	O
138	CD	O
,	,	O
139	CD	O
,	,	O
140	CD	O
,	,	O
141	CD	O
,	,	O
142	CD	O
,	,	O
145	CD	O
,	,	O
146	CD	O
,	,	O
147	CD	O
,	,	O
148	CD	O
,	,	O
149	CD	O
,	,	O
150	CD	O
,	,	O
151	CD	O
,	,	O
152	CD	O
,	,	O
153	CD	O
,	,	O
156	CD	O
,	,	O
157	CD	O
,	,	O
158	CD	O
,	,	O
161	CD	O
,	,	O
163	CD	O
,	,	O
166	CD	O
,	,	O
177	CD	O
,	,	O
178	CD	O
,	,	O
180	CD	O
,	,	O
188	CD	O
,	,	O
193	CD	O
,	,	O
195	CD	O
,	,	O
210	CD	O
,	,	O
225	CD	O
,	,	O
228	CD	O
,	,	O
229	CD	O
,	,	O
232	CD	O
,	,	O
238	CD	O
,	,	O
241	CD	O
,	,	O
242	CD	O
,	,	O
243	CD	O
,	,	O
244	CD	O
,	,	O
245	CD	O
,	,	O
246	CD	O
,	,	O
249	CD	O
,	,	O
250	CD	O
,	,	O
251	CD	O
,	,	O
252	CD	O
,	,	O
253	CD	O
,	,	O
254	CD	O
,	,	O
255	CD	O
,	,	O
256	CD	O
,	,	O
257	CD	O
,	,	O
259	CD	O
,	,	O
260	CD	O
,	,	O
261	CD	O
,	,	O
262	CD	O
,	,	O
263	CD	O
,	,	O
264	CD	O
,	,	O
265	CD	O
,	,	O
266	CD	O
,	,	O
267	CD	O
,	,	O
268	CD	O
,	,	O
269	CD	O
,	,	O
270	CD	O
,	,	O
271	CD	O
,	,	O
272	CD	O
,	,	O
274	CD	O
,	,	O
275	CD	O
,	,	O
276	CD	O
,	,	O
277	CD	O
,	,	O
278	CD	O
,	,	O
279	CD	O
,	,	O
280	CD	O
,	,	O
281	CD	O
,	,	O
282	CD	O
,	,	O
283	CD	O
,	,	O
284	CD	O
,	,	O
285	CD	O
,	,	O
286	CD	O
,	,	O
291	CD	O
,	,	O
294	CD	O
,	,	O
295	CD	O
,	,	O
296	CD	O
,	,	O
297	CD	O
,	,	O
298	CD	O
,	,	O
299	CD	O
,	,	O
300	CD	O
,	,	O
301	CD	O
,	,	O
302	CD	O
,	,	O
303	CD	O
,	,	O
304	CD	O
,	,	O
305	CD	O
,	,	O
306	CD	O
,	,	O
307	CD	O
,	,	O
308	CD	O
,	,	O
309	CD	O
,	,	O
311	CD	O
,	,	O
313	CD	O
,	,	O
315	CD	O
,	,	O
316	CD	O
,	,	O
317	CD	O
,	,	O
319	CD	O
,	,	O
320	CD	O
,	,	O
326	CD	O
,	,	O
328	CD	O
,	,	O
329	CD	O
,	,	O
330	CD	O
,	,	O
332	CD	O
,	,	O
333	CD	O
,	,	O
334	CD	O
,	,	O
335	CD	O
,	,	O
336	CD	O
,	,	O
337	CD	O
,	,	O
338	CD	O
,	,	O
339	CD	O
,	,	O
340	CD	O
,	,	O
341	CD	O
,	,	O
342	CD	O
,	,	O
343	CD	O
,	,	O
344	CD	O
,	,	O
346	CD	O
,	,	O
347	CD	O
,	,	O
348	CD	O
,	,	O
349	CD	O
,	,	O
350	CD	O
,	,	O
351	CD	O
,	,	O
352	CD	O
,	,	O
353	CD	O
,	,	O
354	CD	O
,	,	O
356	CD	O
,	,	O
357	CD	O
,	,	O
358	CD	O
,	,	O
359	CD	O
,	,	O
360	CD	O
,	,	O
361	CD	O
,	,	O
362	CD	O
,	,	O
363	CD	O
,	,	O
364	CD	O
,	,	O
366	CD	O
,	,	O
368	CD	O
,	,	O
369	CD	O
,	,	O
370	CD	O
,	,	O
371	CD	O
,	,	O
372	CD	O
,	,	O
373	CD	O
,	,	O
374	CD	O
,	,	O
375	CD	O
,	,	O
376	CD	O
,	,	O
377	CD	O
,	,	O
378	CD	O
,	,	O
380	CD	O
,	,	O
381	CD	O
,	,	O
382	CD	O
,	,	O
383	CD	O
,	,	O
384	CD	O
,	,	O
385	CD	O
,	,	O
387	CD	O
,	,	O
388	CD	O
,	,	O
393	CD	O
,	,	O
394	CD	O
,	,	O
395	CD	O
,	,	O
396	CD	O
,	,	O
397	CD	O
,	,	O
398	CD	O
,	,	O
399	CD	O
,	,	O
401	CD	O
,	,	O
402	CD	O
,	,	O
403	CD	O
,	,	O
410	CD	O
,	,	O
411	CD	O
,	,	O
412	CD	O
,	,	O
414	CD	O
,	,	O
415	CD	O
,	,	O
417	CD	O
,	,	O
418	CD	O
,	,	O
419	CD	O
,	,	O
420	CD	O
,	,	O
421	CD	O
,	,	O
422	CD	O
,	,	O
423	CD	O
,	,	O
424	CD	O
,	,	O
425	CD	O
,	,	O
426	CD	O
,	,	O
427	CD	O
,	,	O
428	CD	O
,	,	O
429	CD	O
,	,	O
430	CD	O
,	,	O
432	CD	O
,	,	O
433	CD	O
,	,	O
434	CD	O
,	,	O
435	CD	O
,	,	O
436	CD	O
,	,	O
437	CD	O
,	,	O
438	CD	O
,	,	O
439	CD	O
,	,	O
440	CD	O
,	,	O
441	CD	O
,	,	O
442	CD	O
,	,	O
443	CD	O
,	,	O
444	CD	O
,	,	O
445	CD	O
,	,	O
450	CD	O
,	,	O
451	CD	O
,	,	O
452	CD	O
,	,	O
457	CD	O
,	,	O
458	CD	O
,	,	O
462	CD	O
,	,	O
467	CD	O
,	,	O
468	CD	O
,	,	O
469	CD	O
,	,	O
470	CD	O
,	,	O
471	CD	O
,	,	O
472	CD	O
,	,	O
473	CD	O
,	,	O
474	CD	O
,	,	O
demonstrated	VBN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
a	DT	O
Gemin	NNP	O
Gene	NNP	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
these	DT	O
sequences	NNS	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
consist	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
these	DT	O
sequences	NNS	O
.	.	O
The	DT	O
target	NN	O
sites	VBZ	O
to	TO	O
which	WDT	O
these	DT	O
sequences	NNS	O
are	VBP	O
complementary	JJ	O
are	VBP	O
examples	NNS	O
of	IN	O
“	NNP	O
validated	VBD	O
target	NN	O
sites	NNS	O
”	JJ	O
and	CC	O
are	VBP	O
therefore	RB	O
sites	NNS	O
for	IN	O
designing	VBG	O
other	JJ	O
oligomeric	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Claims	NNS	O
(	(	O
16	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
3	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=42332613	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
2	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
1	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
1	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
1	CD	O
)	)	O
Citations	NNPS	O
(	(	O
10	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
11	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
68	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Effective	JJ	O
date	NN	O
:	:	O
20170402	CD	O
